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Abstract
Through continuous exposure to increasing concentrations of carboplatin, three novel 
platinum resistant variants of the human squamous carcinoma cell line, DLKP, were 
established. Cross resistance studies revealed that, while these variants exhibited resistance 
to the platinum analogues carboplatin and cisplatin, no significant resistance or sensitivity 
was observed against the classical MDR drugs, adriamycin and vincristine. Characterisation 
studies demonstrated that the resistant phenotype in the DLKPC variants did not appear to 
be to be either P-glycoprotein or topoisomerase mediated, nor did it appear to be related 
to alterations in either GST or glutathione levels. Metallothionein expression in two of the 
established variants, DLKPC 6.2 and DLKPC 14, was found to be increased, correlating 
with the degreee of platinum resistance. The increased level of metallothionein expression 
in the highest resistant variant, DLKPC 25, however, did not correlate with the platinum 
resistance level. This suggested the involvement of alternative mechanisms in mediating 
resistance in this variant, possibly through decreased intracellular platinum accumulation.
Drug accumulation studies with adriamycin and vincristine, were carried out on a number 
of human MDR cell lines, demonstrating reduced cellular accumulation of drug. The 
subsequent addition of verapamil or cyclosporin A, agents known to interact with P- 
glycoprotein, resulted in complete restoration of cellular drug levels in the MDR cell lines 
SKMES-1/ADR, T24A, T24V, OAW42-A and OAW42-A1, suggesting that the 
accumulation defect observed in these cell lines was P-glycoprotein mediated and that, 
accordingly, these cell lines exhibited characteristics consistent with classical MDR 
phenotype. In contrast, although P-glycoprotein appears to mediate a reduction in the 
cellular accumulation of drug in the DLKPA10 cell line, an alternative transport mechanism 
also appears to be present. Adriamycin subcellular distribution studies revealed the 
presence of an ATP-dependent, vesicular sequestration mechanism, involved in reducing 
adriamycin nuclear accumulation. This was demonstrated through ATP inhibition and 
disruption of the cytoplasmic vesicles, resulting in increased adriamycin accumulation and 
redistribution to the nucleus. In addition, studies indicated that membrane fluidity may be 
altered in these cells and that this may also contribute to a reduction in drug accumulation. 
An antibody was also raised against the DLKPA10 cells to determine if decreased drug 
accumulation was associated with either overexpression or down regulation of an antigen 
in the resistant cells. While overexpression of a 170-180 kDa antigen was observed in the 
DLKP parental cells, its role in mediating resistance remains to be clarified, although 
preliminary studies suggest that this antibody may play a role in cell adhesion or 
intercellular communication.
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Introduction
1.1 General Introduction
Resistance to chemotherapy represents the single most important factor in the failure of 
many cancer treatments. While resistance to chemotherapeutic agents is inherent in many 
human tumours, other tumours, initially responsive to chemotherapy, also develop resistant 
variants. Tumours, inherently resistant to a variety of anticancer drugs, display a minimal, 
if any, response to chemotherapy. In most cases, the basis for this inherent resistance is 
undefined, although, probably involving a combination of kinetic and biochemical factors, 
such as inability to effectively transport the drug into the cell or to convert it into its active 
form. With acquired drug resistance, a population of cells, initially sensitive to the drug, 
develops resistant characteristics. Typically, while there is an initial decrease in tumour 
mass, tumour growth eventually resumes, despite continued treatment. Cells, either 
partially or completely resistant to an anticancer agent are, therefore, more likely to survive 
in a drug-containing environment. Combination chemotherapy was introduced in an attempt 
to overcome this problem. However, many tumours can also develop multidrug resistant 
(MDR) variants. Classical MDR is characterised by cross-resistance to a range of 
chemically unrelated drugs. In general, the cytotoxic agents involved are large molecules, 
containing hydrophobic and hydrophilic regions and include the anthracyclines, vinca 
alkaloids, epipodophyllotoxins, actinomycin D and colchicine (Clynes et al., 1990; Nielsen 
and Skovsgaard, 1992; Clynes et al., 1993; Prat et al., 1994).
Given the widespread lack of sustained response to chemotherapy in human tumours, there 
is considerable interest in understanding the mechanisms of MDR. In attempting to identify 
the factors giving rise to MDR, a number of mechanisms have been described. These 
include an increase in drug efflux, relating with an overexpression of a membrane 
glycoprotein (Juliano and Ling, 1976), reduced expression of the enzyme, topoisomerase 
II, which is involved in DNA replication and repair (Hoffmann and Mattern, 1993), and an 
alteration in the metabolising enzymes, glutathione-S-transferases (Moscow and Dixon, 
1993). The most frequent determinant of MDR in many tumour cell lines, however, 
appears to be the ability of the cells to greatly decrease the cellular accumulation of drug. 
This usually results from the overexpression of the mdrl gene, which encodes the 
transmembrane protein, P-glycoprotein. This protein acts as an ATP-dependent efflux pump 
for a variety of cytotoxic agents, reducing the cellular concentration of the drug (Dano, 
1973; Fojo et al., 1985; Willingham et al., 1986).
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1.2 Pharmacology of MDR drugs
1.2.1 The Anthracyclines
The anthracycline antibiotics are among the most important o f the antitumour agents and 
are routinely used in the treatment of cancer. They are produced by the fungus, 
Streptomyces peucetius var. caesius. Daunorubicin was isolated independently by two 
groups in the early 1960s (DiMarco and Dubost) and adriamycin (doxorubicin) was 
isolated by Arcamone and coworkers in 1969. Although they differ, only slightly, in 
chemical structure, daunorubicin has been used primarily in the treatment of acute 
lymphocytic and acute granulocytic leukaemias, whereas adriamycin displays activity 
against a wide range of human cancers, including a variety of solid tumours. Used 
concurrently with other anticancer agents, adriamycin is used in the treatment o f non- 
Hodgkins lymphoma, as well as carcinomas of the ovary, breast, bladder and lung. 
Adriamycin is also a useful agent in the treatment of metastatic thyroid carcinoma and 
carcinomas of the endometrium, testes, prostate, cervix and head and neck (Prat et ah, 
1984). Unfortunately the clinical value of both agents is limited, due to their toxic side 
effects. These include, nausea, vomiting, loss o f hair, myelosupression and local tissue 
necrosis. Damage to heart muscle is also a major toxicity of the anthracyclines, the 
incidence of which increases with increasing cumulative dosage o f drug (Unverferth et 
ah, 1982). The drug induced cardiomyopathy presents a severe, rapidly progressive, 
congestive heart failure, with the classical signs o f tachycardia, pulmonary edema and 
pleural effusion. Consequently, a large number of drugs are being developed in an effort 
to retain the antitumour therapeutic effects of the anthracyclines while reducing their 
toxicity.
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Figure 1.2.1 Structure of adriamycin and daunorubicin




The antracycline antibiotics consist of tetracycline ring structures with an unusual sugar, 
daunosamine, attached by glycosidic linkages. Cytotoxic agents o f this class all contain 
quinone and hydroquinone moieties on adjacent rings, permitting them to function as 
electron-accepting and -donating agents. The chemical structures o f adriamycin and 
daunorubicin differ only by a single hydroxyl group, on C l4  as shown in figure 1.2 .1. 
A number o f mechanisms have been attributed to the action of the anthracyclines, which, 
as yet, remain to be clarified. Most o f the available data relates to the cytotoxicity to 
binding o f the drugs to DNA, by intercalating between the base pairs. The 
anthracyclines bind tightly to DNA, with their cytotoxicity appearing to be associated 
with this binding, although, the pathway leading to cytotoxicity remains to be confirmed. 
Studies have shown that the anthracyclines may induce single and double strand breaks 
in DNA, by interacting with the enzyme , topoisomerase II (section 1.6.1). It has also 
been proposed that the anthracyclines may undergo metabolism of its quinone ring to 
form a semiquinone radical that reacts with oxygen to form superoxide O2- (Bachur et 
al., 1977). The superoxide is known to undergo several reactions that can ultimately 
lead to cell death, including oxidative damage to cell membranes and DNA. Adriamycin 
and related drugs also bind to cell membranes and thus may exert its toxicity through 
membrane related effects. It has also been demonstrated that adriamycin can cause cell 
death without actually being transported into the cells (Tritton and Yee, 1982; Vichhi 
and Tritton, 1983). However, the transport of anthracyclines into other cells is 
important for toxicity since decrease in the cellular accumulation of drug is an important 
mechanism relating to acquired multidrug resistance (section 1.4).
Adriamycin and daunorubicin are usually administered intravenously and are 
subsequently widely distributed in the body. There is rapid uptake of the drugs in the 
heart, kidney, liver, lungs and spleen. Plasma clearance of the drugs is triphasic with a 
initial half life of approximately 12 minutes, an intermediate half life of approximately
3.3 hours, attributable to metabolism of the drug in the liver, and a final phase of 
approximately 30 hours in which the drug is released from tissue binding sites. 
Although both daunorubicin and adriamycin are metabolised in the liver and excreted in 
the bile, there is notable differences in the metabolism o f the two compounds. 
Daunorubicin is metabolised primarily to daunorubicinol, while a lot of adriamycin is 
excreted unchanged and there appears to be multiple metabolites including adriamycinol 
which retains some cytotoxic activity.
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1.2.2 The Vinca Alkaloids
The vinca alkaloids are compounds derived from extracts o f the periwinkle plant, 
Catharantus roseus G.Don. Noble and coworkers (1958) observed granulocytopenia 
and bone-marrow suppression in rats treated with extracts o f the plant, which led to 
purification of an active alkaloid. Other investigations showed activity of alkaloid 
fractions against acute lymphocytic neoplasm in mice (Johnson et al., 1963; Johnson et 
al., 1968). Fractionation o f these extracts yielded four active dimeric alkaloids: 
vincristine, vinblastine, vinleurosine and vinrosidine. However, only two of these, 
vincristine and vinblastine, have to be clinically useful (Hodes et al., 1960; Costa et a l ., 
1962; Gialani et al., 1966; Nobel et al., 1967). Chemically, the vinca alkaloids are very 
similar. They are asymmetrical dimers. The structure of vincristine and vinblastine are 
shown in figure 1.2 .2 .
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Minor differences in the structure o f these large alkaloidal molecules result in notable 
differences in toxicity and antitumour activity of vincristine and vinblastine. Vinblastine 
is an important drug in combination chemotherapy (with cisplatin or bleomycin) of 
testicular cancer, while vincristine is the most clinically used drug for the treatment of 
childhood leukemia. Alterations in the structure of the molecules can result in decreased 




Figure 1.2.2 Structure of the vinca alkaloids
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acetylation of the hydroxyl groups. Both of these effects can result in the destruction of 
its antileukemic activity. Hydrogenation of the double bond or reductive formation of 
carbinols also reduces or destroys the activity of the alkaloids. Serious side effects have 
been associated with both vinblastine and vincristine. Vinblastine causes major toxicity 
to bone marrow and its use also leads to gastrointestinal disturbances, loss o f hair and 
neurotoxicity. The clinical toxicity of vincristine is mostly neurological with 
parenthesis, loss o f deep tendon reflexes, muscle weakness and neuritic pain. The 
observation that minor structural differences were associated with marked 
pharmacological changes has stimulated much research on the development of 
semisynthetic derivatives, maintaining the antitumour activity, with less toxicity. A 
number of compounds have been entered in clinical trials and include, vindesine 
(Cersosimo et al 1983), vinorelbine (Depierre et ah, 1991), vinzolidine (Khayat et ah,
1992) and vintriptol (Oosterkamp et ah, 1991).
The vinca alkaloids are cell-cycle-specific agents, which block mitosis with metaphase 
arrest. They act by binding to the protein tubulin, thus inhibiting its polymerization, to 
form microtubules. Disruption of the microtubules results in the inhibition of mitotic 
spindle formation and, thus, cell division is arrested in metaphase. In the absence of 
intact mitotic spindles the chromosomes may either disperse throughout the cytoplasm or 
occur in unusual groupings. The inability to segregate chromosomes correctly, 
ultimately leads to cell death. Resistance to the vinca alkaloids has been reported to be 
associated with decreased membrane transport and decreased accumulation o f the drug 
(Fojo et ah, 1987; Chao et ah, 1990; Shalinsky et ah, 1993). Resistance to drugs that 
cause microtubule depolymerization can also be due to alterations in tubulin structure. 
In some instances, these mutations affect drug binding to tubulin (Ling et ah, 1979) .
Vinca alkaloids, usually administered intravenously, are rapidly cleared from the blood. 
Their plasma clearance is described by triphasic curves, with an initial half life of o f 2-5 
minutes, an intermediate half life o f approximately 1.5 hours and a terminal half life of 
approximately 25 hours and 85 hours for vinblastine and vincristine respectively. 
Studies, using radiolabelled drugs, show that the vinca alkaloids are primarily eliminated 
by a combination o f hepatic metabolism and biliary excretion, with only a small amount 
o f parent drug and metabolites recovered in the urine (Owellan et ah, 1977).
5
1.2.3 The Epipodophyllotoxins
Podophyllotoxin is an extract derived from the mandrake plant Podophyllum peltatum. 
It is an antimitotic agent, acting by binding to tubulin at a site different to the vinca 
alkaloids and preventing the formation of microtubules (Pratt and Ruddon, 1979). The 
podophyllotoxins also act by inhibiting the nuclear enzyme topoisomerase II, causing 
DNA damage (Ross et al., 1984). Clinical studies were carried out in the early 1950s to 
evaluate the activity of extracts o f podophyllotoxin. However, it was found that the 
extracts had poor antitumour activity and were extremely toxic, thereby curtailing any 
clinical use. A number of semisynthetic derivatives o f podophyllotoxin have since been 
developed and two compounds in particular, VP 16 (etoposide) and VM-26 (tenoposide) 
have been demonstrated to display antitumour activity. In recent years VP 16 has been 
used increasingly for the treatment of various cancers including small-cell lung cancer, 
testicular cancer and lymphomas, leukaemia and Kaposis sarcoma (Issell et al., 1984; 
van Mannen et al., 1988). VM-26 has proved successful in the treatment o f a wider 
range of cancers, including refractory acute lymphoblastic leukaemias, neuroblastoma, 
small-cell lung cancer, refractory Hodgkins and non-Hodgkins lymphoma and central 
nervous system malignancies. The dose limiting toxicity o f the epipodophyllotoxins is to 
the bone marrow. Treatment with these agents can result in leukopenia and 
thrombocytopenia. Other side effects associated with epipodophyllotoxins include 
gastrointestinal toxicity and loss o f hair.
H
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Figure 1.2.3 Structure of the epipodophyllotoxins
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The epipodophyllotoxin family of drugs share a common multiringed structure, as shown 
in figure 1.2.3. This multiringed structure is referred to as epipodophyllotoxin, from 
which is derived the family name of these compounds. Although the podophyllotoxins 
bind tubulin, VP 16 and VM-26 appear to have very little effect on microtubulin 
assembly or degradation. The drugs can inhibit nucleoside incorporation into RNA and 
DNA and also cause single strand breaks in DNA. The major mechanism underlying the 
antitumour activity of VP 16 and VM-26 therefore appears to be mediated through 
topoisomerase II inhibition (van Mannen et al., 1988). Resistance to the 
epipodophyllotoxins is associated with decreased activity o f the topoisomerase enzyme 
and decreased accumulation of the drug due to the presence of the membrane based P- 
glycoprotein efflux pump.
VP 16 and VM-26 are usually administered by intravenous injection and their plasma 
clearance is based on a biphasic model, with initial and terminal half lives o f 3 hours and 
15 hours respectively. Following administration, approximately 60% of the drug is 
excreted unchanged while the remainder is excreted in the biliary tract.
1.2.4 Cisplatin and platinum analogues
The platinum complexes are a class o f cytotoxic agents, first discovered by Rosenberg 
and coworkers. Growth inhibition of E. coli was observed when an electric current was 
delivered to the bacteria, through platinum electrodes. The inhibitory effect on the 
bacteria was subsequently shown to be due to the formation of inorganic, platinum 
containing, compounds, in the presence of ammonium and chloride ions (Rosenberg et 
al., 1965; Rosenberg et al., 1967). The active compound was found to be cisplatin, 
which was shown to have cytotoxic activity against several tumours in mice (Rosenberg 
et al., 1969). Cisplatin is currently one of the most effective anticancer agents, used in 
the treatment of ovarian, testicular, head and neck, non-small cell lung and brain 
tumours (Rosenberg, 1985). The major toxicity caused by cisplatin is dose related 
nephrotoxicity, causing cumulative impairment of renal tubule function, which may 
ultimately lead to renal failure. Other side effects include, nausea, vomiting, 
myelosupression, tinnitus and loss o f hearing. The severity o f the side effects has led to 
the synthesis o f other platinum compounds, including carboplatin, iproplatin (Sessa et
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al., 1990), oxaliplatin (Extra et a l ., 1990) and tetraplatin (Burchenal et al., 1980). 
Carboplatin is now used frequently as a cytotoxic agent, in particular for the treatment 
o f ovarian and lung carcinomas (Gore et al., 1989; Raghaven et al., 1994). It has 
considerably less nephrotoxicity than cisplatin. However, its antitumour activity 
spectrum and cross resistance pattern has been demonstrated to be very similar to 
cisplatin (Calvert et al., 1982; Canetta et al., 1985; Gore et al., 1989).
Figure 1.2.4 Structure of cisplatin (a) and carboplatin (b)
Cisplatin and its analogues are inorganic water-soluble compounds, with relatively 
simple structural formulas, as presented in figure 1.2.4. They exert their toxicity by 
binding to base pairs o f DNA, resulting in the formation o f intrastrand cross-links and 
intrastrand adducts. This leads to the disruption and unwinding of the double helix of 
the DNA molecule. Therefore, the degree o f toxicity correlates with the number of cross 
links formed between the DNA strands (Fichtinger-Schepman et al., 1987). The leaving 
groups of the platinum complexes may be displaced directly by nucleophilic groups of 
DNA, or indirectly, after the leaving group is displaced by hydroxyl groups, through the 
reaction of the drug with water. Cisplatin and carboplatin bind to two sites on the DNA 
molecule, with the preferred sites for binding being the N-7 positions of guanine and 
adenine bases. Cellular resistance to cisplatin and cisplatin analogues has been 
associated with a number o f mechanisms. These include decreased DNA damage or 
increased DNA repair (Lai et al., 1988; Andrews and Howell, 1990; Johnson et al.,
1994), enhanced inactivation by the intracellular detoxication systems ie glutathione 
(Waxman, 1990) and metallothionein (Bahnson et al., 1991) and reduced drug 
accumulation (Gately and Howell, 1993).
The platinum complexes are usually injected intravenously and following administration 
are rapidly and tightly bound to proteins with more than 90% of the free drug lost in the 
first two hours. The plasma clearance for the free drug is described as a two 
compartmental model. However the clearance for total drug (free and bound) may be 
described as a three compartmental model with a prolonged terminal half life o f 58 to 73 
hours. High concentrations of platinum compounds are found in the kidney, liver, 
intestines and testes, but there is poor penetration into the central nervous system. The 
platinum compounds are excreted mainly via the urine and approximately 15-30% of the 
administered drug is excreted during the first 24 hours.
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1.3 P-glycoprotein in MDR
It was first reported by Kessel et al. (1968) that anthracycline-resistant cells accumulated 
less drug than the sensitive parental cell line. Further studies showed that cellular resistance 
to anticancer agents occurred in association with the activation of an energy dependent pump 
(Dano, 1973) which was subsequently identified by Juliano and Ling (1976) and was 
designated P-glycoprotein, P-gp or P-170 (figure 1.3). P-glycoprotein is an 170 kilodalton 
membrane associated protein of approximately 1280 amino acids in length. It contains 12 
transmembrane domains and consists of a short highly charged cytoplasmic domain followed 
by three membrane loops and a large cytoplasmic domain. This cytoplasmic domain is 
followed by three additional membrane loops and another large cytoplasmic domain (Gros 
et al., 1986a and Chen et al., 1986). ATP binding sites are found in both of the large 
cytoplasmic domains (Walker et al., 1982). Therefore, the P-170 molecule appears to 
comprise of two halves, each of similar structure. When the two halves are aligned a short 
segment called the linker region appears to bridge the amino and carboxy halves (Van der 
Bliek et al., 1987). The linker regions of P-glycoproteins that convey drug resistance 
contain sequences for c-AMP and c-GMP-dependent protein kinase phosphorylation sites, 
however these sequences are not present in P-glycoproteins that are not capable of 
conveying drug resistance (Hsu et al., 1989).
Clear homologies have been shown to exist between P-glycoprotein and several bacterial 
transport proteins, in particular with the conservation of the ATP binding domains. These 
proteins transport substances into bacterial cells and obtain their energy from the hydrolysis 
of ATP. Strong homology exists between P-glycoprotein and the Hly B protein of 
Escherichia coli, which exports a  hemolysin from haemolytic bacteria. The carboxy 
terminal of the Hly B protein contains the ATP binding site and is identical to P- 
glycoprotein in 50% of its amino acid sequence (Juranka et al., 1989). Other homologies 
of the P-glycoprotein include the protein ndvA, which is involved in /3-(l-2)glycan transport 
in Rhizobium Meliloti (Stansfield et al., 1988) and the leukotoxin secretion, Ikt, found in 
Pasteurella Haemolytica (Strathdee and Lo, 1989). In eukaryotes, one defined normal role 
for an MDR homologous gene has been found with the STE6 gene of yeast Saccaromyces 
cerevisiae (McGrath and Varshavsky, 1989). The product of this locus actively transports 
the a  factor mating pheromone in a manner analogous to the efflux of cytotoxic drugs by 
the P-glycoprotein and shares approximately 57% of the amino acid sequence with P-
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glycoprotein. The product of the cystic fibrosis gene also shows homology to P-gp 
(Riordan et al., 1989), the polypeptide contains two repeat motifs each of which consists 
of six membrane spanning domains and a hydrophilic region containing the ATP binding 
sites. The two halves display approximately 21% amino acid identity to each other and 
15% amino acid identity with the mammalian P-glycoproteins. A large highly charged 
cytoplasmic domain, termed the R group, contains a cluster of protein kinase A and protein 
kinase C phosphorylation sites and links the two halves of the molecule at the analogous 
position of the linker region in the P-glycoprotein.
P-glycoprotein is encoded by the mdr-1 gene which is located on the long arm of 
chromosome 7 at position21.1 and was sequenced and cloned in 1986 (Chen et al., 1986; 
Gros et al., 1986b). Two promoter sites for mdr gene expression have been identified, one 
upstream and one downstream (Ueda et al., 1987). The majority of resistant cells in vitro 
appear to utilize the downstream promoter, although both sites may become active (Kohno 
et al., 1989). The mdr gene is translated as a 140 kilodalton precursor protein which 
undergoes post translational modification over a two to four hour period to form the 170 
kDa P-glycoprotein. This process requires enzymatic phosphorylation by protein kinase C 
to achieve the active form (Anderson et al., 1991). The mdr gene was first isolated from 
hamsters which were shown to have three homologes of the gene (Endicott et al., 1987; Ng 
et al., 1989). The mouse mdr gene family has also been shown to have three classes 
(Raymond et al., 1990; Gros et al., 1986b). While other species can display up to six mdr 
gene homologues, humans only have two classes (Chen et a l., 1986; Rononson et al. , 1986; 
Van der Bliek et al., 1988; Chin et al., 1989; Chen et al., 1990). Table 1.1 represents the 
human, hamster and mouse mdr gene families. (Two terminologies are used in the literature 
for the mouse mdr gene family).
Class Human Mouse Hamster









Table 1.1 Classification and nomenclature of the mammalian P-glycoproteins
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In hamsters class I and II only are thought to be responsible for drug resistance. Only class 
I (mdrl) is believed to convey drug resistance in humans. This has been verified by 
transfection of the mdr genes into drug sensitive cells resulting in the establishment of 
multidrug resistant cell lines. Gros et al. (1986a) have shown that transfection of full length 
mdrl cDNA in the drug sensitive hamster cell line LZ, confered a complete multidrug 
resistant phenotype in the cells. In contrast Van der Bliek et al. (1988) demonstrated that 
transfection of the mdr3 gene did not confer the resistant phenotype.
A variety of physical and chemical agents have been demonstrated to affect the expression 
of the mdr gene, predominantly through increased transcription of the gene. The 
differentiating agents dimethyl sulphoxide (DMSO), sodium butyrate and dimethyl 
formamide have all been shown to increase both mdrl mRNA and P-glycoprotein levels in 
a number of colon carcinoma cell lines (including the cell lines KB, SW-620 and HCT-15) 
as measured by in situ hybridization and immunoblotting (Mickley et al., 1989). The renal 
carcinoma cell line, HTB 46, demonstrated a 7 to 8-fold increase in mdrl mRNA levels in 
response to heat shock, ethanol, sodium arsenite and cadmium chloride (Chin et al., 1990). 
These findings were consistent with a role for P-glycoprotein as a stress inducible gene 
product following environmental insults. Phorbol esters, which increase the activity of 
protein kinase C have also been shown to increase mdr expression. Bates et al. (1989) have 
demonstrated the overexpression of mdrl gene in human neuroblastoma cells following 
exposure to retonic acid. The HIV virus can also increase the expression of P-glycoprotein 
of infected cells (Kohno et al., 1989; Gupta et al., 1990).
1.3.1 P-glycoprotein in normal tissues
To date, the physiological role of P-glycoprotein is unknown. Studies of nonmalignant 
tissues using immunohistochemical and in situ hybridization techniques have revealed that 
many normal tissues express high amounts of P-glycoprotein. The expression of P- 
glycoprotein occurs primarily in specialised epithelial cells with secretory or excretory 
functions. Generally the highest levels of P-glycoprotein have been found in the secretory 
cells of the lumina of the proximal tubules in the kidney, in the regions of the zona 
fasciculata and reticulata of the adrenal cortex, on the luminal surface of biliary hepatocytes 
and the mucosal surface of epithelial cells of the small and large intestine (Thiebaut et al. ,
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1987). Strong expression has also been demonstrated in endothelial cells of capillary blood 
vessels at blood tissue barrier sites, primarily capillaries of the central nervous system, testis 
and dermis (Thiebaut et a l., 1989). P-glycoprotein has also been detected in placenta tissue 
(Sugawara et al., 1988) and circulating lymphocytes (Chaudhary et al., 1992). Although 
the actual substrate of P-glycoprotein in these normal tissues is unknown, its presence in 
specialised tissues suggests that P-glycoprotein may have a protective function in the cells 
by actively effluxing toxic substances into the bloodstream, urine or bile. It has also been 
proposed that P-glycoprotein may act as a cellular transporter of endogenous substances 
including corticosteroids and bile (Van Kalken et al., 1993).
1.3.2 P-glycoprotein in human tumours
Numerous studies have been preformed to determine the significance of mdrl expression 
in clinical tumour samples. Both measurement of RNA levels by in-situ hybridization and 
RT-PCR and immunocytochemistry have been employed. In general, tumours derived from 
tissue that naturally express high levels of P-glycoprotein show overexpression of the mdr 
gene. An extensive study on mdrl mRNA levels in over 400 human cancers demonstrated 
elevated expression of the mdrl gene in colon cancer, renal cell carcinoma, adrenotical 
carcinoma, hepatoma and pheochromoctoma, all of which naturally express mdr (Goldstein 
et al., 1989). Messagner RNA levels were quantified using slot blot analysis comparing 
tumour samples to known drug sensitive (KB-3-1) and resistant (KB-8-5) cells. High P- 
glycoprotein expression has also been demonstrated in endometrial and gastric cancers 
(Schneider et a l., 1993; Robey-Cafferty et al., 1991). Overexpression of the mdr gene has 
also been reported in leukemias, lymphomas and some other cancers derived from tissues 
that do not normally express the gene (Rischin and ling, 1993; Goasguen et al., 1993). In 
a study on samples from patients with lymphoblastic leukaemia, 36 out of 104 samples 
screened were positive for P-glycoprotein expression (Sauerberg et al., 1994). Several 
tumours have been demonstrated to express low levels of mdrl and are referred to as drug 
sensitive, including cancer of the ovary and breast and Wilm’s tumour. Dixon and 
coworkers (1992) reported positive immunohistochemical staining with the monoclonal 
antibody C219 in a number of breast cancer samples. Veneroni et al. (1994) also 
demonstrated P-glycoprotein expression in breast cancer patients. In the same study, a 
number of ovarian samples were also found to be positive for P-glycoprotein expression.
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However, other tumours also have low levels of the mdr gene but are drug resistant, such 
as adenocarcinomas of the lung and non-small cell lung carcinoma thus suggesting that other 
mechanisms of resistance are involved.
Many reports have indicated that overexpression of MDR is found more often in samples 
obtained from patients following treatment with chemotherapeutic agents, ie acquired drug 
resistance. In one study preformed on human soft tissue sarcoma samples, P-glycoprotein 
expression was found to be greater in samples obtained from patients following treatment 
with doxorubicin than in samples obtained from untreated patients (Toffoli et al., 1992). 
Increased expression has also been noted in drug resistant leukemias, myelomas, ovarian 
cancers, breast cancers and neuroblastomas (Bourhis et al., 1989; Dalton et al., 1989a; 
Dalton et al., 1989b; Goldstein et al., 1989). The majority of studies so far have included 
relatively too few patients and consequently the clinical significance of MDR expression has 
been difficult to clarify. The lack of uniform testing for P-gp expression and the possible 
contamination by P-gp from normal tissue also makes it difficult to assess the contribution 
of P-glycoprotein to the clinical outcome. Findings from one group showed a significant 
relation between P-glycoprotein expression and poor survival in samples from patients with 
neuroblastoma, while another group using the same monoclonal antibody reported that 
positive staining of the neuroblastoma samples was restricted to the normal cells in the 
tumour and neuroblastoma cells were generally P-glycoprotein negative (Bates et al., 1991; 
Chan et al., 1991; Favrot et al., 1991).
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Figure 1.3 Model o f the MDR Transporter
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1.4 P-glycoprotein in MDR cell lines defective in the accumulation of drug
P-glycoprotein expression has been studied in numerous MDR cell lines selected with 
various anticancer agents, including adriamycin, daunorubicin, vincristine, vinblastine, 
VP16, colchicine and taxol. It has frequently been demonstrated that the overexpression 
of P-glycoprotein in MDR cell lines is associated with a decrease in cellular accumulation 
of the selecting agent and other MDR related drugs. P-glycoprotein acts as an ATP- 
dependent efflux pump for a variety of cytotoxic agents, in this way reducing the cellular 
concentration of the drug. The majority of early studies on the accumulation of anticancer 
agents were carried out using rodent cell lines and Ehrlich ascites tumour cells. Most of 
the literature describes experiments on the uptake of the anthracyclines, in particular 
adriamycin and daunorubicin, as well as the vinca alkaloids. Various techniques have been 
employed to determine the cellular accumulation, retention and efflux of drugs including 
spectrofluorimetry, radiolabel studies, radioautography and more recently HPLC and flow 
cytometry studies. Decreased levels of anthracycline accumulation in resistant cells were 
first observed in resistant variants of Chinese hamster ovary cells (Biedler and Riehm, 1969; 
Biedler and Riehm, 1970; Riehm and Biedler, 1971), in murine leukaemic cell lines 
(Chervinsky and Wang, 1972; Inaba and Johnson, 1978) and in Ehrlich ascitic cells 
(Skovsgaard, 1977; Skovsgaard, 1978a). Studies on the uptake of the vinca alkaloids have 
also revealed a reduction in the cellular accumulation of the drug in resistant variants, 
relative to the sensitive cells. Skovsgaard (1978b) demonstrated decreased cellular 
accumulation of the vinca alkaloid, vincristine, in the vincristine resistant cell line, EHR 
2/V C R +, when compared to the parental wild type cells. A decrease in vincristine uptake 
was also observed in the vincristine resistant cell line, P388 (Tsurno et al., 1981) and in 
a number of murine solid tumour Lewis Lung carcinoma cell lines resistant to vincristine 
(Tsuruo et al., 1983).
Initial observations led to the suggestion that the reduction in drug accumulation in resistant 
cells was primarily due to differences in the cell membranes. It was postulated that 
alterations in the membrane of resistant cells resulted in decreased permeability and thus a 
reduction in the cellular accumulation of the drug. Studies also showed that intracellular 
pH has a marked effect on the net accumulation of the drugs. The pK, of the anthracyclines 
was found to be 8.15-8.45, suggesting that the uptake of the anthracyclines was determined 
by the permeability of the cell membrane to the un-ionized form of the molecule
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(Skovsgaard, 1977). However, indications of an active outward transport of anthracyclines 
was obtained from studies by Dano in 1973, which demonstrated that the release of 
daunorubicin from resistant Ehrlich ascites tumour cells was reduced by metabolic 
inhibitors. Further evidence supporting an active outward efflux model was later reported 
by the same laboratory, from studies on the transport of the anthracyclines, adriamycin, 
daunorubicin and rubidazone in Ehrlich ascitic cells. The results obtained showed that 
treatment of the ascitic cells with the metabolic inhibitor, sodium azide, significantly 
enhanced the cellular accumulation of the three drugs in the resistant cells. A decrease in 
the cellular release of the drugs was also observed (Skovgaard, 1977). Inaba and coworkers 
(1979) demonstrated the presence of an active drug efflux mechanism in the murine 
leukaemia cell line, P388. Earlier reports had demonstrated reduced uptake of adriamycin 
and daunorubicin in anthracycline resistant variants of the P388 cells, when compared to 
the parental wild type cells (Inaba and Johnson, 1978) while these studies showed that the 
accumulation defect observed in the resistant cells could be abolished by the addition of 
metabolic inhibitors, including 2,4-dinitrophenol, sodium azide and valinomycin. These 
metabolic inhibitors enhanced daunorubicin accumulation in both sensitive and resistant 
cells, although daunorubicin uptake was enhanced to a much greater extent in the resistant 
P388 subline.
Initial drug accumulation studies on human epithelial cell lines were carried out by Fojo and 
coworkers in the mid 1980s. Detailed studies on the uptake, retention and efflux of six 
MDR related drugs in four resistant variant of the human colon carcinoma cell line, KB, 
were reported (Fojo et al., 1985). The resistant mutants were selected in increasing 
concentrations of the anticancer drug, colchicine, and were found to be cross-resistant to 
adriamycin, vincristine, vinblastine and actinomycin A. Drug accumulation in the resistant 
cells was found to decrease with increasing levels of resistance and this relationship was 
most clearly observed with colchicine, vincristine, vinblastine and adriamycin, and to a 
lesser extent with actinomycin A. The accumulation of dexamethasone, an agent to which 
all lines were equally sensitive, was similar for the parental cell line and all four resistant 
variants. When drug efflux was investigated, it was found that a greater percentage of the 
drug was released in the more resistant variants. The rate of drug efflux was also found 
to be substantially higher in the resistant cells. A number of studies were also carried out 
on drug accumulation in human glioma cells. Merry et al. (1986) investigated the transport 
of adriamycin in three human glioma cell lines with different inherent sensitivities to
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adriamycin while Kaba et al. (1985) studied the uptake and intracellular accumulation of 
vincristine in a number of glioblastoma derived cell lines.
1.4.1 Circumvention of MDR by interaction with P-glycoprotein
Several studies have since been published investigating the transport of anticancer agents 
in numerous human multidrug resistant cell lines. In general, a decrease in drug 
accumulation and an increase in the rate of drug efflux was observed in the resistant variants 
when compared to the sensitive parental cell lines. Many of the studies specifically 
investigated the effect of various compounds on drug accumulation and efflux in resistant 
cell lines. Several compounds belonging to various pharmacological families have been 
demonstrated to reverse the MDR phenotype in vitro (Steward and Evans, 1989; Ford and 
Hait, 1990). Among these compounds are a number of the calcium channel blockers, 
including verapamil and nifedepine, immunosuppressive agents such as cyclosporin A (and 
its more potent analogue, SDZ PSC 833) and calmodulin inhibitors, including the 
phenothiazines, trifluoroperazine and chloropromazine. These agents may modulate 
resistance by interacting with the chemotherapeutic drug binding sites of the P-glycoprotein 
molecule thereby preventing the drug from binding to the P-glycoprotein and being extruded 
from the cell.
1.4.1.1 Calcium Antagonists
Although a number of calcium channel antagonists have been demonstrated to enhance drug 
accumulation in MDR cell lines, verapamil has been the most widely studied calcium 
channel blocker in the area of MDR circumvention. Many reports have suggested that 
calcium channel antagonists reverse resistance to most chemotherapeutic agents by inhibiting 
extrusion of the drug and consequently increasing the net accumulation of the drug. The 
exact mechanism of action of verapamil is unknown, although there is substantial evidence 
to suggest that the effect is not directly related to either alterations in calcium flux (Ramu 
et al., 1984; Kessel and Wilberding, 1984; Robinson et al. , 1985; Naito and Tsuruo, 1989) 
or to a direct effect on calcium channels (Robert et al., 1987). Photoaffinity labelling 
studies have shown that verapamil binds directly to the P-glycoprotein molecule (Safa et al.,
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1988) but an indirect role via other effects on cell membranes has not yet been ruled out. 
Early studies on verapamil showed that non-toxic doses of the drug enhanced the 
cytotoxicity of vincristine and vinblastine in murine P388 leukaemia and its vincristine 
resistant subline P388/VCR. An increase in vincristine accumulation of approximately 10- 
fold was observed in the P388/VCR cells following treatment with verapamil, with the 
cellular concentration of vincristine comparable to the level observed in the parental cells 
(Tsuruo et al., 1981). Studies have consistently shown that verapamil is an effective agent 
at reversing P-glycoprotein mediated resistance. Research into the effect of verapamil on 
drug accumulation in MDR cell lines has been extensively carried out and includes studies 
on adriamycin resistant and vincristine resistant variants of the murine leukaemia cell line, 
P388 (Tsuruo et al., 1981; Tsuruo et al., 1982; Ramu etal., 1984; Kessel and Wilberding, 
1984; Kessel and Wilberding, 1985), Ehrlich ascitic tumour cells (Friche et al., 1987; 
Sehested et al., 1990), rat hepatocyte primary culture cells (Le Bot et al., 1994), human 
glioma cell lines (Kaba et al., 1985; Merry et al., 1986), resistant variants of the human 
breast cell line, MCF-7 (Fine et al., 1988; Ford and Hait., 1990; Julia et al., 1994), human 
T-lymphoblastoid cell lines (Boer et al., 1994), and human lung cancer cell lines 
(Twentyman et al., 1986).
The antiarrhythmic agent, quinidine, has also been shown to reverse chemotherapy induced 
resistance in rodent and human cells. A number of reports have demonstrated an increase 
in drug accumulation, following treatment with non-toxic levels of the drug. Klohs and 
coworkers (1986) illustrated that the addition of quinidine resulted in a marked increase in 
adriamycin accumulation in resistant P388 murine leukaemia cells. Studies by Tsuruo etal. 
(1984) also demonstrated enhanced cellular accumulation of adriamycin and vincristine in 
resistant variants of the P388 cell line. These studies also showed increased drug 
accumulation in adriamycin resistant K562 leukaemia cells following treatment with 
quinidine. Quinidine has also been shown to enhance drug accumulation in human KB cells 
(Willingham et al., 1986) and in lymphoblastoid cell lines (Boer et al., 1994). Other 
calcium channel antagonists that have proven effective at enhancing the cellular retention 
of drugs include the quinoxaline derivative, caroverine (Tsuruo et al., 1982), nifedipine 
(Kessel and Wilberding, 1984; Tsuruo et al., 1984; Onada et al., 1989) and nicardipine 
(Tsuruo et al., 1986).
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1.4.1.2 Calmodulin Inhibitors
A number of studies have shown that treatment with various calmodulin inhibitors, 
including trifluoroperazine, chloropromazine and fluxpentixol resulted in a decrease in 
resistance in MDR cell lines. The decrease in resistance appeared to be associated with 
enhanced cellular accumulation of the drug. The specific mechanism of action of 
calmodulin inhibitors in enhancing drug accumulation in resistant cells is not clear. 
Calmodulin has a number of complex roles in cell physiology; hence, calmodulin inhibitors 
could potentially augment chemotherapy cytotoxicity in a variety of ways. Calmodulin has 
a high affinity for ionized calcium, and is an activator of enzymes regulated by calcium. 
It also acts as a receptor for drugs, stimulates phospholipase A (which hydrolyzes 
membranous phospholipids, thus increasing membrane permeability and calcium flux), has 
been shown to alter intracellular binding of vincristine and adriamycin and appears to play 
a role in DNA repair pathways (Helson, 1984; Hait and Lazo, 1986). A number of studies 
have been carried out to investigate the effectiveness of calmodulin inhibitors as 
circumvention agents. Non-toxic concentrations of the antipsychotic agent, 
trifluoroperazine, were shown to cause a 5-fold increase in vincristine accumulation and a 
2-fold increase in adriamycin accumulation in P388/VCR and P388/ADM cells respectively 
(Tsuruo et al., 1982). Studies have also demonstrated a 2-fold increase in daunorubicin 
accumulation in P388/DOX cells following treatment with this agent (Ganapathi et al.,
1984). Studies by Kessel and Wilberding (1985) have also shown an increase in drug 
accumulation in resistant variants of the P388 cell line, when treated with trifluoroperazine. 
A range of other calmodulin inhibitors have also proven to be effective circumvention 
agents, including thioridazine (Akiyama et al. , 1986), chloropromazine (Ford et al., 1989) 
and cis- and trans-fluxpentixol (Ford et al., 1989; Ford and Hait, 1990).
1.4.1.3 Cyclosporins
Cyclosporin A, an antifungal undecapeptide immunosuppressive agent, has been reported 
to act as a chemosensitiser in murine and human MDR cell lines. Studies have also shown 
this agent to be more effective than verapamil at reversing MDR in a number of cell lines 
(Coley et al., 1989; Le Bot et al., 1994). The mechanism of action of cyclosporin A is 
unclear, although, as is the case with the calcium channel antagonists, it is thought to
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modulate MDR by competitively interacting with drug binding sites of P-glycoprotein. 
Reports have shown that cyclosporin A effectively inhibits the binding of anticancer drugs 
to P-glycoprotein and consequently has attracted a great deal of attention, as an effective 
P-glycoprotein modulator (Slater et al., 1986; Twentyman et al., 1988). A photoreactive 
analogue of cyclosporin A has been shown to label P-glycoprotein in living cells. However, 
this labelling was inhibited by cyclosporin A, cyclosporin H and verapamil, suggesting 
competition for common binding sites (Foxwell et al ., 1989). Binding studies, using 
membrane vesicles of MDR cells, demonstrated that cyclosporin A competitively interacted 
with a common binding site of P-glycoprotein, to which vinca alkaloids and verapamil also 
bind (Tamai and Safa, 1990). A study by Saeki et al. (1993) using LLC-PK! cells derived 
from epithelial cells of porcine kidney tubules, illustrated that cyclosporin A was also a 
substrate for the P-glycoprotein molecule and consequently that the cellular accumulation 
of cyclosporin A was reduced by the pumping action of P-glycoprotein. Studies by Slater 
et al. (1986) demonstrated that cyclosporin A could reverse daunorubicin resistance in 
Ehrlich ascites carcinoma cells. Treatment with cyclosporin A was also shown to decrease 
vincristine resistance in human lung cancer cells (Twentyman et al., 1987). Cyclosporin 
A has also been found to be very effective at enhancing drug accumulation in Chinese 
hamster ovary cells (Chambers et al., 1989), mouse mammary EMT6 tumour cells (Coley 
et al., 1989; Twentyman and Wright, 1991), murine hepatoma 129 cells (Meador et al.,
1987), rat hepatocytes (Le Bot et al., 1994) and in the human CCRF-CEM T- 
lymphoblastoid cell line (Boer et al., 1994). Enhanced drug accumulation has also been 
reported in a number of sensitive cell lines, following treatment with cyclosporin A 
(Chambers et al., 1989; Gaveriaux et al., 1989) although its effectiveness is greater in 
resistant cell lines. Other cyclosporins have also been investigated for their ability to 
circumvent resistance. Although cyclosporin C, cyclosporin G and cyclosporin H have all 
been found to alter drug accumulation, the activity of these agents was found to be 
substantially lower than cyclosporin A, even at elevated concentrations of drug (Twentyman 
etal., 1987).
A non-immunosuppressive cyclosporin D analogue, SDZ PSC 833, has been shown to 
reverse drug resistance in a number of MDR cell lines at concentrations lower than that 
used for verapamil or cyclosporin A (Gaveriaux et al., 1991). Using a short term retention 
assay SDZ PSC 833 was found to enhance intracellular daunorubicin accumulation in 
murine monocytic leukaemia MDR cells. Full restoration of daunorubicin retention was
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obtained at a substantially lower concentration of SDZ PSC 833 than with cyclosporin A. 
Verapamil could only partially restore the accumulation defect in this cell line (Boesch et 
al., 1991). SDZ PSC 833 has also been shown to induce a stronger and more stable 
inhibition of P-glycoprotein than other resistance modifying agents, including verapamil and 
cyclosporin A (Boesch and Loor, 1994).
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1.5 Non-P-glycoprotein MDR in cell lines defective in the cellular accumulation 
of drug
Over the past number of years evidence has indicated that cell lines treated with a cytotoxic 
agent can develop multiple drug resistance, resulting from reduced drug accumulation, 
despite the absence of detectable levels of the P-glycoprotein efflux pump. Cells exhibiting 
a drug accumulation defect and which subsequently were shown to be negative for P- 
glycoprotein expression were first described in the mid 1980s. In 1985, Bhalla and 
coworkers isolated an adriamycin resistant variant of the human promyelocytic leukaemia 
cell line, HL60, that demonstrated a 2-fold decrease in adriamycin accumulation relative to 
the sensitive cells. While SDS gel electrophoresis revealed no detectable levels of P- 
glycoprotein, two prominent glycoproteins were detected in the resistant HL60/AR cells, 
with molecular weights of approximately 110 and 160 kilodaltons respectively (Bhalla et a l., 
1985). Studies carried out on the HL60/ADR resistant variant of the HL60 cells also 
revealed reduced adriamycin accumulation in the cells. Drug accumulation studies 
illustrated that uptake of adriamycin or daunorubicin was essentially the same throughout 
a 60 minute incubation period in the sensitive and resistant cells. However, after this time 
period, the level of drug in the resistant cells began to decline, whereas in the sensitive cell 
line drug levels continued to increase (March et al. , 1986). A reduction in the cellular drug 
concentration was also observed in a vincristine variant of the parental HL60 cells. 
However, in contrast to the HL60/AR and HL60/ADR resistant variants, overexpression 
of P-glycoprotein was detected in this cell line by the C219 monoclonal antibody (McGrath 
and Center, 1988).
Twentyman et al. (1986) established an adriamycin resistant variant of the human large cell 
lung cancer cell line, COR-L23, which displayed a reduction in drug accumulation relative 
to the parental cells. Further studies revealed that the resistant variant did not overexpress 
the mdrl gene, as determined by Northern blotting, or its product P-glycoprotein, as 
determined by Western blotting and immunocytochemistry with the C219 antibody. The 
resistant cells did, however, show reduced expression of the EGF receptor (Kartner et al., 
1985; Reeve et al., 1990). Studies by Barrand et al. (1993) later demonstrated that the 
COR-L23 resistant line overexpressed a membrane protein slightly larger in size than P- 
glycoprotein. This 190 kDa protein contained a short amino acid sequence, antigenically 
similar to a region of P-glycoprotein close to one of its nucleotide binding sites. Further
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analysis of the two HL60 adriamycin resistant variants and the COR-L23/R cells 
demonstrated that all three cell lines contained an energy dependent efflux mechanism 
distinct from P-glycoprotein that probably contributed to the reduced intracellular drug 
levels observed in these cells (Hindenburg et al., 1989; Coley et al., 1991). Adriamycin 
resistant variants of the human small cell carcinoma cell line, GLC4 and the human non­
small cell lung cancer cell line, SW1573/50 were also shown to exhibit decreased 
intracellular adriamycin levels (Zijlstra et al., 1987; Keizer et al., 1989). Initial results 
suggested that the resistant SW1573 cells were positive for P-glycoprotein. Further studies, 
however, revealed that while P-glycoprotein expression was not detected during the initial 
selection stages (SW1573/2R), the protein was expressed at a later stage (Kuiper et al.,
1990). No detectable levels of P-glycoprotein were observed in the GLC4 resistant line, 
although altered levels of topoisomerase II were observed in both the GLC4/ADR and 
SW1573/2R resistant lines, which may have contributed to the MDR phenotype in these 
cells. Additional studies by Eijdems and coworkers (1992), using somatic fusion 
experiments, demonstrated that genetic lesions contributed to the reduced drug accumulation 
and altered topoisomerase II levels in the SW1573/2R cells.
Slovak et al. (1988) isolated an adriamycin resistant subline of the human fibrosarcoma cell 
line, HT1080, which also exhibited a reduction in drug accumulation in the absence of P- 
glycoprotein. Drug efflux studies revealed that the retention of drug in the resistant cell line 
was substantially less than in the sensitive cell line, thereby suggesting that the resistance 
observed in the cell line may be related to an alternative transport mechanism, capable of 
altering drug efflux. A number of studies have also been carried out on resistant variants 
of the human breast carcinoma cell line, MCF-7. Taylor et al. (1991) studied drug 
accumulation in two resistant variants. The MCF-7/DOX and MCF-7/Mitox were 
established by exposure to adriamycin and mitoxantrone respectively. The adriamycin 
resistant cells were shown to display a classic multidrug resistance phenotype, with 
overexpression of P-glycoprotein, decreased drug accumulation relative to the parental line 
and reversal of resistance by verapamil. The mitoxantrone resistant cells also displayed 
resistance to multiple drugs, but in contrast to the MCF-7/DOX cells, did not overexpress 
P-glycoprotein, as determined by immunoblotting and RNA blot analysis. Net drug 
accumulation was decreased in the MCF-7/Mitox cells, although no selective modulation 
of drug accumulation was observed by the addition of verapamil (Taylor et al., 1991). 
Nakagawa and coworkers (1992) also established a mitoxantrone resistant MCF-7 variant,
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MCF-7/MX, exhibiting approximately 4000-fold resistance to mitoxantrone. Decreased 
drug accumulation was demonstrated in this resistant variant in the absence of P- 
glycoprotein overexpression. The accumulation defect was reversed in the presence of the 
metabolic inhibitors, sodium azide and 2-dinitrophenol, suggesting the involvement of an 
an energy dependent process distinct from P-glycoprotein.
A vincristine resistant variant of the human non-small cell lung cancer, PC-9, was 
established which was also defective in the cellular accumulation of drug. DNA Southern 
and RNA Northern blot hybridization analysis revealed that the PC-9/VCR cell line did not 
contain amplified mdr genes or overexpress P-glycoprotein. Further studies illustrated that 
the addition of ascorbic acid enhanced drug uptake and partially reversed the resistance 
observed in this cell line. These findings suggested the presence of an alternative, ascorbic 
acid sensitive, drug uptake mechanism which may be associated with the non-P-glycoprotein 
resistance observed in the cells (Chiang et al., 1994). A number of leukaemia blast cell 
lysates from patients with acute myeloid leukaemia have recently been described. The 
samples were analysed for P-glycoprotein expression, using the C219 monoclonal antibody, 
and all were found to be negative. Out of the 46 patient samples studied, 16 were shown 
to have reduced daunorubicin accumulation compared with the negative marrow samples. 
These samples were also shown to express a 95 kilodalton membrane protein as detected 
by Western blot analysis. Although the role of this protein is unknown, it may function as 
an efflux transporter, representing an alternative mechanism associated with anthracycline 
resistance in acute myeloid leukaemia (Doyle et al., 1995). Overexpression of this p95 
protein had previously been detected in two human small cell lung cancer cell lines, NCL- 
H1688 and NCL-H660, which displayed intrinsic multidrug resistance. These cell lines did 
not overexpress P-glycoprotein and exhibited an atypical pattern of resistance (Doyle et al.,
1993).
1.5.1 Protein changes in non-P-glycoprotein MDR
Although protein changes have been detected in a number of non-P-glycoprotein MDR cell 
lines, the exact role which these alterations play in the resistant phenotype has yet to be 
clarified. Extensive studies have been carried out to investigate cellular changes occurring 
in HL60 cells isolated for resistance to adriamycin. Studies in the mid 1980s detected a 160
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kDa membrane protein in the HL60/AR resistant variant which was absent in the sensitive 
cell line (Bhalla et a l., 1985). March et al. (1986) also demonstrated the presence of a 150 
kDa membrane associated protein in the HL60/ADR resistant variant. When membrane 
fractions were isolated from the HL60/ADR cells and incubated with a protein 
phosphorylation system containing 32P-ATP, two proteins with molecular weights of 120 and 
150 kDa respectively were found to be phosphorylated (March et al., 1986). Additional 
studies by March and Center (1987) demonstrated that the level of phosphorylation of the 
150 kDa protein, which was present in resistant cells, increased with increasing levels of 
resistance. However, they also found no significant difference in the levels of the protein 
in the sensitive and resistant cells, suggesting that the adriamycin resistance in the 
HL60/ADR cells may be related to a modified form of the protein present in the sensitive 
cells.
Another cellular protein which has been shown to be overexpressed in non-P-glycoprotein 
MDR cell lines and essentially absent in drug sensitive cells is a 190 kDa protein (pl90). 
Overexpression of this protein has been demonstrated in a number of MDR cell lines 
including, HL60/ADR cells, COR-L23/R cells and GLC4/R cells (McGrath et al., 1989; 
Marquardt et al., 1990; Barrand et al., 1992; Barrand et al., 1993). The pl90 protein 
appears to be localised primarily in the endoplasmic reticulum and is capable of binding 
ATP (Marquardt et al., 1990). The contribution of pl90 to MDR is unknown, although 
Barrand et al. (1992) demonstrated that antiserum (ASP-14) raised against a synthetic 
peptide of P-glycoprotein, also detected the p i90 protein present in non-P-glycoprotein cell 
lines. The peptide sequence occurred in a region of the P-glycoprotein molecule close to 
the nucleotide binding site near the C-terminal. This sequence was found to be highly 
conserved amongst ATPase proteins throughout the animal kingdom (Riordan et a l., 1989). 
Very little is actually known about the amino acid sequence or the molecular structure of 
pl90, although the similarity of its known region with regions found in ATP-dependent 
transport proteins suggests that it may also be a pump and subsequently may be involved 
either directly or indirectly with drug efflux.
Scheper et al. (1993) have detected overexpression of a 110 kDa protein (lung resistance 
protein, p i 10) in non-P-glycoprotein MDR cell lines. Initial studies were carried out on 
the human non-small cell lung cancer cell line, SW1573, and its adriamycin resistant 
variant, SW1573/2R. Using a p i 10 specific monoclonal antibody (LRP-56), strong
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immunoreactivity was observed in the SW1573/2R cells, compared to the parental cell line. 
The p i 10 protein did not appear to be localised in the plasma membrane, since staining of 
the LRP-56 was detected primarily in the outer cytoplasmic zone, in a granular fashion 
suggesting that it reacted with molecules closely associated with endoplasmic 
reticular/lysosomal structures. A number of other non-P-glycoprotein MDR cell lines were 
also studied for p i 10 expression, including the GLC4/ADR small cell ling cancer cell line, 
the MCF-7/Mitox human breast cell line, the fibrosarcoma cell line, HT1080/DR4 and the 
myeloma cell line, 8226/MR40. Positive immunoreactivity with LRP-56 was observed in 
each of the resistant cell lines with cytoplasmic granular staining similar to the SW1573/2R 
cell line. Earlier studies, by SDS polyacrylamide gel electrophoresis, also demonstrated the 
expression of a 110 kDa glycoprotein in HL60/AR cells not detected in the sensitive cells 
(Bhalla et al., 1985).
A polyclonal antibody, ASP-14, has been used to detect membrane protein changes inMCF- 
7 variants. Western blot analysis of the parental cells, the adriamycin resistant variant 
MCF-7/Adr and the mitoxantrone resistant variant MCF-7/MX illustrated that, as expected, 
the antibody recognized the 180 kDa P-glycoprotein present in the MCF-7/Adr cells. There 
was, however, no cross reactivity of the antibody with high molecular weight (160-180 
kDa) proteins in either the parental or MCF-7/MX cells. In addition, the antibody was 
found to cross react with two proteins of molecular weights 42 kDa and 85 kDa respectively 
in the MCF-7/MX variant that were absent in the sensitive cells. These two proteins may 
contain sequence homology with P-glycoprotein and thus contribute to the enhanced drug 
efflux system of the MCF-7/MX variant (Nakagawa et al., 1992).
Studies by Mirski and Cole (1991) reported the expression of a 36 kDa protein in the 
H69/AR non-P-glycoprotein MDR cell line, which was later identified as a member of the 
annexin/lipocortin family of Ca2+ and phospholipid binding proteins. This phosphorylated 
protein was found to be membrane associated but not present on the external surface of the 
H69/AR cells. Immunoprécipitation studies showed that 5- to 6-fold more of the 36 kDa 
antigen was immunoprecipitated from the translation products of H69/AR mRNA, relative 
to the parental H69 cells (Cole et al., 1992a). Studies by Cole et al. (1992b) also 
demonstrated that the H69/AR cells overexpressed a multidrug resistant related protein 
(MRP) which had sequence homology with P-glycoprotein and other proteins which may 
be involved in the drug transport process. Although the H69/AR cells are not defective in
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drug accumulation, it has been suggested that the MRP protein may sequester drug into 
certain organelles and, thus, away from potential target sites (Cole et al., 1991). Studies 
have also suggested that MRP mRNA may encode the 190 kDa protein detected in several 
non-P-glycoprotein cell lines (Twentyman et al., 1994). This protein has also been 
demonstrated to confer the MDR phenotype in cells transfected with the MRP gene (Grant 
et al., 1994). Chen and coworkers (1990) described a 95 kDa protein which was 
overexpressed in an adriamycin resistant MCF-7 cell line but was almost undetectable in the 
parental line. Polyclonal antibodies, raised against the protein, demonstrated a positive 
relation between the level of p95 expression and cellular adriamycin resistance. 
Immunohistochemical studies illustrated the localisation of the protein on the surface of 
resistant cells. Further studies by Doyle et al. (1993) demonstrated the expression of the 
p95 protein in two early passage small cell lung cancer cell lines from untreated patients and 
also in blast cell lysates from acute myeloid leukaemia (Doyle et al., 1993; Doyle et al.,
1995).
1.5.2 Circumvention of non-P-glycoprotein MDR
To date, very little information has been obtained on agents capable of reversing the 
accumulation defect observed in non-p-glycoprotein MDR. The most extensive study 
investigated the effect of the calcium channel antagonist, verapamil, an agent which has 
been shown to sensitize P-glycoprotein containing MDR cells, in a non-P-glycoprotein MDR 
cell line (Tsuruo et al., 1981). Studies have shown that, while verapamil can reverse 
resistance in some MDR lines, it is ineffective in other cells. This may indicate that a 
number of different mechanisms are involved in non-P-glycoprotein MDR. Verapamil also 
appears to be specific for resistant cells, since results have shown that this agent has very 
little effect on the parental cell lines. A number of reports have demonstrated the effect of 
verapamil on the HL60 adriamycin resistant variants, HL60/AR and HL60/ADR. 
Treatment of both lines with verapamil enhanced the cellular accumulation and retention of 
adriamycin and daunorubicin (Bhalla et al., 1985; McGrath et al., 1989). These studies 
did not detect any significant alteration in drug accumulation in the parental cell line. Other 
non-P-glycoprotein MDR lines have also been shown to respond to verapamil treatment, 
although the effect was substantially less than that observed in the HL60 resistant variants. 
Studies on the large cell lung carcinoma cell line, COR-L23, revealed that verapamil was 
capable of partially restoring the accumulation defect in the resistant variant. Daunorubicin
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accumulation was unchanged in the parental cell line, while it was increased by 
approximately 60% in the COR-L23/R cells (Coley et al., 1991). Slovak and coworkers 
(1988) also found a slight increase in the net accumulation of adriamycin in HT1080/DR4 
cells, following treatment with verapamil. A number of investigators, however, have shown 
that verapamil has essentially no effect in circumventing resistance in other non-P- 
glycoprotein MDR lines, particularly in cell lines selected for resistance to mitoxantrone. 
Taylor et al. (1991) found that there was no selective modulation of drug accumulation or 
drug resistance by the addition of verapamil in the mitoxantrone resistant variant of the 
breast line MCF-7.
The immunosuppressive agent cyclosporin A and its analogue SDZ PSC 833 have also been 
shown to be capable of enhancing drug accumulation in non-P-glycoprotein cell lines. In 
a study by Barrand et al. (1993), both cyclosporin A and PSC 833 caused a slight, but 
significant, increase in the accumulation of daunorubicin and vincristine in the resistant 
COR-123 cell line. The net accumulation, however, was less than that observed in the 
sensitive parental cells. In the same study, verapamil was shown to be more effective than 
both agents. Enhancement of daunorubicin accumulation by cyclosporin A was also noted 
in the p95 positive MCF-7/AdrVp subline, while no effect was observed in the parental 
cells (Doyle et al., 1995).
The glutathione inhibitor, buthionine sulfoximine (BSO), has also been shown to be capable 
of enhancing drug accumulation and retention in HL60/AR cells. Treatment of the HL60 
cells with BSO resulted in a significant increase in daunorubicin uptake in the resistant cells 
but had no effect on accumulation in the sensitive cell line. The mechanism by which BSO 
exerts its effect on drug accumulation, however, is unknown (Lutzky et al., 1989).
More recently, a number of additional compounds have been studied for circumvention of 
resistance in non-P-glycoprotein MDR and these include the protein kinase inhibitors, 
genistein and staurosporine, the proton ionophores, monensin and nigericin, the Golgi 
disrupting agent, brefeldin A and the lysosomotropic agents, chloroquine and methylamine. 
An extensive study was carried out on the effect of genistein and staurosporine on a number 
of P-glycoprotein and non-P-glycoprotein MDR cell lines. The results obtained illustrated 
that while staurosporine was very effective at enhancing drug uptake in P-glycoprotein 
MDR cells (SW1573/2R160), it did not significantly alter drug accumulation in the non-P-
29
glycoprotein MDR cell lines, GLC4/ADR and SW1573/2R120. In contrast, genistein was 
shown to cause a dose dependent increase in daunorubicin accumulation in both GLC4/ADR 
and SW1573/2R120 but to have no effect on accumulation in P-glycoprotein MDR cell lines 
(Versantvoort et al., 1993).
Marquardt and Center (1991) reported that adriamycin accumulation could be restored in 
the HL60/ADR cell line by treatment with the vacuolar ATPase inhibitors, bafilomycin Al 
and 7-chloro^-nitrobenz-2-oxa, 1,3-diazole (NBD). These agents, in particular NBD, were 
also shown to be effective in the COR-L23/R resistant cell line at reversing the 
accumulation defect in the resistant cells (Rhodes et al., 1994). It has also been 
demonstrated that brefeldin A causes a dose dependent increase in daunorubicin 
accumulation in both sensitive and resistant COR-L23 cell lines (Rhodes et al., 1994). 
However, studies on the effect of brefeldin A in HL60/ADR cells revealed that it did not 
significantly alter the cellular accumulation of daunorubicin in these cells. Further studies 
on the HL60/ADR cells showed that the lysosomotropic agents, methylamine, chloroquine 
and ammonium chloride had no effect on drug uptake or efflux, while the ionophores 
monensin and nigericin induced a significant increase in drug accumulation and inhibited 
drug efflux. Nigericin has consistently been found to be more active than monensin and in 
this study it induced a complete block in daunorubicin efflux from the HL60/ADR cells 
(Marquardt and Center, 1992).
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1.6 Subcellular distribution of anticancer agents in MDR cell lines
Numerous studies have reported that, in addition to a reduction in drug accumulation, many 
MDR cell lines also exhibit altered distribution, together with compartmentalisation of drug 
in vesicles away from the target sites. Consequently, the subcellular localisation of 
anticancer agents has frequently been studied in wild type sensitive and multidrug resistant 
cell lines. Many quantitative studies on the accumulation of drug, in intact cells, have used 
radioactively labelled drugs and spectrofluorometric techniques. These methods, however, 
do not allow examination of the intracellular compartmentalisation of drug in living cells. 
Fluorescence microscopy has therefore been employed to determine the cellular localisation 
of drugs, since a number of the anthracyclines are inherently fluorescent and can easily be 
visualized. Studies on a number of the anthracyclines revealed that adriamycin and 
daunorubicin were localised primarily in the nucleus of living cells (Silvestrini et al. , 1970; 
Egorin et al., 1974). In contrast, a large number of anthracyclines appeared to be localised 
in the cytoplasm, often in discrete granules. Included in this group of anthracycline drugs 
were the N-acetyl and N,N-dibenzyl derivatives of daunorubicin, 4-demethoxydaunorubicin 
and carinomycin. Other anthracyclines, including N-formyl-adriamycin and 13-amino- 
daunorubicin, were not preferentially localised in either the nucleus or cytoplasm appearing 
to be equally distributed in both regions (Egorin et al., 1980).
Cytofluorescent studies on the localisation of adriamycin in MDR cells were first described 
by Chauffert and coworkers in 1984 in adriamycin resistant rat colon cancer cells. 
Fluorescent microscopy demonstrated that adriamycin was distributed in two cellular 
compartments. Initially, adriamycin accumulated rapidly in the nucleus. However, when 
the cells were exposed to the drug for longer incubation periods, no nuclear fluorescence 
was observed. Adriamycin was also shown to accumulate in cytoplasmic granules, which 
occurred slowly and persisted long after the drug was removed from the medium. This 
work indicated that the inherently resistant colon cancer cells were capable of removing 
adriamycin from the nucleus, its main site of action, and through this permanent efflux 
mechanism, the cells were able to survive and grow in drug containing medium. Studies 
by Willingham et al. (1986) demonstrated daunorubicin distribution in drug sensitive and 
multidrug resistant human KB cells. The fluorescence pattern showed a very bright signal 
in the nucleus, the Golgi region and in lysosomes of the sensitive cells. A small amount 
of fluorescence was also detected on the plasma membrane and in the cytoplasm. In
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contrast, resistant cells incubated with daunorubicin showed a significantly reduced amount 
of daunorubicin fluorescence in their nuclei. However, fluorescence in the Golgi region and 
in the lysosomes was as prominent as in the sensitive cells. The distribution of adriamycin 
and daunorubicin in the HL60 and HL60/AR cell lines was first described in 1987 by 
Hindenberg and coworkers. The localisation of the anthracyclines was studied by digitized 
video fluorescence microscopy and the results demonstrated different drug distribution 
patterns in the sensitive and resistant cells. Following exposure to drug, nuclear 
fluorescence was clearly visible in the HL60 parental cells. However, the fluorescence 
pattern observed in the HL60/AR cells was similar to the lysosomal fluorescence seen in 
both HL60 and HL60/AR cells exposed to acridine orange, a dye which preferentially stains 
the lysosomes, thus suggesting the intralysosomal distribution of the drug in resistant cells. 
Further studies showed that the initial fluorescence observed in the HL60/AR resistant cells 
was associated with the Golgi apparatus, although with longer incubation the fluorescence 
of the Golgi apparatus faded and lysosomal fluorescence was visible (Hindenburg et al., 
1989). Numerous studies have since described the distribution of drugs in parental, P- 
glycoprotein and non-P-glycoprotein MDR cell lines. In general, nuclear fluorescence was 
prominent in parental cell lines, while the fluorescent staining observed in resistant lines 
was predominately cytoplasmic.
The initial results obtained for the subcellular distribution of anticancer drugs agreed with 
the proposal that the decreased ability of MDR cells to retain certain drugs was due to the 
active efflux pump, P-glycoprotein. However, this could not explain the drug distribution 
patterns observed in the non-P-glycoprotein MDR HL60/AR cell line. Subsequently, a new 
hypothesis was independently proposed by Beck (1987) and Sehested et al. (1987). This 
hypothesis suggested that the lysosomal system in MDR cells was involved in drug efflux 
and that drugs such as the anthracyclines and vinca alkaloids, which are weak bases, can 
become trapped in these acidic compartments by protonation. Thus, the acidic 
compartments may act as a reservoir to sequester drugs, reducing their concentrations in 
the cytoplasm and nucleus. According to this proposal, the lysosomal vesicles then migrate 
to the plasma membrane, where they fuse with the membrane and extrude their contents to 
the outside. Neutralization of lysosomes has been shown to alter adriamycin resistance in 
the HCT116-VM46 resistant cell line by a factor of 14 over the sensitive strain, thus 
supporting the hypothesis of the involvement of lysosomes in MDR lines (Dubowchik et a l., 
1994). Further evidence supporting this theory has been obtained from studies by Sognier
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and coworkers (1994) on multidrug resistant Chinese hamster cells. A highly resistant 
variant of the LZ Chinese hamster cell line was established (LZ-100), which was shown to 
be the most adriamycin resistant line of the LZ series. The increased level of resistance in 
the LZ-100 variant did not appear to be a consequence of either overexpression of P- 
glycoprotein or more efficient drug efflux. Altered drug distribution was, however, 
observed in the cells. Adriamycin was largely excluded from the nucleus and appeared to 
be sequestered into vesicles within the cytoplasm. Drug distribution was investigated in a 
number of cell lines from the LZ series and the results demonstrated that drug sequestration 
occured rapidly, following exposure to drug and was observed in cells exhibiting different 
levels of resistance. It was also shown that the number of cytoplasmic vesicles observed 
was related to the level of drug resistance achieved by the LZ line studied. Studies by 
Moriyama et al. (1994) on constituted acidic organelles revealed that while no specific 
transporters appeared to be involved in drug uptake into the acidic vesicles the uptake was 
driven by pH changes established by vacuolar-type ATPases.
In addition to cytotoxic drugs, a number of other chemicals act as substrates for P- 
glycoprotein. These include a number of fluorescent dyes which have been used as 
molecular probes in the study of MDR. Early studies showed that adriamycin and 
daunorubicin resistant leukaemia variants accumulated the fluorescent mitrochondrial dye 
rhodamine 123 much less effectively than sensitive cells (Tapiero et al., 1984). This led 
to a number of studies being carried out using fluorescent dyes. An extensive study was 
carried out on djungarian hamster fibroblasts, to test the ability of different fluorescent dyes 
to stain sensitive and resistant cells. While rhodamine 123 and berberin brightly stained 
mitochondria in sensitive cells, no staining was observed in the colchicine resistant variant, 
even with prolonged incubation periods. Slight fluorescence was, however, noted at higher 
concentrations of the dyes. All other tested dyes stained both the sensitive and resistant 
cells, but with different intensity of staining. The fluorescence intensity was found to be 
substantially greater in the sensitive cells (Neyfakh, 1988). The reduced staining related 
well with the multidrug resistant phenotype of the cells and thus fluorescent dyes proved to 
be a useful tool for the investigation of different aspects of multidrug resistance. Additional 
work by Neyfakh and coworkers (1989) demonstrated the role of rhodamine 123 as a 
detector of cells with a high MDR transport system. Experiments with B-lymphoma cell 
lines with different degrees of MDR showed that rhodamine 123 fluorescence was indeed 
inversely proportional to the degree of resistance. The subcellular distribution of rhodamine
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123 has recently been used as a tool to study the MDR phenotype in a number of other 
resistant cell lines, including the murine mammary tumour cell line EMT6/AR1.0, Chinese 
hamster lung fibroblasts, the human large cell lung cancer cell line COR-L23/R, uterine 
epithetial carcinomas and human leukaemia cell lines (Twentyman et al., 1994; Altenberg 
et al., 1994; Lizard et al., 1994; Nare et al., 1994).
1.6.1 Agents that alter drug distribution in MDR cell lines
Studies have shown that a number of agents have the ability to modulate the subcellular 
distribution of anthracyclines within MDR cell lines. Early reports showed that verapamil 
was effective at restoring nuclear fluorescence in resistant rat colon cancer cells and also 
at enhancing the toxicity of adriamycin in the cells (Chauffert et al., 1984). Willingham 
and coworkers (1986) also demonstrated restoration of nuclear fluorescence in resistant 
human KB cells, to a level comparable with the sensitive cells, following treatment with 
verapamil. Verapamil has since been demonstrated to increase nuclear fluorescence in 
numerous multidrug resistant human cell lines, including the adriamycin resistant non small 
cell lung carcinoma cell line, SW1573 (Versantvoort et al., 1993), the human ovarian 
A2780/AD cell line (Schuurhuis et al., 1993) and the human leukaemia cell line, K562R 
(Sebille et al., 1994). The mechanism by which verapamil exerts its effect on drug 
distribution is unclear, although early results suggested that verapamil altered drug 
distribution by inhibiting the efflux across the plasma membrane and thus increasing the 
cellular concentration of drug (Willingham et al., 1986). The protein responsible for 
accelerated efflux was later identified as the membrane associated P-glycoprotein pump, and 
therefore inhibition of P-glycoprotein was thought to be involved in modulating drug 
distribution patterns.
This hypothesis, however, could not explain the effect of verapamil in non-P-glycoprotein 
MDR cell lines. Verapamil has been shown to alter subcellular drug distribution in non-P- 
glycoprotein MDR cell lines, although its effectiveness is not as great as in P-glycoprotein 
MDR cells. Studies by Versantvoort et al. (1993) demonstrated an increase in nuclear 
fluorescence, following exposure to verapamil in the non-P-glycoprotein MDR human lung 
cell lines GLC4/ADR and SW1573/2R. Verapamil also proved to be effective at restoring 
nuclear fluorescence in the human leukaemia HL60/AR cell line (Hindenburg et al., 1987)
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and in the human large cell lung cancer cell line, COR-L23/R (Barrand et al., 1993). It 
is generally believed that verapamil reverses resistance in non-P-glycoprotein MDR cell 
lines by altering intracellular drug localisation. The exact mechanism by which this is 
achieved remains unknown. Hindenburg and coworkers (1987) proposed that verapamil 
could circumvent resistance in the HL60/AR cells by altering the hydrophobic/hydrophilic 
solubility of anthracyclines in the resistant cell, causing the drug to redistribute and thereby 
increasing its cytotoxicity.
The immunosuppressive agent cyclosporin A and its more potent analogue PSC 833 have 
also been reported to alter subcellular distribution of drug in MDR cell lines. Photoaffinity 
labelling studies have shown that, similar to verapamil, cyclosporin A may increase nuclear 
fluorescence by binding to the drug efflux pump, P-glycoprotein, in such a way as to reduce 
its ability to expel cytotoxic drugs from the resistant cells. Supporting this hypothesis, 
Sebille et al. (1994) reported that, in the presence of cyclosporin A, the intracellular 
concentration of adriamycin in the human P-glycoprotein MDR leukaemia cell line, K562/R, 
was approximately six times higher than without the modulator. Cyclosporin A and PSC 
388 have also been demonstrated to alter drug distribution patterns in non-P-glycoprotein 
MDR cell lines, although generally the effect was substantially less than in P-glycoprotein 
cell lines. The way in which this is achieved is unknown. Reports have shown that these 
agents increase nuclear fluorescence in the non-P-glycoprotein cell lines, HL60/AR and 
COR-L23/R (Hindenburg et al., 1987; Barrand et al., 1993).
The ionophores, monensin and nigericin, have also been shown to increase drug 
accumulation and to alter the subcellular distribution of drug in MDR cell lines. These 
agents are thought to act by elevating intravesicular pH and by disrupting acidic vesicular 
traffic within the cell (Tartakoff, 1983). The ionophores are also capable of altering 
cytosolic pH (Pressman, 1976) and may in this way alter cellular distribution and block the 
efflux pathway. Sehested and coworkers (1988) demonstrated an increase in daunorubicin 
toxicity in resistant Ehrlich ascites tumour cells, following treatment with both monensin 
and nigericin. An increase in the subcellular accumulation of daunorubicin and a decrease 
in drug efflux was also observed in the cells. In studies by Klohs and Steinkampf (1988) 
these agents were also shown to potentiate adriamycin toxicity and inhibit adriamycin efflux 
in the resistant leukaemia cell line, P388R. A number of other agents known to interact 
with acidic compartments, including chloroquine and methylamine, were found to have the
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same effect. More recent studies have shown that, in addition to increasing drug 
accumulation, the ionophores are capable of altering the distribution of drug. Marquardt 
and Center (1992) reported that treatment with monensin and nigericin induced an increase 
in adriamycin accumulation and inhibited adriamycin efflux in HL60/ADR cells. Studies 
were also carried out to examine the effect of nigericin on the subcellular distribution of 
adriamycin. Using fluorescent microscopy techniques, a complete retention of drug was 
found in the nuclei of resistant cells, in the presence of nigericin. The uptake of the 
fluorescent dye, rhodamine 123, in sensitive and resistant murine RFLC3 leukaemia cells 
was also investigated in the presence of nigericin and the results obtained showed that the 
increase in rhodamine 123 accumulation was accompanied by a redistribution of the dye 
throughout the cell (Canitrot et al., 1994). Nigericin was also demonstrated to increase 
daunorubicin nuclear fluorescence in BNLCL.2 cells. Further studies revealed that 
decreased accumulation of adriamycin and daunorubicin within acidic organelles of the 
BNLCL.2 cells, following treatment with nigericin, was associated with an increase in the 
internal pH of the organelles (Moriyama et al., 1994). Overall, these results show that the 
ionophores can modulate the cytotoxicity of anthracyclines by altering the subcellular 
distribution of the drug. The exact mechanism by which this is achieved is unknown, 
although evidence would suggest that these agents inhibit the sequestration of drug into the 
acidic vesicles and/or cause disruption of the vesicles, thus increasing the nuclear 
concentration of the drug. Other lysosomotropic agents which have also been demonstrated 
to increase drug retention and nuclear drug accumulation in resistant cells include 
chloroquine, methylamine and quinacrine (Zamora and Beck, 1986; Shiraishi et al., 1986a; 
Klohs and Steinkampf, 1988). These agents have been found to alkalinize the lysosomal 
compartment in several cell lines (Ohkuma and Poole, 1978; Poole and Ohkuma, 1981).
The fungal antibiotic, brefeldin A, has also been identified as a modulator of intracellular 
distribution of anthracyclines in MDR cell lines. In a study on the distribution of 
adriamycin in the MDR cell line, COR-L23/R, the addition of brefeldin A resulted in a shift 
of the drug from cytoplasmic to nuclear regions (Rhodes et al., 1994). Earlier studies had 
shown that brefeldin A protected the murine leukaemia L1210 cell line from adriamycin 
cytotoxicity (Vichi and Tritton, 1993). Brefeldin A has been shown to disassemble the 
Golgi complex thus interfering with the vesicular trafficking between the Golgi apparatus 
and the endoplasmic reticulum (Misumi et al., 1986; Fujiwara et al., 1988). Any effect of
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brefeldin A may therefore be related to its function as a Golgi inhibitor.
Studies have also been carried out on the tyrosine kinase inhibitor, genistein, to investigate 
its effect on the distribution of drug in MDR cell lines. Reports have shown that genistein 
can reverse the drug accumulation defect in a number of cell lines which overexpress the 
190 kDa protein, while it appears to have little effect in P-glycoprotein mediated MDR cell 
lines. Takeda and coworkers (1994) demonstrated an increase in nuclear concentration of 
adriamycin in the non-P-glycoprotein MDR human leukaemia cell line, K562/TPA, 
following cotreatment with genistein. Versantvoort et al. (1993) reported an increase in the 
nuclear/cytoplasmic distribution ratio in the GLC4/ADR and SW1573/2R120 cell lines. In 
contrast, genistein had no effect on adriamycin distribution in the P-glycoprotein MDR cell 
lines SW1573/2R160, MCF-7/DOX and KB8-5.
The vacuolar H+-Adenosine triphosphatase inhibitors, bafilomycin A, and 7-chloro-4- 
nitrobenz-2-oxa-l ,3-diazole (NBD), have also proved effective at modifying the intracellular 
distribution of anthracyclines. The vacuolar H+-ATPase is a proton pump which maintains 
low internal pH within cells (Forgac, 1989). It has been suggested that these proton pumps 
play a pivotal role in acidification and protein degradation within lysosomes in cultured cells 
(Yoshimori et al., 1991). Studies have shown that the addition of bafilomycin A, to 
cultured cells results in increased intralysosomal pH, as a consequence of the inhibition of 
the vacuolar proton pump (Yoshimori et al., 1991). Therefore, the modifying effect of 
bafilomycin A, and NBD on intracellular drug distribution may be due to inhibition of 
lysosomal formation. Marquardt and Center (1991) reported an increase in both cellular 
and nuclear accumulation of daunorubicin in the non-P-glycoprotein MDR cell line, 
HL60/ADR, in the presence of bafilomycin At and NBD. These agents were also shown 
to increase daunorubicin accumulation in the P-glycoprotein cell line HL60/Vinc, although 
bafilomycin A! did not compete with [3H]azidopine binding to P-glycoprotein thus 
suggesting that bafilomycin Aj does not act as a substrate for P-glycoprotein. A shift of 
drug from cytoplasmic to nuclear regions was also observed by laser-scan confocal 
microscopy in COR-L23/R cells, following treatment with bafilomycin A, and NBD. These 
agents were found to modify the distribution in the resistant cells towards that observed in 
the sensitive parental cells (Rhodes et al., 1994).
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Radiation exposure has recently been shown to alter drug distribution patterns in adriamycin 
resistant Chinese hamster LZ-100 cells. Adriamycin was found to be largely excluded from 
the nucleus and appeared to be sequestered into vesicles within the cytoplasm of the resistant 
cells. Radiation exposure immediately preceeding adriamycin treatment was shown to 
decrease the number of cytoplasmic vesicles formed and also to alter the subcellular 
distribution of adriamycin, from cytoplasmic to a more homogenous nuclear/cytoplasmic 
distribution. The inhibitory effect of radiation on vesicle formation was also found to 
increase with radiation dose. The mechanism by which radiation treatment redistributes the 
drug is unknown, although it does not appear to result from radiation inhibition of P- 
glycoprotein (Sognier et al., 1994).
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1.7 Alternative mechanisms of MDR
1.7.1 Topoisomerase II
Topoisomerases are Mg2+- and ATP-dependent nuclear enzymes which play a role in DNA 
replication, chromosome scaffold formation, chromosomal segregation and possibly 
recombination and gene transcription (Wang, 1985; Liu, 1989). Use of the topoisomerases 
as novel targets for cancer chemotherapy was first described in the early 1980s and study 
is ongoing to determine their mechanisms of action and to develop inhibitors which could 
prove to have therapeutic use in cancer chemotherapy (Liu et al., 1980; Liu, 1983; Hsieh 
and Brutlag, 1980). A number of clinically useful antitumour agents have been found to 
inhibit the topoisomerase enzymes, including the DNA intercalators, adriamycin and 
daunorubicin, amsacrine, ellipticine, camptothecin and its related compound topotecan and 
the epipodophylotoxins, etoposide and tenoposide. Many of the topoisomerase II inhibitors 
such as the anthracyclines (adriamycin and daunorubicin) and the epipodophylotoxins 
(etoposide and teniposide) are exported from the cell by the high levels of the P- 
glycoprotein membrane associated efflux pump expressed in the "classic" or "typical" 
multidrug resistant cell lines (Ling, 1992). However, a second mechanism of MDR 
involving reduced or mutated topoisomerase II has been termed "atypical" MDR (Beck,
1989). Eukaryotic topoisomerases have been categorized into two types. The type I 
enzymes make transient single-strand breaks in DNA, whereas type II topoisomerases make 
transient double-strand breaks (Wang, 1985). Many of the functions of one type of 
topoisomerase can, in theory, be carried out by the other class, although it is likely that the 
topoisomerase I enzyme does not perform functions requiring double-strand DNA scission 
(Wang, 1985). Topoisomerase II was first isolated from human cells by Miller et al. 
(1981). The gene encoding the human topoisomerase II has been sequenced and found to 
be localised on chromosome 17 at position 21-22 (Tsai-Pflugfelder et al., 1988). The 
cDNA encodes a 6.2 kilobase mRNA which codes for a 1530-amino acid protein of deduced 
molecular mass of 174 kilodaltons.
The mechanism of action of the eukaryotic topoisomerase II has been described by Osheroff 
(1986) as a five step process. The first step involves the recognition and binding of the 
topoisomerase enzyme to DNA. The second step involves the cleavage of the first double­
stranded segment of the DNA, resulting in a covalent bond between the 5‘-terminus of each
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strand and a topoisomerase II polypeptide tyrosyl subunit. This step is followed by the 
passage of a second double strand of DNA through the break and this in turn is followed 
by the religation of the strand-cleaved DNA. The final step involves the ATP-dependent 
turnover of the topoisomerase II enzyme. The topoisomerase II inhibitors are thought to 
exert their inhibitory action by binding to the topoisomerase II enzyme, forming a cleavable 
compound, which then binds to the DNA forming a potentially lethal ternary complex in 
the cells (Takano et al., 1992; Lui, 1989). The ternary complex halts the catalytic activity 
of the topoisomerase II enzyme prior to the religation of the cleaved DNA intermediate 
(Robinson and Osheroff, 1990). The stabilized intermediate complexes form barriers to 
DNA fork progression and so become lethal lesions when cells attempt to utilize these 
regions as templates (Liu, 1989). The topoisomerase II inhibitors therefore cause cell kill 
by stabilizing the enzyme-DNA complex and thus preventing DNA replication.
Protein, chemical and molecular cloning analyses have revealed two distinct isoforms of the 
topoisomerase II enzyme, with molecular weights of 170 kilodaltons and 180 kilodaltons 
respectively. The two isoforms are also referred to as topoisomerase I la  and topoisomerase 
II/? (Drake et al., 1987; Chung et al., 1989; Tsutsui et al., 1993). The isoforms have been 
shown to have different intranuclear localisation and tissue distribution (Capranico et al., 
1992; Zini et al., 1992: Tsutsui et al., 1993), suggesting their differential roles in cell 
function with special regard to cell proliferation. The level of topoisomerase II has been 
shown to vary throughout the stages of the cell cycle (Estey et al., 1987: Woessner et al., 
1991). Topoisomerase I la  is expressed primarily during the proliferative phases of growth 
and is downregulated at plateau phase. The level of topoisomerase I la  increases at the onset 
of DNA replication and continues to increase throughout the S and G2 phases. The level 
reaches a plateau in the late G2 to M phase of the cell cycle and then decreases after mitosis 
has occurred (Heck et al., 1988). Immunoblotting studies have demonstrated that, unlike 
the topoisomerase I la  isoform, the level of topoisomerase 11(8 does not appear to vary 
greatly throughout the cell cycle (Woessner et al., 1991).
The regulation of topoisomerase II during the cell cycle may be relevant in identifying 
which phase of the cycle is most sensitive to the effect of topoisomerase II inhibitors. 
Drake et al. (1987) have shown that the a  isoform of the topoisomerase enzyme is the 
better target for the topoisomerase II inhibitors and this may explain why some of the 
inhibitors are proliferation-specific with regard to their toxicity. Chow and Ross (1987)
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demonstrated that following serum stimulation of BALB-c 3T3 cells, actively proliferating 
cells showed much greater sensitivity to etoposide than quiescent cells. The increase in 
sensitivity commenced during the S phase of the cell cycle and reached a peak just before 
mitosis, with a maximal 2.5-fold increase in drug sensitivity. Modulation of the 
topoisomerase II enzyme during the cell cycle may involve phosphorylation of the enzyme. 
It has previously been shown that topoisomerase II is phosphorylated at specific serine 
residues, resulting in an increase in enzyme activity, with dephosphorylation resulting in 
inactivation of the enzyme (Fry and Hickson, 1993). A second mechanism of regulating 
topoisomerase II activity may be to vary the cellular content and localisation 
(compartmentalisation) of the enzyme. It is not fully understood how compartmentalisation 
is achieved, although it is known that topoisomerase II is a nuclear matrix protein and thus 
changes in the components of the nuclear matrix during the cell cycle may result in 
alteration in the accessibility of the enzyme to DNA (Beck and Danks, 1991).
1.7.1.1 Topoisomerase II and drug resistance
A number of the classical MDR cell lines that overexpress P-glycoprotein also exhibit cross­
resistance to topoisomerase II inhibitors. However, no alteration in the cellular content of 
the topoisomerase II enzyme is detected i i  these cells, since these compounds act as 
substrates for the P-glycoprotein and are exported from the cells (Beck and Danks, 1991). 
Various studies have been carried out demonstrating the "atypical" multidrug resistance 
phenotype in numerous cell lines. Characteristically, the cell lines exhibit cross resistance 
to the full range of anti-topoisomerase II (Jrugs, but do not show cross resistance to the 
vinca alkaloids, which are classical MDR drugs. Two types of "atypical" MDR have been 
described, the type being defined according to whether there is a reduction in the level of 
topoisomerase II or an alteration in the enzyme that renders it resistant to the topoisomerase 
II inhibitor. Examples of resistant cell lines with reduced levels of topoisomerase II include 
the leukaemia cell line, P388/AMSA, selected for resistance to amsacrine (Johnson and 
Howard, 1982) and the adriamycin rpsisunt small cell lung cancer cell line, H69AR (Cole 
et al., 1991). Lower levels of i*ni|iunoreactive topoisomerase II were observed in both cell 
lines compared to their respective parental cells.
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A number of mechanisms of résistance, resulting in the alteration of the topoisomerase II 
enzyme have been postulated and include the presence of point mutations and 
hypermethylated sites on the topoisomerase II enzyme. A number of investigators have 
detected the presence of mutated topoisomerase II in "atypical" MDR cell lines. The cell 
lines, HL60/AMSA, VpmR-5 and KBM3/AMSA, have all been found to contain point 
mutations in a single specific region of the topoisomerase l ia  gene and all mutations were 
G to A transitions (Hinds et al. , 1991; Chan et al., 1993; Lee et al., 1992). Several studies 
have also demonstrated the presence of hypermethylated sites on the topoisomerase II 
enzyme which may be of significance in regulating the transcription of non-mutant alleles. 
Work by Tan et al. (1989) revealed that in the amsacrine resistant cell line, P388/AMSA, 
the «  isoform of topoisomerase II was rearranged in one of two alleles and that the enzyme 
was hypermethylated in a number of sites. Both of these findings would be expected to be 
associated with a decrease in the cellular content of functional topoisomerase II, as was 
observed by Johnson and Howard (1982). Another mechanism of resistance to the 
topoisomerase II inhibitors has been attributed to the upregulation of the topoisomerase I 
enzyme. An increase in topoisomerase I levels has previously been demonstrated in 
"atypical" MDR cell lines. The level of topoisomerase I may increase as a compensatory 
effect for the down regulation of the topoisomerase II enzyme (Gellert et al., 1982). The 
topoisomerase I enzyme may be able to carry out the functions of topoisomerase II when 
it is down regulated and therefore lead to resistance in the cells.
Although alterations in topoisomerase II activity are usually associated with resistance to the 
epipodophylotoxins and anthracyclines, recent reports have also demonstrated an increase 
in the activity of the topoisomerase II enzyme in cisplatin resistant cells. Although cisplatin 
is not a classical MDR drug, Barret et al. (1994) found that the cisplatin resistant murine 
leukaemia cell line, L1210/10, was approximately 2.5-fold more resistant than the parental 
cells to the cytotoxic effects of topoisomerase II inhibitors. Nuclear extracts of the resistant 
cells demonstrated a 3-fold increase in topoisomerase II activity, compared with the parental 
cells, which contributed to the resistant phenotype of the cells. Mestdagh et al. (1994) also 
reported an increase in topoisomerase II activity in the L1210/10 cell line and demonstrated 
that the activity of the topoisomerase was greater in the cisplatin resistant variant than in 
an adriamycin resistant variant, relative to the parental cells. Recent studies have also 
reported an increase in topoisomerase I levels in cisplatin resistant cell lines (Kotoh et a l.,
1994).
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1.7.1.2 Clinical implications of topoisomerase inhibitors
Work is ongoing to elucidate the clinical significance of altered topoisomerase II in tumour 
samples and cell lines and to identify possible methods of circumventing "atypical" MDR. 
Studies undertaken thus far, on reversal of "at-MDR", have been based on two principles. 
The first of these states that the cytotoxicity of the topoisomerase II inhibitors is directly 
related to the number of functional topoisomerase II enzymes in the cell and that increasing 
the number of active topoisomerases could circumvent the resistance. Phosphorylation of 
the topoisomerase II enzyme results in an increase in its activity; agonists whose activity is 
related to phosphorylation may therefore be capable of increasing the activity of the 
topoisomerase enzymes. Nambi et al. (1989) illustrated that both vasopressin and thrombin 
stimulated the activity of the topoisomerase I enzyme and in later studies demonstrated that 
the increase in activity observed in the topoisomerase I and topoisomerase II enzymes was 
regulated by cyclic nucleotide- and phospholipid- dependent protein kinases (Mattern et al.,
1991). Other agonists that have been found to increase the enzyme activity include tumour 
necrosis factor and leukotreine D4 (Utsudi et al. , 1990; Mattern et al. , 1990). Cotreatment 
with a combination of topoisomerase inhibitors and these agonists could therefore play a 
role in the circumvention of "at-MDR", since it was previously shown that an increase in 
the cytotoxicity of the topoisomerase inhibitors, teniposide and amascrine, was observed 
when cotreated with tumour necrosis factor in the murine L929 fibrosarcoma cell line 
(Utsudi et al., 1990).
The second principle states that the activity of topoisomerases I and II is regulated to 
maintain cellular homeostasis. Consequently, if the level of functional topoisomerase II 
enzyme is decreased in the cell then a compensatory upregulation of topoisomerase I will 
occur. Combination treatment with topoisomerase I and topoisomerase II inhibitors, 
therefore, has the potential to prevent "at-MDR". Lefevre et al. (1991) have shown that 
the human breast cell line, CALcl8/AMSA, which was resistant to the topoisomerase II 
inhibitor amsacarine, exhibited a three-fold decrease in topoisomerase II levels when 
compared with the parental cells. In contrast, the cell line exhibited a three-fold increase 
in topoisomerase I levels and also expressed hypersensitivity to the topoisomerase I inhibitor 
camptothecin. These findings suggested an upregulation of the topoisomerase I gene to 
compensate for the reduced topoisomerase II expression. Further studies by Woessner et 
al. (1993) demonstrated an increase in resistance to the topoisomerase II inhibitor etoposide
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in the P388 cell line that had been made hyperresistant to the topoisomerase I inhibitor 
camptothecin, thus showing an upregulation of the topoisomerase II enzyme, compensating 
for the decrease in the topoisomerase I. Another possible mechanism for circumventing 
topoisomerase resistance could involve molecular design. This theory has been studied in 
amsacrine resistant human leukaemia cell sublines that expressed MDR and also altered 
transport of the topoisomerase II inhibitor. Findlay and coworkers (1990) demonstrated that 
by altering substituents on the aniline acridine nucleus of the amsacrine molecule, resistance 
to both mechanisms was overcome.
1.7.2 Glutathione and Glutathione-S Transferase
The glutathione-S-transferases (GST) are a family of multifunctional cellular enzymes first 
discovered in the early 1960s (Booth et al., 1961). The function of these enzymes was 
originally believed to involve the intracellular transport of various proteins and endogenous 
ligands such as bilirubin, haem and bile acids. However, it has long been known that the 
GST enzymes are an integral part of the Phase I (oxidation)/Phase II (conjugation) systems 
that metabolize many lipophilic drugs and other foreign compounds. The overall result of 
metabolism by this system is the conversion of these lipophilic compounds to more polar 
derivatives in a manner that can facilitate their inactivation and elimination. GSTs catalyze 
the conjugation of glutathione (glutamylcysteinglycine), through the sulphur atom of its 
cysteine residue, to various electrophiles, forming stable secretory metabolites and 
preventing oxidative damage through intrinsic peroxidase activity (Jokoby, 1978). 
Glutathione is the principal non-protein thiol in mammalian cells and functions as a 
scavenger of electrophilic toxins. It is a tripeptide, synthesised in two successive ATP- 
requiring steps. The first step involves the formation of an amide linkage between cysteine 
and glutamate, catalyzed by the enzyme glutathione synthetase and in the second step the 
enzyme mediates the reaction of glycine to the carboxyl terminal of cysteine to form 
glutathione. There is growing evidence that, in addition to protecting normal cells and 
tissues from chemical injury, glutathione and the glutathione-S-transferases may play an 
important role in the MDR phenotype by protecting malignant tissue from chemotherapeutic 
agents (Arrick and Nathan, 1984; Green et al., 1984; Evans et al., 1987; Hosper et al.,
1988).
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In human, GSTs exist in cytosolic or microsomal forms and may constitute up to ten percent 
of total cellular protein of the liver. GSTs have also been localised in human kidney, lung, 
brain, intestine, skeletal muscle and adrenal glands (Tsuchida and Sato, 1992). There are 
three main classes of cytosolic GST: 7r, a  and /x, the classification being based on the 
enzymes N-terminal amino acid sequence, the substrate specificity, sensitivity to inhibitors 
and immunological techniques. Each of the GST enzymes is composed of subunits arranged 
as hetero- or homo-dimers of 25-29 kilodaltons. The exact structure of each subunit is 
unknown, but it is believed that each subunit contains two domains; the COOH terminus 
which has been designated the H-site and to which the electrophilic substrate binds and the 
glutathione binding site or G-site. The G-site is common to each subunit, while the H-site 
is specific for each subunit (Picket and Lu, 1989; Waxman, 1990).
1.7.2.1 Glutathione and GST in classic MDR
Altered expression of GST, in particular the ir isoform, has been reported in a number of 
human cancers. Increases in the RNA and protein levels have been detected in tumours of 
the colon, bladder, oesophagus, stomach, pancreas and ovary relative to normal tissue 
(Kodateeta l., 1986; Singh etal., 1990; Hayes et al., 1991). Increased expression of GST 
has also been demonstrated in lymphoblastic leukaemia, where samples from 52 patients out 
of a total of 104 stained positive for G ST t (Sauerberg et al., 1994). Alterations in the 
activity and levels of glutathione and glutathione-S-transferases have been studied in several 
cell lines associated with resistance to chemotherapeutic drugs. At least 30 cell lines that 
were selected for resistance to MDR drugs (adriamycin, etoposide, vincristine, vinblastine 
and colchicine) have been described in which GST activity has been characterised (reviewed 
by Moscow and Dixon, 1993). The majority of the cell lines studied were selected to 
adriamycin. However, of the 25 resistant lines studied only 10 demonstrated increased GST 
activity with respect to the parental cell line and only 5 of these had increases of 2-fold or 
greater. Two resistant variants of the human breast cell line MCF-7 that exhibited 192- and
2.6-fold resistance to adriamycin were found to exhibit 44.7- and 2.6- fold increases in GST 
activity respectively (Batist et el., 1986; Whelan et al., 1989). Cole et al. (1990) reported 
an increase in GST activity in MDR variants of two human lung cell lines, H69 and 
SW1573, that were also selected for resistance to adriamycin. Chao and coworkers (1992) 
reported a 2.5 fold increase in GST activity in the human colon cell line SW620 which
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exhibited 75-fold resistance to adriamycin. The v isoform of the GST enzyme was found 
to be increased in four of the cell lines that demonstrated an increase in GST activity.
When cell lines selected with other MDR chemotherapeutic agents were studied, it was 
observed that three resistant variants of the human breast cell line MCF-7 demonstrated an 
increase in GST activity. The cell lines that were 5.1-fold resistant to etoposide, 11.1-fold 
resistant to vincristine and 24-fold resistant to colchicine showed an increase of 6.7-fold,
6.7-fold and 70-fold in GST activity respectively. Contrary to the results obtained for the 
MCF-7 cell line, there was no evidence to suggest that alterations in GST activity were 
associated with particular cell lines, since a number of other MCF-7 resistant lines studied 
did not show increased levels of GST activity. There was also no direct relationship 
between GST activity and resistance in the lines studied since GST activity was unaltered 
in some of the most resistant cell lines.
The involvement of GST in the cell lines studied is, therefore, difficult to clarify, and while 
results obtained would indicate that increased GST activity is not necessary for MDR, they 
do not indicate whether increased GST activity contributes to resistance in the cell line that 
expressed elevated levels. A number of groups have studied GST activity in resistant cells 
that had reverted back to the sensitive wild type when grown in the absence of the selecting 
agent, to determine if the cell line retained the elevated level of GST. In one such study 
by Yusa et al. (1988), a revertant of a colchicine resistant MCF-7 cell line that had lost 
resistance to colchicine and adriamycin, was found to still express the 70-fold increase in 
GST activity that was noted in the resistant variant. In contrast, Bastist and coworkers 
(1986) found decreased levels of GST ir in a drug sensitive line that had reverted from one 
of the drug resistant MCF-7 cells that expressed increased levels of the GST enzyme. 
Transfection and expression of cDNA clones of the different GST isoforms in drug sensitive 
cell lines has been performed in various laboratories to determine if the transfectants display 
the resistant phenotype. A number of studies were carried out using the MCF-7 cell line, 
although the increased level of GST did not confer significant resistance to any of the MDR 
agents tested (Moscow et al., 1989; Fairchild et al., 1990; Leyland-Jones et al., 1991). 
The co-transfection of GST and MDR genes showed no significant additive effect, in that 
no change in the sensitivity of the cells to drugs associated with the MDR phenotype was 
observed (Fairchild et al., 1990).
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1.7.2.2 Glutathione and GST in cisplatin resistance
Alteration in the cellular concentration of glutathione and levels of GST has been identified 
in several cell lines associated with resistance to alkylating agents, in particular to the 
alkylating agent, cisplatin. Cisplatin is sufficiently electrophilic to react directly with 
glutathione (Eastman, 1987), resulting in a decrease in the level of drug metabolites that can 
react with cisplatin intracellular targets such as DNA. Increases in GST activity and/or 
glutathione levels could, therefore, protect cells from exposure to cisplatin. Several groups 
have demonstrated increases in both glutathione levels and GST activity in cisplatin resistant 
cells, although its role in contributing to resistance remains controversial. Meijer et al. 
(1990) reported a 2.6-fold increase in glutathione levels in the cisplatin resistant human 
small cell lung cancer cell line, GLC4-CDDP, with respect to the parental GLC4 cells. 
When the cells were continuously exposed to cisplatin, a 2.6-fold increase in the glutathione 
level was observed in the parental cells within 5 hours. However, no further increase was 
noted in the GLC4-CDDP cell line. Glutathione levels in the BE human colon cancer cell 
line were also studied. The BE cells were 5-fold resistant to cisplatin and showed a 3-fold 
increase in glutathione levels. When the cells were grown in the absence of drug for six 
weeks the revertant cells showed significantly lower levels of glutathione than the resistant 
cells. These results would suggest that glutathione plays a major role in the emergence of 
cisplatin resistance in this cell line (Fram et al., 1990). Oldenburg and coworkers (1994) 
detected an increase in glutathione in two cisplatin resistant variants of the rat colon 
adenocarcinoma cell line. The two relatively stable cell lines, RL2 and RL4, were 6- and 
20-fold resistant to cisplatin and showed an increase of approximately 2.5-fold and 4.8-fold 
in glutathione levels respectively. When the cells were cultured in the absence of drug for 
12 weeks there was a decrease in resistance, although no responding decrease in glutathione 
levels was observed. Therefore, the results implied that cisplatin resistance was mediated 
by some alternative mechanism in the resistant variants.
Several investigators have also reported a relationship between cisplatin resistance and 
glutathione-S-transferase activity (Teicher et al., 1987; Saburi et al., 1989; Sharma et al., 
1993). However, the relation between GST and cisplatin resistance has not been clarified. 
In one study, GST activity and glutathione content were determined in two cisplatin resistant 
variants of the human small cell lung cancer cell line, H69. The two variants, H69/CDDP
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and H69/CDDP0 2 were 6- and 11-fold resistant to cisplatin compared with the parental 
cells. While GST activity was unaltered in the lower resistant variant, a 6.5-fold increase 
in activity was noted in the higher resistant line. Inhibition of GST activity resulted in 
sensitisation of both variants although the relative resistance of the two variants remained 
unchanged. This suggested that while GST may contribute to cisplatin resistance, other 
factors must be responsible for the observed initial difference in resistant levels (Kasahara 
et al., 1991). Transfection and expression of GST isoforms in drug sensitive and low level 
cisplatin resistant lines has been associated with increased resistance to cisplatin. Miyazaki 
et al. (1990) showed a decrease in cisplatin sensitivity in the Chinese hamster ovary cell 
line, CHO, transfected with the GSTir gene and Teicher et al. (1987) reported an increase 
in cisplatin resistance in the transfected head and neck squamous cell carcinoma cell line, 
SCC-25/CP. Clinical studies have also shown increased GST levels in tumours resistant 
to cisplatin. In one such study, Kodera et al. (1994) demonstrated increased GSTx 
expression in 30 gastric cancer specimens that were inherently resistant to cisplatin when 
compared with drug sensitive controls. However, no inverse relation between expression 
and cisplatin resistance was noted.
1.7.2.3 Inhibitors of glutathione and glutathione-S-transferase
Glutathione and related enzymes have been shown to be susceptible to inhibition by a 
number of non-cytotoxic drugs (Van Bladeren and Van Ommen, 1991) and consequently 
the effect of various agents that target these enzymes has been studied. Inhibitors of 
glutathione and related enzymes include ethacrynic acid, a non-cytotoxic diuretic drug, 
buthionine sulphoxamine (BSO) and sulphasalazine, a drug used in the treatment of 
inflammatory bowel disorders. It is probable that these compounds act by one or more of 
the following mechanisms:
•  competition with the alkylating agent for metabolism at the GST active site
• depletion of intracellular GSH
• inactivation of cellular GSTs by covalent modification of the enzyme
Ethacrynic acid is a specific inhibitor for glutathione-S-transferase and has been shown to 
enhance the cytotoxic effects of certain alkylating agents. However, a number of groups
48
have also reported that inhibition of GST by ethacrynic acid does not alter the cytotoxicity 
of cisplatin. Tew et al. (1988) demonstrated a reduction in resistance to the alkylating agent 
chlorambucil in two human colon carcinoma cell lines, HT29 and BE, following treatment 
with ethacrynic acid. Following this treatment both GST activity and cellular glutathione 
levels were decreased in both cell lines. However, when Kasahara and coworkers (1991) 
investigated the role of GST in the cisplatin resistant human small cell lung cell line, 
H69/CDDP, using ethacrynic acid they found that although GST activity was markedly 
decreased, the relative resistance of the cell line to cisplatin had not changed. Ethacrynic 
acid has also recently been shown to inhibit the activity of the GSH reductase enzyme. 
However, ethacrynic acid appears to have approximately 10 times greater potency in 
inhibiting glutathione-S-transferase relative to GST reductase activity (Hoffman et al.,
1995). Recently, the drug sulphasalazine has been reported to act as an effective inhibitor 
of the glutathione-S-transferase enzyme. Awasthi et al. (1994) used sulphasalazine to 
evaluate the relative role of GSTs in mediating cisplatin resistance in two human small cell 
lung cancer cell lines, NCI H-69 and H-2496. Both cell lines were found to have elevated 
levels of GSTx by Western blot and Northern blot analyses. Sulphasalazine inhibited the 
purified GSTs from both cell lines and cytotoxicity studies revealed that sulphasalazine also 
increased the cytotoxic effects of cisplatin in the two cell lines.
The effect of buthionine sulfoximine has been studied in a number of cell lines resistant to 
cisplatin and other alkylating agents. BSO is an effective and specific irreversible inhibitor 
of glutathione formulation, which acts by inhibiting the glutathione synthetase enzyme and 
thus inhibits the biosynthesis of glutathione (Griffith and Meister, 1979). Modulation of 
cellular glutathione levels in this way can lead to substantial reversal of alkylating agent 
resistance in drug resistant tumour cells. BSO was found to enhance the susceptibility of 
two human colon carcinoma cisplatin resistant cell lines, CP2.0 and RT, to cisplatin 
cytotoxicity following pretreatment for 24 hours (Yang et al., 1993). Inhibition of 
glutathione biosynthesis by BSO also resulted in an increase in cisplatin toxicity in the 
human small cell lung cancer cisplatin resistant cell line, GLC4-CDDP (Meijer et al., 1990). 
A number of studies, however, have also shown that BSO did not significantly alter 
resistance in other platinum resistant cell lines. Osmak and Eljuga (1993) found that 
inhibition of glutathione by BSO did not alter the sensitivity of two human cisplatin resistant 
cervical carcinoma HeLa sublines to cisplatin.
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1.7.3 Metallothioneins
Metallothioneins (MT) were first discovered in 1957, by Margoshes and Vallee, in the 
adrenal cortex of horses while searching for a tissue component responsible for the natural 
accumulation of cadmium in mammalian kidney. They are sulfhydryl-rich metalloproteins 
which bind to heavy metals, including zinc, copper, cadmium and platinum. Mammalian 
MTs have a molecular weight of 6000-7000 daltons, usually containing 61 to 62 amino acid 
residues, of which 20 are cysteines which bind a total of 7 equivalents of bivalent ions. All 
the cysteine residues occur in the reduced form and are coordinated to the metal ions 
through mercaptide bonds. Two major isoforms of metallothioneins have been identified 
in vertebrates, MT-I and MT-II (Hamer, 1986; Kobayashi and Sayto-Suzuki, 1988), which 
differ at neutral pH by a single negative charge. A third class of MTs, MT-III, has also 
been identified, however this class of MT has only been found in certain plants and 
microorganisms. There are at least five different human metallothionein I subtype proteins: 
MT-Ia, MT-Ib, MT-Ie, MT-If and MT-IG and one human metallothionein II, MT-HA, which 
have been separated by chromatographic techniques (Kagi and Schaffer, 1988; Kelley et al.,
1988). All the isoforms exhibit extremely high amino acid homology. The physiological 
role of each subtype, however, remains to be identified. Metallothioneins are found in all 
organs but are most abundant in the liver, kidney and intestine (Danielson et al., 1982). 
They appear to be located primarily in the cytoplasm of cells, however they have also been 
located in the nuclei of hepatic and renal cells (Banerjee et al., 1982). The subcellular 
distribution of metallothioneins has been reported to change during development and also 
with prolonged exposure to metals (Banerjee et al., 1982; Nartey et al., 1987). Although 
the functional significance of this altered distribution is as yet unknown, it is suspected that 
nuclear accumulation may occur with increased cellular metallothionein load or when cells 
are stimulated to undergo rapid proliferation.
The physiological function of metallothioneins remains unknown, although a number of 
specific functions have been postulated and include heavy metal detoxification, regulation 
of intracellular Cu and Zn levels, free-radical scavenging, protection from ionizing radiation 
and control of growth and differentiation. The most conclusive evidence supports the role 
of metallothioneins in heavy metal detoxification. Several laboratories have shown that cells 
exposed to heavy metals overexpress MT and are less sensitive to cytotoxicity of other 
heavy metals (Durnam et al., 1984). It has also been demonstrated that cell lines which
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express low levels of metallothioneins are extremely sensitive to cadmium toxicity (Compere 
and Palmiter, 1981). These results would suggest a prominent role for metallothioneins in 
heavy metal detoxification, although it does not appear to be their only biological role. 
Metallothioneins have been proposed to have a regulatory role in Zn and Cu homeostasis 
(Cousins, 1985), since the level of intestinal MT is inversely related to the absorption of 
Zn and Cu. This has been exploited in the treatment of Wilson‘s disease (an autosomal, 
recessively inherent disease involving abnormal copper handling by the liver) where 
intestinal MT expression can be increased by oral Zn therapy, with a concomitant decrease 
in Cu absorption (Brewer et al., 1983). Metallothioneins may also have a regulatory role 
in growth development, this concept being supported by the findings of programmed 
regulation of MT mRNA and protein levels in the course of embryogenesis (Nemer et al., 
1984; Andrews et al., 1991) and fetal development (Andrews etal., 1984). It has also been 
reported that increased expression of metallothioneins is observed in proliferating cells and 
consequently metallothioneins may also serve as proliferation markers (Nagel et al., 1995). 
There is also evidence that metallothioneins can scavenge free radicals that are produced 
during acute-phase response, reperfusion of hypoxic tissue and ionizing radiation (Thornally 
and Vasek, 1985).
Metallothionein expression can be induced by various factors, such as heavy metals, 
hormones, cathecolamines, corticosteroids and alkylating agents. The MT content of 
organs, most notably kidney and liver, as well as cultured cells can be increased by 
exposure to these agents. The induction of MT following exposure to heavy metals was 
first noticed in the liver of rabbits in 1964 following exposure to cadmium (Piscator, 1964). 
However, since then the number of agents that have been found to increase metallothionein 
expression has increased dramatically. Table 1.7.3 lists many of the factors that have been 
shown to induce metallothionein synthesis. The induction of metallothioneins by heavy 
metals such as cadmium, zinc and lead acetate has been extensively studied and has been 
found to result from transcriptional activation of the MT genes (Durnam and Palmiter, 
1981). Cellular metallothionein levels usually reach their maximum within 24 hours 
following exposure to the metal, however peak levels have been observed after shorter 
intervals. In cultured HeLa cells, maximum levels were noted after a 6 - 8 hour exposure 
to cadmium. The half-life of induced metallothioneins is 1 - 4 days, although this can vary 
depending on the metal state of the metallothionein (Hamer 1986). In human tissue and 
cells, expression of the metallothionein isoforms appears to be tissue specific and induction
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appears to be regulated differentially. Sadhu and Gedamu (1988) analyzed the pattern of 
expression of three human metallothionein genes (MT-IF, MT-IG and MT-IIA) in the human 
hepatoblastoma cell line, HepG2, in response to the metal ion inducers cadmium, copper 
and zinc. The absolute number of transcripts of each of the three genes was measured and 
the results obtained indicated differential regulation of the genes by the different inducers 
both in terms of rate and extent of transcript accumulation. They also found that these three 
MT genes responded differently to induction by the metal ion inducers. The lowest level 
of transcript accumulation was observed for the MT-IF gene and copper was shown to be 
its weakest inducer. Cadmium was shown to be the weakest inducer of MT-IG even though 
transcript of this gene accumulated at comparatively higher level than those of MT-IF. 
Cadmium was also found to be the weakest inducer of the MT-IIA gene.
Metallothioneins are also induced by stressful conditions such as heat, cold and starvation. 
These conditions raise circulating steroid hormone levels which act as inducers of 
metallothioneins. A number of groups have studied the effect of glucocorticoids on 
metallothionein induction. Glucocorticoids were first shown to regulate MT levels in 
cultured rat liver parenchymal cells (Failla and Cousins, 1978) and were subsequently found 
to stimulate MT synthesis in intact rodents, primarily in the liver but also in the kidney, 
spleen and skeletal muscle (Hager and Palmiter, 1981). In human cells grown in culture, 
glucocorticoids strongly induced the MT-IE and MT-IIA isoforms and slightly induced the 
MT-IA isoform although it did not appear to have an effect on the other isoforms (Schmidt 
and Hammer, 1986). In addition to steroid hormones, metallothionein synthesis is also 
stimulated by glucagon, angiotensin II and by a- and 13- adrenergic agonists (Cousins,
1985). Increased expression of metallothioneins has also been demonstrated following X- 
irradiation, hypoxia and inflammation. Shiraishi et al. (1986b) reported an increase in 
metallothionein content in rat liver and kidney following radiation treatment, with the degree 
of expression comparable to levels observed following induction with heavy metals. 
Northern analysis and Western blotting showed an increase in MT-IIA mRNA and total MT 
protein levels in the human squamous carcinoma cell line, A431, following hypoxia and 
during reoxygenation. The level of MT-IIA increased as a function of time and the highest 
level was observed after 14 hours of hypoxia and the message was sustained for at least 24 
hours of hypoxia (Murphy et al., 1994). Increased synthesis of MT has also been noted 
in response to inflammation (Durnam et al., 1984). The cytokines interferon and 
interleukin-1 have also been shown to increase intracellular MT concentrations (Friedman
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et al., 1984; Karin et al., 1985).
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Table 1.7.3 Factors that induce metallothionein synthesis (Bahnson et al., 1991)
1.7.3.1 Metallothionein in human tumours
The presence of metallothioneins in a number of human tumours has been demonstrated by 
immunohistochemical studies. Nartey and coworkers (1987) reported the detection of 
metallothioneins in 31 of 34 human thyroid tumours in archival paraffin embedded tissue 
samples while less than 20 percent of normal thyroid glands showed diffused distribution 
of metallothioneins. The positive staining was present in both nucleus and cytoplasm of 
thyroid adenomas and carcinomas. A number of studies also reported the presence of 
metallothioneins in testicular tumours (Chin et al., 1993). There was a distinct difference 
between MT staining in seminomas and non-seminomas (embryonal carcinoma, 
teratocarcinoma and choricocarcinoma) in human testicular tumours. Pure seminomas 
showed little or no staining for MT, irrespective of the clinical stage while non-seminomas 
stained heavily, especially in the more advanced clinical stages (Chin et al., 1993). 
Metallothionein staining in pleomorphic adenoma and adenoid cystic carcinoma of salivary 
gland has also been studied and the staining was found to be present, mainly in 
myoepithelial cells with intense staining in the proliferating edge (Chauvin et al., 1992). 
Studies by Ofner et al. (1994) in 109 colorectal adenocarcinomas demonstrated strong
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expression of metallothioneins in 34 cases and positivity in a further 24 cases. The 
remaining cases were negative for MT expression. The differences in MT expression were 
found to be significant and associated with the tumour stage and the lymph node 
involvement at the time of the operation. Expression of metallothionein has also been 
demonstrated in initial and relapsed childhood acute lymphoblastic leukaemia. Sauerbrey 
et al. (1994) found that in the group of patients studied, MT expression was detected in 
approximately 33% of patients with acute initial lymphoblastic leukaemia and in 
approximately 33% of patients in the relapsed state. There was no difference observed in 
the intensity and proportion of positively stained cells between initial and relapsed patients. 
Studies on nonmelanoma skin cancer have shown that metallothionein levels in a variety of 
tumours mirror the progressive potential of the tumours. In one example, well 
differentiated squamous cell carcinomas only showed MT labelling in peripheral cell layers, 
while in poorly differentiated squamous carcinomas, irregular clusters of tumour cells above 
the level of the peripheral cell layers showed MT labelling (Zelger et al., 1994). In a study 
of samples from patients with ductal carcinoma of the breast, metallothionein expression 
was shown to be associated with a more aggressive behaviour. In general, myoepithelial 
cells surrounding benign and malignant structures stained uniformly strongly for 
metallothioneins (Douglas-Jones et al., 1995). The immunohistochemical studies show that 
metallothioneins are expressed in a wide variety of human tumours, however the staining 
for MT is not universal to all tumour growth. The results demonstrate that expression of 
metallothioneins may depend on various factors, which may be related to the type of 
tumour, its cellular origin, morphological heterogeneity or its stage of growth.
1.7.3.2 Metallothionein and cisplatin resistance
The observation that metallothioneins play a role in heavy metal detoxification led to 
investigations exploring the relationship between cellular metallothionein levels and 
sensitivity to cisplatin. This concept was first demonstrated by Bakka and coworkers (1981) 
where they found that cadmium resistant human and mouse cultured cells, which contained 
increased levels of metallothioneins, were cross-resistant to cisplatin. Further studies 
showed that the platinum content was higher in the resistant cells than in the non-resistant 
cells and therefore excluded the possibility of decreased uptake or increased efflux as a 
mechanism for the observed differences in cisplatin resistance. These studies also showed
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that the major portion of the platinum in the resistant cells was associated with 
metallothionein. Numerous reports have since been published implicating metallothioneins 
as a cause of cellular resistance to cisplatin and other alkylating agents. In summary the 
reports have shown that:
•  tumour cells with increased MT content are resistant to both alkylating agents and 
cisplatin
• cells with acquired resistance to cisplatin frequently have increased MT levels and 
overexpress MT mRNA
• reversal of the cisplatin resistant phenotype is accompanied by a decrease in MT content
•  introduction of a eukaryotic expression vector encoding human MT-IIA into murine cells 
confers the drug resistant phenotype.
Teicher et al. (1987) isolated a cisplatin resistant variant of the human head and neck 
squamous cell carcinoma, SCC-25. No difference in non-protein sulfhydryl content was 
noted, although an increase of approximately 2-fold was observed in the protein sulfhydryl 
content in the resistant line compared to the parental cell line. Further studies by Kelley 
et al. (1988) demonstrated that the increase in protein sulfhydryl content was due to an 
increase in MT expression. Kelley et al. (1988) generated a panel of drug resistant human 
cell lines by repeated exposure to increasing concentrations of cisplatin and included the 
breast cell line, MCF-7/CP, the small cell lung carcinoma cell line, SW2/CP, the large cell 
lung carcinoma cell line, SL6/CP, and the melanoma cell line G336/CP. With the 
exception of the MCF-7/CP cell line, all the tumour cell lines expressed elevated levels of 
metallothioneins compared to the corresponding parental cell line.
Andrews and Howell (1990) reported increases in MT levels in the cadmium chloride 
resistant human ovarian carcinoma cell line, 2008, that was cross resistant to cisplatin. 
Elevated levels of MT have also been demonstrated in two cisplatin resistant variants of the 
human small cell lung carcinoma cell line H69. The two variants were 6-fold and 11-fold 
resistant to cisplatin and displayed cross resistance to cadmium chloride. The expression 
of MT mRNA was higher in the resistant variants and the expression was related to the 
sensitivity of the cells to cisplatin (Kasahara et al., 1991). Kondo et al. (1995) investigated 
the cellular content and subcellular distribution of metallothioneins in four human hormone- 
independent prostatic carcinoma cell lines. Different levels of MT expression were 
observed in the four cell lines and it was also demonstrated that the cell lines exhibited 
different patterns in the subcellular distribution of MT. The cells which had primarily
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nuclear MT were more resistant to cisplatin compared to the lines that had more diffuse 
cytoplasmic, perinuclear and nuclear staining. Metallothionein expression has also been 
studied in murine cell lines. In one study, a cisplatin variant of the mouse leukaemia cell 
line, L1210, was shown to have elevated levels of MT when compared to the parental cells 
and the degree of resistance was found to correspond with MT content in the resistant cells 
(Kelley et a l . , 1988). It was also demonstrated that the cisplatin revertant cell line exhibited 
decreased levels of metallothionein, thus suggesting that MT was involved in the resistant 
phenotype.
The above evidence suggests that increases in metallothionein expression occur with 
acquired resistance to cisplatin, although not all cell lines with acquired cisplatin resistance 
overexpress MT. A cisplatin variant of the MCF-7 human breast cancer cell line was 
shown to be approximately 3-fold resistant to cisplatin, although no alteration in 
metallothionein levels were noted in this cell line when compared to the parental cells 
(Kelley et al., 1988). Andrews et al. (1987) demonstrated that the human ovarian cell line, 
2008, which was 3-fold resistant to cadmium chloride had unaltered levels of MT. Finally 
Mellish et al. (1993) studied MT levels in a panel of five human cervical squamous 
carcinoma cell lines that exhibited acquired resistance to cisplatin and found that there was 
no significant difference in cellular MT levels.
A number of studies have been carried out modulating the toxicity and resistance of cisplatin 
by induction and inhibition of metallothionein synthesis. Cisplatin, when administered has 
various side effects including nephrotoxicity, gastrointestinal toxicity and pulmonary 
toxicity. The objective in a number of studies was to develop treatments to prevent toxicity 
of cisplatin by induction of metallothionein synthesis without compromising its antitumour 
activity. Naganuma et al. (1987) showed that preinduction of MT in the kidney by 
administration of bismuth nitrate decreased the renal and gastrointestinal toxicity in mice 
caused by a single injection of cisplatin administered 24 hours later. The renal MT content 
of the mice was significantly increased in comparison to the control mice and a distinctive 
relation was found between the protective effect of bismuth nitrate and the preinduced MT 
levels in the kidney. When the effect of pretreatment of bismuth nitrate on the antitumour 
activity of cisplatin was examined it was found that this pretreatment had no effect on the 
antitumour activity of cisplatin against several transplantable tumours. Preinduction of 
pulmonary MT by bismuth nitrate and zinc compounds has also been demonstrated in mice.
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Cisplatin is known to induce lung tumours, however Satoh and coworkers (1994a) showed 
that pretreatment with zinc or bismuth nitrate resulted in a decrease in the occurrence of 
pulmonary adenomas following cisplatin treatment. An increase in pulmonary MT was 
noted which appeared to protect the mice from secondary carcinogenesis. Studies have also 
been reported on compounds which inhibit metallothionein synthesis and enhance the 
sensitivity of cells to cisplatin. An example of such a compound is proparglycine, an 
inhibitor of cystathionase (an enzyme involved in the conversion of methionine of cysteine) 
which has been shown to decrease MT induction by zinc in human bladder tumour cells 
(NMB-1) that were inoculated in nude mice. Pretreatment of the tumour bearing mice with 
zinc salts resulted in an increase in MT content and a marked reduction of the antitumour 
activity of cisplatin. When proparglycine was then administered a decrease in MT levels 
and diminished resistance to cisplatin was observed (Satoh et al., 1994b).
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1.8 Antibodies in the study of MDR
Antibodies to multidrug resistant-associated antigens are now widely used in the 
characterisation and analysis of MDR in cell lines and clinical samples. Over the last 
decade a number of monoclonal and polyclonal antibodies useful in the study of MDR have 
been generated, including antibodies to P-glycoprotein, topoisomerase, glutathione-S- 
transferase enzymes and metallothionein. The technique for producing virtually unlimited 
quantities of a single antibody, specific for a particular antigenic determinant has been a 
major breakthrough in MDR research. Biological production involves manipulation of the 
hybridization technique first developed by Cotton and Milstein (1973) and Kohler and 
Milstein (1975). The technique involves cell fusion or somatic cell hybridization between 
a normal antibody-producing B cell obtained from the spleen of mice immunized with a 
specific antigen and a myeloma cell line. This is followed by the selection of fused cells 
that secrete antibody of the desired specificity, derived from the normal B cells (figure 
1.8 . 1).
The success of this technique depended on the development of cultured myeloma lines that 
would grow in normal culture medium but would not survive in defined selection medium 
lacking functional genes required for DNA synthesis. Normal cells synthesize nucleotides 
de novo from phosphoribosyl pyrophosphate and uridylate in several steps, one of which 
involves the transfer of a methyl or formyl group from activated tetrahydrofolate. 
Antifolate drugs, such as aminopterin, block the reactivation of tetrahydrofolate, thereby 
inhibiting the synthesis of purine and thymidlylate. Since these are necessary components 
of DNA, aminopterin blocks DNA synthesis through the de novo pathway. However, 
purine synthesis can occur through a salvage pathway from exogenously supplied 
hypoxanthine using the enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) 
and thymidylate can be synthesised from thymidine using the enzyme thymidine kinase. 
Therefore, cells grown in aminopterin can synthesize DNA if supplemented with 
hypoxanthine and thymidine (figure 1.8.2). Antibody production, therefore involves 
selecting for fused cells that grow in medium containing hypoxanthine, aminopterin and 
thymidine (HAT). The principle behind this approach is that the parent myeloma cell line 
is HAT sensitive lacking the enzymes, HGPRT and thymidine kinase (TK) and therefore 
can not chemically synthesise DNA and RNA when grown in the selecting HAT medium.
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While the parent lymphocytes contain these enzymes, they can not grow indefinitely. The 
myeloma cells confer immortality on the antibody producing B lymphocyte fused cells, and 
allows them to grow in culture. This technology has allowed the production of essentially 
unlimited quantities of pure homogenous antibodies against a large variety of antigens 
including enzymes, hormones, lipids, carbohydrates, bacteria, synthetic peptides and cellular 
extracts. This technology has been applied in MDR research with the production of both 
polyclonal and monoclonal antibodies to a number of multidrug resistant cell lines and 
synthetic peptides to MDR proteins.
1.8.1 Anti-P-glycoprotein monoclonal antibodies
A number of antibodies to P-glycoprotein have been reported including the mABs C219, 
MRK16, MRK17, JSB-1, 265/F4 and UIC2. Ling and coworkers established a number of 
monoclonal antibodies by immunization of BALB/c mice with a mixture of purified plasma 
membrane fractions from a colchicine resistant Chinese hamster ovary cell line, CHRB30 and 
a vinblastine resistant variant of a human leukaemia cell line, CEM/VBL500 (Kartner et 
al., 1985). Included in this series of antibodies is the C219 mAB which recognizes a 
cytoplasmic epitope of the P-glycoprotein molecule six residues away from the consensus 
sequence that is believed to be the ATP-binding domain of the protein. This epitope is 
highly conserved in all P-glycoprotein isoforms, thus the C219 antibody recognizes all 
classes of the mdr gene in both human and murine cell lines (Georges et al., 1990; Barrand 
et a l., 1992). Also included in this group of P-glycoprotein specific antibodies is the C494 
mAB which is gene specific and binds to a sequence present only in the class I isoform of 
hamster and human P-glycoprotein and the mAB C32 which recognizes a sequence in 
hamster class 1 and II isoforms (Georges et al., 1990). The C219 antibody has been used 
successfully for the detection of P-glycoprotein for immunohistochemistry, immunoblotting 
and flow cytometry.
The monoclonal antibodies, MRK16 and MRK17, were raised against the adriamycin 
resistant human myelogenous leukaemia cell line, K562/ADM. They recognise an 
extracellular epitope of the P-glycoprotein molecule and are specific for the human mdr-1 
(Hamada and Tsuruo, 1986). MRK16 has been shown to increase intracellular 
accumulation of vincristine and actinomycin-D and enhance vincristine cytotoxicity in the
59
K562 resistant cells. However, the MRK17 antibody was found to inhibit the growth of 
resistant cells only. Later studies demonstrated that the MRK16 antibody effectively 
prevented tumour development in athymic mice innoculated with drug resistant human 
ovarian cancer cells (Tsuruo et al., 1989). The MRK16 antibody can also be used 
successfully for immunohistochemistry and immunoblotting. The JSB-1 antibody was 
established by immunization of BALB/c mice with whole intact colchicine resistant Chinese 
hamster ovary cells (Scheper et al., 1988). This antibody is not species specific and 
recognizes a cytoplasmic epitope closely linked to that recognized by C219. The UIC2 
antibody was established by immunization of BALB/c mice with vinblastine resistant 
BALB/c 3T3-1000 cells. Similar to the MRK16 antibody, the UIC2 mAB recognizes an 
external epitope of the human P-glycoprotein. UIC2 has been shown to inhibit the efflux 
of P-glycoprotein substrates from MDR cells and also to significantly increase the 
cytotoxicity of various MDR drugs (Mechetner and Roninson, 1992).
1.8.2 Antibodies against non-P-glycoproteins
Monoclonal antibodies to a number of other MDR-associated antigens have also been 
described which have proved to be useful tools in the study of MDR. Polyclonal antibodies 
have frequently been used to detect levels of topoisomerase II isoforms (Drake et al., 1987; 
Drake et al., 1989; Hwang et al., 1989). However, more recent studies have utilized a 
series of topoisomerase II specific polyclonal and monoclonal antibodies to enable detection 
of the topoisomerase II isoforms. A number of polyclonal antibodies were raised against 
two synthetic peptides of human topoisomerase II cDNA. Antibodies raised against one 
peptide (SPI) specifically recognized the 170 kDa a  form of the topoisomerase II, while 
antibodies raised against the second peptide (SPII) selectively recognized the 180 kDa B 
isoform (Chung et al., 1989). Robinison et al. (1993) established two murine monoclonal 
antibodies directed against a 70 kDa polypeptide which responded to the carboxyl-terminal 
of human topoisomerase Ilex. The antibodies were found to be specific for human 
topoisomerase II, although only recognizing the topoisomerase Ila  isoform. Monoclonal 
antibodies specific for human topoisomerase isoforms have also been established by Negri 
et al. (1992). The two antibodies, 6G2 and 8F8, specifically recognize the a  and ft 
isoforms respectively.
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Polyclonal and monoclonal antibodies have also been generated against multidrug resistance- 
associated protein (MRP), the 180 - 195 kDa membrane glycoprotein involved in non-P- 
glycoprotein multidrug resistance of human tumour cells. Rabbit antisera against three 
synthetic peptides responding to the deduced sequence of MRP was prepared. Western blot 
analysis with the antiserum, ASPKE, raised against one of the peptides demonstrated the 
presence of a 190 kDa protein contained in membranes of HL60/ADR resistant cells but 
absence in membranes prepared from the parental HL60 cells (Krishnamachary and Center,
1993). Rat and murine monoclonal antibodies were also raised by Flens et al. (1994), 
against two different peptide sequences of MRP, FPI and FPIII. Hybridomas secreting 
antibodies that reacted with MRP were selected on the basis of strong immunocytochemical 
staining with GLC4/ADR cells, the non-P-glycoprotein MDR subline of the small cell lung 
cancer cell line, GLC4. The antibodies recognized a protein of 195 kDa protein in isolates 
of the GLC4/ADR cells, indicating that they reacted with MRP. One rat monoclonal 
antibody, MRPrl, and one mouse monoclonal antibody, MRPm6, were subcloned and 
further characterized. Cole et al. (1992) established rabbit polyclonal antibodies against a 
synthetic peptide, the sequence of which was predicted from that of the clones MRP cDNA. 
The purified anti-MRP antibody recognized a glycosylated, integral membrane protein with 
an apparent molecular weight of 190 kDa. Five murine monoclonal antibodies were raised 
against extracts of the resistant H69/AR cell line. The antibodies reacted specifically with 
membrane proteins of the MRP positive H69/AR cells, and three of the antibodies also 
selectively immunoprecipitated a 190 kDa protein from 35S-labelled H69/AR cells (Hipfner 
etal., 1994).
A monoclonal antibody has also been raised to the 110 kDa lung resistance protein (LRP) 
by imunization of BALB/c mice with cellular extracts of the P-glycoprotein-negative cell 
line SW1573/2R120 (Scheper et al., 1993). The hybridomas secreting antibodies were 
selected by enzyme-linked immunosorbent assays with the resistant SW1573/2R120 and the 
parental SW1573 cells. One of the hybridomas, LRP-56, was subcloned by limiting 
dilution and the LRP-56 immunoglobulin purified from ascites. A number of antibodies to 
glutathione-S-transferase have been established, in particular to the GST7T isoform. 
Mannervik et al. (1985) developed a polyclonal anti-human glutathione-S-transferase ir 
antibody that recognized a 47 kDa protein, consistent with the reported molecular weight 
of GSTir. Polyclonal antibodies to GST-tt have also been established by Kodate et al. 
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Figure 1.8.2 Pathways of nucleotide synthesis (a) and drug selection for viable hybridomas (b)
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1.9 Aims of thesis
The aim of the work performed in the early part of the studies described in this thesis was 
to establish and characterise novel, platinum resistant, variants of the human lung carcinoma 
cell line, DLKP. The establishment of the resistant variants was effected through 
continuous exposure to increasing concentrations of the the drug, carboplatin, chosen 
because of its lower toxicity and its widespread clinical application, particularly in the 
treatment of lung and ovarian carcinomas. The characterisation work involved biochemical, 
immunological and toxicological studies on the established variants.
Given that reduced drug accumulation is a characteristic of many MDR cell lines, the 
objective of the work done in the next phase was to investigate the accumulation of the 
anticancer agents, adriamycin and vincristine in a number of human MDR cell lines and 
also to determine the effect of a range of compounds on drug retention in the resistant cells. 
In addition, since many MDR cell lines have also been shown to display altered subcellular 
distribution, studies were carried out to investigate the effect of a number of agents on the 
subcellular distribution of adriamycin. These agents had previously been included in the 
studies carried out on the accumulation of anticancer agents. Since adriamycin is inherently 
fluorescent under ultraviolet illumination, it was considered to be an ideal drug for use in 
these subcellular distribution studies
The results obtained from the studies carried out on the investigation of the accumulation 
of anticancer agents and on the subcellular distribution of adriamycin, indicated the 
existance of alternative mechanisms involved in the decreased drug accumulation in MDR 
cell lines. Consequently, the objective of the work carried out in the final phase was to 
raise antibodies which may be associated with this reduced drug accumulation in MDR cell 
lines. These antibodies were raised against an adriamycin resistant variant of the human 
lung carcinoma cell line, DLKPA10, which displayed a reduction in drug accumulation and 
an altered subcellular drug distribution pattern relative to the parental cells.
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Materials and Methods
2.1 Preparation of cell culture media
2.1.1 Water quality
All water used in the preparation of cell culture media was purified by a Milli-Pore 
ultrapure water system or an ELGA UHP system. The water was first prefiltered, followed 
by a double distillation step (ELGA) or passage through a reverse osmosis system (Milli-Q). 
It was then passaged through two ion-exchange filters and a carbon filter to remove organic 
solutes. Finally the water was passed through a 0.22/xm cellulose acetate filter resulting in 
ultrapure water which was continuously monitored by an on-line conductivity meter.
2.1.2 Glassware treatment
All items of glassware used in cell culture (media bottles, roller bottles, waste bottles etc.) 
were soaked in a warm 2% solution (v/v) of the non-ionic detergent RBS (Chemical 
products; Belgium) for 1-2 hours. They were then individually scrubbed with bottle brushes 
and rinsed thoroughly with tap water to remove all RBS residue. This was followed by 
three separate washes in deionised water before a final rinse in ultra pure water.
2.1.3 Sterilization
All glassware used in cell culture, such as media bottles, roller bottles etc. were sterilized 
by autoclaving. All items were autoclaved before use at 121°C and 15 psi pressure for 20 
minutes. Phosphate buffered saline (PBS), water and the relevant solutions for media 
preparation (HEPES, HC1, NaOH and NaHC03) were sterilized using the above conditions. 
Filter sterilization was employed for unstable reagents, including cell culture media and 
protein solutions. Sterile disposable 0.22fim filters (Millex-GV, SLGV025BS) were used 
for small volumes. Larger volumes, such as culture media, were filter sterilized through 
a micro-culture bell filter (Gelman 12158) which has a filtering capacity of 10 litres.
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2.1.4 Basal medium preparation
The preparation of basal medium was carried out under sterile conditions in a class 11 
laminar flow cabinet. All media were prepared from a 10X stock of liquid or powder 
concentrates and made up in batches of 5 litres with sterile ultrapure water. Hams F I2 was 
made up exclusively from a powdered batch to 5 litres (Gibco 21700-109). The powder 
was dissolved in 4.7 litres of ultrapure water and supplemented with 1M HEPES (Sigma 
7365-45-9), and 7.5% NaHC03 (BDH 30151). The pH was adjusted with 5M NaOH 
(Merck 1.06482.1000) and 1.5M HCL (BDH 10158) to give the desired pH of 7.45 - 7.55. 
The liquid concentrates were prepared by the addition of 500 mis of the 10X stock to 4.3 
litres of ultrapure water and were supplemented with 1M HEPES and 7.5 % NaHC03. The 
PH was again adjusted with 5M NaOH and 1.5M HC1. Table 2.1.4 illustrates the 
components required for the preparation of 5 litres of the three basal media used in these 
studies. The medium was then filter sterilized through a micro culture capsule bell filter 
into 500 ml sterile bottles and aliquots from each bottle were removed for sterility tests. 
The bottles were labelled and stored at 4°C and used only after the sterility tests proved 
negative.










DMEM 12501-029 4.3L 500mls lOOmls 45mls
MEM 21430-020 4.3L 500mls lOOmls 45 mis
Hams F12 21700-109 4.7L 5 L  concentrate 100 mis 45mls
Table 2.1.4 Preparation of basal medium from 10X stock.
2.1.5 Preparation of HEPES and NaHC03
The HEPES buffer was prepared by dissolving 23.8g of HEPES in 80 mis of ultrapure 
water and the solution was then autoclaved. Following autoclaving, 5 mis of sterile 5M 
NaOH was added to give an approximate volume of 100 mis. NaHCOa was prepared by 
dissolving 7.5g in 100 mis of ultrapure water and autoclaving the resulting solution.
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2.1.6 Media supplements
A 200 mM solution of L-glutamine (Gibco 28030-024) was added to the basal media to give 
a final dilution of 1:100 L-glutamine. The L-glutamine is a relatively unstable component 
of cell culture medium and was therefore only added to the media three days before use. 
100 mis of L-glutamine was aliquoted and stored at -20°C until required.
100 mM sodium pyruvate (Gibco 11360-039) and also a 1:100 dilution of 100X stock of 
non essential amino acids (NEAA; Gibco 11140-035) were added to the MEM basal 
medium to supplement the growth medium for the SKMES-1 and SKMES-1/ADR cell lines.
2.1.7 Serum
All basal media used throughout these studies were supplemented with 5 % foetal calf serum 
(unless otherwise stated). Due to batch to batch variability of the serum, routine batch 
screening was carried out to select a serum suitable for the particular cell line being used. 
10-15 samples of serum were screened on a number of cell lines and suitable foetal calf 
serum was chosen for adherent cells (Seromed SOI 15) and hybridoma cells (Advanced 
protein products AS-302-50). The serum screen was carried out using miniaturised assays 
similar to the toxicity assays described in section 2.6. The serum was purchased in bulk 
and stored longterm at -20°C until required.
2.1.8 Sterility tests
Sterility checks were carried out on all IX bottles of basal media prior to the preparation 
of complete growth medium. Aliquots of medium were removed and treated in a number 
of ways. A 3 ml sample of medium was incubated to test for bacterial contamination. 1ml 
samples were inoculated in sabauraud broth (Oxoid CM 147) which supports the growth of 
fungus and thioglycollate broth (Oxoid CM173) which supports the growth of anaerobic 
bacteria. A further sample was streaked on blood agar plates (Columbian base agar: Oxoid 
CM331) to test for aerobic bacterial and yeast contamination. All sterility tests were 
incubated at 37°C and left for 3-5 days to test for bacterial contamination and a minimum 
of 14 days to test for fungal or yeast contamination. The media was only used if all tests 
were negative after this time. After the basal medium was supplemented with FCS, L- 
glutamine and other supplements required for the particular cell line, aliquots of medium 
were removed and sterility checked, as above, prior to use.
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2.2 Routine maintenance of cell lines
2.2.1 Cell lines used in studies
All cell culture work was performed aseptically in class II vertical down-flow recirculating 
laminar flow cabinets (Nuair or Holten cytoguard). The cell lines used throughout this 
work are outlined in table 2.2. The lines used were all human cell lines and anchorage 
dependent, with the exception of the SP2 cell line (murine myeloma cell line) that attaches 
only loosely. The human cell lines were grown in 25cm2 (Costar 3055) and 75cm2 (Costar 
3375) tissue culture treated unvented flasks and the SP2 cells were grown in 25cm2 (Costar 
3056) and 75cm2 (Costar 3276) vented flasks. All cell lines were incubated at 37°C in an 
atmosphere of 5% C 0 2 and were fed every two to three days.
Cell tine Source Description Basal medium
DLKP G. Grant 
NCTCC’
Human lung squamous 
carcinoma
50% DMEM:50% Hams F12




50% DMEM:50% Hams F12
SKMES-1 ATCC" Human lung squamous 
carcinoma
MEM





T24 ATCC Human bladder 
carcinoma
50% DMEM:50% Hams F12




50% DMEM:50% Hams F12
T24V G. Grant 
NCTCC
VP16 resistant variant 
of T24
50% DMEM:50% Hams F12
OAW42 ATCC Human ovarian 
carcinoma
50% DMEM:50% Hams F12
0AW42-A NCTCC Adriamycin resistant 
variant o f OAW42S
50% DMEM:50% Hams F12
SP2 Immune Systems Murine myeloma IX  DMEM
1 National Cell &  Tissue Culture Centre, Dublin City University. 
b American Tissue Culture Collection, Rockville, MD, USA.
Table 2.2 Cell lines used in this work
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2.2.2 Subculturing of cell lines
Adherent cells grown as monolayers in tissue culture flasks were generally subcultured 
before confluency was reached. The cells were enzymatically detached from the flask using 
a 0.25% (w/v) trypsin (Gibco 25090-028)/0.01% (w/v) EDTA (BDH 10093) solution in 
PBS (Oxoid BR14A). The waste medium was decanted from the flasks and the cells rinsed 
with 2ml of prewarmed trypsin/EDTA solution. The cells were then incubated at 37°C with 
a further 2ml of trypsin/EDTA (5 ml for a 75cm2 flask) for 5-15 minutes (depending on 
the cell line) until a single cell suspension was obtained, as determined microscopically. 
An equal volume of complete medium was added to inhibit the action of the trypsin/EDTA 
and the resulting cell suspension was pelleted by centrifugation at 1000 rpm for 5 minutes. 
The supernatant was removed and the cells were resuspended in 5ml of fresh complete 
medium. An aliquot of cell suspension was removed for cell counting and the cells were 
reseeded at the desired concentration in tissue culture flasks. Complete medium was added 
to the flasks to give approximately 8ml of medium in a 25cm2 flask and 15ml in a 75cm2 
flask.
2.2.3 Cell counting
An aliquot of the single cell suspension was removed for counting and mixed in a ratio of 
4:1 with trypan blue dye (Gibco 043-05250H). The suspension was left for approximately 
1 minute to ensure equal mixing of the trypan blue with the cells before a small quantity 
was applied to a haemocytometer. The suspension moved into the 0.01mm deep depression 
of the haemocytometer by capillary action. Cells in the 16 squares of the four outer corner 
grids were counted (both stained and unstained cells) and averaged. The average number 
of cells was multiplied by 1.2 x 104 to give the number of cells per ml (1.2 being the 
dilution factor of the trypan blue). Non viable cells stained blue with the trypan blue dye 
while the viable cells remained unstained.
2.2.4 Large scale cell culture
In order to gain sufficient stocks of the cell lines used throughout this work the cells were 
grown in either glass or plastic disposable roller bottles (Falcon 3027) to acquire large 
numbers of cells. The roller bottles were first rinsed with 15ml of complete medium, after
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which approximately 5xl06 cells were added (number dependent on cell line used). The 
roller bottle was then incubated at a rotor speed of 0.25 rpm for approximately 24 hours, 
after which time the rotor speed was increased to 0.5 rpm. The cells were fed every 3-4 
days until 80% confluency was reached. The cells were then frozen for stocks.
2.2.5 Cell freezing
All the cell lines used throughout this work were stored long term at -196° C in a liquid 
nitrogen refrigerator. Cells in subconfluent exponential phase were most suitable for long 
term storage. The cells for freezing were trypsinised and a single cell suspension was 
obtained as described in section 2.2.2. The pellet was resuspended in 100% FCS. An 
equal volume of a 10% (v/v) DMSO (dimethylsulphoxide, Sigma D-5879) in FCS was 
added drop wise with continuous mixing over a number of minutes. After the DMSO was 
added the suspension was transferred to sterile cryovials (Greiner 122 278). The vials were 
labelled with the name of the cell line, the passage number, the date and finally the 
operators initials before being placed in the vapour phase of the liquid nitrogen container 
for 3 hours. After this time the cells were transferred to the liquid phase and stored until 
required. A protective face visor and protective gloves were worn at all times during 
handling of the liquid nitrogen.
2.2.6 Cell thawing
The vial of cells to be thawed was removed from the liquid phase and placed in the vapour 
phase for 2-3 minutes to allow any liquid nitrogen present in the vial to evaporate. The 
cells were then thawed rapidly in a water bath at 37°C and transferred to a sterile universal 
container containing 9ml of complete medium. The cells were pelleted by centrifugation 
at 1000 rpm for 5 minutes. The medium was decanted and the pellet resuspended in 5 ml 
of complete medium. The cell viability was determined and the cell suspension was then 
transferred to tissue culture flasks and incubated for 24 hours. After this time the cells 
were refed with fresh complete medium.
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2.3 Mycoplasma detection
The cell lines used during this project were routinely screened for the presence of 
mycoplasma infection. Unlike other microbial contamination, mycoplasma are not visible 
microscopically and infected cells may continue to grow and divide. However, infection 
can result in decreased proliferation rates, changes in the morphology and granulation of 
the cells. To detect the presence of mycoplasma, the cells were examined by a direct 
culture method and an indirect staining method (Hoechst 33258). The cells to be screened 
were grown for 3 days in drug free and antibiotic free medium and after this time the 
medium was collected and used for the screening process.
2.3.1 Hoechst DNA staining method
In this method, since cell integrity is well maintained during the fixation procedure, an 
indicator cell line NRK (normal rat kidney fibroblast cell line) was used. The NRK cells 
(2xl03) were grown on sterile coverslips overnight in 1ml of DMEM supplemented with 5% 
FCS and 1% L-glutamine. The cells were incubated at 37°C in 5% C 0 2. 1ml of the 
culture medium was added to duplicate coverslips which were then incubated for 4-5 days. 
After this time the cells were approximately 50% confluent. The medium was removed and 
the cells were rinsed twice in PBS followed by one rinse in a 1:1 cold solution of 
PBS.Carnoys reagent (1:3 Glacial acetic acid (BDH 27013) and methanol (BDH 10158)). 
The cells were then fixed in 2ml of Carnoys reagent for 10 minutes. The samples were 
allowed to air dry before 2 ml of Hoechst (Sigma B-2883) working stock (50ng/ml in PBS) 
was added for 10 minutes. The Hoechst is light sensitive so all staining was carried out in 
darkness. The coverslips were then rinsed 3 times with ultrapure water and mounted on 
a slide in a drop of glycerol mounting medium (50% glycerol (BDH 10118) in 0 .1M citric 
acid ; 0.2M disodium sulphate at pH 5.5). The slides were then examined using a mercury 
fluorescence microscope. The Hoechst stain binds specifically to DNA, staining the nucleus 
of the cells and any extranuclear DNA that may be present. If mycoplasma contamination 
was present, small fluorescent bodies were visible in the cytoplasma of the cells. 
Mycoplasma contaminated medium and medium not exposed to cells were used as positive 
and negative controls respectively.
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2.3.2 Mycoplasma culture method
100 mis of mycoplasma agar (Oxoid CM401) and mycoplasma broth (Oxoid CM403) were 
prepared and 90 mis of each were supplemented with 20 ml FCS, 1 ml fungizone (Gibco 
042-05290), 250/d penicillin (Sigma Pen-3), 1.3 ml of a 0.2% stock of DNA (BDH 42026) 
and 10 mis of a 25 % (w/v) stock of yeast extract (which was boiled for 5 minutes before 
being filtered and aliquoted). 0.5 ml of the growth medium from the cell lines was 
incubated in 3 ml of mycoplasma broth for 48 hours at 37°C and then a streak from the 
broth was inoculated onto 10 mis of the solidified agar. The agar plates were incubated in 
a C 0 2 gaspak system for 3-4 weeks during which time the plates were examined for colony 
formation. If mycoplasma contamination was present, typical "fried egg" type colonies, 
consisting of a dense centre and a less dense surround would have been visible.
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2.4 Safe handling of cytotoxic drugs
Cytotoxic drugs were treated with extreme caution in the laboratory at all times due to the 
potential risks in handling these drugs. Generally two pairs of latex disposable gloves 
(Medical Supplies Company Ltd) and a face mask were worn when dealing with the 
concentrated stocks of the drugs and all work was carried out in cytotoxic cabinets (Gelman 
cytoguard or Holten Laminar Air cytotoxic cabinet). All drugs were stored in a safety 
cabinet at room temperature or in designated areas at 4°C or at -20°C. Table 2.4 outlines 
the storage and means of disposal of the cytotoxic drugs used in this work. All liquid drug 
waste was disposed of in the same way as the drug.




Farmitalia 4°C in darkness Inactivated with 1 % 
hyperchloride solution 






4°C in darkness Inactivated by 
autoclaving and 









Farmitalia Room temperature in 
darkness
Inactivated with 5M 









Room temperature in 
darkness
Incineration
Table 2.4 Storage and disposal of cytotoxic drugs
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2.5 Adaptation of MDR variants
A toxicity assay was initially carried out (section 2.6.1) on the parental cell lines in order 
to determine the concentration of the selective agent that resulted in 90% cell kill. The 
selective agent was then added to cells in the exponential phase of growth at the relavant 
concentration. The cells were grown at this concentration of drug until they appeared 
healthly and had reached approximately 70% confluency, after which time the concentration 
of drug to which the cells were exposed was increased. This process was continued over 
a number of months until the desired concentration was reached. The selection process for 
the DLKP cell line with the cytotoxic agent carboplatin was commenced at 1/ig/ml 
carboplatin and increased to a final concentration of 25/ig/ml carboplatin (DLKPC 25).
2.6 Miniaturized in vitro toxicity assays
The toxicity profile of the cell lines used throughout this work was determined using 
miniaturized toxicity assays. Two days prior to the assay, the cells were subcultured and 
reseeded in a 75cm2 flask at a concentration of 5xl05 cells per ml. The cells were allowed 
to attach and the following day the cells were refed in complete medium and incubated 
overnight at 37°C. The cells were trypsinised and a single cell suspension was prepared as 
described in section 2.2.2. The cell count and cell viability was then determined using 
trypan blue.
2.6.1 Toxicity assay - 96 well plates
The cells were plated in 96 well plates (Costar 3596) at a concentration of lxlO3 cells/well 
in 100/d of complete medium. The first lane of each plate was used as a cell blank to 
which 100/d of complete medium was added. The plates were gently rotated to ensure 
equal distribution of the cells within the wells. The cells were then allowed to attach 
overnight at 37°C in 5% C 0 2. The following day a series of 2X drug dilutions were 
prepared ranging from a non toxic concentration to a concentration that resulted in 100% 
cell kill. 100/d of the drug dilution was added to each well in replicates of eight and 100/d 
of complete medium was added to lanes one and two which served as a blank and a 100%
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cell survival control respectively. The plates were then incubated for 5-6 days until cells 
in the control wells had reached approximately 80% confluency. The medium was decanted 
from the wells and the cells were rinsed twice in PBS. 100/d of the assay substrate (lOmM 
p-nitrophenyl phosphate (Sigma 104) in 0 .1M sodium acetate (Sigma S-2889), 0.1 % Triton 
X-100 (Sigma X100)) was added to each well (Martin and Clynes, 1991). The assay 
substrate was prepared just before use and the pH was adjusted to pH 5.5. The plates were 
incubated for two hours at 37°C in 5 % C 0 2 and then read in a dual beam ELISA plate 
reader at a wavelength of 405nm (reference wavelength 620nm). The first lane of each 
plate was used to blank the ELISA plate reader. If the colour obtained was slight it was 
enhanced by the addition of 50/d of IN NaOH which also stopped the enzymatic reaction.
2.6.2 Toxicity assays - 24 well plates
Cells were plated in 24 well plates (Costar 3424) at a concentration of 2x10s cells per well 
in 500/d of complete medium. The first lane of each plate was used as a blank to which 
500/d of medium was added, The cells were allowed to attach overnight at 37°C in 5% 
C 0 2. A series of 2X drug dilutions were prepared and 500/d of each dilution was added 
to four replica wells. The plates were incubated for a further 5-6 days, until the control 
cells had reached approximately 80% confluency. The medium was then decanted from the 
plates and the cells rinsed twice in PBS. The cells were then fixed in 10% formalin (Riedel 
de Haen D-3016) for 10 minutes, after which time the formalin was removed and the plates 
air dried. The cells were stained with 0.25% crystal violet (Sigma C-3886) for 10 minutes 
and then washed thoroughly to remove the excess stain. The plates were allowed to air dry 
and the stain eluted by the addition of 33% glacial acetic acid (BDH 27013). 200/d of the 
resulting solution was transferred to 96 well plates and read on a dual beam plate reader at 
a wavelength of 570nm (reference wavelength 620).
2.6.3 Circumvention assay - 96 well plates
The cells were plated in 96 well plates at a concentration of lxlO3 cells per well in 100/d 
of medium. 100/d of medium was added to the first lane of each plate which served as a 
blank. The cells were incubated for 24 hours at 37°C in 5% C 0 2, to allow the cells to 
attach. A series of 4X drug dilutions were prepared and 50/d of the drug was added to the
wells in replicas of eight. A 4X stock of the circumvention agent was also prepared (the 
concentration that resulted in 95% cell survival, as determined from its toxicity profile, was 
used in the assays) and 50/d was added to each of the appropriate wells. Control wells 
containing only the drug or circumvention agent were also set up. The plates were then 
incubated at 37°C in 5 % C 0 2 for 5-6 days until the control wells had reached approximately 
80% confluency. The medium was decanted and the cells rinsed twice with PBS before the 
toxicity was determined using the acid phosphatase method, as described in section 2.6.1.
2.6.4 Transport circumvention assays - 96 well plates
The effect of the circumvention agents cyclosporin A (Sandoz), verapamil (Sigma V-4629) 
and monensin (Sigma M-5273) on the toxicity of adriamycin was studied under conditions 
similar to those used in the adriamycin accumulation assays ie similar concentrations and 
time length exposures (section 2.10). The cells were plated in 96 well plates at a 
concentration of lx l0 3 cells per well in 100/d of medium. 100/d of medium was added to 
the wells in the first lane which served as a blank. The cells were allowed to attach for 24 
hours at 37°C in 5 % C 0 2. The following day the appropriate drug dilutions were prepared 
and 100/d of medium was added to the first three lanes, 100/d of a 2X stock of adriamycin 
(10/iM) was added to lanes 4,5 and 6 and 100/d of a 2X stock of the circumvention agent 
was added to lanes 7,8 and 9. To the remaining three lanes 50/d of a 4X stock of 
adriamycin and 50/d of a 4X stock of the circumvention agent were added. The plates were 
then incubated at 37°C in 5% C 0 2. After 2 hour and 4 hour incubation time periods, the 
medium was decanted and the cells rinsed twice with fresh medium. 200/d of medium was 
then added to each well and the plates incubated at 37°C in 5 % C 0 2 for 5-6 days until the 
cells in the control wells had reached approximately 80% confluency. The medium was 
then decanted from the wells and the cells rinsed twice in PBS. The toxicity of adriamycin 
and the circumvention agent alone or in combination was determined by the acid 
phosphatase method, as described in section 2.6.1.
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2.7 Protein analysis by Western blotting
Protein analysis was carried out by Western blotting using whole cell extracts, purified cell 
membrane extracts and purified nuclear extracts. The extracts were prepared as follows:
2.7.1 Whole cell extract preparation
The cells used in the preparation of whole cell extracts were grown in 75cm2 flasks until 
approximately lxlO7 cells were obtained. The cells were then trypsinised and pelleted by 
centrifugation at 1000 rpm for 5 minutes. The cell pellet was washed three times in PBS 
by centrifugation. Once the cell pellet was obtained the procedure was carried out on ice. 
Cell pellets were resuspended in 5ml of a lysis buffer containing lOmM KC1 (BDH 10198), 
1.5mM MgCl2 (Sigma M-1250), 2mM PMSF (Sigma P-7626) and lOmM Tris-HCl (Sigma 
T-8404) pH 7.4. PMSF was added to the lysis buffer just before use and the buffer was 
stored on ice. The cells were then sonicated (Labsonic U) until lysis occurred, as 
determined microscopically. The cellular extracts were used immediately.
2.7.2 Cell membrane preparation
The cells used for membrane preparations were grown in 75cm2 flasks until approximately 
2xl07 cells were obtained. Cells were trypsinised in the exponential phase of growth and 
pelleted by centrifugation at 1000 rpm for 5 minutes. The pellet was washed three times 
by centrifugation at 2000 rpm for 5 minutes and then placed on ice. The cells were 
resuspended in 5ml of lysis buffer (lOmM KC1, 1.5mM MgCl2, 2mM PMSF and lOmM 
Tris-HCl pH 7.4). The cells was then sonicated until cell lysis was observed 
microscopically. The lysed cells were centrifuged at 7,800 rpm in an ultracentrifuge at 4°C 
for 10 minutes. The supernatant was collected and centrifuged at 38,000 rpm at 4°C for 
1 hour. The resulting pellet was resuspended in 0.5 - 1ml of lysis buffer and a 50/d aliquot 
of the suspension was removed for total protein analysis. The remaining supernatant was 
aliquoted in 100/d lots in eppendorf tubes and lyophilized overnight. The lyophilized 
samples were stored at -20°C until required.
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2.7.3 Nuclear extract preparation
The cells used for nuclear extracts were grown in 75cm2 flasks until approximately lxlO7 
cells were obtained. Cells were then trypsinised and pelleted by centrifugation. The cell 
pellet was washed three times after which the cells were permeabilized by incubation for 
10 minutes in 3 ml of a hypotonic buffer (5mM KH2P 04, 2mM MgCl2, 4mM DTT, O.lmM 
Na2EDTA and ImM PMSF, pH 7.0). The cells were then pelleted at 1500 rpm for 5 
minutes. The resulting pellet was resuspended in 300/d of a 0.1% SDS (Riedel-de Haen 
62862) solution. An aliquot was removed for protein determination and the remaining 
supernatant was used immediately.
2.7.4 Quantification of protein
The protein levels in the cellular extracts were determined using the BCA protein assay 
(Pierce). The Bicinchoninic acid protein assay reagent is a highly sensitive reagent for the 
spectrophotometric determination of protein concentration. It is based on the reaction of 
the protein with Cu2+ in an alkaline medium containing bicinchoninic acid which is a 
detection reagent for Cu+ (Smith et al., 1985). The BCA protein assay working reagent 
was prepared by mixing 50 parts of reagent A (containing sodium carbonate, sodium 
bicarbonate, BCA detection reagent and sodium tartrate in 0.2N NaOH) with one part of 
reagent B (4% copper sulfate solution). A set of protein standards of known concentrations 
were prepared by diluting the BSA standard (2mg/ml stock). 0.1ml of each standard or 
unknown protein sample was pipetted into a test tube and 2 ml of the working reagent was 
added to each tube. 0.1 ml of diluent was used as a blank. The test tubes were then 
incubated at 60°C for 30 minutes and the absorbance of each sample measured at 562nm. 
A standard curve was plotted of the known protein standards and the protein concentration 
of the unknown samples was determined by extrapolation from the standard curve.
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2.7.5 Separation of proteins by SDS - Polyacrylamide gel electrophoresis (PAGE)
7.5% and 10% polyacrylamide gels were used in this work to separate proteins present in 
the cellular extracts. The gels were prepared as shown in table 2.7.5.




30% Acrylamide Stock 3.8 ml 5.0 ml 0.8 ml
Ultrapure H20 8.0 ml 6.8 ml 3.6 ml
1.875 M Tris-HCl pH 8.8 3.0 ml 3.0 ml -
1.25 M Tris-HCl pH 6.8 - - 0.5 ml
10% SDS (Sigma L-4509) 150 /tl 150 ixl 50 n\
10% Ammonium Persulphate 
(Sigma A-1433)
60 /il 50 ni 17 /il
TEMED (Sigma T-8133) 9 n\ 7.7 n 1 5 ^1
Table 2.7.5 Preparation of resolving and stacking gels for electrophoresis
The 30% acrylamide stock was prepared by dissolving 29. lg  of acrylamide (Sigma A-8887) 
and 0.9g of NN-Methylene bis-acrylamide (Sigma M-7279) in 100 mis of ultrapure water. 
The resolving gels were immediately cast into two gel cassettes which comprised of a glass 
plate and an aluminium plate separated by two 0.75cm2 plastic spacers. The gels were 
allowed to polymerise and then the stacking gel was carefully poured on top of the resolving 
gel. Combs of suitable thickness were then inserted into the stacking gel. When the 
stacking gel had set and the wells had been formed, the gels were transferred to an LKB 
mini-gel system to which electrode buffer was added (1.9M glycine (Sigma G-6761), 0.25M 
Tris (Sigma T-8404) and 0.1 % SDS - pH 8.3). The samples to be separated were adjusted 
to equal protein concentration by the addition of an appropriate volume of loading buffer 
(1.25M Tris-HCl, 1% SDS, 5% glycerol (BDH 10118), 5% 2-mercaptoethanol (Sigma M- 
6250) and 0.1% bromophenol blue (BDH 44305)). 10/tg/10/d of each sample was loaded 
onto the gel. The gels were run for approximately 50 minutes at a voltage of 250V and at 
a current of 45mA.
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2.7.6 Western blotting
Western blotting was preformed by the method of Towbin et al. (1979). Following SDS- 
polyacrylamide gel electrophoresis (PAGE), the gels were equilibrated for 15 minutes in 
transfer buffer (25mM Tris, 192mM glycine (Sigma G-8898) - pH 8.5 without adjustment). 
The gels were then aligned onto nitrocellulose sheets (Amersham, Hybond-C) which had 
been equilibrated in the same transfer buffer. A number of sheets of Whatman 3mm filter 
paper were soaked in transfer buffer and then placed underneath the nitrocellulose paper and 
also on top of the gel. The transfer of protein from the acrylamide gel to the nitrocellulose 
fdter was carried out using a Bio-Rad semi-dry blotting system for approximately 20 
minutes at 15 volts and a maximum of 345 mA. Following protein transfer, the 
nitrocellulose sheets were placed in blocking buffer which consisted of 5% non-fat dried 
milk (Marvel skimmed milk) in TBS (20mM Tris, 500mM NaCl (BDH 1.060400.1000), 
pH 7.5) for 90 - 120 minutes. The nitrocellulose blots were then rinsed with Tris buffered 
saline (TBS, 0.05M Tris/HCl, 0.15M NaCl) prior to the addition of the primary antibody.
2.7.6.1 P-glycoprotein
The primary antibody used to detect the presence of P-glycoprotein was the anti-P- 
glycoprotein monoclonal antibody, C219 (Centicor Diagnostics). 0.25/xg/ml of the C219 
in TBS containing 0.1% Tween-20 (Sigma P-1379) was added to the nitrocellulose and 
incubated overnight at 4°C. The blots were then washed three times with TBS containing 
0.5% Tween-20 and then exposed to the secondary antibody, at a 1:10,000 dilution of the 
alkaline phosphatase conjugated anti-mouse IgG and IgM antibody (Pierce), for 90 minutes. 
The blots were washed three times and developed in an alkaline phosphatase substrate.
2.7.6.2 Topoisomerase II
The antibody used to detect the presence of topoisomerase II was a mixture of 
topoisomerase II a  and 13 monoclonal antibodies (gifts from Dr. G. Astaldi-Ricotti). A 
1:700 dilution of the serum in TBS containing 0.1% Tween-20 was prepared and incubated 
with the nitrocellulose blots overnight at 4°C. Following this incubation period, the blots 
were washed three times with TBS containing 0.5% Tween-20 and incubated with the 
secondary antibody (1:500 dilution of anti-mouse immunoglobulin (DAKO) in TBS
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containing 0.1% Tween-20) for 90 minutes at room temperature. The blots were then 
washed three times before development in the alkaline phosphatase substrate.
2.7.6.3 D8-8 antibody
When the D8-8 antibody, raised against the DLKPA10 cell line, was characterized using 
western blotting, a 1:100 dilution of the ascitic fluid in TBS containing 0.1 % Tween-20 was 
added to the nitrocellulose blots and incubated overnight at 4°C. The blots were then 
washed three times and incubated with 1:500 dilution of the anti-mouse immunoglobulin 
secondary antibody (DAKO) for 90 minutes at room temperature. The blots were washed 
three times with TBS containing 0.5% Tween and then developed using the alkaline 
phosphatase substrate.
2.7.7 Development of Western blots
All nitrocellulose blots were developed using an alkaline phosphatase substrate. A 0.1 % 
stock (w/v) of nitroblue tetrazolium (Sigma H-5514) in lOmM Tris-HCl, pH 8.9 and a 
5mg/ml stock of 5-bromo-4-chloro-3-indoxyl phosphate (Sigma B-0274) in N,N- 
dimethylformamide (Sigma D-8654) were prepared. 5ml of the nitroblue tetrazolium stock 
and 2 ml of the 5-bromo-4-chloro-3-indoxyl phosphate stock were added to 44 ml of a 0.5M 
Tris-HCl buffer, pH 8.9 containing 0.2 ml of 1M MgCl2. The blots were developed by 
incubating the nitrocellulose with the developing substrate until bands of suitable colour 
development were visible. The developing reaction was stopped by decanting the 
developing substrate and rinsing the blots thoroughly in water. The blots were then 
carefully dried and stored protected from the light to prevent the bands from fading.
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Glutathione-S-transferase activity was determined using cytosolic extracts of the DLKP cells 
and the DLKPC resistant variants. The activity was determined spectrophotometrically and 
the assay was based on the conjugation of glutathione to 2,4-dinitrochlorobenezene forming 
2,4-dinitropheny 1-glutathione which absorbs light at 340nm and has an extinction co­
efficient of 9.6 mM/cm (Gibson et al., 1987).
2.8.1 Cytosolic extract preparation
Approximately 2xl07 cells at the exponential phase of growth were trypsinised and pelleted 
by centrifugation. The pellet was washed three times with PBS and then resuspended in 2 
ml of lysis buffer (lOmM KC1, 1.5mM MgCl2, 2mM PMSF and lOmM Tris-HCl, pH 7.4). 
The cells were sonicated until cell lysis was observed microscopically. The lysed cells were 
centrifuged at 7,800 rpm for 10 minutes at 4°C. The supernatant was collected and 
centrifuged at 38,000 rpm for 1 hour at 4°C. An aliquot of the supernatant was retained 
for protein determination by the BCA assay and the remaining supernatant was used directly 
in the glutathione-S-transferase activity assay.
2.8.2 Assay for glutathione-S-transferase
A 30 mM stock of glutathione (Sigma G-4251), a 30 mM stock of dinitrochlorobenezine 
(BDH 10076) in ethanol and a 100 mM potassium phosphate buffer (KH2P 0 4 and HK2P 04) 
pH 6.5 were prepared. 2 cuvettes containing 0.1 ml of the glutathione stock, 0.1 ml of the 
dinitrochlorobenzene stock and 2.2 ml of potassium phosphate buffer were placed in the 
constant temperature chamber of a dual beam spectrophotometer (Shimadzu UV 160A). 0.6 
ml of the cytosolic extract was added to the sample cuvette and 0.6 ml of water was added 
to the reference cuvette. The reaction was followed at 340nm over a time period of three 
minutes. The change in absorbance per minute was calculated and this was related to the 
conjugation of glutathione by the extinction co-efficient. The rate of glutathione conjugation 
was calculated from the following formula:
glutathione conjugated m in1 mg protein'1 =  OD min1 / extinction coefficient x [protein]
2.8 Determination of Glutathione-S-transferase activity
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2.9 Immunological studies
Throughout the course of this work immunological studies were carried out on both live and 
fixed cells. Immunofluorescence was performed on live cells to detect the presence of cell 
surface antigens and immunocytochemistry was performed on fixed cells to detect the 
presence of both intracellular and membrane associated antigens.
2.9.1 Live cell immunofluorescence
The cells used for immunofluorescence were grown in 75cm2 flasks until they had reached 
approximately 80% confluency. The cells were then trypsinised and pelleted by 
centrifugation. The cell pellet was washed three times and resuspended in PBS. An aliquot 
of the cell suspension was removed and the cells counted using a haemocytometer. A single 
cell suspension of lxlO6 cells per ml was prepared and 100/d of this suspension was added 
to two eppendorf tubes. 100/d of the test antibody was added to one eppendorf (1:100 
dilution of the D8-8 ascitic fluid in PBS) and 100/d of PBS was added to the second 
eppendorf tube as a negative control. As a positive control for the study, 100/d of a cell 
suspension of the SCC-9 cell line (human squamous carcinoma of the tongue) was incubated 
with 100/d of the monoclonal antibody, EP-16. The cells were incubated with the primary 
antibody for 30 minutes at 4°C and then washed three times with PBS by centrifugation. 
The cell pellet obtained was resuspended in 100/d of PBS. 100/d of the secondary antibody 
(FITC-labelled anti-mouse IgM (Sigma F-9259) diluted to 1:50 in PBS for the EP-16 
antibody and FITC-labelled antimouse IgG (Boehringer Mannheim) for the D8-8 antibody) 
was added and the cells were incubated for a further 30 minutes at 4°C. The FITC-labelled 
antibodies were light sensitive, consequently the reactions were carried out in darkness. 
After the 30 minute incubation period the cells were washed three times with PBS. The 
supernatant was aspirated and the cell pellet was resuspended in one drop of mounting 
medium (Vectra shield H1000). Approximately 20/d of the cell suspension was then 
mounted on a glass slide and the cells were viewed for fluorescence under ultra violet 
illumination using a Nikon microscope equipped with a mercury lamp. If the antibody 
recognised a cell surface antigen a ring of fluorescence was visible on the surface of the 
cells.
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2.9.2 Immunocytochemistry of fixed cells
2.9.2.1 Preparation of cytospins
The glass micro slides (Chance propper LTD) used for the cytospins were washed 
thoroughly in hot water containing 0.5% Tween-20 and then rinsed in running water for 
approximately 15 minutes. Following this washing step, the slides were soaked in alcohol 
for 15 minutes and then dried thoroughly. The slides were then coated with poly-l-lysine 
(Sigma P-1274) by adding approximately 10/d of poly-l-lysine (lmg/ml in ultrapure water) 
to one end and spreading it evenly over the slide to give an equal coating of the poly-l- 
lysine. The slides were air dried overnight and stored at -20°C until required.
The cells required for the cytospins were grown in 75cm2 flask until they had reached 
approximately 80% confluency. The trypsinisation procedure was carried out and a single 
cell suspension of lxlO6 cells per ml was prepared. Two 100/d aliquots of the cell 
suspension was cytofuged (Heraeus Labofuge 400) onto the glass slide at 400 rpm for 4 
minutes. A number of cytospins were prepared and allowed to air dry overnight. The 
cytospins were stored at -20°C until required.
2.9.2.2 Immunocytochemistry
The cytospins were removed from -20°C and allowed to stand at room temperature for 
approximately 20 minutes prior to starting the assay. Fixation of the cells was carried out 
by incubating the cells in acetone (BDH 10003) for 10 minutes at -20°C. The slides were 
then allowed to air dry for approximately 15 minutes. The cells were incubated in 0.6% 
hydrogen peroxide (BDH 10128) in methanol (BDH 10158) for 5 minutes to quench any 
endogenous peroxidase activity. The slides were rinsed with water and then washed for 5 
minutes in TBS (Tris buffered saline; 0.05M Tris/HCl, 0.15M NaCl, pH 7.6) containing 
0.1% Tween-20. Non-specific background in the cells was blocked by the addition of a 1:5 
dilution of normal rabbit serum (DAKO X0902) for 20 minutes. The primary antibody 
was added and the cells were incubated either at room temperature for 1 - 2 hours or 
overnight at 4°C (depending on the antibody used) after which time the slides were washed
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three times with TBS/0.1 % Tween-20. The cells were incubated with 50/d of a biotinylated 
secondary antibody for 1 hour at room temperature and then washed thoroughly three times 
with TBS/0.1% Tween-20. 50/d of a freshly prepared stock of Streptavidin-binding 
complex (DAKO K377) was added to each of the sections and incubated for 30 minutes at 
room temperature. The slides were washed thoroughly and the cells incubated with 50/d 
of the peroxidase substrate, 3,3-diaminobenzidine tetrahydrochloride (DAB, DAKO S3000). 
When suitable colour had developed (red-brown reacting product) the cells were rinsed in 
water and counterstained with hematoxylin (Bayers). A series of dehydration steps in 
alcohol (70%, 90% and 100% methanol) were carried out before the cells were mounted 
in DPX (BDH 36029) and viewed under a Nikon microscope when dry.
2.9.2.3 Metallothionein
The presence of metallothionein in a number of cell lines was investigated using a 
monoclonal mouse anti-metallothionein antibody. The cells were incubated at 4°C for 16 
hours with a 1:20 dilution of the metallothionein antibody (DAKO-MT M0639). After this 
incubation period, the slides were washed thoroughly with TBS/0.1% Tween-20 and the 
secondary antibody added for 1 hour at room temperature. A 1:300 dilution of the 
biotinylated rabbit anti-mouse IgG antibody (DAKO E354) was used as the secondary 
antibody for the detection of metallothioneins.
2.9.2.4 Lung resistance protein (LRP)
The presence of LRP in a number of DLKP variants was detected using a mouse 
monoclonal antibody to LRP (LRP-56) which was a generous gift from Prof. Rik Scheper‘s 
laboratory (Dept, of Pathology and Oncology, Free University Hospital, De Boelelaan 
1117, 1081 HV Amsterdam). The cells were incubated with a 1:500 dilution of the primary 
antibody, LRP-56, for 2 hours at room temperature and then washed three times over a 
period of 15 minutes. The cells were then incubated with the secondary antibody (1:300 
dilution of the biotinylated rabbit anti-mouse IgG antibody) for 1 hour at room temperature.
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2.9.2.5 Multidrug resistance related protein (MRP)
The primary antibody used for the detection of MRP was a rat monoclonal antibody MRPrl 
which was also a generous gift from Prof. Rik Scheper's laboratory. The cells were 
incubated with a 1:40 dilution of the antibody for 2 hours at room temperature and then 
washed three times in TBS/0.1% Tween-20. The binding of the MRPrl antibody was 
detected using a 1:100 dilution of a biotinylated rabbit anti rat IgG antibody (DAKO E0468) 
with which the cells were incubated for 1 hour at room temperature.
2.9.2.6 D8-8 antibody
For immunocytochemical studies, the cells were incubated with a 1:100 dilution of the 
primary D8-8 antibody at 4°C overnight. The cells were then washed thoroughly and 
incubated with the secondary antibody, 1:300 dilution of the biotinylated rabbit anti-mouse 
IgG antibody, at room temperature for 1 hour.
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2.10 Drug transport studies
2.10.1 Adriamycin accumulation studies
The accumulation of adriamycin in a number of cell lines was measured by a modification 
of the method of Ganapathi and Grabowski (1983). The cells used in the studies were 
grown in 75cm2 flasks until approximately 80% confluency was reached. The cells were 
then trypsinised and a single cell suspension prepared. 1ml of the cell suspension was 
added to each well of 6 well cluster plates (Costar 3516) at a concentration of 1x10s - 5x10s 
cells per ml (concentration dependent on the cell line). A further 3 ml of complete medium 
was added to each well and the cells incubated at 37°C in 5% C 0 2 for approximately 48 
hours. After this time the medium was decanted and 4 ml of complete medium, containing 
10/iM adriamycin, was added to each of the wells except the control wells, to which 4 ml 
of complete medium was added. These plates were incubated at 37°C in 5 % C 0 2. After 
specified time intervals the drug containing medium was decanted and the cells were rinsed 
twice in ice-cold PBS. 2 ml of ice-cold ultrapure water was added to the wells and left for 
approximately 5 minutes to facilitate lysis of the cells. The adriamycin was then directly 
extracted from the cells by the addition of 2 ml of 0.6N HCl-Methanol solution for 
approximately 5 minutes, The resulting solutions were transferred to universal containers 
and centrifuged at 4000 rpm for 10 minutes at 4°C. The supernatants were collected and 
the fluorescence of each solution determined using a Perkin Elmer LC50 luminescence 
spectrometer with an excitation wavelength of 470nm and an emission wavelength of 
585nm. The slit widths for excitation and emission were lOnm and 15nm respectively. 
The concentration of adriamycin present in each sample was quantitated from a linear 
standard curve prepared from the fluorescence of known adriamycin concentrations.
2.10.2 Adriamycin efflux studies
The efflux of adriamycin was studied following preloading of the cells with the drug. The 
cells were plated in 6 well plates at a concentration of 1x10s - 5x10s cells per well 
(concentration dependent on cell line) and fed with 3 ml of complete medium. Following 
an incubation period of approximately 48 hours at 37°C, the medium was decanted and 4 
ml of glucose free medium (DMEM: Gibco 11963-022) containing 10/iM adriamycin and 
either 10/nM antimycin A or lOmM sodium azide was added to each of the wells with the
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the exception of the control wells, to which complete medium was added. After 3 hours 
the drug containing medium was removed and the cells were rinsed twice with medium. 
4 ml of medium containing glucose was added to each of the wells and the cells were 
further incubated at 37°C in 5% C 0 2. After specified time intervals the medium was 
decanted and the cellular adriamycin was extracted. The resulting solution was centrifuged 
and the supernatants collected. The fluorescence of the supernatants was determined and 
the concentration of adriamycin determined from the standard linear curve.
2.10.3 Vincristine accumulation studies
The cellular uptake of vincristine was determined by measuring the quantity of radiolabelled 
vincristine (Amersham, TRK.478) accumulated in the cells. Cells at the exponential growth 
phase were trypsinized and a single cell suspension prepared. These cells were plated in 
6 well plates at a concentration of 1x10s - 5x10s cells per well (concentration dependent on 
cell line) and incubated at 37°C for approximately 48 hours. Following this incubation 
period, the medium was decanted and medium containing 3H-vincristine was added to the 
cells. The plates were incubated at 37°C in 5% C 0 2. After specified time intervals the 
medium was quickly aspirated, and the cells washed twice in ice-cold PBS. The plates were 
blotted dry and the cells solubilized by overnight incubation in 0.2N NaOH at room 
temperature. The cell lysates were neutralized by the addition of 0.2N HC1 and the 
radioactivity determined by liquid scintillation counting (Beckman LS 6500). The 
concentration of vincristine accumulated was quantitated from a standard curve prepared 
from known concentrations of vincristine.
2.10.4 Vincristine efflux studies
The efflux of vincristine was investigated following preloading of the cells with vincristine. 
The cells were plated in 6 well plates and incubated at 37°C in 5% C 0 2. Approximately 
48 hours after plating, the medium was removed and the cells incubated in glucose free 
medium containing radiolabelled vincristine and 10/iM antimycin A for two hours. At the 
end of the uptake period, the cells were rinsed thouroghly and incubated in complete 
medium at 37°C in 5 % C 0 2. After specified time intervals the medium was decanted and 
the vincristine extracted as described in section 2.10.3
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2.11 Subcellular distribution of adriamycin
The subcellular localisation of adriamycin in a number of cell lines was investigated by 
fluorescence microscopy and confocal laser microscopy. The cells studied were grown on 
glass coverslips and then viewed under ultraviolet illumination.
2.11.1 Fluorescence microscopy
Microscope glass coverslips (Chance propper LTD) were washed with 70% alcohol and 
flamed with a bunsen burner. The sterile cover slips were placed in 35mm petri dishes 
(Greiner 627160). The cells used in the studies were grown in 25cm2 flasks until 
approximately 80% confluent and then trypsinised at the exponential phase of growth. The 
cells were pelleted by centrifugation and a single cell suspension of 1x10s cells per ml was 
prepared. 1 ml of the cell suspension was added to each of the petri dishes which were then 
incubated overnight at 37°C in 5% C 0 2 to allow attachment of the cells to the sterile 
coverslips. The following day the medium was carefully removed from the petri dishes and 
the cells incubated with 1 ml of medium containing 10/zM adriamycin for 2 hours. After 
this time the drug containing medium was decanted and the cells were washed twice with 
ice-cold PBS. The coverslips were then inverted onto clean glass slides and the edges 
sealed with silicon grease to protect the cells against dehydration. The cells were viewed 
for fluorescence under ultraviolet illumination using a Nikon microscope equipped with a 
mercury lamp. The ultraviolet illumination induced an orange fluorescence at the site of 
adriamycin accumulation and as a result the localisation of adriamycin within the cells could 
be studied. The cells were viewed immediately after mounting since fading of the 
fluorescence occured very rapidily.
2.11.2 Confocal laser microscopy
Cells were grown on sterile coverslips and exposed to adriamycin (10^M) as described in 
section 2.11.1. After specified incubation time periods the medium was decanted and the 
cells rinsed with ice-cold PBS. The coverslips were inverted on to glass slides and sealed 
with silicon grease and viewed using an Odyssey XL digital video confocal laser scanning 
imaging system.
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2.12 Effect of a number of compounds on adriamycin accumulation and distribution
A number of compounds were tested to determine if they were effective at altering the 
accumulation and/or subcellular distribution of adriamycin in various cell lines. Table
2.12.1 and table 2.12.2 illustrates the solubility and concentration of each of the compounds 
used for the study of adriamycin accumulation and adriamycin distribution respectively.
Compound Supplier Solubility Concentration
Verapamil Sigma V-4629 Soluble in methanol 30 - 100 /tg/ml
Cyclosporin A Sandoz Soluble in medium 10 - 100 /tg/ml
Sodium azide Sigma S-8032 Soluble in medium 500 - 2500 /xg/ml
2-Deoxy-D-Glucose Sigma D-6134 Soluble in medium 10 - 50 mg/ml
Antimycin A Sigma A-8674 Soluble in ethanol 10 pM
Brefeldin A Sigma B-7651 Soluble in methanol 10 - 50 /iM
Bafilomycin A1 Sigma B-8281 Soluble in DMSO 10 - 50 /ig/ml
Genestein Sigma G-6649 Soluble in DMSO 100 - 1000 /ig/ml
Monensin Sigma M-5273 Soluble in ethanol 5 - 100 ^g/ml
Stearic Acid Sigma S-4751 Soluble in medium 50 - 500 fiM
Cholestryl hemisuccinate Sigma C-6512 Soluble in medium 50 - 500 /iM
Table 2.12.1 Compounds used to alter adriamycin accumulation
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Compound Supplier Solubility Concentration
Verapamil Sigma V-4629 Soluble in methanol 10 - 30 /xg/ml
Cyclosporin A Sandoz Soluble in medium 1 0 -5 0  /xg/ml
Sodium azide Sigma S-8032 Soluble in medium 10 - 100 mM
2-Deoxy-D-glucose Sigma D-6134 Soluble in medium 1 0 -2 5  mg/ml
Antimycin A Sigma A-8674 Soluble in ethanol 10 n M
Brefeldin A Sigma B-7651 Soluble in methanol 10 - 50 /xM
Bafilomycin A1 Sigma B-8281 Soluble in DMSO 10 - 50 /xg/ml
Chloroquine Sigma C-6628 Soluble in medium 10 - 100 /xM
Methylamine Sigma M-0505 Soluble in ethanol 1 - 1 0  mM
Monensin Sigma M-5273 Soluble in ethanol 10 /xg/ml
Nigericin Sigma N-7143 Soluble in chloroform 5 /xg/ml
Genestein Sigma G-6649 Soluble in DMSO 300 /xg/ml




The immunogen used for the production of hybridomas was a whole cell preparation of the 
human lung tumour cell line, DLKPA10. The cells were grown in 75cm2 flasks until they 
had reached approximately 80% confluency. Trypsinisation procedure was carried out and 
the cells were pelleted by centrifugation. The cell pellet was washed three times in PBS and 
a single cell suspension of lx l0 7 cells per 0.5 ml was prepared. Intraperitoneal injection 
of the immunogen (0.5ml) was performed on day one, on day 14 and on day 28 on male 
Balb/c mice. The fusion was carried out three days after the final injection.
2.13.2 Fusion protocol
The murine myeloma cell line, SP2, was grown in 75cm2 vented flasks until approximately 
80% confluency was reached. The cells were then harvested and at least lxlO7 cells were 
resuspended in serum free DMEM (Hybri-Max IX  DMEM; Sigma D-5660) containing L- 
glutamine (1%) and penicillin/streptomycin (Gibco 15140-023).
The immunized mouse was sacrificed and a splenectomy was performed. The spleen was 
filtered through a gauze and suspended in 10 ml of serum free medium. The debris was 
allowed to pellet and the supernatant was then decanted and centrifuged at 1000 rpm for 5 
minutes. The spleen cells were resuspended in serum free medium and a cell count was 
performed. The myeloma cells and spleen cells were mixed at a ratio of 1:10 in a final 
volume of 10 mis and then centrifuged at 2000 rpm for 5 minutes. The resulting cell pellet 
was resuspended in 10 mis of serum free medium and centrifuged at 2000 rpm for a further 
5 minutes. After the second centrifugation the supernatant was removed and 1 ml of 
prewarmed polyethylene glycol (PEG 1500, Boehringer) was slowly added to the cell pellet 
over 1 minute. This was followed by the addition of 10 mis of medium containing 10% 
foetal calf serum over a time period of 7 minutes during which time the cells were gently 
rotated. 1 ml was added over the first minute, a second ml was added during the second 
minute and a third ml was added over the third minute. The final 7 mis was slowly added 
over 4 minutes. The cells were then centrifuged at 1000 rpm for 5 minutes and the pellet 
resuspended in approximately 25 ml of DMEM complete medium containing 5 % FCS, 1 %
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L-glutamine, 1% pen/strep, 5% Briclone (Bioresearch Ireland) and 1% HAT (5xlO'3M 
hypoxanthine, 2xlO'5M aminopterin and 8x1 O^M thymidine; Sigma H-0262). The fused 
cells were incubated at room temperature for 15 minutes and plated in 8 x 48 well tissue 
culture plates (Costar 3548). Complete medium was added to give a final volume of 0.5 
ml per well. The plates were incubated at 37°C in 5% C 0 2 for 7 - 10 days. After this 
incubation time, the plates were examined for hybridoma formation and any clones present 
were fed with complete medium. The cells were refed with HAT medium at least twice. 
After this time the cells were fed twice with medium containing 1% HT (Sigma H-0137; 
5xlO‘3M hypoxanthine and 8x1 O^M thymidine) in which the aminopterin was omitted.
2.13.3 Screening of hybridomas for antibody production
All hybridomas, resulting from the fusion, were screened against the immunogen 
(DLKPA10 cell line) and the parental cell line DLKP for antibody production to establish 
if antibodies produced were raised to an antigen that was overexpressed or downregulated 
in either the parental or resistant cell line. When the hybridoma cells had reached 
approximately 50% confluency the supernatants were removed and screened by the ELISA 
method. The DLKP and DLKPA10 cells were plated in 96 well plates at a concentration 
of 2xl04 cells per well and incubated overnight at 37°C in 5 % C 0 2 to allow the cells to 
attach. The following day the medium was decanted and the plates were washed twice in 
TBS prior to fixation in 70% acetone for 5 minutes at room temperature. The cells were 
blocked with a 0.1 % gelatin (Sigma G-9382) solution for approximately 90 minutes at room 
temperature. Following the blocking step, the cells were washed with TBS and incubated 
with 100 /d of the supernatants that were removed from the cells. 100 ¡tl of diluted serum 
from the immunized mouse and 100 /d of irrelevant supernatant were included as a positive 
and negative control respectively. The cells were incubated with the primary antibody for 
90 minutes at 37°C after which time the primary antibody was removed and the cells were 
washed thoroughly three times with TBS containing 0.1% Tween-20. The cells were 
incubated with the secondary antibody (1:10,000 dilution of Pierce IgG/IgM antibody) for 
1 hour at 37°C. The plates were washed three times with TBS/0.1% Tween-20 and then 
100 /d of a lmg/ml solution of p-nitrophenyl phosphate (PNPP, Sigma N-9389) substrate 
was added to each well. The substrate was prepared by dissolving the PNPP in a buffer 
consisting of lOOmM glycine, ImM MgCl2 and ImM ZnCl (Merck 8816). The cells were 
incubated at 37°C until a bright yellow colour had developed in positive wells. The 
absorbance of each well was read at 405nm on a dual beam ELISA plate reader.
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2.14 Determination of antibody class
The class and subclass of the antibodies produced were determined using a commercial 
isotyping kit from Serotec (MMT RC1). The kit was used specifically for tissue culture 
supernatants and was based on red cell agglutination. A positive agglutination result was 
obtained when specific antibodies recognised and bound to the particular isotype to which 
it was directed. The following rat monoclonal antibodies were used to isotype the 
antibodies that were screened; IgGl, IgG2a, IgG2b, IgG3, IgA and IgM. Negative control 
cells that were coupled to irrelevant antibodies and positive control cells coupled to a 
polyclonal antibody directed against mouse immunoglobulins were also included in the 
assay. 30 /d of the supernatant to be tested was added to 30 /d of each of the specific 
isotyping reagent across a microtitre plate (Greiner 650160). The solutions were mixed 
gently and then incubated at room temperature for 1 hour. The plate was then examined 
for agglutination, a carpet of agglutination indicated a positive result and a small red circle 
represented a negative result.
2.15 Production of ascitic fluid
In order to produce large quantities of antibodies the hybridomas were injected into mice 
(Balb/c) and grown as ascites tumours. The mice were initially given an intraperitoneal 
injection of 0.5 ml of pristane (2,6,10,14-tetra-methylpenta-decane) to stimulate the immune 
system. 7 days later the mice were injected intraperitoneally with the hybridomas (lxlO7 
cell/0.5 ml PBS) and then observed for tumour growth over 1 - 2  weeks. When tumour 
growth was evident the mice were sacrificed and the ascitic fluid was collected from the 
peritoneal cavity using a sterile needle. The ascitic fluid was centrifuged at 2000 rpm for 
5 minutes and the supernatant was removed, aliquoted and stored at -20°C until required. 
The cell pellet was resuspended in complete medium (containing FCS, L-glutamine, 
Briclone and pen/strep) and reseeded in tissue culture flasks. The cells were cultured and 
frozen in liquid nitrogen for stock.
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Results
3.1 Establishment of novel platinum resistant cell lines
3.1.1 Establishment of DLKPC 6.2, DLKPC 14 and DLKPC 25
Three new carboplatin resistant variants of the human lung squamous carcinoma cell line 
DLKP were established, as described in section 2.5. The parental DLKP cells readily 
adapted to growth in carboplatin. The cells were initially exposed to 1/ng/ml carboplatin 
and adjusted to growth in 6.2 /¿g/ml after approximately four months, to 14/ig/ml after a 
further six months and to a final concentration of 25/xg/ml within another three months. 
The resistant cell lines selected to and maintained in 6.2/xg/ml, 14/xg/ml and 25/^g/ml were 
designated DLKPC 6.2, DLKPC 14 and DLKPC 25 respectively.
3.1.2 Cross resistance profile of the DLKPC variants
The sensitivities of the three resistant variants to a range of chemotherapeutic agents was 
determined, in order to establish their cross resistance profile. The chemotherapeutic agents 
included the selective drug carboplatin, the alkylating platinum agent cisplatin, the 
anthracycline adriamycin, the vinca alkaloid vincristine, the semisynthetic derivative of 
podophyllotoxin VP16 and the antimetabolite agent, 5-fluorouracil. Table 3.1.2.1 
represents the IC50 values of each of the chemotherapeutic agents for the parental DLKP cell 
line and the three DLKPC selected variants, ascertained from the toxicity profile as 
described in section 2.6. Table 3.1.2.2 represents the fold resistance of the DLKPC 
variants relative to the control DLKP cell line. All three DLKPC variants showed similar 
cross resistance profiles. They were found to be resistant to the selective agent, carboplatin 
and cross resistant to cisplatin. There was no significant cross resistance to the 
chemotherapeutic agents, adriamycin, vincristine and 5-fluorouracil observed in the DLKPC 
cells. The resistant variants showed slight cross resistance to VP16. The fold resistant 
values illustrated that the three variants were most resistant, not to the selecting agent 
carboplatin but to cisplatin (approximately 5-, 12- and 25-fold respectively), then to the 
selecting agent carboplatin (approximately 4-, 8.3- and 15.8- fold respectively) and finally 
to VP16 (approximately 2 fold for DLKP 14 and 2.5 fold for the DLKPC 25 variant).
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IC50 <nM) DLKP DLKPC 6.2 DLKPC 14 DLKPC 25
Carboplatin 1400 ± 61.9 5678 ± 369 11894 ± 892 22708 ±817
Cisplatin 1500 ± 90 7650 ±  712 18300 ± 774 37650 ±817
Adriamycin 12.9 ± 0.9 20.6 ± 1.3 21.5 ± 1.5 20.5 ± 1.44
Vincristine 1.3 ± 0.2 1.35 ± 0.17 1.49 ± 0.2 1.29 ± 0.13
VP16 76 ± 6.3 100 ± 5.2 144.6 ± 9.8 190 ± 10.2
5-Fluorouracil 5000 ± 210 4600 ± 358 3850 ± 192 4550 ± 223
Table 3.1.2.1 IC50 values for DLKP and the DLKPC variants
Dnig DLKPC 6.2 DLKPC 14 DLKPC 25
Carboplatin 4.04 8.26 15.77
Cisplatin 5.1 12.2 25.1
Adriamycin 1.6 1.67 1.59
Vincristine 1.04 1.12 0.9
VP16 1.34 1.9 2.5
5-Fluorouracil 0.92 0.77 0.91
Table 3.1.2.2 Fold resistance of the DLKPC variants relative to the parental DLKP cell
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3.1.3 Stability of the DLKPC variants
The stability of the DLKPC variants, when maintained in the absence of carboplatin was 
studied over a number of months. Up to three months out of drug, all three cell lines 
maintained their resistance to carboplatin. After this time, however, the cells began to lose 
their resistance to the drug. Figure 3.1.3 illustrates the toxicity profile of the DLKPC 25 
after three months and six months maintained in the absence of drug. After six months 
maintenance in drug free medium a decrease of approximately 1.3-fold was observed in the 
IC50 value.
Carboplatin Concentration (ng/ml)
Figure 3.1.3 The toxicity profile of carboplatin in the DLKPC 25 cell line. The cells were 
cultured in the absence of the selecting agent for 3 months and 6 months.
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3.1.4 Morphology of the DLKPC variants
The morphology of the three variants was studied and compared to the DLKP cells, to 
determine if the resistant cells differed from the parental cells from which they were 
derived. Figure 3.1.4 presents the morphology of the parental DLKP cells and the three 
carboplatin resistant variants. The morphology of the variants were similar to the parental 
DLKP cell line, in that all three variants had the squamous cell type, typical of the parental 
DLKP cell line.
3.1.5 Doubling times in the DLKPC variants
The rate of cell growth, calculated during the exponential phase, was determined in the 
DLKP parental cells and in the DLKPC variants over a time period of 72 hours. The cells 
were plated in 25cm2 tissue culture flasks and cell counts performed every 12 hours. The 
results obtained are presented in table 3.1.5. The DLKP and the DLKPC 6.2 cells were 
found to have similar doubling times of approximately 30.1 and 30.63 hours respectively. 
However, both the DLKPC 14 and DLKPC 25 resistant variants were shown to have longer 
doubling times than the parental cells. The doubling time observed in the DLKPC 14 was 
approximately 39 hours and approximately 41 hours in the DLKPC 25 variant.









Figure 3.1.4 Morphology of the parental DLKP and carboplatin resistant DLKP variants. DLKP 
(a), DLKPC 6.2 (b), DLKPC 14 (c) and DLKPC 25 (d).
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3.1.6 DNA fingerprint analysis of the DLKPC 25 variant
DNA fingerprint analysis was carried out on the DLKPC 25 variant to establish its genetic 
identity to the DLKP cells from which they were established. DNA was extracted from the 
cell lines by Cellmark Diagnostics, Abingdon, Oxfordshire and fingerprints analysed with 
the multilocus probes 33.15 and 33.6. The results obtained illustrated that the DLKPC 25 
variant shared almost identical bands with the DLKP cell line and therefore must have 
originated from the DLKP cell line. Since the DLKPC 25 variant was derived from the 
DLKPC 6.2 and DLKPC 14 lines, DNA fingerprint analysis was not carried out on these 
variants.
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3.2 Protein Analysis in the DLKPC variants
Alterations in the expression of multidrug resistance associated proteins was studied by 
Western blot analysis, as described in section 2.7. The expression of the membrane 
associated P-glycoprotein pump was investigated in the sensitive DLKP cells, its adriamycin 
resistant variant, DLKPA10 and in the DLKPC resistant variants. Possible alterations in 
the level of the nuclear enzyme, topoisomerase II a  and II /3, were studied in the DLKP 
cells and also in the highest carboplatin resistant variant, DLKPC 25.
3.2.1 Western blot analysis of P-glycoprotein expression
The expression of P-glycoprotein in the DLKPC variants was investigated, using the anti-P- 
glycoprotein monoclonal antibody, C219, by Western blotting on purified membrane 
fractions prepared, as described in section 2.7.2. The results obtained for the each of the 
cell lines studied are presented in figure 3.2.1 Strong immunoreactive P-glycoprotein 
expression was observed in the adriamycin resistant DLKPA10 cell line at a molecular 
weight of approximately 170 kDa. However, no detectable level of P-glycoprotein 
expression was evident in the parental DLKP or in the carboplatin resistant variants.
3.2.2 Western blot analysis of topoisomerase II a  and /3
The expression of the enzyme topoisomerase II in the parental DLKP and the DLKPC 25 
variant was determined by western blotting, using a mixture of polyclonal antibodies raised 
against the topoisomerase II a  and topoisomerase II /3 isoforms. Total cell lysates were 
prepared, as in section 2.7.1 and analysed for topoisomerase II expression. As illustrated 
in figure 3.2.1, both the DLKP and DLKPC cell lines possessed immunoreactive 
topoisomerase II, although no significant difference in the expression of the topoisomerase 
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Figure 3.2.1 Western blot detection of P-glycoprotein in cell membrane preparations of the DLKP, 
DLKPA10 and DLKPC resistant variants (a) and Western blot detection of topoisomerase Ha and 
B in nuclear extracts of the DLKP and DLKPC 25 variants (b).
3.3 Glutathione studies in the DLKP variants
3.3.1 Determination of Glutathione-S-Transferase activity in DLKPC variants
Alterations in the activity of the metabolising enzyme, glutathione-S-transferase, was 
investigated in the DLKPC resistant variants using cytosolic cellular extracts, prepared as 
described in section 2.8.1. A decrease in GST activity was observed in the DLKPC 6.2 
and DLKPC 14 variants when compared to the parental cells, although the level of activity 
in the DLKPC 25 variant was comparable to that noted in the parental cells (Figure 3.3.1). 
The range from the highest level of activity to the lowest activity level, however, was not 
significant, a decrease of less than two fold being noted.
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DLKP DLKP 6.2 DLKPC 14 DLKPC 2S
Cell Line
Figure 3.3.1 The activity of the glutathione-S-transferase enzyme in the parental DLKP and DLKPC 
resistant variants.
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3.3.2 Toxicity of BSO and ethacrynic acid in the DLKPC variants
The toxicity profdes of buthionine sulphoxamine (BSO), an inhibitor of glutathione synthesis 
and ethacrynic acid, a specific inhibitor of glutathione-S-transferase, were determined in the 
DLKP cells and DLKPC variants. The toxicity of BSO, over a concentration range of 0 - 
250/iM, was investigated in both the sensitive DLKP and DLKPC 25 cell lines. Figure
3.3.2.1 illustrates that the DLKP parental cells exhibited far greater susceptibility to BSO 
toxicity than the DLKPC 25 variant. The calculated IC50 values for BSO in the DLKP and 
DLKPC 25 cells were approximately 20/xM and 120/tM respectively. The effect of BSO 
on the toxicity profile of carboplatin was investigated in the DLKPC variants. The 
concentration of BSO resulting in more than 95 % cell survival (IC95) was chosen for the 
assay, in which the cells were exposed to both carboplatin and BSO. The results obtained 
illustrated that the non-toxic concentration of BSO had no significant effect on the toxicity 
profile of carboplatin. Figure 3.3.2.1 presents the results obtained for the DLKPC 25 cell 
variant.
The toxicity profile of ethacrynic acid, over a concentration range of 0 - 5mg/ml, was also 
studied in the parental DLKP cells and DLKPC resistant variants. Figure 3.3.2.2 illustrates 
that all four cell lines studied exhibited slightly different toxicity profiles. Although the 
DLKPC cells were found to be more susceptible to ethacrynic acid than the parental cells, 
only a maximum of a two fold difference in the IC50 values was observed. The effect of 
ethacrynic acid (IC95) on the toxicity of carboplatin was studied in the three resistant 
variants and the results obtained illustrated that ethacrynic acid did not significantly alter 
the toxicity profile in any of the cell lines studied. Figure 3.3.2.2 illustrates the results 
obtained for the DLKPC 25 variant.
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BSO C oncentra tion  jiM
Curboplatin C oncentration  Mg/ml
Figure 3.3.2.1 The toxicity profile of the glutathione inhibitor, BSO in the parental DLKP and the
carboplatin resistant DLKPC 25 variants (a) and the effect of BSO on the toxicity profile of
carboplatin in the DLKPC 25 variant (b).
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Ethacrynic acid concentration Mg/ml
Carboplatin concentration fig/ml
Figure 3.3.2.2 The toxicity profile of ethacrynic acid in the parental DLKP and in the carboplatin
resistant DLKPC variants (a) and the effect of ethacrynic acid on the toxicity profile of carboplatin
in the DLKPC 25 variant (b).
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3.4.1 Camptothecin toxicity in the DLKPC variants
The toxicity of the topoisomerase I inhibitor, camptothecin, in DLKP and DLKPC variants 
was investigated to determine if the DLKPC variants were susceptible to topoisomerase I 
inhibition. The toxicity profde of camptothecin, over a concentration range of 0 - 2500 
ng/ml (0 - 2.5/u.g/ml), was determined in the parental DLKP and DLKPC cells. Figure 3.4.1 
illustrates that the camptothecin exhibited slightly lower toxicity in all three variants, 
relative to the parental cell line. However, there was only a maximum of a two fold 
decrease between the DLKP cells, where camptothecin proved to be the most toxic and 
DLKPC 14 variant, which were the least susceptible to camptothecin toxicity.
0 1 2  3
Camptothecin Concentration (jig/ml)
Figure 3.4.1 The toxicity profile of the topoisomerase I inhibitor, camptothecin in the parental 
DLKP cells and in the DLKPC resistant variants.
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3.4.2 Amphotericin B toxicity in the DLKPC variants
The effect of the polyene antibiotic, amphotericin B, on carboplatin resistance was 
investigated in the DLKPC resistant variants. Amptothericin B alters membrane 
permeability by binding to cholesterol and forming pores in the membranes. The aim of 
this work was to determine if alterations in membrane permeability affected the toxicity of 
carboplatin in the DLKPC resistant variants. An initial toxicity assay for amphotericin was 
carried out, over a concentration range of 0 - 40/ig/ml, in the DLKP and DLKPC cell lines. 
Figure 3.4.2 illustrates that a similar toxicity profde was observed in the four cell lines 
studied, with IC50 values of approximately 3.5 - 5/tg/ml amphotericin B. Figure 3.4.2 also 
illustrates the effect of a non-toxic concentration of amphotericin B (0.2/xg/ml) on 
carboplatin toxicity in DLKPC 25 cells. Although this agent has been shown to reverse 
platinum resistance in a number of cell lines, the results obtained showed that amphotericin 
B did not significantly alter the toxicity profde of carboplatin in the DLKPC 25 cells. The 
effect of amphotericin B was also studied in the DLKPC 6.2 and DLKPC 14 variants. 
However, no significant effect was observed.
3.4.3 Ouabain toxicity in the DLKPC variants
Since the Na+ K +-ATPase inhibitor, ouabain, has been demonstrated to decrease platinum 
accumulation in a number of cell lines, the effect of the compound on carboplatin toxicity 
was studied in the DLKPC variants. The aim of this work was to investigate the role of 
Na+K +-ATPases in drug accumulation in the DLKPC variants. The toxicity profde of 
ouabain, over a concentration range of 0 - 50ng/ml, was initially determined in the parental 
DLKP and the three DLKPC resistant variants. The results obtained illustrated that the 
DLKP cells were slightly more susceptible to ouabain toxicty than the resistant lines, having 
an IC50 value of 8.5ng/ml. The DLKPC 14 and DLKPC 25 cells exhibited similar toxicity 
profiles with IC50 values of approximately 16ng/ml while the DLKPC 6.2 cells had an IC50 
value of 10.5ng/ml (figure 3.4.3). Studies on the effect of ouabain (0.2ng/ml) on 
carboplatin toxicity in the DLKPC variants revealed that ouabain did not significantly alter 
the toxicity profile in any of the variants studied. Figure 3.4.3 illustrates the results 
















Figure 3.4.2 The toxicity profile of amphotericin B in the parental DLKP and carbopiatin resistant
DLKPC variants (a) and the toxicity profile of amphotericin B (0.2/xg/ml) on the toxicity profile of
carbopiatin in the DLKPC 25 variant (b).
Ouabain concentration ng/ml
Carboplatin concentration ng/ml
Figure 3.4.3 The toxicity profile of ouabain in the parental DLKP and carboplatin resistant DLKPC
variants (a) and the effect of ouabain (0.2/ag/ml) on the toxicity profile of carboplatin in the DLKPC
25 variant (b).
3.4.4 Cadmium chloride toxicity in the DLKPC variants
Since resistance to the heavy metal, cadmium chloride is associated with increased levels 
of metallothionein expression the toxicity of cadmium chloride in the DLKP parental cells 
and in the DLKPC resistant variants was studied. This work was carried out to establish 
if there was any alteration in the level of the cytoplasmic protein, metallothionein, in the 
carboplatin resistant lines. Cadmium chloride was shown to exhibit a notably different 
toxicity profde in all four DLKP variants studied. It proved to be the most toxic to the 
DLKP parental cells, having an IC50 value of approximately 0.22 /¿g/ml and least toxic to 
the DLKPC 25 resistant variant, with an IC50 of approximately 2.2 /xg/ml (Figure 3.4.4). 
There was approximately a ten fold decrease in cadmium chloride toxicity from the DLKP 
to the DLKPC 25 variant. The DLKPC 14 cells exhibited approximately a nine fold 
resistance to cadmium and the DLKPC 6.2 a 2.7 fold resistance to cadmium.
Cadmium Chloride Concentration (ng/ml)
Figure 3.4.4 The toxicity profde of cadmium chloride in the parental DLKP and DLKPC resistant 
cell lines.
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3.5 Immunological Studies in the DLKPC variants
3.5.1 Immunological detection of metallothionein in the DLKPC variants
The presence of metallothionein in the parental DLKP cells and the DLKPC variants was 
investigated, using a monoclonal mouse anti-metallothionein antibody as outlined in section 
2.9.2.3. Metallothionein expression was predominantly observed in the cytoplasm of the 
cells, with the intensity of staining observed varying, depending on the DLKP variant studied. 
Faint cytoplasmic staining was visible in approximately 60% of the DLKP parental cells. All 
three DLKPC variants stained positive for metallothionein expression. However, the staining 
intensity increased with increasing level of resistance. The DLKPC 6.2 variant was only 
slightly more positive than the DLKP cells as shown in figure 3.5.1.1. However, both the 
DLKPC 14 and DLKPC 25 variant proved to be substantially more immunoreactive to the 
anti metallothionein antibody than the parental cells (figure 3.5.1.2). Intense cytoplasmic 
staining was noted in approximately 85% of the DLKPC 25 cells. Cells that were incubated 
in the absence of the primary metallothionein antibody were negative for metallothionein 
expression.
3.5.2 Immunological detection of LRP and MRP in the DLKPC variants
The presence of the 110 kilodalton protein, LRP, was investigated in the parental DLKP and 
the resistant DLKPC cells, using the LRP-56 antibody, as described in section 2.9.2.4. A 
typical staining pattern for LRP in the DLKP and DLKPC 25 cells is shown in figure 3.5.2. 
LRP expression was localized predominantly in the cytoplasmic regions of the DLKP and 
DLKPC cells. Approximately 60% of the DLKP cells were positive for LRP, although the 
intensity of staining varied within a cell population, from faint staining in some cells to very 
intense staining in others. The three DLKPC variants showed similar LRP staining patterns 
to the parental cells. Cytoplasmic staining was observed in the cells and the intensity of 
staining again varied within the cell populations. There was no significant difference in LRP 
staining and intensity observed in the DLKPC 6.2, DLKPC 14 and DLKPC 25 cells. The 
presence of MRP was investigated using the rat monoclonal antibody MRPrl in the DLKP 
and DLKPC cell variants. No detectable levels of MRP was observed in any of the four 
variants studied. Very faint staining was observed, however, the staining pattern was similar 
to the negative control cells.
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Figure 3.5.1.1 Immunocytochemical detection of metallothionein in the parental DLKP (a) and 
DLKPC 6.2 resistant variant (b) with a mouse monoclonal anti-metallothionein antibody.
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Figure 3.5.1.2 Immunocytochemical detection of metallothionein in the DLKP 14 (a) and DLKPC 
25 resistant variants (b) with a mouse monoclonal anti-metallothionein antibody.
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Figure 3.5.2 Immunocytochemical detection of LRP (pi 10) in the parental DLKP (a) and DLKPC
25 resistant variant (b) with the mouse monoclonal anti-LRP 56 antibody.
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3.6 Establishment of MDR cell lines
3.6.1 Establishment of DLKPA10 and SKMES-1/ADR cell lines
The DLKPA10 variant of the human lung carcinoma cell line DLKP was established by 
further exposing the adriamycin resistant variant, DLKP-A (selected to 2.1/xg/ml 
adriamycin; Clynes et al., 1992) to increasing concentrations of adriamycin over a time 
period of approximately three months. The cells readily adapted to growth in the higher 
drug concentrations. The cells were exposed to a final concentration of 10/xg/ml adriamycin 
and were designated DLKPA10. The SKMES-1/ADR variant of the human lung cell line, 
SKMES-1, was established by exposing the low level adriamycin resistant variant, SKMES- 
1A, to increasing concentrations of adriamycin over a time period of four months. The IC50 
value for adriamycin in the SKMES-1A cell was found to be approximately 350nM before 
the selection process was started. The cells adapted slowely to increasing concentration of 
the drug over the first two months, although after this time they readily adapted to growth. 
The cells were exposed to a final concentration of 0.25/xg/ml adriamycin. The cells were 
routinely maintained at this concentration and were designated SKMES-1/ADR.
3.6.2 Cross resistance profile of the DLKPA10 cell line
The sensitivity of the DLKPA10 variant to a number of chemotherapeutic drugs was 
determined in order to establish its cross resistance profile. The chemotherapeutic agents 
included the selecting agent, adriamycin, the vinca alkaloid, vincristine, the antimetabolite 
agent, 5-fluorouracil, the semisynethic derivative of podophyllotoxin, VP16 and the 
alkylating agent, carboplatin. Table 3.6.2.1 represents the IC50 values obtained for each of 
the chemotherapeutic agents for the parental DLKP cells and the DLKPA10 resistant 
variant. Table 3.6.2.2 represents the fold resistance of the DLKPA10 and DLKP-A cell 
lines relative to the control DLKP parental cells. The DLKPA10 cells were found to be 
resistant, not only to the selecting agent adriamycin but also to vincristine and VP16. The 
cells exhibited greatest cross resistance to vincristine (3000-fold approximately), then to the 
selecting agent adriamycin (765-fold approximately), showing the least resistance to VP16 
(approximately 63-fold). The DLKPA10 cells were found to exhibit slight sensitivity to the 
chemotherapeutic agents carboplatin and 5-fluorouracil. However, a significance difference 
was not noted.
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IC *  (nM) DLKP DLKPA10
Adriamycin 8.75 ±  0.77 6696 ±  453
Vincristine 0.728 ±  0.062 2184 ±  132
VP16 233 ±  18.5 1448 ±  98.2
Carboplatin 3243 ±  278 2676 ±  198
5-Fluorouracil 7923 ± 5 7 . 7 7308 ±  522







ND - not determined
Table 3.6.2.2 Fold resistance of the DLKP-A and DLKPA10 cells relative to the parental 
DLKP cells
3.6.3 Cross resistance profile of the SKMES-1/ADR cell line
To determine if the SKMES-1/ADR cell line exhibited the multidrug resistant phenotype, 
the sensitivity of the resistant cells to a number of chemotherapeutic agents was 
investigated. Table 3.6.3.1 represents the IC50 values obtained for the SKMES-1 parental 
cells and the SKMES-1/ADR cell line with the selecting agent adriamycin, the vinca
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alkaloid vincristine, the alkylating agent carboplatin and the podophyllotoxin VP16. Table
3.6.3.2 presents the fold resistant values obtained for the SKMES-1/ADR cells, relative to 
the control SKMES-1 parental cells. The SKMES-1/ADR cells were found to be most 
resistant, not to the selecting agent adriamycin but to vincristine. The cells exhibited 
approximately a 50-fold resistance to vincristine and a 45-fold resistance to adriamycin. 
The cells also showed cross resistance to VP16, although only a three fold resistant level 
was noted. A 2-fold resistance level was observed with carboplatin in the SKMES-1/ADR 
cells.
1C«, (nM) SKMES-1 SKMES-1/ADR
Adriamycin 26.8 ±  3.1 1205 ±  98.9
Vincristine 9.1 ±  0.86 455 ±  32.2
VP16 114.3 ±  10.6 343 ±  27.8
Carboplatin 337.8 ±  25.7 729.9 ±  55.4






Table 3.6.3.2 Fold resistance values for SKMES-1/ADR with respect to the SKMES-1 
cells
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3.7 Stability of the DLKPA10 and SKMES-1/ADR cell lines
The stability of the DLKPA10 cells when maintained, in the absence of adriamycin, was 
studied over a number of months. Over a time period of six months the cells maintained 
their resistance to adriamycin and, therefore, was characterised as a stable cell line. The 
stability of the SKMES-1/ADR cell line was also investigated over a time period of four to 
six months. Although the cells maintained their resistance to adriamycin over a four month 
time period, a slight decrease in the resistance levels was observed following six months 
maintenance in drug free medium. The SKMES-1/ADR cells were, therefore, exposed to 
adriamycin every four months to maintain their resistance level.
3.8 DNA fingerprint analysis of the DLKPA10 and SKMES-1/ADR cell lines
DNA fingerprint analysis was carried out on the DLKPA10 cells and SKMES-1/ADR cells 
to establish its genetic identity to the DLKP and SKMES-1 parental cells, from which they 
were established. The DLKPA10 cell line was found to share almost identical bands with 
the DLKP cells and, therefore, must have originated from the DLKP cells. The SKMES- 
1/ADR cells were found to share almost identical bands with the SKMES-1 cells and 
consequently must have originated from this cell line.
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3.9 Protein analysis in the DLKP and SKMES-1 variants
The expression of the MDR associated membrane protein, P-glycoprotein, was studied in 
the DLKPA10 and SKMES-1/ADR resistant cell lines by western blot analysis. The results 
obtained were compared to the levels of protein detected in the parental DLKP and SKMES- 
1 cells respectively.
3.9.1 Western blot analysis of P-glycoprotein expression
Alterations in the levels of P-glycoprotein expression was investigated in the parental DLKP 
and SKMES-1 cells and in the MDR variants, DLKPA10 and SKMES-1/ADR. Purified 
membrane fractions of each of the cell lines were prepared, as described in section 2.7.2 
and and stored lyophilized until required. The extracts were reconstituted and the protein 
separated by gel electrophoresis. The expression of P-glycoprotein was detected, using the 
anti-P-glycoprotein monoclonal antibody, C219. Figure 3.9.1. illustrates the results 
obtained for the four cell lines. The results show that the C219 antibody reacted with a low 
level of P-glycoprotein in the DLKP and SKMES-1 parental cells. In contrast strong 
immunoreactivity was observed in both the DLKPA10 and SKMES-1/ADR cell lines, 
indicating high expression of P-glycoprotein. The most significant increase in P- 
glycoprotein expression was noted in the DLKPA10 cells,
To determine if P-glycoprotein localisation was confined to cellular membrane extracts, the 
expression of P-glycoprotein was also studied in nuclear extracts of the DLKP and DLKA10 
cell lines. Nuclear extracts were prepared, as outlined in section 2.7.3 and western blot 
analysis carried out using the anti-P-glycoprotein monoclonal antibody, C219. The results 
obtained are presented in figure 3.9.2. The overexpression of P-glycoprotein in the nuclear 
extracts was comparable to the level detected in the membrane preparations. Strong 
immunoreactivity was observed in the nuclear extracts of the DLKPA10 cells, while only 
a very low level was detected in the parental DLKP cells. Western blot analysis was also 
carried out on membrane preparations of both cell line to compare the expression of P- 
glycoprotein in the different cellular extracts. The results show that the level of P- 
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Figure 3.9.1 Western blot detection of P-glycoprotein in cell membrane preparations of the DLKP, 
DLKPA10, SKMES-1 and SKMES-1/ADR cell lines with the C219 monoclonal antibody.
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Probed with C219 Negative Control
Figure 3.9.2 Western blot detection of P-glycoprotein in cell membrane and nuclear extract 
preparations of the DLKP and DLKPA10 cell lines with the C219 monoclonal antibody.
3.10 Adriamycin accumulation in SKMES-1 and SKMES-1/ADR cell lines
The cellular concentration of adriamycin in the SKMES-1 and SKMES-1 /ADR cells was 
determined after various incubation time periods, as described in section 2.10.1. The effect 
of a number of compounds on adriamycin accumulation in both cell lines was also 
investigated.
Figure 3.10.1 illustrates the time course of adriamycin accumulation in the parental 
SKMES-1 and the multidrug resistant SKMES-1/ADR cell lines. The results show that over 
a four hour time period an increase in the accumulation of adriamycin in the SKMES-1 cells 
was observed up to three hours incubation, after which time a steady state of arimaycin 
uptake was reached. Adriamycin accumulation was significantly reduced in the SKMES- 
1/ADR cells relative to the parental cell line. The SKMES-1 cells accumulated 
approximately 525 pmoles of adriamycin per 106 cells within four hours. However, only 
135 pmoles of adriamycin accumulated per 106 cells was noted in the SKMES-1/ADR cells 
within the same time period. The rate of accumulation was greatest within the first hour 
in the SKMES-1/ADR cells following the addition of drug, after which time a steady rate 
was observed. No further increase in adriamycin accumulation was noted in the SKMES- 
1/ADR cells following exposure to the drug for longer incubation periods.
3.10.1 Effect of verapamil on adriamycin accumulation
The effect of the calcium channel antagonist, verapamil, on adriamycin accumulation was 
investigated in the SKMES-1 and the SKMES-1/ADR cell lines. An initial concentration 
response assay was carried out, over a range of 0 - 100/xg/ml, and a suitable working 
concentration of verapamil was determined. When the cells were coincubated with 
verapamil (30/ig/ml) a slight increase in the cellular concentration of adriamycin was 
observed in the parental cell line within a four hour time period, although verapamil did not 
significantly alter the rate of accumulation. The addition of verapamil to the SKMES- 
1/ADR cells resulted in an marked increase in the rate of adriamycin accumulation and also 
in the cellular concentration of the drug. Verapamil reversed the accumulation defect in this 
cell line and restored the maximum level of adriamycin accumulated to that observed in the 
parental SKMES-1 cell line (Figure 3.10.1).
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3.10.2 Effect of cyclosporin A on adriamycin accumulation
The effect of the immunosupressive agent, cyclosporin A (10/zg/ml), on adriamycin 
accumulation was also studied in the SKMES-1 and SKMES-1/ADR cells. A concentration 
response curve was established, over the range of 0 - 100/xg/ml and a suitable working 
concentration was determined. Cotreatment with cyclosporin A resulted in an increase in 
the cellular concentration of adrimaycin over the four hour time period studied. 
Cyclosporin A was found to be more effective than verapamil at reversing the accumulation 
defect in the SKMES-1/ADR cells. The presence of cyclosporin A enhanced adriamycin 
accumulation in the SKMES-1/ADR cells to a level greater than that observed in the 
SKMES-1 cell line (figure 3.10.1). The addition of cyclosporin A also caused a slight 
increase in the cellular concentration of adriamycin in the parental cells .
Tim e (h ours)
Figure 3.10.1 The time course of adriamycin accumulation in the SKMES-1 and SKMES-1/ADR 
cell lines. The effect of verapamil (30/tg/ml) and cyclosporin A (10/xg/ml) on adriamycin 
accumulation in SKMES-1/ADR cells.
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3.10.3 Effect of energy inhibition on adriamycin accumulation
The effect of sodium azide (an inhibitor of oxidative phosphorylation) and 2-deoxy-D- 
glucose (an inhibitor of glycolysis) on adriamycin accumulation in the SKMES-1 and 
SKMES-1/ADR cell lines was studied, to determine if the accumulation defect observed in 
the SKMES-1/ADR cells could be restored by the inhibition of ATP production. 
Adriamycin accumulation was first determined in the presence of glucose free medium, 
containing sodium azide (lOmM), over a time course of three hours, as described in section 
2.10.1. An increase in adriamycin accumulation was observed in the SKMES-1 cell line 
in the presence of sodium azide when compared to treatment with adriamycin alone. When 
incubated with sodium azide, the maximum cellular concentration of adriamycin was 1 
nmole per 106 cells after three hour incubation. The SKMES-1 cells accumulated 
approximately 600 pmoles adriamycin per 10fi cells when incubated with adriamycin for the 
same time period. A marked increase in adriamycin accumulation was observed in the 
SKMES-1/ADR cells following treatment with sodium azide. Figure 3.10.3 illustrates that 
the accumulation defect was restored in the resistant cells and that the cellular concentration 
of drug was comparable to the level observed in the SKMES-1 parental cell.
The addition of 2-deoxy-D-glucose (25mM) resulted in a slight decrease in adriamyicn 
accumulation in the SKMES-1 parental cells. However, when the SKMES-1/ADR cells 
were exposed to 2-deoxy-D-glucose, an increase in the uptake of adriamycin to a level 
comparable to the parental cell line was again observed.
3.10.4 Adriamycin efflux in SKMES-1 and SKMES-1/ADR cell lines
Adriamycin efflux was studied in the SKMES-1 and SKMES-1/ADR cells after the cells 
were preloaded with adriamycin in the presence of sodium azide (lOmM) for three hours, 
as described in section 2.10.2. Figure 3.10.3 illustrates adriamycin efflux in the SKMES-1 
and SKMES-1 /ADR cell lines over a period of four hours. The results obtained 
demonstrated that when the cells were reintroduced to drug free complete medium, a 
marked decrease in the cellular concentration of adriamycin was observed in the SKMES- 
1/ADR cells within the first hour. Over the next two hours a slight decrease was recorded, 
after which time the cellular concentration had reached a level of approximately 75 pmoles
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per 106 cells. Drug efflux was also observed within the first hour in the parental SKMES-1 
cells when the cells were reintroduced into drug free medium, although the decrease in 
cellular concentration of adriamycin was not as marked as in the SKMES-1/ADR cell line. 
A further decrease in adriamycin accumulation was noted within the next hour, after which 
time the cellular concentration of adriamycin reached a steady level of approximately 900 
pmoles per 106 cells.
T im e  (H o u r s )
Figure 3.10.3 Adriamycin accumulation and efflux in the SKMES-1 and SKMES-1/ADR cell lines. 
The cells were preloaded with adriamycin in glucose free medium, containing sodium azide (lOmM), 
for 3 hours and then washed and incubated in drug free complete medium. Drug efflux was studied 
over a period of four hours.
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3.10.5 Vincristine accumulation in SKMES-1 and SKMES-1/ADR cell lines
Vincristine accumulation was also studied in the SKMES-1 and SKMES-1/ADR cells over 
a period of three hours. The results obtained illustrated a decrease in the cellular 
concentration of vincristine in the SKMES-1/ADR, relative to the parental cell line. A 
linear increase in vincristine accumulation was observed in the SKMES-1 parental cells, 
within the three hour period studied. An increase in vincristine accumulation was also 
noted in the SKMES-1/ADR cells up to a thirty minute time period, although after this time 
a steady state of accumulation of approximately 0.3 pmoles per 106 cells was reached. 
Accordingly, a decrease of approximately six fold was observed in the resistant cells within 
the time period studied. W hen the cells were coincubated with cyclosporin A (10/tg/ml), 
a marked increase in vincristine accumulation was noted in the SKMES-1 /ADR cells. The 
cellular concentration of vincristine in the resistant cells after three hour incubation with 
cyclosporin A was over two fold greater than the concentration in the parental cells which 
were exposed to vincristine for the same time period (figure 3.10.5). The effect o f the 
carboxylic ionophore, monensin, on vincristine accumulation was also investigated in the 
SKMES-1/ADR cells. The results obtained illustrated that, although monensin was not as 
effective as cyclosporin A at enhancing vincristine accumulation in the resistant cells, the 
addition of monesnin completely reversed the accumulation defect observed in the cells. 
The maximun level o f drug accumulated within the three hour period studied was greater 
than the level observed in the parental cells.
3 .1 0 .6  Effect of cell density on adriamycin accumulation in SKMES-1 and SKMES- 
1/ADR cell lines
The uptake of adriamycin in the SKMES-1 and SKMES-1/ADR cell lines at different cells 
density was investigated to determine if drug accumulation was cell density dependent. The 
cells were plated at two different cell densities, 7.5x10* and 2x10s cells per well and 
incubated for approximately 48 hours. The cells were exposed to adriamycin for two and 
four hour time periods and the cellular concentration of adriamycin was determined, as 
described in section 2.10.1. Both the SKMES-1 and the SKMES-1/ADR cell lines were 
found to be cell density dependent, when plotted as pmoles adriamycin accumulated per 106 
cells (figure 3.10.6). The results illustrated that when the cells were plated at a low seeding 


























greater than that observed when the cells were plated at a higher density (2 x 10s cells per 
well). As the cell density was increased the cellular concentration of adriamycin per 106 
cells decreased.
Time (minutes)
Figure 3.10.5 The time course of vincristine accumulation in the SKMES-1 and SKMES-1/ADR 
cell lines. The effect of cyclosporin A (10/ig/ml) and monensin (10/tg/ml) on vincristine 
accumulation in SKMES-1/ADR cells.
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Figure 3.10.6 The effect of cell plating density on adriamycin accumulation in the SKMES-1 (a) 
and SKMES-1/ADR (b) cell lines. The cells were plated at a concentration of 2x10s and 0.75x10s 
cells per well and adriamycin accumulation determined after 48 hours.
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3 .1 1 .1  Adriamycin accumulation in DLKP and DLKPA10 cell lines
Adriamycin accumulation was investigated in the DLKP and DLKPA10 cell lines to 
determine if these cell lines exhibited similar accumulation patterns to those observed in the 
SKMES-1 and SKMES-1/ADR cell lines. The effect of a number of compounds on 
adriamycin accumulation was also studied. Figure 3.11.1 represents the time course of 
adriamycin accumulation in the DLKP and DLKPA10 cells. An increase in accumulation 
was observed in the DLKP cells within the four hours studied, with maximum accumulation 
of approximately 950 pmoles per 106 cells. A marked reduction in adriamycin accumulation 
was observed in the DLKPA10 cell line, with respect to the parental DLKP cells. A 
decrease of approximately 16-fold in the cellular concentration of adriamycin was observed 
in the DLKPA10 cells. A maximum accumulation level of approximately 60 pmoles per 
106 cells was reached after two hour exposure. No further increase in accumulation was 
noted in the DLKPA10 cell lines at longer exposure times. Studies were carried out on the 
DLKP and DLKPA10 cell lines to determine the time point at which the cellular 
concentration of adriamycin was equivalent in both cell lines. Adriamycin accumulation 
was determined in the parental cells over a time period of 0 - 30 minutes and over a time 
period of 0 - 4 hours in the DLKPA10 cell lines. The cellular concentration of adriamycin 
in the DLKPA10 cells after a 4 hour incubation period was approximately 75 pmoles per 
106 cells. W hen the DLKP cells were exposed to adriamycin, rapid uptake of the drug was 
observed in the cells. The cellular concentration of adriamycin in the DLKP cells after a 
five minute incubation period was comparable to the level observed in the DLKPA10 cells 
after four hours. After five minutes the concentration of adriamycin in the DLKP cells was 
found to be 79 pmoles per 106 cells.
3 .1 1 .1 .1  Effect of verapamil on adriamycin accumulation
The addition of verapamil (30/ig/ml) resulted in a slight increase in the maximum cellular 
concentration of adriamycin in the DLKP cell line within the time period studied, although 
no significant alteration in the rate of accumulation was observed. Verapamil also increased 
adriamycin accumulation in the DLKPA10 cell line but only to a level o f approximately 
45% of that observed in the parental cells after four hour exposure (figure 3.11.1). The
3.11 Drug accumulation studies in DLKP and DLKPA10 cell lines
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accumulation defect could not be reversed in the DLKPA10 cell lines following longer 
incubation periods with verapamil, or at higher concentrations of verapamil (up to 100/xg/ml 
verapamil was studied).
3 .1 1 .1 .2  Effect of cyclosporin A on adriamycin accumulation
W hen the cells were incubated with cyclosporin A (10/xg/ml), the maximum adriamycin 
accumulation was, again, slightly enhanced in the parental DLKP cells but the rate of 
accumulation was unaltered within the four hour time period. However, in the DLKPA10 
cell line, the addition of cyclosporin A resulted in an approximate 10-fold increase in 
adriamycin accumulation after four hour exposure and, therefore, was more effective than 
verapamil (Figure 3.11.1). No further increase in the cellular concentration of adriamycin 
in the DLKPA10 cells was observed following exposure to increasing concentration of 
cyclosporin (up to 100/xg/ml).
Time (Hours)
Figure 3.11.1 The time course of adriamycin accumulation in DLKP and DLKPA10 cell lines. The 
effect of verapamil (30/xg/ml) and cyclosporin A (10/xg/ml) on adriamycin accumulation in DLKPA10 
cells.
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3.11.1.3 Effect of cyclosporin A pretreatment on adriamycin accumulation
The cellular concentration o f adriamycin was determined in the DLKPA10 cells, following 
pretreatment with cyclosporin A (10jig/ml) for two hours. The aim of this work was to 
determine if pretreatment was more effective than cotreatment with cyclosporin A at 
restoring the accumulation defect observed in the DLKPA10 cells. Figure 3.11.1.3 
illustrates the time course of adriamycin accumulation in the DLKPA10 cells following 
pretreatment and cotreatment with cyclosporin A. The results show that, although 
cyclosporin A pretreatment increased accumulation, it did not fully restore the accumulation 
defect in the DLKPA10 cell line. Cyclosporin A pretreatment was, however, found to be 
m ore effective at increasing the cellular concentration of drug.
Ti me (Hours)
Figure 3.11.1.3 The effect of cyclosporin A pretreatment on adriamycin accumulation in DLKPA10 
cells. The cells were pretreated with cyclosporin A (10/xM) for two hours prior to the addition of 
adriamycin (10/xM).
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3.11.1.4 Effect of energy inhibition on adriamycin accumulation
The effect o f the energy inhibitors sodium azide, 2-deoxy-D-glucose and antimycin A on 
adriamycin accumulation in the parental DLKP and resistant DLKPA10 cells was studied 
to determine if the accumulation defect observed in the DLKPA10 cell line could be 
reversed by inhibition of ATP production. The cells were incubated in glucose free 
medium, containing either sodium azide (lOmM), 2-deoxy-D-glucose (25/ig/ml) or 
antimycin A (10/tM). Adriamycin accumulation was then determined over a period of three 
hours (figure 3.11.1.4). Following exposure to sodium azide, an increase in the maximum 
level o f adriamycin accumulated was observed in the DLKP cells, although the rate of 
accumulation was unaltered. The cellular concentration of adriamycin in the presence of 
sodium azide was found to be approximately 660 pmoles adraimycin per 106 cells after three 
hour exposure, in comparison to 444 pmoles accumulated per 10  ^cells following incubation 
in standard culture medium. Coincubation with sodium azide resulted in a 2.5-fold increase 
in adriamycin accumulation in the DLKPA10 cells within the same time period. 
Adriamycin accumulation in the DLKPA10 cells was determined over a concentration range 
of sodium azide (5 - 50mM). However, it was found that the accumulation defect could not 
be reversed at higher concentrations. When the cells were exposed to sodium azide at 
concentations greater than lOmM cell lysis was observed in both the DLKP and DLKPA10 
cell lines.
W hen the effect o f 2-deoxy-D-glucose on adriamycin accumulation in DLKP and DLKPA10 
cells was investigated, the results were similar to those obtained with sodium azide. A 
slight increase in adriamycin accumulation was observed in the DLKP parental cells 
following three hour exposure to the drug. Coincubation with 2-deoxy-D-glucose resulted 
in an increase of approximately 2-fold in adriamycin accumulation in the DLKPA10 cells, 
thus indicating that it was not as effective as sodium azide at enhancing the cellular 
concentration of drug. 2-deoxy-D-glucose proved to be more toxic than sodium azide to 
the cells within the time period studied. The accumulation of adriamycin in the presence 
of antimycin A was also investigated in the DLKP and DLKPA10 cell lines. The addition 
of 10/iM antimycin A resulted in an increase of greater than 2-fold in the cellular 
accumulation of adriamycin in the parental DLKP cells. The DLKP cells accumulated 
approximately 444 pmoles of adriamycin per 106 cells within the three hour period, while 
the subcellular concentration was approximately 980 pmole per 106 cells following 
incubation with antimycin A. Antimycin A was even more effective at enhancing the
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cellular levels of adriamycin in the DLKPA10 cells. Following treatment with antimycin 
A, an 8.5-fold increase in the level of adriamycin accumulation was noted in the DLKPA10 
cells. The cellular concentration of adriamycin was approximately 70 pmoles per 106 cells 
after a three hour incubation period, while the subcellular concentration was approximately 
590 pmoles following incubation of the cells in the presence of antimycin A. Accordingly, 
antimycin A was shown to completely restore adriamycin accumulation in the DLKPA10 
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Figure 3.11.1.4 The effect of sodium azide (lOmM), 2-deoxy-D-glucose (25/tg/ml) and 
antimycin A (10/xM) on adriamycin accumulation in DLKPA10 cells.
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The effect of cotreatment with cyclosporin A and sodium azide on adriamycin 
accumulation was studied in the DLKP and DLKPA10 cells. W hen the cells were 
incubated in glucose free medium, containing cyclosporin A (10/xg/ml) and sodium azide 
(lOmM), a decrease in adriamycin accumulation was observed in the DLKP parental 
cells. The cellular concentration of adriamycin, following four hour incubation, was 
approximately 750 pmoles per 106 cells with cotreatment, as opposed to 920 pmoles 
adriamycin per 106 cells when the cells were treated with adriamycin alone. Cotreating 
the DLKPA10 cells with cyclosporin A and sodium azide resulted in an increase in 
adriamycin accumulation from approximately 70 pmoles per 106 cells to 550 pmoles per 
106 cells, representing an increase to approximately 60% of the adriamycin accumulated 
in the DLKP cells (figure 3.11.1.5).
3.11.1.5 Effect of cotreatment with cyclosporin A and sodium azide on adriamycin
accumulation
T i m e  ( H o u r s )
Figure 3.11.1.5 The effect of cotreatment with cyclosporin A (10^g/ml) and sodium azide 
(lOmM) on adriamycin accumulation in DLKP and DLKPA10 cells.
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3.11.2 Adriamycin efflux in DLKP and DLKPA10 cell lines
The efflux of adriamycin from the DLKP and DLKPA10 cells was studied over a period 
of three hours, following preloading of the cells for three hours in glucose free medium, 
containing either sodium azide or antimycin A (Figure 3.11.6). When the cells were 
coincubated with sodium azide (lOmM), the cellular accumulation of adriamycin in the 
DLKP and DLKPA10 cell lines after three hours was approximately 660 pmoles per 106 
cells and 150 pmoles per 10s cells respectively. When the drug was removed and the 
cells incubated in drug free complete medium, a rapid efflux of adriamycin was observed 
in the DLKP cells within the first hour. After this time the cellular concentration of 
adriamycin increased slightly and then a steady rate was reached over the next two 
hours. Rapid drug efflux was also noted in the DLKPA10 variant within the first hour 
when the cells were reintroduced into drug free medium. Over the next two hours there 
was a slight decrease in the cellular concentration of adriamycin to a level comparable 
with that observed in the time course assay (figure 3.11.2.1).
Following coincubation with antimycin A (10/xM), the cellular concentration of 
adriamycin in the DLKP and DLKPA10 cells was approximately 1.4 nmoles per 10s 
cells and 1 nmole per 106 cells respectively. When the drug was removed, a decrease 
in  the cellular drug concentration was observed in both cell lines, although a greater 
decrease was noted in the DLKPA10 cells. W ithin the first 60 minutes, rapid efflux of 
adriamycin from the DLKPA10 cells was observed, after which time a slower rate of 
efflux was noted. After three hour incubation in drug free medium, the cellular 
concentration of adriamycin in the DLKPA10 cells was approximately 200 pmoles per 
106 cells. A decrease in the maximun level of cellular adriamycin was also noted in the 
DLKP parental cells when incubated in drug free medium, although the efflux rate was 
slower than that observed in the DLKPA10 cells. The cellular concentration of 
adriamycin was approximately 800 pmoles per 106 cells following three hour incubation 
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Figure 3.11.2.1 Adriamycin efflux in DLKP and DLKPA10 cell lines following preloading with 
(a) sodium azide (lOmM) and (b) antimycin A (10j*M) for three hours.
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3.11.2.1 The effect of cyclosporin A on adriamycin efflux in DLKP and DLKPA10 
cells
The effect o f cyclosporin A (10^g/ml) on adriamycin efflux was studied in the DLKP and 
DLKPA10 cell lines, following preloding with antimycin A (40^g/ml) for three hours. 
Figure 3.11.2.1 illustrates the efflux pattern observed in both the DLKP and DLKPA10 
cells in the presence of cyclosporin A. The results show that cyclosporin A did not 
significantly alter adriamycin efflux in the parental cells within the first two hours studied. 
Although, after this time an increase in the cellular concentration of ariamycin was noted 
in the presence of cyclosporin A. A marked decrease in adriamycin efflux was observed 
in the DLKPA10 cells when incubated with cyclosporin A. The cellular concentration of 
drug after three hours was approximately 2.5-fold greater than that observed in the absence 
of the circumvention agent.
Time (hours)
Figure 3.11.2.1 The effect of cyclosporin A (10/xg/ml) on adriamycin efflux in DLKP and 
DLKPA10 cells lines. The cells were preloaded in the presence of antimycin A (10/xM) for three 
hours and efflux was studied over a further three hours
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3.11.3 Vincristine accumulation in the DLKP and DLKPA10 cell lines
Vincristine accumulation was also studied in the DLKP and DLKPA10 cells, over a period 
of three hours. The results obtained illustrated a marked reduction in the cellular 
concentration of vincristine in the DLKPA10 cells, relative to the parental cells (figure 
3.11.3). Vincristine accumulation was shown to increase with increasing incubation time 
in the DLKP cells within the three hours studied, with the maximum level of drug 
accumulation of approximately 4 pmoles per 106 cells. In contrast, the maximum level of 
vincristine accumulated in the DLKPA10 cells after the same time exposure was only 
approximately 0.25 pmoles per 106 cells, representing a 16-fold decrease in drug 
accumulation in the resistant cells. The addition of verapamil enhanced vincristine 
accumulation in the DLKPA10 cells, although only a 3.6-fold increase in the cellular 
concentration of drug was observed. An increase in vincristine accumulation was also noted 
in the parental cells following treatment with cyclosporin A. Cyclosporin A was found to 
more effective than verapamil at increasing drug accumulation, in both the DLKP and 
DLKPA10 cells. Although treatment with cyclosporin A resulted in a greater enhancement 
of vincristine accumulation, the maximum cellular concentration of drug was still 
substantially less than that observed in the parental cells. The cellular concentration of drug 
after three hours was approximately 1.25 pmoles per 106 cells, representing a 5-fold 
increase in vincristine accumulation in the resistant cells. No further increase in 
accumulation was observed following longer exposure to the drug.
3 .1 1 .4  Vincristine efflux in the DLKP and DLKPA10 cell lines
The efflux of vincristine from the DLKP and DLKPA10 cells was studied, following 
preloading of the cell in the presence of antimycin (10/*M) for two hours. W hen the cells 
were reintroduced to drug free complete medium, a marked decrease in drug retention was 
observed in both the DLKP and DLKPA10 cell lines within the first 60 minutes. After this 
time, a steady level of drug retention was reached in the DLKP cells. However, in the 
DLKPA10 cells, a further decrease was observed within the second hour, although a slower 
rate of drug efflux was noted (figure 3.11.4). The cellular concentration of vincristine in 
the DLKPA10 cells was comparable to the level observed following two hour exposure to 
the drug (figure 3.11.3). The addition of cyclosporin A resulted in an increase in drug 
retention in the DLKPA10 cells o f approximately 3.6-fold after two hours. A significant
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decrease in the rate of drug efflux was also observed in the DLKPA10 cells, following 
treatment with cyclosporin A. The addition of cyclosporin A did not significantly alter 
either the rate o f drug efflux or the retention of drug in the DLKP cells within the first 60 
minutes, although after this time a decrease in vincristine retention was observed.
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Figure 3.11.3 The effect of verapamil (30/xg/ml) and cyclosporin A (10/ig/ml) on the time course 



























Figure 3.11.4 The effect of cyclosporin A (10/ig/ml) on vincristine efflux in the DLKP and 
DLKPA10 cell lines. The cells were preloaded in the presence of antimycin A (10/xM) for two 
hours, washed and incubated in drug free medium.
3 .1 1 .5  Effect of cell density on adriamycin accumulation in DLKP and DLKPA10 cell 
lines
Adriamycin accumulation was determined in the DLKP and DLKPA10 cells at three 
different cell plating densities to establish if drug accumulation was cell density dependent. 
The cellular concentration of adriamycin was deterined following two and four hour 
incubation periods. The results obtained are presented in figure 3.11.5. Drug uptake in 
both DLKP and DLKPA10 cell lines was found to be cell density dependent, within the 
time course studied. W hen the DLKP cells were plated at a low cell density (7.5 x 104 cells 
per well) approximately 1.5 nmoles adriamycin was accumulated per 106 cells within four 
hours as opposed to 780 pmoles accumulated per 106 cells when plated at a high density (2 
x 10s cells per well). Therefore, a two fold increase was observed in adriamycin 
accumulation in the low cell plating density, relative to the high cell plating density. Figure
3.11.5 also illustrates that, as the cell density increased, the level of adriamycin 
accumulated per 106 cells decreased. Similar results were noted in the DLKPA10 cell when 
plated at different cell densities. Following four hours incubation, approximately 240 
pmoles adriamycin was accumulated per 106 cells when the cell were plated at a low density 
(7.5 x 104 cells per well). However, when the cells were plated at a higher density (2 x 105 
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Figure 3.11.5 The effect of cell plating density on adriamycin accumulation in the DLKP (a) and 
DLKPA10 (b) cell lines. The cells were plated at a concentration of 2x10s, 1x10s and 0.75x10s cells 
per well and adriamycin accumulation determined after 48 hours.
■ 2 hours
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3.12 Adriamycin accumulation in the DLKPA clones
Adriamycin accumulation was studied in four adriamycin resistant clones previously isolated 
from the resistant cell line, DLKP-A. The cellular concentration of adriamycin in each of 
these clones was determined and the maximum level of accumulation compared with the 
levels observed in the parental DLKP and the DLKPA10 resistant cell line. Figure 3.12.1 
illustrates the level o f adriamycin accumulated in the six cell lines following two hour and 
four hour exposure to the drug. A significant difference was noted in the cellular 
concentration of adriamycin in each cell line. The DLKP parental cells accumulated 
approximately 620 pmoles adriamycin per 106 cells, which represented the highest level of 
adriamycin uptake. The DLKPA10 cells were found to accumulate the least amount of drug 
within the same time period (approximately 120 pmoles per 106 cells). Of the four clones 
studied, the highest cellular concentration of adriamycin was observed in the DLKPA 2B 
clone, followed by the DLKPA 6B clone and then the DLKPA 11B clone. The cellular 
concentration of adriamycin was found to be the lowest in the DLKPA 5F clone.
3 .1 2 .1  Effect of verapamil on adriamycin accumulation
The effect o f verapamil on adriamycin accumulation was studied to determine if the 
accumulation defect observed in the DLKPA clones could be reversed. The addition of 
verapamil (30^g/ml) resulted in an increase in adriamycin accumulation in all four clones, 
although a significant difference in the cellular concentration of adriamycin was observed 
(Figure 3.12.2). Following four hour exposure, verapamil fully reversed the accumulation 
defect in the DLKPA 5F and DLKPA 2B clones, causing an increase in adriamycin 
accumulation to a level greater than that seen in the parental DLKP cells. Although 
verapamil also enhanced adriamycin accumulation in the DLKPA 6B and DLKPA 11B 
clones, the maximum cellular concentration of the drug was only 70% of that observed in 
the parental DLKP cells.
3 .1 2 .2  Effect of cyclosporin A on adriamycin accumulation
The effect o f cyclosporin A on adriamycin accumulation was also investigated in the 
DLKPA clones. The addition of cyclosporin A was found to enhance adriamycin
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accumulation in all o f the clones, although as was the case with verapamil, a notable 
difference in the cellular concentration of the drug was observed in each clone (Figure
3.12.2). Cyclosporin A appeared to be most effective at reversing the accumulation defect 
in the DLKPA 5F clone, enhancing adriamycin accumulation to a level significantly greater 
than the parental DLKP cells (approximately 100 pmoles per 10  ^cells more adriamycin was 
accumulated within the same time period). Cyclosporin A restored drug accumulation in 
the DLKPA 2B clone to a level comparable with the DLKP cell line. However, the 
presence of cyclosporin A only restored the accumulation to approximately 50% in the 
DLKPA 6B clone and 70% in the DLKPA 11B clones. The results, therefore, illustrated 
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Figure 3.12.1 Adriamycin accumulation in DLKP, DLKPA10 and DLKPA clones following two 
hour and four hour exposure to the drug.
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Figure 3.12.1 The effect of (a) verapamil (30/xg/ml) and (b) cyclosporin A (10/tg/ml) on the 
cellular concentration of adriamycin in the parental DLKP cells and DLKP resistant clones. The 
cells were exposed to the drugs for four hours.
146
3.13 Adriamycin accumulation in T24, T24A and T24V cell lines
Adriamycin accumulation was studied in the human bladder carcinoma cell line, T24 and 
its M DR resistant variants, T24A and T24V. The T24A and T24V resistant lines were 
previously derived in the laboratory by continuous exposure to adriamycin and VP16 
respectively. The T24A cells were exposed to a maximum concentration of 2.2/ig/ml 
adriamycin and the T24V cells to a maximum concentration of 20/xg/ml YP16. Figure
3.13.1 presents the time course of adriamycin accumulation in the parental and resistant cell 
lines. The cellular concentration o f adriamycin was found to increase with drug exposure 
time in the T24 cells over a period of three hours. However, after this time the level of 
accumulation decreased, probably due to the toxicity exerted by the high concentration of 
adriamycin on the cells. The accumulation of adriamycin in the T24A and T24V cells was 
significantly reduced relative to the level observed in the parental cells. The T24A cells 
accumulated the least amount of intracellular drug within the time period studied. 
Following four hour adriamycin exposure, only approximately 30% of the level 
accumulated in the T24 cells was observed in the T24A cells.
3 .1 3 .1  Effect o f verapamil on adriamycin accumulation
The addition of verapamil (30/xg/ml) resulted in a slight increase in the cellular 
concentration of adriamycin in the parental T24 cells, although it did not significantly alter 
the rate of accumulation. W hen adriamycin accumulation in the presence of verapamil was 
studied in the T24A and T24V cells, both the rate of accumulation and the maximum 
cellular level of adriamycin accumulated were significantly altered. In the presence of 
verapamil the cellular level o f adriamycin in both resistant variants reverted to a level 
comparable with the parental T24 cells (figure 3.13.1).
3 .1 3 .2  Effect of cyclosporin A on adriamycin accumulation
The addition of cyclosporin A (10/xg/ml) also enhanced the accumulation of adriamycin in 
the T24A and T24V cell lines. Cyclosporin A proved to be more effective than verapamil 
causing a marked increase in the uptake of adriamycin to levels greater than that observed 
in the T24 cells (figure 3.13.1). Under similar experimental, conditions cyclosporin A did 





Figure 3.13.1 The effect of verapamil (30/ig/ml) and cyclosporin (10/xg/ml) on the time course of
adriamycin accumulation in the T24A (a) and T24V (b) resistant variants.
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3.14 Adriamycin Studies in the OAW42 variants
3.14.1 C ross resistance profile of the  OAW 42 variants
Adriamycin accumulation was studied in a number of variants of the human ovarian cell 
line, OAW42. The OAW42 parental cell line, originally derived from the ascites of a 
patient with cystadenocarcinoma of the ovary, was obtained from the EC ACC (European 
collection of animal cell cultures). One of the variants studied, OAW42-SR, was a 
spontaneous M DR resistant strain of the parental cell line. Two resistant variants, OAW42- 
A1 and OAW42-A, were established by exposing the OAW42-SR cells to increasing 
concentrations of adriamycin. An adriamycin sensitive variant, OAW42-S, was also 
included in the study. The OAW42-S variant was a clonal subpopulation derived from the 
OAW42-SR cell line. The cross resistance profiles of a number of chemotherapeutic agents 
in the OAW42 variants were determined and table 3.14.1 presents the IC50 values obtained 
for each of the chemotherapeutic agents studied. Table 3.14.2 illustrates the fold resistance 
of the resistant variants relative to the sensitive OAW42-S line.
D rug IC jo (nM) OAW42-S OAW 42-SR OAW42-A1 OAW42-A
A driam ycin 53.5 ± 6.2 444.1 ± 33. 749 ± 54.2 1380.5 ± 429
V incristine 15.2 ± 1.3 304 ± 16.7 212.8 ± 19.7 608 ± 51
VP16 914.9 ± 77 1921.3 ± 128 1829 ± 102 6861 ± 421
C isplatin 1667 ± 127 1100 ± 94.6 1533 ± 102 2517 ± 177
5-FIuorouracil 9231 ± 654 4808 ± 319 6923 ± 234 8864 ± 906
Table 3.14.1 IC50 values for the OAW42 variants
D rug OAW 42-SR OAW42-A1 OAW 42-A
A driam ycin 8.3 14 25.8
V incristine 20 14 40
VP16 2.1 2 7.5
C isplatin 0.66 0.92 1.55
5-Fluorouracil 0.52 0.75 0.99
Table 3.14.2 Fold resistance of the OAW42 resistant variants relative to OAW42-S cells
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3.14.2 Adriamycin accumulation in the OAW42 variants
The time course of intracellular adriamycin accumulation was studied in the OAW42 
variants. Figure 3.14.1 illustrates the cellular concentration of adriamycin in each of the 
four variants over a period of three hours. The results demonstrate a linear increase in the 
cellular concentration of adriamycin in the OAW42-S cells within the time period studied. 
After three hours, the OAW42-S cells had accumulated approximately 600 pmoles 
adriamycin per 106 cells. Adriamycin accumulation was significantly reduced in both the 
OAW42-SR and OAW42-A1 variants with respect to the OAW42-S cell line, with a 
maximum cellular concentration of approximately 390 pmoles per 106 cells. The uptake 
rate and cellular drug concentrations were similar in these variants to the OAW42-S cells 
within the first hour studied. However, after this time a steady rate was observed in both 
the OAW42-SR and OAW42-A1 cells. The lowest level of drug accumulated was observed 
in the OAW42-A resistant variant. The cellular concentration of adriamycin after three 
hours was approximately 200 pmoles per 105 cells representing only 25 % of the level 
observed in the sensitive OAW42-S cells after the same time period.
3 .1 4 .3  Effect of verapamil on adriamycin accumulation
The effect o f verapamil on adriamycin accumulation was investigated in the four OAW42 
variants. W hen the cells were coincubated with the circumventing agent (30/xg/ml), a 
significant increase in adriamycin accumulation was observed in the OAW42-SR, OAW42- 
A1 and OAW42-A cells (figure 3.14.2). The addition of verapamil reversed the 
accumulation defect in the three resistant cell lines and restored the cellular concentration 
of adriamycin to a level observed in the OAW42-S cell line. Verapamil also caused a slight 
increase in the cellular concentration of adriamycin in the OAW42-S variant.
3 .1 4 .4  Effect of cyclosporin A on adriamycin accumulation
The addition of cyclosporin A (10^g/ml) also enhanced adriamycin accumulation in the 
OAW42-SR, OAW42-A1 and OAW42-A cell lines (figure 3.14.2). A marked increase in 
adriamycin uptake was observed in each of the cells lines. Cyclosporin A again proved to 
be more effective than verapamil, causing an increase in the cellular concentration of the
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drug to levels greater that observed in the OAW42-S cells. The addition of cyclosporin A  
also resulted in a slight increase in adriamycin accumulation in the OAW42-S cells. The 
results illustrate that both cyclosporin A and verapamil effectively restore the accumulation 
defects seen in the resistant variants, indicating that the mechanism of resistant in the 
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Figure 2.14.2 The effect of (a) verapamil (30/tg/ml) and (b) cyclosporin A (10/xg/ml) on the time 
course of adriamycin accumulation in the OAW42-S, OAW42-SR, OAW42-A1 and OAW42-A 
variants.
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3.15 Adriamycin subcellular localisation studies
3 .1 5 .1  Subcellular distribution of adriamycin in SKMES-1 and SKMES-1/ADR cell 
lines
The subcellular localisation of adriamycin in the SKMES-1 and SKMES-1/ADR cell lines 
was studied by fluorescent microscopy, as described in section 2.11. The effect o f a 
number of compounds on adriamycin distribution was also investigated. The compounds 
tested included verapamil, cyclosporin, sodium azide and 2-deoxy-D-glucose.
Figure 3.15.1.1 illustrates the fluorescence pattern observed in the parental SKMES-1 cells 
and the resistant SKMES-1/ADR cells following two hour exposure to adriamycin (10^M). 
Intense nuclear fluorescence was observed in the SKMES-1 cells with distinct areas of more 
intense fluorescence visible within the nuclei. Faint cytoplasmic fluorescence was also 
visible, consistent with the localisation of adriamycin in cytoplasmic vesicles. W hen the 
cells were exposed to adriamycin for longer time periods, an increase in the intensity of 
nuclear fluorescence and a decrease in cytoplasmic fluorescence was noted. W hen the 
SKMES-1 /ADR cells were exposed to adriamycin under the same experimental conditions, 
the fluorescence pattern was notably different from that observed in the SKMES-1 parental 
cell line. While cytoplasmic fluorescence was visible in the majority of cells viewed, only 
faint fluorescence was visible within the nuclei of the cells. An increase in adriamycin 
cytoplasmic fluorescence was observed following longer exposure times. However, no 
corresponding increase in the intensity of nuclear fluorescence was noted.
3 .1 5 .1 .1  Effect of verapamil on adriamycin distribution
W hen the subcellular localisation of adriamycin was studied in the presence of verapamil 
(30/xg/ml) only a slight increase in the intensity o f nuclear fluorescence was observed in the 
SKMES-1 cell line. However, a decrease in the intensity of cytoplasmic fluorescence was 
noted, in particular with longer time exposure to the drug. In contrast, when the SKMES- 
1/ADR cells were coincubated with verapamil, a marked increase in nuclear fluorescence 
was observed after two hours in the majority of cells. Adriamycin nuclear fluorescence was 
enhanced in the SKMES-1/ADR with the intensity similar to that observed in the SKMES-1 
cells (Figure 3.15.1.1). A decrease in the cytoplasmic fluorescence was also noted.
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Figure 3.15.1.1 The subcellular adriamycin (10/iM) distribution pattern in the SKMES-1 and 
SKMES-1/ADR cell lines following two hour exposure to the drug; (a) SKMES-1, (b) SKMES- 
1/ADR, (c) SKMES-1 in the presence of verapamil (30/tg/ml) and (d) SKMES-1/ADR in the 
presence of verapamil.
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3.15.1.2 Effect of cyclosporin A on adriamycin distribution
Cyclosporin A (10/ig/ml) was also found to enhance adriamycin nuclear fluorescence in the 
SKMES-1/ADR cells. The intensity of nuclear fluorescence observed appeared to be 
greater than that seen in the parental SKMES-1 cells, within the same time period (Figure
3.15.1.2). Cytoplasmic fluorescence was still visible within the cells, although an overall 
cytoplasmic fluorescence pattern was observed, in contrast to the fluorescence pattern 
observed when the cell were exposed to adriamycin alone.
3 .1 5 .1 .3  Effect of energy inhibition on adriamycin distribution
The effect o f the metabolic inhibitors, sodium azide and 2-deoxy-D-glucose, in glucose free 
medium on the localisation of adriamycin in the SKMES-1 and the SKMES-1/ADR cell 
lines was also investigated. The aim of this work was to determine if depletion of ATP 
levels resulted in an increase in nuclear fluorescence in the resistant cells. W hen the 
SKMES-1 cells were exposed to sodium azide (lOmM) for two hours, cell lysis was 
observed in approximately 75% of the cells. The viable cells, however, displayed nuclear 
fluorescence, with the intensity similar to that observed when the parental cells were 
exposed to adriamycin alone. Reducing the concentration to ImM  sodium azide resulted 
in an increase in cell viability but no significant alteration in the intensity of nuclear 
fluorescence. The addition of lOmM sodium azide did not appear to have a toxic effect on 
the SKMES-1/ADR cells within the time period studied. Treatment with sodium azide was 
found to effectively enhance adriamycin nuclear fluorescence in the SKMES-1/ADR cells. 
The intensity of fluorescence observed was comparable to the SKMES-1 parental cells 
(Figure 3.15.1.2). A decrease in cytoplasmic fluorescence was also noted in the SKMES- 
1/ADR cells following exposure to sodium azide.
W hen the subcellular distribution of adriamycin was studied in the presence of 2-deoxy-D- 
glucose (25/xg/ml), cell lysis was observed in both the SKMES-1 cells (100%) and the 
SKMES-1/ADR cells, (approximately 50%). The viable SKMES-1/ADR cells displayed 
intense nuclear fluorescence, similar to that noted with sodium azide. W hen the 
concentration of 2-deoxy-D-glucose was reduced to 2.5/ig/ml, although nuclear fluorescence 
was observed in the SKMES-1/ADR cells, the intensity of fluorescence was low, with 
respect to the parental SKMES-1 cell line.
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Figure 3.15.1.2 The subcellular adriamycin (10/xM) distribution pattern in the SKMES-1 and 
SKMES-1/ADR cell lines following two hour exposure to the drug in the presence of cyclosporin A 
(10/ig/ml) or sodium azide (lOmM); (a) SKMES-1 in the presence of cyclosporin A, (b) SKMES- 
1/ADR in the presence of cyclosporin A, (c) SKMES-1 in the presence of sodium azide and (d) 
SKMES-1/ADR in the presence of sodium azide.
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3.15.2 Adriamycin distribution studies in DLKP and DLKPA10 cell lines
3 .1 5 .2 .1  Subcellular distribution of adriamycin in DLKP and DLKPA10 cell lines
The localisation of adriamycin in the DLKP and DLKPA10 cells was also investigated by 
fluorescent microscopy. Figure 3.15.2.1 illustrates the fluorescence pattern observed in the 
parental DLKP and resistant DLKPA10 cells following two hour incubation with the drug 
(IOjiM). The results obtained showed intense nuclear fluorescence in the DLKP cells, with 
more distinct regions of intense fluorescence visible within the nuclei. Faint cytoplasmic 
fluorescence was also observed in a small proportion of cells viewed. W hen the DLKPA10 
cells were incubated with adriamycin for the same time period, the majority of cells 
displayed only faint nuclear fluorescence, although speckles of more intense fluorescence 
were visible throughout the cytoplasmic region. Increasing the concentration of adriamycin 
to a maximum level of 50/aM  resulted in an increase in the intensity of cytoplasmic 
fluorescence in the DLKPA10 cells, although no corresponding increase in nuclear 
fluorescence was observed (figure 3.15.2.2). W hen the subcellular distribution of 
adriamycin was studied in the DLKPA10 cells, following longer exposure time periods to 
10/iM adriamycin (up to 48 hours), an increase in the intensity and quantity of fluorescent 
cytoplasmic speckles was again noted. However, no significant alteration in the intensity 
o f nuclear fluorescence was observed (Figure 3.15.2.3).
The subcellular distribution of adriamycin was investigated in the DLKP and DLKPA10 cell 
lines following 5 minute and 4 hour exposure times respectively. These time periods 
represented the time at which equivalent amounts o f drug were present in the cells, as 
determined from quantitative accumulation assays (section 3.11.1). After 4 hour exposure 
to adriamycin, cytoplasmic fluorescence was clearly visible in the DLKPA10 cells, although 
no nuclear fluorescence was observed. However, after 5 minutes exposure to the drug, 
faint nuclear fluorescence was observed in the DLKP cells, thus showing the rapid 
localisation of adriamycin within the nucleus (figure 3.15.2.4). These results demonstrate 
the different subcellular distribution of adriamycin in the sensitive and resistant cell lines. 
The results also indicate that intracellular mechanisms, in addition to bulk uptake/efflux 
rates may play a role in intracellular drug distribution in multidrug resistant cell lines.
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Figure 3.15.2.1a The subcellular adriamycin (10/*M) distribution pattern in the DLKP cell line 
following two hour exposure to the drug (a). Light microscopy image of the DLKP cells illustrating 
the localisation of adriamycin in the nuclear region (b).
a.
Figure 3.15.2.1b The subcellular adriamycin (10/xM) distribution pattern in the DLKPA10 cell line 
following two hour exposure to the drug (a). Light microscopy image of the DLKPA10 cells 
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Figure 3.15.2.2 The subcellular adriamycin distribution pattern in the DLKP and DLKPA10 cell 
lines. The DLKP cells were exposed to adriamycin (10/xM) for 2 hours (a); the DLKPA10 cells were 
exposed to increasing concentrations of adriamycin; lOfiM (b), 25/xM (c) and 50/xM (d) for 2 hours.
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a. b.
Figure 3.15.2.3 The time course for the subcellular adriamycin distribution pattern in the DLKPA10 
cell line. The cells were exposed to adriamycin (10/xM) for 2 hours (a), 4 hours (b), 12 hours (c) and 
24 hours (d).
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Figure 3.15.2.4 The subcellular adriamycin (10/xM) distribution pattern in the DLKP cells following 
5 minute exposure to adriamycin (a) and in the DLKPA10 cells following 4 hour exposure to the 
drug (b).
3.15.2.2 Effect of verapamil on adriamycin distribution
W hen the cells were incubated with verapamil (30/xg/ml), a slight increase in the intensity 
of nuclear fluorescence was observed in the DLKP cells with faint cytoplasmic fluorescence 
also visible in a small proportion of the cells. In contrast, the addition of verapamil to the 
DLKPA10 cells resulted in a marked increase in nuclear fluorescence in all o f the cells 
viewed (Figure 3.15.2.5). However, the intensity of fluorescence was substantially less 
than that observed in the parental cells. Pretreatment with verapamil for two hours prior 
to the addition of adriamycin did not result in any further increase in the intensity o f nuclear 
fluorescence in the DLKPA10 cells. W hen the concentration of verapamil was increased 
(concentrations up to 100^ g/m l), no significant alteration in the intensity of nuclear 
fluorescence was observed.
3 .1 5 .2 .3  Effect of cyclosporin A on adriamycin distribution
The addition of cyclosporin A (10^g/ml) also enhanced adriamycin nuclear fluorescence in 
the DLKPA10 cell line. Although the intensity of fluorescence was greater than that 
observed with verapamil treatment, it was still substantially less than that observed in the 
parental cell line (Figure 3.15.2.5). Increasing the concentration of cyclopsorin A 
(concentrations up to 100/xg/ml) did not significantly alter the intensity o f nuclear 
fluorescence observed in the DLKPA10 cells. W hen the cells were pretreated with 
cyclosporin A for two hours, prior to the addition of adriamycin, no significant increase in 
the intensity of fluorescence was noted. The addition of cyclosporin A resulted in a slight 
increase in the intensity o f nuclear fluorescence in the parental DLKP cells.
3 .1 5 .2 .4  Effect of energy inhibition on adriamycin distribution
To determine if the inhibition of ATP production could alter the subcellular distribution of 
adriamycin in the DLKPA10 cells, the effect of sodium azide, 2-deoxy-D-glucose and 
antimycin A was investigated. W hen the cells were incubated with sodium azide (lOmM) 
in a glucose free environment, cell lysis was observed in the majority of the DLKP parental 
cells. However, the viable cells displayed intense nuclear fluorescence, similar to that 
observed in the DLKP cells when incubated with adriamycin. W hen the concentration of
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sodium azide was reduced to ImM, an increase in cell viability was noted, although no 
significant alteration in the intensity of nuclear fluorescence was observed. The addition 
of sodium azide did not appear to have a toxic effect on the DLKPA10 cells within the two 
hour period studied. Although, with longer incubation periods, cell lysis was observed in 
a large percentage of the cells. When the DLKPA10 cells were incubated with sodium 
azide, in glucose free medium, an increase in cytoplasmic adriamycin fluorescence was 
observed in the cells. However, no significant alteration in nuclear fluorescence was noted. 
Distinct regions of fluorescence were clearly visible throughout the cytoplasm, in particular, 
in areas close to the nucleus where very intense fluorescence was observed (Figure 
3.15.2.6). W hen the concentration of sodium azide was increased to 25mM, no significant 
enhancement o f nuclear fluorescence was observed. Coincubating the cells with higher 
concentrations of sodium azide resulted in total cell lysis. Adriamycin distribution in the 
DLKPA10 cells was also studied, following pretreatment with sodium azide. When the 
cells were treated with sodium azide (lOmM) two hour prior to the addition of adriamycin, 
nuclear fluorescence was observed in all of the cells viewed (figure 3.15.2.6). The intensity 
of nuclear fluorescence, however, was less than that noted in the parental cells.
Treatment with 2-deoxy-D-glucose (25/xg/ml) was also found to be toxic to the parental 
DLKP cells, even at low concentrations (2.5/ig/ml). Although cell lysis was not observed 
in the DLKPA10 cells within the two hour incubation period studied, it appeared to be toxic 
to the cells, following longer exposure periods. Coincubating the DLKPA10 cells with 2- 
deoxy-D-glucose resulted in an increase in adriamycin cytoplasmic fluorescence, to a level 
comparable with that observed with sodium azide treatment. No significant increase in the 
intensity o f nuclear fluorescence was observed when the cells were coincubated with 2- 
deoxy-D-glucose for longer time periods. However, pretreatment with 2-deoxy-D-glucose 
also resulted in a marked increase in the nuclear fluorescence. The intensity of fluorescence 
was comparable with that observed with verapamil treatment and sodium azide pretreatment.
The subcellular distribution of adriamycin was also studied in the DLKP and DLKPA10 cell 
lines, in the presence of lOjuM antimycin A (figure 3.15.2.7). Treatment with antimycin 
A resulted in an increase in the intensity of nuclear fluorescence in the parental DLKP cells. 
Intense nuclear fluorescence was also observed in the DLKPA10 cells, following incubation 
with antimycin A. The fluorescence intensity appeared greater than the intensity observed 
in the DLKP cells treated with adriamycin alone. Coincubation with antimycin A also 
resulted in a decrease in the intensity of cytoplasmic fluorescence in the DLKPA10 cells.
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The effect of antimycin A on adriamycin distribution was also studied in the DLKPA10 
cells following preloading with adriamycin (10/iM). The cells were exposed to adriamycin 
for two hours, washed and incubated in adriamycin free medium, containing antimycin A 
(10/dVI) for a further two hours. When the cells were viewed after two hour exposure to 
the drug, the typical cytoplasmic fluorescence pattern was observed. Intense fluorescence 
was clearly visible in distinct regions throughout the cytoplasm. Following treatment with 
antimycin A, faint nuclear fluorescence was observed in the majority of cells viewed. A 
decrease in cytoplasmic fluorescence was also distinguishable, in particular in the number 
of fluorescent vesicles scattered throughout the cytoplasmic region (figure 3.15.2.8).
3 .1 5 .3 .1  Subcellular distribution of adriamycin in the DLKPA clones
The subcellular localisation of adriamycin in the DLKPA clones was studied, to establish 
if the four adriamycin resistant clones displayed similar drug distribution patterns. The 
effect o f verapamil and cyclosporin A on adriamycin distribution within the four DLKPA 
resistant clones was also investigated.
Figures 3.15.3.1 - 3 .15.3 .4  illustrates the fluorescence patterns observed in the four 
DLKPA clones following exposure to adriamycin (10/zM) for two hours. The results 
obtained showed notably different adriamycin fluorescence patterns in each of the four 
clones. Following exposure to adriamycin, nuclear fluorescence was clearly visible in the 
DLKPA 2B cells, although the intensity of the fluorescence varied within the cell 
population. Approximately 65% of the cell population displayed intense nuclear 
fluorescence, while the remaining cells had faint nuclear fluorescence (figure 3.15.3.1). 
Faint nuclear fluorescence was observed in the majority of the DLKPA 5F cells, although 
quite intense distinct areas of fluorescence were noted in the cytoplasmic regions. An 
intense area of fluorescence was also visible in the proximity of the nucleus (figure
3.15.3.2). The DLKPA 6B and DLKPA 11B clones displayed a mixed fluorescence pattern 
within the population of cells viewed. The DLKPA 6B cells displayed quite intense nuclear 
fluorescence in approximately 50% of the cells while very faint nuclear fluorescence was 
observed in the remaining cells. Distinct spots of cytoplasmic fluorescence were also 
visible, particularly in the cells that displayed faint nuclear fluorescence (figure 3.15.3.3). 
W hen adriamycin distribution was studied in the DLKPA 1 IB cells approximately 35 % of 
the population had quite intense nuclear fluorescence, while the remaining cells had faint
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nuclear fluorescence, with distinct areas of fluorescence visible within the cytoplasm (figure 
3.15.3.4).
3 .1 5 .3 .2  Effect of verapamil on adriamycin distribution in the DLKPA clones
W hen the subcellular distribution of adriamycin in the DLKPA clones was studied in the 
presence of verapamil (30^g/ml), the intensity o f fluorescence was notably different in each 
o f the DLKPA clones (figures 3.15.3.1 - 3.15.3.4). Intense nuclear fluorescence was 
observed in the DLKPA 2B cells, with more intense regions of fluorescence visible within 
the nucleus. The DLKPA 5F cells displayed a similar fluorescence pattern as the DLKPA 
2B cells, with the majority of cells displaying very intense nuclear fluorescence. The 
addition of verapamil also resulted in an increase in the intensity of nuclear fluorescence in 
the DLKPA 6B and DLKPA 1 IB clones, although the intensity of nuclear fluorescence was 
significantially less than that observed in the DLKPA 2B and DLKPA 5F clones. W hen 
the cells were exposed to higher concentrations of verapamil (concentration range 5 - 
50/xg/ml), or for longer incubation periods (time periods up to 10 hours), no further 
increase in nuclear fluorescence was observed.
3 .1 5 .3 .3  Effect of cyclosporin A  on adriamycin distribution in  the DLKPA clones
Treatment of the DLKPA clones with cyclosporin A (10^g/ml) resulted in subcellular 
distribution patterns, similar to that observed with verapamil. The intensity of adriamycin 
nuclear fluorescence was again enhanced in both the DLKPA 2B cells and DLKPA 5F cells, 
to a level comparable with the parental DLKP cells. Cyclosporin A also increased the 
nuclear fluorescence in the DLKPA 6B cells and DLKPA 11B cells, although the intensity 
o f  fluorescence was significantly less than that observed in the DLKPA 2B and DLKPA 5F 
clones. Treatment with higher concentrations of cyclosporin (10-50/ig/ml) did not result 
in any further increase in the intensity of nuclear fluorescence observed in the DLKPA 6B 
and DLKPA 11B clones. Although the cells were exposed to cyclosporin A for incubation 
time periods up to 10 hours, no further increase in fluorescence intensity was noted in any 
o f the DLKPA clones.
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Figure 3.15.2.5 The subcellular adriamycin (10/xM) distribution pattern in the DLKPA10 cell line 
following two hour exposure to the drug in the presence of verapamil (30/xg/ml) or cyclosporin A 
(10/ig/ml); (a) DLKP, (b) DLKPA10 (c) DLKPA10 in the presence of verapamil and (d) DLKPA10 
in the presence of cyclosporin A.
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Figure 3.15.2.6 The effect of metabolic inhibitors on the subcellular distribution of adriamycin 
(10/tM) in the DLKP and DLKPA10 cell lines. The cells were exposed to the drug for 2 hours in 
the presence of sodium azide (lOmM) or 2-deoxy-glucose (25/xg/ml); (a) DLKP in the presence of 
sodium azide, (b) DLKPA10 in the presence of sodium azide, (c) DLKPA10 in the presence of 2- 
deoxy-glucose and (d) DLKPA10, following pretreatment with sodium azide for 2 hours.
167
Figure 3.15.2.7 The subcellular adriamycin distribution pattern in the DLKP (a) and DLKPA10 (b) 
cells following 2 hour exposure to the drug in the presence of the metabolic inhibitor, antimycin A 
(10/xM).
Figure 3.15.2.8 The subcellular adriamycin distribution pattern in the DLKPA10 cells. The cells 
were preloaded with adriamycin (10/xM) for 4 hours (a), washed and incubated with antimycin A 
(lO^iM) for 2 hours (b).
a.
Figure 3.15.3.1 The subcellular adriamycin distribution pattern in the DLKPA 2B cells. The cells 
were exposed to adriamycin (10/tM) for 2 hours in the absence (a) or presence (b) of verapamil 
(30/xg/ml).
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Figure 3.15.3.2 The subcellular adriamycin distribution pattern in the DLKPA 5F cells. The cells 
were exposed to adriamycin (10/xM) for 2 hours in the absence (a) or presence (b) of verapamil 
(30/tg/ml).
Figure 3.15.3.3 The subcellular adriamycin distribution pattern in the DLKPA 6B cells. The cells 
were exposed to adriamycin (10/xM) for 2 hours in the absence (a) or presence (b) of verapamil 
(30/ig/ml).
Figure 3.15.3.4 The subcellular adriamycin distribution pattern in the DLKPA 1 IB cells. The cells 
were exposed to adriamycin (lOftM) for 2 hours in the absence (a) or presence (b) of verapamil 
(30/xg/ml).
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3.15.4 Subcellular distribution of adriamycin in the OAW42 variants
Adriamycin distribution was also studied in the OAW42-S, OAW42-SR, OAW42-A1 and 
OAW42-A cells. Figure 3.15.4.1 illustrates the subcellular adriamycin distribution pattern 
observed in each of the four variants following two hour exposure to the drug. The results 
showed that adriamycin fluorescence was predominantly localised in the nucleus of the 
OAW42-S, OAW42-SR and OAW42-A1 cells. However, the intensity of nuclear 
fluorescence was found to be greatest in the sensitive OAW42-S cell line. The OAW42-SR 
and OAW42-A1 variants displayed similar fluorescence patterns, predominately displaying 
nuclear fluorescence, although regions of faint cytoplasmic fluorescence were also visible 
in the resistant variants. W hen the OAW42-A cells were exposed to adriamycin, only faint 
nuclear fluorescence was observed. The intensity of fluorescence was substantially less than 
that noted in the OAW42-S, OAW42-SR and OAW42-A1 cell lines. Cytoplasmic 
fluorescence was also visible in the OAW42-A cells. No significant alteration in the 
fluorescence pattern in the OAW42-A cells was observed following longer incubation time 
periods (up to 8 hours). The addition of cyclosporin A and verapamil resulted in an 
increase in the intensity of nuclear fluorescence in each of the variants, to a level greater 
than that observed in the OAW42-S sensitive cells. However, the most significant increase 
in fluorescence intensity was noted in the OAW42-A cell line (figure 3.15.4.2).
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Figure 3.15.4.1 The subcellular adriamycin (10/tM) distribution in the OAW42 variants following 
2 hour exposure to the drug; (a) OAW42-S, (b) OAW42-SR, (c) OAW42-A1 and (d) OAW42-A.
a.
Figure 3.15.4.2 The subcellular adriamycin distribution pattern in the OAW42-A resistant variant. 
The cell were exposed to the drug for 2 hours in the absence (a) or presence of cyclosporin A (b).
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3.16 Confocal laser microscopy studies
The subcellular localisation of adriamycin in the SKMES-1 and DLKP parental cells and 
in their resistant variants, SKMES-1/ADR and DLKPA10, was also studied by confocal 
laser microscopy. W hen the SKMES-1 cells were incubated with adriamycin (10/*M) for 
two hours, intense nuclear fluorescence was observed in all of the cells viewed. The 
nuclear envelope was quite distinct, with more intense regions of fluorescence clearly visible 
within the nucleus of the cell (Figure 3.16.1). The addition of verapamil (30¿ig/ml) and 
cyclosporin A (10/xg/ml) resulted in an increase in the intensity of nuclear fluorescence. 
The DLKP parental cell line exhibited a similar fluorescence pattern when exposed to 
adriamycin (Figure 3.16.1). Intense nuclear fluorescence, with more intense regions within 
the nucleus, was again observed. Verapamil and cyclosporin A caused a slight increase in 
the intensity of adriamycin nuclear fluorescence in the DLKP cells.
Following exposure of the SKMES-1/ADR cells to adriamycin, faint nuclear fluorescence 
was observed in the majority of cells viewed, although the intensity was substantially less 
than that observed in the parental SKMES-1 cells. Distinct regions of fluorescence were 
also visible, scattered throughout the cytoplasm, particularly in areas close to the nucleus 
o f the cells (Figure 3.16.2). The addition of verapamil or cyclosporin A enhanced the 
intensity of nuclear fluorescence in the SKMES-1/ADR cells to a level comparable with the 
SKMES-1 cell line. A decrease in cytoplasmic fluorescence was also observed in the 
presence of verapamil and cyclosporin A. W hen adriamycin distribution was studied in the 
DLKPA10 cells, faint nuclear fluorescence was observed in a small number of cells, 
although the majority of cells displayed no nuclear fluorescence. Distinct spots of intense 
fluorescence were clearly visible within the cytoplasm, with more intense regions of 
fluorescence distinguishable in the perinuclear region (Figure 3.16.3). The cytoplasmic 
fluorescence was quite intense following two hour exposure to adriamycin. Although 
exposure of the cells to adriamycin for longer incubation periods resulted in an increase in 
cytoplasmic fluorescence, no corresponding increase in nuclear fluorescence was observed. 
Verapamil and cyclosporin A enhanced the nuclear fluorescence in the DLKPA10 cells, 
although the intensity observed was significantly less than that observed in the DLKP 
parental cells. Both agents also decreased the intensity of cytoplasmic fluorescence, while 
reducing the quantity of fluorescent vesicles visible in the cytoplasm. No further increase 
in nuclear fluorescence was observed in the DLKPA10 cells following longer exposure 




Figure 3.16.1 Confocal laser microscopy illustrating the subcellular distribution of adriamycin 





Figure 3.16.2 Confocal laser microscopy illustrating the subcellular distribution of adriamycin 
(10//M) in the SKMES-1/ADR cells. The cells were exposed to the drug for 2 hours in the absence 
(a) or presence (b) of cyclosporin A (10/ig/ml).
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Figure 3.16.3 Confocal laser microscopy illustrating the subcellular distribution of adriamycin 
(10/xM) in the DLKPA10 cells. The cells were exposed to the drug for 2 hours in the absence (a) 
or presence (b) of cyclosporin A (10^g/ml).
3.17 Circumvention studies in DLKP and SKMES-1 cells
3 .1 7 .1  Effect of verapamil and cyclosporin A on adriamycin toxicity in SKMES-1 and 
SKMES-1/ADR cell lines
The effect o f verapamil and cyclosporin A on the toxicity of adriamycin in the SKMES-1 
and SKMES-1/ADR cell lines was investigated, under conditions similar to those employed 
in the accumulation studies. The toxicity was determined, as described in section 2.6. 
Adriamycin proved to be extremely toxic to the parental SKMES-1 cells, with total cell kill 
observed following two hour and four exposure to the drug (10^M). The addition of 
verapamil (30/xg/ml) or cyclosporin A (10^g/ml), again resulted in total cell kill in the 
SKMES-1 cells. When the SKMES-1/ADR cells were exposed to adriamycin, 
approximately 15% kill was noted after two hours, with 25% cell kill after four hour 
exposure. The addition o f verapamil resulted in a decrease in cell viability of 
approximately 10% and 40% following two hour and four hour exposure respectively 
(Figure 3.17.1). Cyclosporin A also enhanced the toxicity of adriamycin in the SKMES- 
1/ADR cell line. W hen the cells were exposed to cyclosporin A for two hours, a decrease 
of approximately 20% and 50% was observed following, two and four hour exposures 
(figure 3.17.1).
3 .1 7 .2  Effect o f verpamil and cyclosporin A on adriamycin toxicity in DLKP and 
DLKPA10 cell lines
Adriamycin toxicity was also studied in the DLKP and DLKPA10 cell lines, in the presence 
of verapamil and cyclosporin A. Treatment of the parental DLKP cells with adriamycin 
(10/xM) resulted in total cell kill after a two hour time period. When the cells were 
coincubated with verapamil (30/zg/ml) or cyclosporin A (10fig/ml) total cell kill was, again, 
observed in the parental cells. W hen the DLKPA10 cells were exposed to adriamycin only 
slight toxicity was observed even, after four hour incubation (approximately 5 % cell kill 
noted). However, the addition of cyclosporin enhanced adriamycin toxicity in the cells. 
Following two hour incubation with cyclosporin A (10^g/ml) a decrease of approximately 
38% cell viability was observed, while exposure for four hours resulted in a decrease of 
approximately 45% (Figure 3.17.2). Verapamil also increased the toxicity o f adriamycin, 
causing a decrease of approximately 25% and 40% cell viability after two hour and four 
hour time periods respectively.
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Figure 3.17.1 The effect of verapamil (a) and cyclosporin A (b) on adriamycin toxicity in the 
SKMES-1/ADR cell line. The cells were exposed to adriamycin (lOptM) in the presence of verapamil 




































C ontro l A driam ycin  V«r Adr + Ver
Treatm ent
C ontrol A driam ycin  CSA Adr + CSA
Treatm ent
Figure 3.17.2 The effect of verapamil (a) and cyclosporin A (b) on adriamycin toxicity in the 
DLKPA10 cell line. The cells were exposed to adriamycin (lO^iM) in the presence of verapamil 
(10|ig/ml) and cyclosporin A (30/xg/ml) for two and four hour incubation periods.
■ 2 hours
■ 2 h o u rs
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The effect o f various compounds on the accumulation and subcellular distribution of 
adriamycin in the DLKP and DLKPA10 cell lines was investigated. The compounds studied 
included the fungal antibiotic brefeldin A, the tyrosine kinase inhibitor genestein, the 
macrolide antibiotic bafilomycin A l, the carboxylic ionophores monensin and nigericin, the 
calmodulin inhibitor trifluoroperazine and the lysosomotropic agents chloroquine and 
methylamine. The aim of these studies was to determine if the cytoplasmic vesicles observed 
in the resistant cells could be eliminated, enabling the adriamycin to enter the nucleus of the 
cells.
3.18.1 The effect of brefeldin A on adriamycin accumulation and distribution
The effect o f the Golgi apparatus disrupting agent, brefeldin A, on the accumulation and 
subcellular distribution of adriamycin was investigated in the DLKP and DLKPA10, cells to 
establish if the cytoplasmic fluorescent vesicles observed were associated with the Golgi 
apparatus. Figure 3.18.1 illustrates the time course of adriamycin accumulation in the 
parental DLKP and resistant DLKPA10 cell lines following incubation with brefeldin A 
(10/xM). No significant difference in adriamycin uptake was noted in the DLKPA10 cells. 
However, the addition of brefeldin A resulted in a slight decrease in adriamycin accumulation 
in the DLKP parental cells. W hen the cells were pretreated with brefeldin A (10//M) for two 
hours prior to the addition of adriamycin, no significant alteration in adriamycin accumulation 
was observed in the DLKPA10 cells. Pretreatment with brefeldin A, again, resulted in a 
slight decrease in drug accumulation in the DLKP cells. When the subcellular localisation 
of adriamycin was examined following two hour exposure to brefeldin A, intense nuclear 
fluorescence was observed in the parental DLKP cells. The intensity o f fluorescence was 
comparable to that observed in the control cells incubated with adriamycin alone. W hen the 
cells were exposed to brefeldin A for longer incubation periods, cell lysis was observed in 
the DLKP cells. The addition of brefeldin A did not significantly alter the distribution of 
adriamycin in the DLKPA10 cells. Faint nuclear fluorescence was observed in a small 
number of cells, although the majority of cells displayed only cytoplasmic fluorescence. 
Distinct regions of cytoplasmic fluorescence were still visible in all o f the cells viewed 
following longer exposure to brefeldin A. Brefeldin A did not exert an observable toxic
3.18 Investigation of a number of compounds on adriamycin accumulation and
distribution in DLKP and DLKPA10 cell lines
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effect on the DLKPAIO cells within the four hour time period studied.
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Figure 3.18.1 The effect of pretreatment (2 hours) and cotreatment with the Golgi apparatus 
disrupting agent, brefeldin A (10/iM) on the time course of adriamycin accumulation in the DLKP 
and DLKPAIO cell lines.
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The effect o f the tyrosine kinase inhibitor genistein on adriamycin accumulation was 
investigated in the DLKP and DLKPA10 cell lines. Genistein (300^g/ml) was coincubated 
with adriamycin and its effect on the accumulation of adriamycin was monitored over four 
hours. The results obtained showed that genistein did not significantly alter the rate or 
maximum level o f adriamycin accumulation in either the DLKP or DLKPA10 cells within 
the time period studied (Figure 3.18.2). W hen the concentration of genistein was increased 
up to lm g/m l, no further increase in the cellular concentration of adriamycin was observed. 
W hen the subcellular localisation of adriamycin was studied in the presence of genistein 
(300jiig/ml), intense nuclear fluorescence was noted in the parental cells, while only 
cytoplasmic fluorescence was observed in the DLKPA10 cell line. When the concentration 
of genistein was increased to 500/ig/ml, cell lysis was observed in the majority of the cells 
viewed. No significant difference in adriamycin distribution was noted in the viable cells.
3.18.2 The effect of genistein on adriamycin accumulation and distribution
T im e (H ou rs)
Figure 3.18.2 The effect of genistein (300^g/ml) on the time course of adriamycin accumulation
in the DLKP and DLKPA10 cells.
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3.18.3 The effect of bafilomycin A1 on adriamycin accumulation and distribution
The effect of the vacuolar H+ATPase inhibitor, bafilomycin A l, on the subcellular 
distribution of adriamycin was also investigated in the DLKP and DLKPA10 cell lines. 
This work was carried out to determine if vacuolar H+ATPases were involved in the 
sequestration of adriamycin into the cytoplasmic vesicles, observed in the DLKPA10 cells 
following exposure to the drug. When the DLKP cells were exposed to bafdomycin Al 
(10/Ag/ml), nuclear fluorescence was observed in all of the cells viewed. The intensity of 
fluorescence was comparable with that noted in cells exposed to adriamycin alone. 
Bafilomycin A l did not appear to exert a toxic effect on the parental cells following 
incubation time periods of up to six hours. Coincubation with bafilomycin A l did not 
significantly alter the fluorescent pattern observed in the DLKPA10 cell line. No significant 
increase in nuclear fluorescence was noted, with regions of intense fluorescence still visible 
throughout the cytoplasmic regions. When the time course of adriamycin accumulation was 
studied in the presence of bafilomycin A l, no significant alteration in either the rate of 
accumulation or maximum level of adriamycin accumulated was observed in the DLKP and 
DLKPA10 cells.
3.18.4 The effect of trifluoroperazine on adriamycin distribution
The effect of the calmodulin inhibitor, trifluoroperazine on adriamycin distribution was 
studied to determine if it could enhance the nuclear level of adriamycin in the DLKPA10 
cells. When the DLKP cells were incubated with trifluoroperazine (ICtyig/ml), total cell 
lysis was observed after two hours. The DLKPA10 cells were not as susceptible to the 
toxicity of trifluoroperazine, although some cell kill was observed. The addition of 
trifluoroperazine did not enhance the intensity of nuclear fluorescence in the DLKPA10 
cells. Speckles of cytoplasmic fluorescence were still clearly visible in the cells.
3.18.5 The effect of lysosomotropic agents on adriamycin distribution
The subcellular distribution of adriamycin, in the presence of the lysosomotropic agents, 
chloroquine and methylamine was investigated to determine if the cytoplasmic fluorescence 
observed in the DLKPA10 cell line was associated with the lysosomal regions of the cells.
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No significant alteration in the adriamycin fluorescence pattern was observed in the 
DLKPA10 cells following coincubation with chloroquine (100//M) or methylamine (lOmM). 
The speckled cytoplasmic fluorescence was still clearly distinguishable in all the cells 
viewed. No further increase in nuclear fluorescence was observed following longer 
incubation time periods. The effect of increasing concentrations of chloroquine and 
methylamine on adriamycin distribution was also studied. However, when the cells were 
exposed to higher concentrations of the drugs, lysis was observed in the majority of cells. 
When the parental DLKP cells were exposed to chloroquine and methylamine, no alteration 
in the intensity of nuclear fluorescence was observed. When the time course of adriamycin 
accumulation was studied in the presence of chloroquine and methylamine, no significant 
increase in the cellular concentration of drug was observed.
3.18.6 The effect of carboxylic ionophores on adriamycin distribution
The effect of the ionophores, monensin and nigericin, on the localisation of adriamycin in 
the DLKP and DLKPA10 cells was studied to determine if these agents could enhance drug 
uptake in the cells. Coincubation with monensin (10/xg/ml) resulted in a slight increase in 
the intensity of nuclear fluorescence in the parental DLKP cells, when compared with the 
intensity observed in the control cells exposed to adriamycin alone. When the DLKPA10 
cells were exposed to monensin, a marked increase in nuclear fluorescence was observed 
in all of the cells viewed. Distinct regions of intense fluorescence were still visible within 
the cytoplasmic regions, although the quantity and intensity of the regions of fluorescence 
was less than that observed in the absence of monensin. Although a marked increase in 
nuclear fluorescence was observed in the DLKPA10 cells in the presence of monensin, the 
intensity of fluorescence was significantly less that that observed in the parental cell line 
(figure 3.18.6).
Coincubation with nigericin (10^g/ml) also resulted in an increase in nuclear fluorescence 
in the DLKPA10 cells. Although, similar to the effect observed with monensin treatment, 
the intensity was less than that observed in the DLKP parental cell line. Cytoplasmic
fluorescence was still visible in the majority of cells studied, although a decrease in the
intensity of cytoplasmic fluorescence was observed in all of the cells viewed. A slight 
increase in the intensity of nuclear fluorescence was also observed in the DLKP cells 
following treatment with nigericin.
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a. b.
Figure 3.18.6 The subcellular adriamycin (10/tM) distribution in the DLKP and DLKPA10 cell 
lines. The cells were exposed to adriamycin for 2 hour in the presence of monensin (10/xg/ml) or 
nigericin (10/xg/ml); (a) DLKP in the presence of monensin, (b) DLKPA10 in the presence of 
monensin, (c) DLKP in the presence of nigericin and (d) DLKPA10 in the presence of nigericin. *
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3.19 Monensin Studies
The toxicity of the carboxylic ionophore, monensin, in the DLKP and DLKPA10 cell lines 
was investigated within the concentration range of 0 - 5/xg/ml monensin. The parental 
DLKP cells were found to be more susceptible to the toxicity of monensin than the resistant 
DLKPA10 cells. The IC50 values obtained for the DLKP and DLKPA10 cells were 
approximately 0.005/xg/ml and 0.05/ig/ml monensin respectively, thus representing a 10- 
fold difference in monensin toxicity. Monensin appeared to be relatively non-toxic to the 
DLKPA10 cells at concentrations below 0.02/xg/ml and relatively non-toxic to DLKP 
parental cells at concentrations less than 0.006/xg/ml.
The effect of non-toxic concentrations (IC9S) of monensin on the toxicity of the 
chemotherapeutic agents adriamycin, vincristine and VP16 was also examined in the DLKP 
and DLKPA10 cell lines. The aim of this work was to determine if monensin could 
modulate the toxicity profde of these drugs. The addition of monensin did not significantly 
alter adriamycin toxicity in the DLKP parental cells. However, an increase in adriamycin 
toxicity was observed in the DLKPA10 cells (Figure 3.19.1.1). A 2-fold decrease was 
observed in the IC50 value for adriamycin toxicity in the DLKPA10 cells when treated with 
monensin. The addition of monensin also enhanced the toxicity profile of VP16 in the 
DLKPA10 cells. Figure 3.19.1.1 represents the toxicity profile of VP16 in the presence 
and absence of monensin. Coincubation with monensin resulted in a decrease in the IC50 
value obtained from 9.5/xg/ml to 4.8/ng/ml in the DLKPA10 cell line, representing a 2-fold 
increase in the potency of VP16. Monensin was found to have no significant effect on 
VP16 toxicity in the DLKP cells. When the effect of monensin on the toxicity profile of 
vincristine was studied, no alteration in toxicity was noted in either the DLKP or DLKPA10 
cell lines (Figure 3.19.1.2). No significant difference in the IC50 values obtained for 
vincristine was observed in the presence and absence of monensin. The effect of monensin 
on carboplatin toxicity in the parental DLKP and the carboplatin resistant DLKPC 25 cell 
lines was also studied. However, no significant alteration was observed in the toxicity 
profile of carboplatin in either cell line following treatment with monensin (figure 3.19.1.2).
3.19.1 Monensin toxicity in DLKP and DLKPA10 cell lines
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Figure 3.19.1.1 The effect of monensin on the toxicity profile of adriamycin (a) and VP16 (b) in




Figure 3.19.1.2 The effect of monensin on vincristine toxicity in the DLKPA10 cell line (a) and
carboplatin toxicity in the DLKPC 25 ceil line(b).
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3.19.2 The effect of monensin on drug accumulation in DLKP and DLKPA10 cells
Since monensin proved to be effective at increasing the nuclear accumulation of adriamycin 
in the DLKPA10 cells, the effect of monensin on the cellular concentration of adriamycin 
and vincristine was studied in the DLKP and DLKPA10 cell lines. An initial concentration 
response curve was established over a range of 0 - 100/xg/ml and a suitable working 
concentration of monensin was determined. Figure 3.19.2.1 illustrates the time course of 
adriamycin accumulation in both cell lines over a period of four hours. The addition of 
monensin (10^ig/ml) resulted in only a slight increase in adriamycin accumulation in the 
parental cells within the four hours studied. However, monensin proved to be effective in 
partially reversing the accumulation defect observed in the DLKPA10 cells within the same 
time period (Figure 3.19.2.1). Although coincubation with monensin resulted in a 6-fold 
increase in adriamycin accumulation in the DLKPA10 cells, the maximum level of 
adriamycin was still significantly less than that observed in the DLKP cells. Exposure of 
the cells for longer incubation time periods (4-10 hours) or with increasing concentration 
of monensin did not lead to any further increase in adriamycin accumulation in the 
DLKPA10 cells. Figure 3.19.2.2 illustrates the time course of vincristine accumulation in 
the DLKP and DLKPA10 cells. No significant increase in the cellular concentration of 
vincristine was observed in the parental cells following treatment with monensin. However, 
monensin was found to enhance drug accumulation in the DLKPA10 resistant cells. An 
increase in the cellular concentration of vincristine of approximately 3.2 fold was observed 
in the cells.
3.19.3 Effect of monensin pretreatment on adriamycin accumulation
Adriamycin accumulation was also investigated in the DLKP and DLKPA10 cells following 
pretreatment with monensin, to establish if adriamycin accumulation could be completely 
restored in the resistant cells, to a level comparable with the parental DLKP cells. The cells 
were pretreated with monensin (10^g/ml) for two hours prior to the addition of adriamycin. 
The results obtained showed that monensin pretreatment was more effective than cotreatment 
at enhancing adriamycin accumulation in both the DLKP and DLKPA10 cells. The cellular 
concentration of adriamycin following pretreatment was approximately 900 pmoles per 106 
cells in the DLKP cells, as opposed to 830 pmoles per ltf  cells in the absence of monensin. 
A significant increase in adriamycin accumulation was observed in the DLKPA10 cells
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(figure 3.19.2.1). After a four hour incubation period, approximately 750 pmoles 
adriamycin per 106 cells was observed in the DLKPA10 cells, representing a 7.5-fold 
increase in drug accumulation.
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Figure 3.19.2.1 The effect of monensin pretreatment (2 hours) and cotreatment on the time course 















Figure 3.19.2.2 The effect of monensin (10/xg/ml) on the time course of vincristine accumulation 
in DLKP and DLKPA10 cell lines
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The effect of monensin and cyclosporin A cotreatment on adriamycin accumulation was 
studied, to determine if cotreatment could effectively reverse the adriamycin accumulation 
defect in the DLKPA10 cells. The addition of monensin and cyclosporin A resulted in a 
marked increase in adriamycin accumulation in the DLKPA10 cells, to a level comparable 
with that observed with monensin pretreatment (Figure 3.19.4). Although an increase in 
adriamycin accumulation was also noted in the DLKP cells, the maximum level of 
adriamycin accumulation was lower than that observed with monensin pretreatment.
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Figure 3.19.4 The effect of monensin (10/ig/ml) and cyclopsorin A (10/xg/ml) cotreatment on the 
time course of adriamycin accumulation in DLKPA10 cells.
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The effect of monensin on adriamycin efflux in the DLKP and DLKPA10 cell lines was 
investigated, to determine if monensin could enhance drug retention in the cells. The cells 
were preloaded with adriamycin for three hours, by incubation in glucose free medium, 
containing antimycin A (IOjuM). The cells were then incubated in drug free medium and 
the adriamycin efflux studied over a period of three hours. A rapid efflux was observed 
in both cell lines within the first hour, after which time the rate of efflux decreased, as 
illustrated in figure 3.19.5. When adriamycin efflux was studied in the presence of 
monensin, no significant alteration in the rate of efflux was observed in the DLKP parental 
cells. However, treatment with monensin resulted in a decrease in the rate of adriamycin 
efflux in the DLKPA10 cells and a significant increase in the cellular retention of drug.
3.19.5 Effect of monensin on adriamycin efflux in DLKP and DLKPA10 cell lines
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Figure 3.19.5 The effect of monensin (10/xg/ml) on adriamycin efflux in DLKP and DLKPA10 cell 
lines. The cells were preloaded with adriamycin for three hours in glucose free medium containing 
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3.19.6 Effect of monensin on vincristine efflux in DLKP and DLKPA10 cells
The effect of monensin on vincristine retention in the DLKP and DLKPA10 cells was also 
investigated. The cells were preloaded with vincristine for two hours, in the presence of 
antimycin A. A rapid efflux was observed in both cell lines within the first hour when 
incubated in drug free medium (figure 3.19.5). After this time, a decrease in the rate of 
efflux was observed in the DLKPA10 cells, while a steady state of drug retention was noted 
in the parental cells. Treatment with monensin resulted in approximately a 4-fold decrease 
in drug efflux in the resistant cells. However, an increase in drug efflux was observed in 
the parental DLKP cells, following treatment with monensin.
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Figure 3.19.5 The effect of monensin (10/^g/ml) on vincristine efflux in the DLKP and DLKPA10 
cell lines. The cells were preloaded with vincristine in the presence of antimycin A (10/xM) for two 
hours and efflux was studied over a further 2 hours.
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The effect of monensin on the toxicity of adriamycin in the DLKP and DLKPA10 cells was 
investigated under conditions similar to those employed in the accumulation assay (section 
2.6). The parental DLKP cells were found to be extremely susceptible to adriamycin 
toxicity. When the cells were treated with the drug for two hour and four hour incubation 
periods, total cell kill was observed in the cells, as determined by the acid phosphatase assay 
(section 2.6.1). When the cells were incubated with monensin, total cell kill was again 
observed in the DLKP cells.
Figure 3.19.7 illustrates the results obtained for the DLKPA10 cells. The DLKPA10 cells 
were much less susceptible to adriamycin toxicity. Following exposure to adriamycin, 
approximately 95% cell survival was observed after two and four hour incubations. When 
the cells were treated with monensin (10pig/ml), approximately 45% cell kill was observed 
after two hours and 50% after four hour exposure. Coincubation with adriamycin and 
monensin resulted in a further decrease in the percentage of cell survival in the DLKPA10 
cells. After two hours, the cell viability was reduced to approximately 40%, while after 
four hours, only 25% cell viability was observed.
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Figure 3.19.7 The effect of monensin on adriamycin toxicity in the DLKPA10 cell line. The cells 
were exposed to adriamycin (10/iM) in the presence of monensin (10/xg/ml) for two and four hour 
incubation periods.
3.20 Effect of membrane altering agents in DLKP and DLKPA10 cell lines
3.20.1 Toxicity of membrane rigidifying agents in DLKP and DLKPA10 cells
The toxicity of the fatty acids, stearic acid and cholesteryl hemisuccinate, was studied in the 
DLKP and DLKPA10 cells. The resistant DLKPA10 cells were found to be more 
susceptible than the parental cell to the toxicity of both compounds. The IC50 values 
obtained for the DLKP and DLKPA10 cells with stearic acid were approximately 36/xg/ml 
and 10^g/ml respectively, representing a 3.6-fold difference in stearic acid toxicity in the 
cell lines. Cholestryl hemisuccinate proved to be more toxic than stearic acid to the 
parental and resistant cell lines. The IC50 values obtained for the DLKP and DLKPA10 
cells were approximately 6.2^g/ml and 3.3^g/ml respectively. However, only a maximum 
of a 2-fold difference was noted (figure 3.20.1.1). The effect of stearic acid and cholesteryl 
hemisuccinate on adriamycin toxicity in the cells was also investigated, to determine if 
alterations in membrane properties could increase in the toxicity profde of adriamycin. 
When the toxicity of adriamycin was studied, in the presence of a non-toxic concentration 
of cholestryl hemisuccinate (IC95), no significant enhancement of toxicity was noted in the 
DLKP and DLKPA10 cell lines (Figure 3.20.1.2). The addition of stearic acid did not 
significantly alter the toxicity of adriamycin in the parental DLKP cells, although a slight 
increase was observed in the DLKPA10 cells (Figure 3.20.1.2).
3.20.2 Effect of stearic acid and cholesteryl hemisuccinate on adriamycin 
accumulation
The cellular concentration of adriamycin in the DLKP and DLKPA10 cells was determined 
in the presence of stearic acid and cholestryl hemisuccinate over a time course of four 
hours. Following coincubation with stearic acid (100/xM), no significant increase in 
adriamycin accumulation was observed in either the parental DLKP cells or the DLKPA10 
cells over the time period studied. The addition of cholestryl hemisuccinate (100/dVl) 
resulted in a slight increase in adriamycin accumulation in the DLKPA10 cells while having 
no observable effect on adriamycin accumulation in the DLKP cells (Figure 3.20.2). When 
the concentration of stearic acid and cholestryl hemisuccinate were increased (concentrations 
up to 500/xM), no further increase in adriamycin accumulation was observed in either the 
parental DLKP or the DLKPA10 cells.
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Figure 3.20.1.1 The toxicity profdes of stearic acid (a) and cholestryl hemisuccinate (b) in the




Figure 3.20.1.2 The effect of stearic acid and cholestryl hemisuccinate on the toxicity profile of
adriamycin in the DLKP (a) and DLKPA10 (b) cell lines.
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Figure 3.20.2 The effect of stearic acid (100/iM) and cholestiyl hemisuccinate (lOO^M) on the time 
course of adriamycin accumulation in the DLKP and DLKPA10 cell lines.
204
3.21 Immunization and fusions
Since the adriamycin transport and circumvention work described earlier indicated that 
mechanisms other than P-glycoprotein overexpression may be involved in adriamycin 
exclusion in the DLKPA10 cell line, an attempt was made to identify antigens 
overexpressed in the DLKPA10 cells relative to the parental cell line. Monoclonal 
antibodies were raised against the DLKPA10 cell line to establish if overexpression of a 
novel antigen was involved in the accumulation defect observed in this cell line. An 
immunization programme was carried out using whole cell extracts of the resistant cell line 
DLKPA10, as described in section 2.13.1. Following the immunizations, three separate 
fusion were carried out using the murine myeloma cell line, SP2 (section 2.13.2). Of the 
three fusions carried out, the first displayed a low fusion rate of 25%-30% and while 
positive clones were obtained, no significant difference in the immunoreactivity was 
observed when the clones were screened against the immunogen (DLKPA10) and the DLKP 
parental cells. The second fusion proved unsuccessful due to the condition of the SP2 cells, 
while the third resulted in a fusion rate of approximately 65 %. When the clones produced 
from the third fusion were screened using the ELISA method, against the parental DLKP 
and the resistant DLKPA10 cells, only a small number of the clones tested positive. A 
number of these hybridomas differentiated before the screening process was carried out, 
while other clones stopped producing antibodies during the screening process. One 
hybridoma was selected for further characterisation and was designated D8-8.
3.21.1 Screening of the selected hybridoma by ELISA
The supernatent from the D8-8 hybridoma was screened against the parental DLKP and 
DLKPA10 cell lines, using the ELISA method, as described in section 2.13.3. The D8-8 
hybridoma was found to be more positive against the parental cell line than the immunogen, 
DLKPA10. Strong immunoreactivity was observed with the DLKP cells. The selected 
hybridoma was then grown up as ascitic fluid in Balb/c mice and the antibody titre 
determined through serial dilution (1:10-1:10000 dilutions) of the ascitic fluid, again using 
the ELISA method. A suitable working dilution for the D8-8 hybridoma was found to be 
a 1:100 dilution of the ascitic fluid. The ascitic fluid was aliquoted and stored at -2CPC, 
until required.
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3.21.2 Determination of antibody class
The supernatent from the selected hybridoma was used to determine the class and sub-class 
of the antibodies produced. A monoclonal antibody isotyping kit (Serotec) was employed 
to determine the class of antibody, as described in section 2.14. Table 3.21.2 represents 
the profile of the antibody class and subclass for the D8-8 hybridoma. The results show 










Table 3.21.2 Antibody class, subclass determination of the D8-8 antibody 
3.21.3 Protein Analysis of cell membrane preparations
Purified membrane fractions of the immunogen, DLKPA10 and the parental DLKP cells 
were prepared and freeze dried, as described in section 2.7.2. The protein concentrations 
of the preparations were determined from standard curves obtained from the BCA protein
assay (section 2.7.4).
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3.21.3.1 SDS PAGE electrophoresis and western blotting
The D L K P  and D L K P A 1 0  membrane proteins were separated on  7 .5 %  po lyacrylam ide  
denaturing ge ls and transferred to nitrocellulose paper, as described in section 2.7.6. 
Prestained m olecu lar w eight m arkers were run sim ultaneously w ith the membrane proteins. 
F o llo w in g  the transfer o f  the membrane protein to nitrocellulose, the blotted proteins were 
probed w ith the D 8 -8  antibody. F igu re  3.21.3.1 represents the results obtained for the D 8 -  
8 antibody (1:100 d ilution  o f  ascitic flu id) w ith  a 7 .5 %  po lyacrylam ide gel. The  results 
obtained illustrate that the D 8 -8  antibody preferentially b inds to an antigen o f  approxim ately  
180 kilodaltons, although it exhibits b ind ing  on ly  in  the D L K P  membrane protein, under 
the experimental conditions employed.
'1—
M.W. ISOkD
Probed with D8-8 Negative Control
Figure 3.21.3.1 Western blot analysis of the D8-8 antibody in cell membrane preparations of the
DLKP and DLKPA10 cell variants.
3.21.4 Immunological Studies
3.21.4.1 Indirect immunofluorescence studies
Immunofluorescence was carried out on live cells to detect the presence of cell surface 
antigens on the DLKP and DLKPA10 cells, as described in section 2.9.1. The D8-8 ascitic 
fluid (1:100 dilution) was used as the primary antibody in the study. The EP16 monoclonal 
antibody, which is specific for a cell surface antigen on normal human epithelial cells, was 
included in the study as a positive control, with the SCC-9 cell line (a cell line derived from 
human squamous carcinoma of the tongue). When the EP16 antibody was used as the 
primary antibody, cell surface fluorescence was clearly visible in the SCC-9 cells (Figure 
3.21.4.1). Following exposure to the D8-8 antibody, the DLKP cells showed only faint 
surface fluorescence. However, cell surface fluorescence was clearly visible in the 
DLKPA10 cells. Figure 3.21.4.2 illustrates the results obtained with the D8-8 antibody 
when exposed to the DLKP and DLKPA10 cells. The results show that the D8-8 antibody 
recognised a surface antigen on the DLKPA10 cells, producing a ring of fluorescence 
around the cell surface. The faint fluorescence observed on the surface of the DLKP cells 
was comparable to that seen on the negative control cells, in which PBS was used as the 
primary antibody.
Live cell immunofluorescence was also performed on the SKMES-1, SKMES-1/ADR, 
OAW42-S and OAW42-A cell lines, with the D8-8 antibody. Intense fluorescence was 
clearly visible on the surface of both the parental SKMES-1 and the resistant SKMES- 
1/ADR cell lines following exposure to the antibody. Differences in the intensity of 
fluorescence in the two cell lines, however, were not distinguishable (figure 3.21.4.3). 
Figure 3.21.4.4 illustrates the surface staining of the D8-8 antibody on the human ovarian 
cancer cell lines, OAW42-S and OAW42-A. The results show that the antibody binds to 
the surface of both cell lines thus producing intense fluorescence. Although as with the 
results obtained for the SKMES-1 cell lines, differences in the intensity of fluorescence 
were not distinguishable. Slight autofluorescence was observed for the negative controls 
(PBS) for each of the cell lines, although relative to the test cell lines, the intensity of the 
fluorescence observed was low.
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Figure 3.21.4.1 Live cell immunofluorescence of the human squamous carcinoma tongue cell line, 
SCC-9, with the EP16 monoclonal antibody (a); negative control (b).
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a.
Figure 3.21.4.2 Live cell immunofluorescence of the DLKP (a) and DLKPA10 (b) cell lines with
1:100 dilution of the D8-8 ascitic fluid.
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a.
Figure 3.21.4.3 Live cell immunofluorescence of the SKMES-1 (a) and SKMES-1/ADR (b) cell
lines with 1:100 dilution of the D8-8 ascitic fluid.
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a.
Figure 3.21.4.4 Live cell immunofluorescence of the OAW42-S (a) and OAW42-A (b) cell lines
with 1:100 dilution of the D8-8 ascitic fluid.
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3.21.4.2 Immunohistochemical studies
The immunoreactivity of the D8-8 antibody was also studied against the DLKP / 
DLKPA10, the SKMES-1 / SKMES-1/ADR and the OAW42-S / OAW42-A cell lines. 
Cytospin preparations of each of the cell lines were prepared and the cells fixed in acetone, 
as described in section 2.9. Immunohistochemal analysis was carried out on the cytospin 
preparations to detect the presence of internal and membrane associated antigens. When 
the DLKP and DLKPA10 cells were incubated with the D8-8 (1:100 dilution of ascitic 
fluid), the antibody displayed the strongest immunoreactivity against the DLKP cells. 
Positive cytoplasmic and cell surface staining was clearly visible in the majority of the cells 
viewed. The DLKPA10 cells did show some faint staining with the D8-8 antibody, 
although relative to the DLKP cells the proportion of cells stained and the intensity of 
staining was low (Figure 3.21.4.5). Similar staining patterns to the DLKP and DLKPA10 
cell lines were observed with the OAW42-S and OAW42-A cell lines. Cytoplasmic staining 
was observed in approximately 75% of the OAW42-S sensitive cells. However, the 
intensity of staining varied within the cell population. Surface staining with the D8-8 
antibody was also noted in the OAW42-S cells. A large percentage of the OAW42-A 
resistant cells also demonstrated positive immunoreactivity with the D8-8 antibody, 
however, the overall intensity staining was substantially less than that observed in the 
sensitive cells (figure 3.21.4.6). When the reactivity of the D8-8 antibody with the 
SKMES-1 and SKMES-1/ADR cell lines was investigated, cytoplasmic staining was 
observed in both cell lines. A typical staining pattern for the D8-8 antibody in SKMES-1 
and SKMES-1/ADR cells is presented in figure 3.21.4.7. The staining intensity appears 
slightly greater in the parental SKMES-1 cells.
The immunoreactivity of the D8-8 antibody was also studied in 3 clones, isolated from the 
parental DLKP cell line. The results obtained were compared with those obtained from the 
parental cells. The three clones showed positive staining with the D8-8 antibody. 
However, variations in the staining intensity were observed. The DLKP-I and the DLKP- 
SQ clones showed very similar staining patterns, with positive staining observed in the 
majority of cells. The D8-8 appear to react with a larger percentage of cells in these two 
clones than in the parental DLKP cells. The intensity of the staining was also slightly 
greater in these cells. The DLKP-M clone was found to have a lot less staining than the 
parental cells and the other two clones. The staining observed was also less intense than 
in the DLKP cells.
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Figure 3.21.4.5 Immunocytochemical staining of the DLKP (a) and DLKPA10 (b) cell lines with
1:100 dilution of the D8-8 ascitic fluid.
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F ig u re  3 .2 1 .4 .6  Im munocytochem ical staining o f the OAW 42-S (a) and OAW 42-A (b) cell lines 
w ith  1:100 dilu tion  o f the D8-8 ascitic fluid.
F ig u re  3 .2 1 .4 .7  Im m unocytochem ical staining o f the SKMES-1 (a) and SK M ES-1/A D R (b) cell 
lines w ith 1:100 d ilu tion  o f the D8-8 ascitic fluid.
Discussion
4.1 Platinum resistance
Cisplatin and its analogues are among the most widely used chemotherapeutic agents, either 
alone or in combination with other agents. These agents have proved to be effective in the 
treatment of ovarian, testicular, head-and-neck, non-small cell lung and brain tumours 
(Rosenberg, 1985). However, many of these tumours which are initially responsive to 
chemotherapy develop resistance to cisplatin during therapy leading to treatment failure. 
Cancer patients treated with cisplatin have approximately a 50% response rate. Within 12 
to 24 months, however, the majority of these patients relapse. At present, the dominant 
mechanism involved in clinically acquired cisplatin resistance is unknown. However, a 
significant number of platinum resistant cell lines have now been developed which have 
proved useful tools in the study of acquired resistance in cancer therapy. Table 4.1 presents 
a number of cisplatin resistant human cell lines that have been established and used in the 
study of cisplatin resistance. These cell lines were developed in vitro from a number of 
tumour types, including ovarian carcinomas, lung carcinomas, colon carcinomas, 
teratocarcinomas, breast carcinomas, bladder carcinomas and head-and-neck carcinomas. 
Cisplatin resistant cells display a unique cross resistance profde to multiple agents including 
antimetabolites, such as 5-fluorouracil and methotrexate, topoisomerase inhibitors such as 
camptothecin and etoposide and DNA polymerase inhibitors such as azidothymidine. This 
"atypical" multidrug resistance is distinct from the classical multidrug resistance which 
usually involves resistance to the anthracyclines and vinca alkaloids and is frequently due 
to the overexpression of the P-glycoprotein membrane associated efflux pump.
The cell lines resistant to cisplatin have been shown to have multifactorial mechanisms of 
resistance. Four biological alterations capable of producing cisplatin resistance have been 
reported and include decreased cellular accumulation of cisplatin (Gately and Howell,
1993), increased levels of glutathione or increased glutathione-S-transferase activity 
(Waxman, 1990), increased levels of intracellular metallothionein (Saijo and Lazo, 1993) 
and enhanced DNA repair (Johnson et al., 1994a). Mechanisms that have been implicated 
in cisplatin resistance include alterations in mitochondrial membrane potential and signal 
transduction pathways, oncogene expression (in particular c-fos and c-jun gene expression) 
and alterations in the expression of the nuclear enzymes, topoisomerase I and II, DNA 
polymerases and thymidylate synthase, all of which are involved in DNA repair.
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Cell Line Description Reference
PC10-B3
PC10-E5
Human lung squamous 
carcinoma
Katabami et al., 1993
PC14/CDDP Human non-small-cell lung 
carcinoma
Ohmori etal., 1993
GLC4-CDDP Human small-cell lung 
carcinoma
Hosper et al., 1988
SW2/CP Human small-cell lung 
carcinoma
Kelley et al., 1988
H69/CDDP02
H69/CDDP
Human small-cell lung 
carcinoma
Hong et al., 1988 
Kasahara et al., 1991
SL6/CP Human large cell lung 
carcinoma
Kelley et al., 1988
Tera-CP Human teratocarcinoma Timmer-Bosscha et al., 1993
HeLa CA 
HeLa CK
Human cervical carcinoma Osmak and Eljuga, 1993










Human ovarian carcinoma Masuda et al., 1988 
Behrens et al., 1987 
Godwin et al., 1992




Human ovarian carcinoma Loh e ta l.,  1992
LoVo CP2.0 
LoVo RT
Human colon carcinoma Yang et al., 1993
SCC-25/CP Human carcinoma of the tongue Teicher etal., 1986
KB-rc Human oral epidermoid 
carcinoma
Hori et al., 1993
Hep2 CA3 
Hep2 CK2
Human larynx carcinoma Osmak, 1992
K562 DDP Human erythroleukaemia Shionoya et al., 1986
MCF-7/CP Human breast carcinoma Kelley et al., 1988
G3361/CP Human melanoma Kelley et al., 1988
Table 4.1 Human cisplatin resistant cell lines
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One of the aims of this thesis was to establish novel platinum resistant cell variants and to 
investigate their underlying mechanisms of resistance. The platinum analogue, carboplatin, 
was chosen as the selecting agent for the procedure. Carboplatin has been shown to have 
a similar spectrum of antitumour activity to cisplatin. However, it causes considerably less 
nephrotoxicity and neurotoxicity compared to cisplatin. Consequently, it is now frequently 
used in cancer therapy, in particular for the treatment of ovarian and lung cancers (Gore 
et al., 1989; Raghaven et al., 1994). As carboplatin is not in fact a more active anticancer 
agent than cisplatin, its role in cancer therapy is primarily as an alternative to cisplatin in 
patients with pre-existing renal dysfunction and also in patients with a clear predisposition 
to neurotoxicity or ototoxicity. A selection process was initiated to establish carboplatin 
resistant variants of the human cell lines, DLKP and OAW42. The DLKP cell line was 
derived from a poorly differentiated lymph node metastases of a squamous cell carcinoma 
of the lung (Law et al., 1992) and the OAW42 cell line was established from the ascites of 
a patient with serous cystadenocarcinoma of the ovary (Wilson, 1984). While platinum 
resistant variants were successfully isolated from the DLKP cells, the OAW42 cells did not 
adapt to growth in the drug and therefore the selection process was discontinued.
Three carboplatin resistant variants were isolated by continuous exposure of the DLKP 
parental cells to increasing concentrations of the selecting agent. The three variants, 
DLKPC 6.2, DLKPC 14 and DLKPC 25 were selected to 6.2/ig/ml, 14/xg/ml and 25/ig/ml 
of carboplatin respectively. The cells readily adapted to growth in the drug and the 
selection procedure was carried out over a period of approximately one year. To verify that 
the variants were derived from the DLKP cells, DNA fingerprint analysis was carried out 
on DNA extracted from both the parental DLKP cells and also the highest resistant variant, 
DLKPC 25. The results obtained showed that the DLKPC 25 cells shared almost identical 
bands with the parental cells implying that the DLKPC 25 cells must indeed have originated 
from the parental DLKP cell line. Only one extra band was visible in the DLKP cells with 
the 33.15 locus probe. Since the DLKPC 25 variant was derived from the DLKPC 6.2 and 
DLKPC 14 variants it was concluded that these variants also originated from the DLKP 
cells. The morphology of each of the carboplatin resistant variants was also investigated 
to determine if exposure to the drug resulted in any significant alteration. The variants 
were found to be similar to the parental cells with all three variants displaying the squamous 
type cell population evident in the DLKP parental cells.
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4.2 Cross resistance profile in the DLKPC variants
Cross resistance studies of the variants revealed that all three DLKPC variants had similar 
resistance profiles. They were found to be resistant to the selecting agent, carboplatin (4-,
8.3- and 15.8-fold) and also cross resistant to cisplatin (5.1-, 12.2- and 25.1-fold). A low 
level of cross resistance was also observed to the topoisomerase II inhibitor, VP16, in 
particular with the DLKPC 25 variant (2-fold). However, there was no significant 
resistance or sensitivity to the classical MDR anticancer agents, adriamycin and vincristine 
or to the antimetabolite 5-fluorouracil. The results obtained were similar to results 
previously reported for cisplatin resistant cell lines. Generally cisplatin resistant cell lines 
exhibit cross resistance to platinum agents, including cisplatin, carboplatin, transplatin and 
ormaplatin while showing little cross resistance to the classical MDR drugs (table 4.2). In 
a study on the human small cell lung cancer cell line, H69/CDDP, that was selected for 
resistance with cisplatin, the cells were found to be cross resistant to the cisplatin analogue, 
cis-diammine(glycolato)platinum while showing no resistance to adriamycin, vincristine or 
VP16 (Kasahara et al., 1991). The cisplatin resistant ovarian cell lines, A2780/CP20 and 
A2780/CP70 were also shown to be resistant to both cisplatin and carboplatin although these 
cell lines also exhibited resistance to VP16. Only a low level of resistance was observed 
with adriamycin (Hamaguchi et al., 1993). In a study on the cisplatin resistant 
teratocarcinoma cell line, Tera-CP, the cells were found to be cross resistant to the platinum 
analogues and also to 5-fluorouracil but showed only a low level of resistance to adriamycin 
and the topoisomerase II inhibitor, VM-26 (Timmer-Bossacha et al., 1993). The cross 
resistance profile of the platinum resistant human Burkitt lymphoma cell line, Raji/CP and 
the human head-and-neck carcinoma cell line SCC-25/CP revealed that both cell lines were 
cross resistant to the platinum agents. The SCC-25/CP cells also exhibited cross resistance 
to methotrexate, while the Raji cell exhibited approximately a 2-fold resistance to 5- 
fluorouracil. The two cell lines were found to be hypersensitive to adriamycin and 
vincristine toxicity (Teicher et al., 1988). Similar toxicity profiles were reported for 
platinum resistant rodent cell lines. In a study on Chinese hamster ovary cells, CHO/CDP- 
2, Saburi et al. (1989) reported that the cells exhibited cross resistance to cisplatin, 
carboplatin and melphalan, but not to adriamycin, VP16 or 5-fluorouracil. Cross resistance 
to cisplatin and carboplatin was also observed in the platinum resistant murine cells, 
L1210PtR4 and L1210DDP5, but again no cross resistance to adriamycin was observed 
(Kraker and Moore, 1988).
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y ............
Cell line Cisplatin Carboplatin M ethotexrate Adriamycin Vincristine VP16 VM-26 5-fluorouracil Reference
Raji/CP 7.3 ND 1.6 0.2 0.2 ND ND 1.9 Teicher et al., 1986
SCC-25/CP 12.0 ND 23.8 0.6 0.9 ND ND 0.6 Teicher et al., 1986
GLC4-CDDP 6.4 1.5 ND 4.0 0.48 ND ND ND Hosper et al., 1988
L1210DDP5 25.8 9.0 ND 0.6 ND ND ND ND Kraker and Moore, 1988
P388PtR4 24.1 5.4 ND 0.5 ND ND ND ND Kraker and Moore, 1988
CHO/CDP-2 10.0 5.0 ND 1.0 ND 1.0 ND 0.9 Saburi et al., 1989
LoVo/CP2.0 6.4 ND ND 2.6 7.8 1.1 ND 2.6 Yang et al., 1993
Tera-CP 3.7 ND ND 1.3 1.3 ND 1.3 2.3 Timmer-Bossacha ef al., 1993
A2780/CP20 5 21 ND 3.0 ND 8.0 ND ND Hamaguchi et al., 1993
A2780/CP70 17 24 ND 6 ND 22.2 ND ND Hamaguchi et al., 1993
T24DDP10 8.4 ND ND 0.8 8.1 1.1 ND ND Kotoh et al., 1994
ND - not determined
Table 4.2 Fold-resistance profile of a number of human and rodent platinum resistant cell lines with respect to the parental cell line
4.3 Mechanisms of resistance in DLKPC variants
4.3.1 Glutathione and glutathione-S-transferases
Glutathione is one of the most prevalent cellular sulfhydryl peptides and has been shown 
to be involved in many cellular functions, including drug metabolism, intracellular 
detoxification and protection from oxidative stress (Arrick and Nathan, 1984). Numerous 
studies have reported increased glutathione levels in cisplatin resistant cell lines, although 
its role in contributing to drug resistance remains unclear. The anticancer agent, cisplatin, 
is sufficiently electrophilic to react with sulfhydryl containing nucleotides, consequently 
glutathione may play a role in modulating cisplatin cytotoxicity. Several investigators have 
reported a significant correlation between cellular glutathione levels and cisplatin resistance, 
although in the majority of studies, increases in glutathione levels were less than the 
corresponding increase in cisplatin resistance. The GLC4 human small cell lung carcinoma 
cell line, resistant to cisplatin, was found to exhibit a 3.4-fold increase in glutathione levels 
which was associated with a 6.4-fold increase in cisplatin resistance (Hosper et al., 1988). 
Batist et al. (1986) reported a 3.2-fold increase in glutathione levels in the cisplatin resistant 
human carcinoma cell line, A2780/CP, which was 14 fold resistant to the selecting agent. 
The BE human colon carcinoma cell line, resistant to cisplatin, showed a 3-fold increase 
in glutathione levels which was associated with a 5-fold increase in cisplatin resistance 
(Fram et al., 1990). These results would suggest that, although elevated levels of 
glutathione may play a role in mediating platinum resistance, other mechanisms of 
resistance must also be involved in order to account for the higher levels of cisplatin 
resistance observed in the cell lines.
To investigate the possible role of glutathione in the resistance phenotype observed in the 
carboplatin resistant DLKPC variants, the effect of the glutathione biosynthesis inhibitor, 
BSO, on the cytotoxicity of carboplatin was studied. A number of studies have reported 
a substantial reversal of resistance in cisplatin resistant tumour cell lines following treatment 
with non-toxic concentrations of BSO. The cell lines involved all contained elevated levels 
of glutathione. Increased glutathione levels were reported from a study on the cisplatin 
resistant cell line, GLC4-CDDP. When the resistant cells were treated with BSO, a 
decrease in the level of glutathione and an increase in the cytotoxicity of cisplatin was 
observed (Meijer et al., 1990). Oldenburg et al. (1994) also found an increase in the
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2,4-dinitrobenzene as the substrate for the GST enzyme. The results obtained showed a 
slight decrease in activity in the DLKPC 6.2 and DLKPC 14 variants relative to the parental 
DLKP cells. However, the level of activity in the DLKPC 25 variant was comparable to 
the parental cells. A maximum of a 1.5 fold decrease was observed in the lower resistant 
cell line, thus suggesting that alterations in GST activity does not play a major role in drug 
resistance in the DLKPC resistant sublines. These results were also confirmed from studies 
with the GST inhibitor, ethacrynic acid. Ethacrynic acid has been reported to cause a 
reduction in the levels of GST activity and an increase in the cytotoxicity of a number of 
alkylating agents in resistant cells lines (Tew et al., 1988; Hoffman et al. ,1995). However, 
no significant alteration in the cytotoxicity of carboplatin was observed in the DLKPC 
variants following treatment with ethacrynic acid.
4.3.2 Metallothionein
Metallothioneins (MTs) comprise a family of small, thiol-rich metalloproteins having 
molecular weights of 6000-7000 daltons. They are involved in Zn2+ and Cu2+ homeostasis 
and in the binding and detoxification of heavy metals (Hamer, 1986). Metallothioneins are 
composed of approximately 30% cysteine and can account for a large percentage of the 
intracellular thiol content. The observation that metallothioneins play a role in heavy metal 
detoxification led to investigations exploring the relationship between cellular 
metallothionein levels and sensitivity to cisplatin. Since metallothioneins are rich in thiol 
groups they are likely targets for electrophilic agents such as cisplatin and other heavy 
metals. Although the majority of these intracellular thiols are bound to Zn2+, it appears that 
they are still capable of reacting with platinum compounds and thus may serve as 
intracellular reservoirs, inactivating incoming cisplatin. Several reports have implicated 
metallothionein as a major cause of cellular resistance to cisplatin and other alkylating 
agents. Generally, cells resistant to cisplatin also exhibited cross resistance to the heavy 
metal, cadmium chloride. Consequently, resistance to the cytotoxic effects of cadmium 
chloride has been used as an indicator of increased intracellular metallothionein content. 
Overexpression of metallothionein has also been studied by Northern blotting, Western 
blotting, immunocytochemistry and radioactivity studies. Early studies by Bakka et al. 
(1981) reported that human epithelial cells and mouse fibroblasts, selected for resistance to 
cadmium chloride and containing large amounts of metallothioneins, were also cross
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resistant to cisplatin. Numerous studies have since reported overexpression of 
metallothionein in cell lines selected directly for cisplatin resistance. Table 4.3 presents the 
metallothionein content in a number of cell lines resistant to cisplatin. Teicher et al. (1987) 
demonstrated a 2-fold increase in cadmium chloride resistance in the human head-and-neck 
carcinoma cell line, SCC-25/CP. The increase in the level of resistance correlated well 
with the increase observed in the total protein sulfhydryl content in the cells. Later studies 
by Kelley et al. (1988) reported approximately a 4.4-fold increase in metallothionein content 
in the SCC-25/CP cell line as determined by an indirect competitive ELISA technique. 
Metallothionein levels have also been studied in two human ovarian cell lines, 2008 and 
COLO 316, that were resistant to cadmium chloride. The 2008 and COLO 316 cells 
exhibited a 3.2-fold and 1.2-fold increase in cadmium chloride resistance and were shown 
to be 4.1-fold and 3.3-fold cross resistant to cisplatin respectively. Metallothionein levels 
were determined by analysis of radiolabelled 203HgCl2 binding assays and an increase was 
reported in both cell lines. The 2008 cells exhibited a 23-fold increase in metallothionein 
levels, while the COLO 316 cells exhibited a 9-fold increase (Andrews et al., 1987).
In a comprehensive study by Kelley and coworkers (1988) metallothionein levels and 
expression of metallothionein mRNA levels were investigated in a number of platinum 
resistant human and murine cell lines. Increased metallothionein levels were detected in the 
human melanoma cell line, G3361/CP, the human small cell lung carcinoma cell line, 
SW2/CP, the human large cell lung carcinoma SL6/CP cell line and the murine leukaemia 
cell line, L1210/CP, compared to levels observed in the corresponding parental cell lines. 
An increase in metallothionein levels was also reported in the carboplatin resistant L1210 
cell line and the cadmium chloride resistant head-and-neck carcinoma cell line, A-253/CD. 
The elevated levels of metallothioneins correlated well with the level of cisplatin resistance 
in some of the cell lines studied, including the SW2/CP and the L1210/DACH cell lines. 
The cisplatin resistant ratio for the SW2/CP cell line was found to be 4.5, while the 
increase in metallothionein content was found to be 5.1-fold. The L1210/DACH cell line 
exhibited a 2.74-fold increase in metallothionein levels, which was associated with a 2.7- 
fold increase in cisplatin resistance. The results obtained for both cell lines would indicate 
that metallothioneins play a major role in mediating the resistant phenotype observed in the 
cells. However, results obtained from other cell lines in this study suggests that although 
metallothioneins may be involved in mediating resistance, other mechanisms must also play 
a role in order to account for the high level of cisplatin resistance observed. One such
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example, where alternative mechanism may be involved is the cisplatin resistant murine 
leukaemia cell line, L1210/CP. This particular cell line, while shown to have a 44-fold 
increase in cisplatin resistance only displayed a 13.3-fold increase in metallothionein levels. 
The cisplatin resistant human small cell lung carcinoma cell line, H69/CDDP has also been 
shown to have elevated levels of metallothionein relative to the parental H69 cells. Results 
obtained from radiolabelled 203Hg binding assays showed approximately a 2.3-fold increase 
in Hg binding to metallothionein, thus representing a 2.3-fold increase in metallothionein 
levels, while Northern blot analysis revealed a 4.3-fold increase in metallothionein mRNA 
expression (Kasahara et al., 1991). Overexpression of metallothionein levels in tumour 
samples and established cell lines has also been detected by immunohistochemical and 
immunocytochemical techniques. In a study by Kondo et al. (1995) metallothionein 
overexpression was detected in a number of prostatic tumour cell line by antibodies which 
recognized all isoforms of human metallothionein. Overexpression of metallothionein has 
also been demonstrated immunohistochemically, using a number of monoclonal anti- 
metallothionein antibodies, in colerectral adenocarcinoma cells (Ofner et al., 1994), in 
human thyroid tumour cells (Nartey et al., 1987) and in childhood acute lymphoblastic 
leukaemia cells (Sauerberg et al., 1994).
The role of metallothionein in drug resistance in the DLKPC variants was investigated by 
two methods, cadmium chloride toxicity and immunocytochemical analysis. Cadmium 
chloride toxicity was studied in the parental DLKP cells and in the three carboplatin 
resistant variants. All three carboplatin resistant variants were shown to be cross resistant 
to cadmium chloride, although the results obtained demonstrated a different toxicity profile 
in each variant. The DLKPC 6.2 variant exhibited a 2.7-fold increase in cadmium chloride 
toxicity which was associated with a 5.1-fold increase in cisplatin resistance. The DLKPC 
14 variants, which was 12.2-fold resistant to cisplatin, was shown to have a 9-fold increase 
in cadmium toxicity. A 10-fold increase in cadmium chloride toxicity was observed in the 
highest cisplatin resistant variant, DLKPC 25 (25.1-fold resistant to cisplatin). When 
immunocytochemical analysis was performed on the DLKPC variants immunoreactivity was 
clearly shown to be related to the level of resistance in the variants. The three sublines 
displayed positive immunoreactivity for metallothionein expression, although the intensity 
of cellular staining differed in each variant. Metallothionein expression was predominantly 
observed in the cytoplasm of the cells, as found in other reports published. A low level of 
staining was observed in approximately 30% of the DLKPC 6.2 cells, while approximately
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80% of the DLKPC 14 cells reacted postively with the anti-metallothionein antibody. The 
intensity of staining was also found to be greater in the DLKPC 14 cells. Intense 
cytoplasmic staining was observed in the majority of the DLKPC 25 cells, thus indicating 
a high level of metallothionein expression. Overall the results, indicated an overexpression 
of metallothionein which may be involved in mediating drug resistance in the DLKPC 
variants. The involvement of alternative resistance mechanisms may also explain the results 
obtained with the DLKPC 25 variant. Although the DLKPC 25 variant displayed higher 
resistance to carboplatin and cisplatin than the DLKPC 14 variant, only a slight difference 
(1.2-fold increase) was observed in cadmium chloride toxicity.
C ell line T u m o u r type Fold  R esistance M T  con ten t 
fo ld  increase
R eference
2008 Human ovarian 
carcinoma
4.1 23 Andrews et a l., 1987
COLO 316 Human ovarian 
carcinoma
3.3 9 Andrews et al., 1987
SCC-25/CP Human head and
neck carcinoma
7.1 4.4 Kelley et al., 1988
G3361/CP Human melanoma 6.7 2.0 Kelley et al., 1988
SW2/CP Human small-cell 
lung carcinoma
4.5 5.1 Kelley et al., 1988
SL6/CP Human large cell 
lung carcinoma
2.5 3.4 Kelley et al., 1988
MCF-7/CP Human breast 
carcinoma
2.5 0.95 Kelley et al., 1988
L1210/CP Murine leukaemia 44 13.3 Kelley et al., 1988
H69/CDDP Human small-cell 
lung carcinoma
11 2.3 Kasahara et a l., 1991
Table 4.3 Role of metallothionein in cisplatin resistance
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4.3.3 P-glycoprotein, topoisomerase, LRP and MRP expression
In an attempt to further identify the mechanism of resistance in the DLKPC resistant 
variants, alterations in the levels of a number of cellular proteins were investigated. The 
level of P-glycoprotein, topoisomerase I, topoisomerase II, lung resistance protein (LRP) 
and multidrug resistant associated protein (MRP) was studied. P-glycoprotein is a plasma 
membrane associated efflux pump that actively extrudes drug from the cells. Although 
overexpression of P-glycoprotein is usually associated with resistance to the classical MDR 
drugs (anthracyclines, vinca alkaloids and epipodophyllotoxins) studies by Yang and 
coworkers (1993) have reported alterations in P-glycoprotein levels in the cisplatin resistant 
cell line, LoVo CP2.0. This cell line was selected by continuous exposure to cisplatin and 
was found to be 6.4-fold resistant to the drug. Immunocytochemical studies and Western 
blot analysis, using the C219 monoclonal antibody, revealed an increased level of P- 
glycoprotein in the LoVo CP2.0 cells relative to the parental cells, although Northern blot 
analysis demonstrated no increase in mRNA levels. Since the LoVo CP2.0 cells were also 
shown to have elevated levels of metallothionein, glutathione and glutathione S-transferase 
mRNA, the authors suggested that P-glycoprotein mediated MDR and cisplatin resistant 
phenotype could coexist in cells with primary resistance to cisplatin. To determine if P- 
glycoprotein mediated MDR and a cisplatin resistant phenotype coexisted in the DLKPC 
resistant variants, Western blot analysis was performed on purified membrane preparations 
of the DLKPC cells, using the C219 monoclonal antibody. Analysis was also carried out 
on preparations from the parental DLKP cell line and the adriamycin resistant variant, 
DLKPA10. Overexpression of P-glycoprotein was detected in the DLKPA10 cell line 
(positive control), however no detectable levels of P-glycoprotein was observed in the 
parental cells or in any of the DLKPC variants. These results therefore suggested that 
overexpression of P-glycoprotein was not involved in cisplatin resistance in the DLKPC 
variants.
Topoisomerases are nuclear enzymes that catalyze the interconversion of topological forms 
of single and double strand DNA. The enzymes are involved in processes related to cell 
growth and division and appear to be structural and functional components of the cell 
nucleus (Liu et al., 1983). Eukaryotic topoisomerases have been categorized into two 
types. The type I enzymes make transient single strand breaks in DNA, while the type II 
enzymes make double strand breaks (Wang, 1985). Topoisomerase enzymes have been
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implicated as the target for a number of antitumour agents, including adriamycin, 
daunorubicin, VP16, VM-26 and camptothecin. Camptothecin appears to be a specific 
inhibitor for the DNA topoisomerase I enzyme (Hsiang and Liu, 1988), while the other 
drugs inhibit DNA topoisomerase II enzymes. Decreased activity of the topoisomerases has 
been associated with drug resistance in a number of cell lines. Although resistance, due to 
alterations in the topoisomerase enzymes is usually associated with drugs such as VP 16, 
VM-26 and camptothecin, recent reports have suggested a role for topoisomerases in 
mediating cisplatin resistance in a number of platinum resistant cell lines. Barret et al. 
(1994) demonstrated a 3-fold increase in DNA topoisomerase II activity in nuclear extracts 
of the cisplatin resistant murine leukaemia cell line, L1210/10, compared to the parental 
L1210 cells. However, no alteration in the activity of the topoisomerase I enzymes was 
observed. Topoisomerase II activity was also studied in two other cisplatin resistant 
sublines of the L1210 cells. The L1210/DDP5 and L1210/DDP8 cells were established in 
vivo (5mg/kg and 8mg/kg) and grown for several weeks in culture. Topoisomerase II 
activity was shown to be higher in the cisplatin resistant lines than in the parental cells. 
The L1210/DDP8 resistant line, exhibited the highest level of topoisomerase II activity. 
Elevated levels of glutathione-S-transferase was also reported in the L1210/DDP5 and 
L1210/DDP8 cell lines suggesting that glutathione metabolism as well as increased levels 
of topoisomerase II activity were involved in mediating resistance in both cell lines 
(Mestagh et al., 1994). Elevated levels of DNA topoisomerase I enzyme has also been 
demonstrated in cisplatin resistant cell lines. Studies by Kotoh et al. (1994) on three 
cisplatin resistant variants of the human bladder cell line, T24, showed an increase in 
topoisomerase I cellular levels. Increased levels of mRNA and protein was detected by 
immunoblot and Northern blot analysis respectively. The cisplatin variants were also 
demonstrated to exhibit collateral sensitivity to camptothecin derivatives that target DNA 
topoisomerase I.
The possible involvement of topoisomerase enzymes in the resistant phenotype of the 
DLKPC variants was investigated. Toxicity studies showed that the variants exhibited slight 
cross resistance to the topoisomerase inhibitor, VP16. Consequently, the level of 
topoisomerase II in the highest resistant variant, DLKPC 25, was investigated by Western 
blot analysis. The results showed that although topoisomerase II was detected in the 
resistant cell line, there was no significant difference observed relative to the DLKP parental 
cells. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis also demonstrated
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no detectable alteration in the level of topoisomerase II mRNA in any of the DLKPC 
variants (Lorraine 0 ‘Driscoll, personal communication). To investigate the role of 
topoisomerase I in mediating resistance in the DLKPC variants, the toxicity of the 
topoisomerase I inhibitor, camptothecin was studied. The results showed that camptothecin 
exhibited slightly lower toxicity in all three variants relative to the parental cells. However, 
only a maximum of a 2-fold decrease was observed in the DLKPC 25 variant. RT-PCR 
analysis again revealed no significant alteration in topoisomerase I mRNA levels in the 
platinum resistant variants (Lorraine 0 ‘Driscoll, personal communication). Results 
therefore from studies on topoisomerase I and II levels would suggest that topoisomerases 
do not play a major role in the resistant phenotype in the DLKPC variants. However, 
further studies are required to determine the level of enzyme activity before the involvement 
of topoisomerases can be completely ruled out, since Barret and coworkers (1994) reported 
an increase in topoisomerase II activity in the cisplatin resistant variant, L1210/10, without 
a corresponding increase in protein or mRNA levels, as determined by immunoblotting and 
Northern blot analysis respectively.
The expression of the 110 kDa protein, LRP (lung resistance protein) was studied in the 
DLKPC variants to determine if LRP was involved in the resistance phenotype of the cells. 
LRP is associated with low level resistance and has been shown to be overexpressed in a 
number of multidrug resistant cell lines (Scheper etal., 1993). However, to date no studies 
suggesting a possible role for LRP in cisplatin resistance have been reported. LRP 
expression was detected by immunocytochemical analysis in all three DLKPC resistant 
variants, although no significant difference was observed in the level of immunoreactivity, 
relative to the parental cell line. Immunocytochemical studies on the expression of the 190 
kDa protein, MRP (multidrug resistant related protein) revealed no alteration in the level 
of MRP in any of the DLKPC resistant variants, thus suggesting that MRP was not involved 
in cisplatin resistance in these cell lines. Further evidence to support this theory was 
obtained from RT-PCR studies, where no significant difference was observed in the MRP 
mRNA levels (Lorraine 0 ‘Driscoll, personal communication). MRP has been shown to be 
associated with resistance in some non-P-glycoprotein MDR cell lines (Cole et al., 1992b), 
however, to date no studies implicating the involvement of MRP in cisplatin resistance has 
been reported. In a study by Hamaguchi et al. (1993) on the expression of MRP in a series 
of cisplatin resistant sublines of the ovarian cell line, A2780, no detectable levels of MRP 
was observed by either Northern blot or Southern blot analysis.
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4.3.4 Cisplatin accumulation studies
Decreased intracellular cisplatin accumulation has been reported in many, but not all, 
cisplatin resistant cell lines (Andrews and Howell, 1990; Andrews et al., 1991; Loh et al., 
1992 and Ohmori et al., 1993). Generally, the decreased level of cisplatin accumulation 
did not correlate with the level of cisplatin resistance, indicating that other mechanisms of 
resistance were also involved. Several reports have shown that cisplatin enters the cells 
through passive diffusion, since saturation level was not reached, even at high platinum 
concentrations (Gale et al., 1973; Ogawa et al., 1975). However, reports also suggest that 
cisplatin transport may be mediated by an active carrier mechanism. Energy and sodium 
dependence along with inhibition of cisplatin transport by the Na+K +ATPase inhibitor, 
ouabain points to the presence of an active uptake mechanism. However, changes in 
membrane phospholipid structure might also contribute to decreased passive diffusion.
Na+K +-ATPases have been postulated to play a central role in cisplatin accumulation. The 
enzyme regulates the transmembrane Na+ gradient, which in turn has been found to regulate 
cisplatin accumulation (Kawai et al., 1987; Andrews et al., 1991). In a study by Andrews 
and coworkers (1991) ouabain, was shown to decrease cisplatin accumulation by 
approximately 50% in the human ovarian cell line, 2008. Similar inhibition of cisplatin 
accumulation was observed when the Na+K +-ATPase was blocked by ATP depletion or by 
incubating the cells in K + medium. Further studies demonstrated that the cisplatin resistant 
subline, 2008/CDDP, was cross resistant to ouabain, as indicated by continuous exposure 
clonogenic assays. The 2008/CDDP cells that were approximately 3-fold resistant to 
cisplatin were found to be 2.3-fold resistant to ouabain. The authors suggested that the 
decrease in cisplatin accumulation in the 2008/CDDP cells was due to direct inhibition of 
Na+K +-ATPase and dissipation of the Na+ gradient, which then altered cisplatin influx. 
In contrast, several studies have also shown decreased cisplatin accumulation in resistant cell 
lines that was not mediated by Na+K +-ATPase inhibition. Loh et al. (1992) demonstrated 
reduced drug accumulation in the cisplatin resistant cell line, 41McisR6, relative to the 
parental cell line. However, the 41McisR6 cells did not exhibit cross resistance to ouabain, 
suggesting that the decreased accumulation in the resistant cells was probably not regulated 
by alterations in Na+K +-ATPase. Studies on the non-small cell lung carcinoma cell line, 
PC-14, also showed reduced drug accumulation in the cisplatin resistant subline, PC- 
14/CDDP. Although ouabain was demonstrated to decrease accumulation in the parental
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cells it had no effect on cisplatin accumulation in the resistant cell line. Lack of cross 
resistance to ouabain was observed in the PC-14/CDDP cells suggesting that Na+K +- 
ATPases were not involved in the decreased cisplatin accumulation in the resistant cells.
Ouabain toxicity studies in the DLKP parental cells and DLKPC resistant variants revealed 
that the DLKPC cells exhibited slight cross resistance to ouabain relative to the parental 
cells. The DLKPC 25 variant was found to exhibit the highest cross resistance exhibiting 
approximately a 2-fold resistant to the Na+K +-ATPase inhibitor. Since neither cisplatin nor 
carboplatin accumulation was directly determined in the DLKPC variants, the involvement 
of Na+K +-ATPase in the resistant phenotype in the DLKPC cells remains to be clarified. 
However, results obtained from metallothionein studies showed that although 
metallothioneins appeared to play a role in platinum resistance, other mechanisms must also 
have been involved. This could sugest that reduced cisplatin accumulation may account for 
the non-metallothionein mediated resistance observed in the resistant cells. Since the 
DLKPC cells exhibited slight cross resistance to ouabain, Na+K +-ATPases inhibition may 
be involved.
Reduced platinum accumulation could, alternatively, be due to decreased membrane 
permeability of the resistant cells. A number of studies have shown that agents capable of 
altering membrane permeability could increase cisplatin toxicity in resistant cell lines. The 
antifungal agent, amphotericin B, has been demonstrated to increase cisplatin toxicity by 
increasing membrane permeability and thus the intracellular concentration of the drug. 
Amphotericin B has a unique mechanism of action, related to its affinity for sterols in the 
cell membrane. Studies have shown that amphotericin B binds to cholesterol and forms 
pores in the cell membrane, increasing permeability and facilitating uptake of various 
molecules (Presant et al., 1981). Morikage and coworkers (1993) reported an increase in 
cisplatin cytotoxicity in the human lung cancer cell line, PC-14/CDDP following treatment 
with amphotericin B. An increase in cisplatin accumulation was also observed in the 
resistant cell line which led to the suggestion that the increase in platinum accumulation was 
at least in part responsible for the mechanism of the sensitizing effect. Amphotericin B has 
also been shown to increase cisplatin accumulation in the human ovarian cell line, 
HRA/CDDP. The increase in accumulation was associated with a 12.1-fold increase in 
cisplatin toxicity when treated with amphotericin B (Kojima et al. , 1994). Studies by Sharp 
et al. (1994) reported potentiation of cisplatin and carboplatin cytotoxicity by amphotericin
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B in two human platinum resistant ovarian cell lines, 41McisR6 and HX/62. Previous 
studies had shown that resistance in both cell lines was due primarily to reduced platinum 
uptake. No significant potentiation was observed in the parental cell lines or in the resistant 
cell line, C H lcisR6, where reduced drug accumulation did not play a role in mediating 
cisplatin resistance. The potentiation effect of amphotericin B was shown to be lower with 
carboplatin than cisplatin, although, as in the case of cisplatin, the 41M,.isR6 and MX/62 cell 
lines were the only cell lines where potentiation was observed. The effect of amphotericin 
B on carboplatin toxicity were not found to be statistically significant.
Treatment of the DLKPC variants with non-toxic concentrations of amphotericin B did not 
significantly alter the toxicity of carboplatin in any of the variants. The results could 
indicate that decreased membrane permeability was not involved in platinum resistance in 
the DLKPC cells or alternatively that amphotericin B selectively potentiates platinum drug 
sensitivity in resistant cells exhibiting a reduction in drug accumulation. Morikage and 
coworkers (1993) also showed a similar lack of sensitization by amphotericin B with the 
lipophilic platinum analogue, ormaplatin.
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4.4 Drug accumulation studies in P-glycoprotein MDR cell lines
Decreased drug accumulation has been implicated as the mechanism of resistance in many 
MDR cell lines, although for several years it was not clear whether decreased accumulation 
reflected decreased drug uptake or increased drug efflux. Observations however, that 
exposure of MDR cells to metabolic inhibitors, including sodium azide and 2-deoxy-D- 
glucose, led to increased intracellular drug levels, strongly suggested that decreased 
accumulation was in fact due to accelerated drug efflux (Dano, 1973). It has since been 
demonstrated that reduction in the cellular accumulation of antitumour agents usually occurs 
as a result of overexpression of the mdrl gene, which encodes the transmembrane protein 
pump, P-glycoprotein. Studies have shown that P-glycoprotein can bind diverse cytotoxic 
agents and extrude them from the cells in an energy requiring reaction, thus reducing the 
cellular concentration of the drug (Endicott and Ling, 1989). Several observations have 
supported the proposal that P-glycoprotein is the transporter responsible for the multidrug 
resistant phenotype in many MDR cell lines. Photoaffinity labelling studies, using 
photoactive analogues of vincristine, have shown that P-glycoprotein can bind drugs that 
are transported out of MDR cells (Cornwell et al., 1986). Analysis of the structure of P- 
glycoprotein also revealed that the peptide has conserved structural features which were 
consistent with it being an energy dependent transporter. In addition, numerous reports 
have also shown that development of MDR is accompanied by amplification of the mdrl 
gene while transfection of the cDNAs for human and mouse mdrl into drug sensitive cells 
resulted in the expression of the multidrug resistant phenotype (Gros et al., 1986b; Ueda 
etal., 1987).
Early studies on drug accumulation in multidrug resistant cell lines were predominantly 
carried out using rodent cell lines. A number of techniques were employed in these studies 
to determine drug accumulation, including autoradiography, spectrofluorometric techniques 
and radioactivity studies. Since several of the anthracyclines were found to be naturally 
fluorescent under ultraviolet illumination (Egorin et al., 1974), the accumulation of these 
agents could easily be determined by spectrofluorometric analysis. The drugs could also 
be radiolabeled and thus accumulation could be determined by measuring the cellular 
concentration of radiolabelled drug by scintillation counting. Initial drug accumulation 
studies were carried out on Chinese hamster ovary cell lines. Biedler and Riehm (1970) 
demonstrated by autoradiography the uptake of actinomycin D in sensitive wild-type and
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a number of resistant variants of the Chinese hamster ovary CLM/AD cell line. The 
procedure involved labelling the cells with tritiated actinomycin D and counting the number 
of grains per nucleus in each of the cell lines studied. The results obtained demonstrated 
that uptake of drug, in terms of mean number of grains per nucleus, was diminished in the 
resistant cells and also that the degree of resistance was inversely related to the degree of 
nuclear labelling by actinomycin D. A reduction in the cellular accumulation of drug was 
also evident in a number of resistant variants of the Ehrlich ascites tumour cell line (Dano, 
1973). The accumulation of the anthracycline, daunomycin, was studied in a number of 
resistant variants of the EHR 2 cell line. These variants were selected for resistance to 
daunomycin, adriamycin, vincristine and vinblastine. Daunomycin accumulation was 
analysed spectrofluorometrically by determining the daunomycin content in the medium and 
subtracting it from the total amount added to the cells. Daunomycin was found to be highly 
concentrated in the cells, although lower levels were detected in the resistant variants than 
in the parental cells. Ehrlich ascites tumour cells selected for resistance to adriamycin, 
vincristine and vinblastine, all of which exhibited cross resistance to daunomycin, showed 
the same low level of daunomycin accumulation as the cells selected by treatment with the 
drug itself. Accumulation of daunomycin was greatly enhanced in the resistant variants by 
the metabolic inhibitors, 2-deoxyglucose and iodoacetate, suggesting an active extrusion of 
the drug from the resistant cells.
Daunomycin uptake in Ehrlich ascites tumour cells was also investigated by Skovsgaard and 
coworkers (1978b). These studies involved spectrofluorometric analysis, although, the 
cellular uptake of daunomycin was determined by measuring the total drug fluorescence 
extracted from the cells as opposed to measuring the drug content in the medium. The 
results obtained were consistent with those previously reported by Dano (1973), in which 
the resistant variants accumulated less drug than the parental cells. These studies also 
demonstrated increased drug uptake in the cells following treatment with the metabolic 
inhibitor, sodium azide, which again suggested an active efflux mechanism. A number of 
anthracycline accumulation studies have also been carried out on sensitive and resistant 
sublines of the murine leukaemia P388 cell line. Initial studies by Inaba and Johnson (1978) 
reported a decrease in drug accumulation in the adriamycin resistant and the daunorubicin 
resistant cell lines, P388/ADR and P388/DAU, when compared with the sensitive parental 
cells. The uptake was determined by measuring the cellular levels of radiolabelled drug 
(3H-daunorubicin and 14C-adriamycin) in each of the cell lines studied. Further studies 
revealed that drug uptake was accelerated by metabolic inhibitors (sodium azide, 2,4-
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dinitrophenol, oligomycin and vainomycin) in the resistant variants to a level comparable 
to the parental cells. Furthermore, in sensitive and resistant cells preloaded with adriamycin 
or daunorubicin, drug efflux was inhibited by the addition of 2,4-dinitrophenol. These 
results suggested that an active outward transport mechanism for anthracyclines was present 
in the P388 leukaemia cells and that enhanced activity of this efflux process rendered the 
cells highly resistant to the cytotoxic effects of adriamycin and daunomycin (Inaba et al., 
1979). Studies on the accumulation of the vinca alkaloids have also demonstrated a 
reduction in the cellular content of the drug in resistant cell lines. The majority of studies 
to date have used radioactivity to determine the cellular accumulation of the vinca alkaloids. 
Skovsgaard (1978a) reported a decrease in the cellular accumulation of radiolabeled 
vincristine ([3H]VCR) in the vincristine resistant Ehrlich cell line, EHR2/VCR+ relative 
to the parental cell line. Breier et al. (1994) reported a decrease in vincristine accumulation 
in two resistant variants of the murine leukaemia cell line, L1210, when compared with the 
sensitive cell line. A decrease in the accumulation of labelled vincristine was also observed 
in the vincristine resistant murine leukaemia P388/VCR cell line (Tsuruo et al., 1981).
Drug accumulation studies on human cell lines were initially carried out in the mid 1980s 
by Fojo and coworkers (1985) on a number of resistant variants of the human colon 
carcinoma cell line, KB. Four resistant variants were selected, with increasing 
concentrations of colchicine, and were shown to be cross resistant to the classical MDR 
drugs (adriamycin, vincristine, vinblastine and actinomycin D). Drug uptake was 
determined in each of the four resistant variants by radiolabeled studies and the results 
obtained indicated that drug accumulation decreased with increasing level of resistance. 
This relationship was seen most clearly with colchicine, vincristine, vinblastine and 
daunorubicin and to a lesser extent with actinomycin D. Drug efflux studies revealed that 
efflux occured rapidly in all the variants, although in the more resistant variants a greater 
percentage of the drug was released more rapidly. These findings again suggested that 
decreased accumulation was due to active efflux of the drug rather than decreased uptake. 
Several studies have since reported a reduction in the cellular drug accumulation in human 
resistant cell lines. In the majority of studies, drug uptake was determined either 
spectrofluorometrically or by radioactivity analysis of labelled compounds. However, more 
recent reports have demonstrated drug accumulation defects in resistant cell lines by flow 
cytometry and high-preformance liquid chromatography (HPLC). In one such study, Wiebe 
et al. (1992) reported a reduction in adriamycin accumulation in the resistant human breast
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cancer cell line, MDA A-l. Cellular levels of the drug were quantified by HPLC following 
extraction of the drug from the cells. Total adriamycin accumulation, as measured by the 
area under the concentration curve, was shown to be reduced in the resistant MDA A-l 
cells, relative to the parental cells. Flow cytometry was also used in this study to determine 
adriamycin retention in the sensitive MDA 231 and resistant MDA A-l cells. Flow 
cytometry has also been utilized to study drug retention in Chinese hamster ovary CHrC5 
cells (Bruno and Slate, 1990), in the murine P388/Adr leukaemia cell line (Gupta et al.,
1994), in human leukaemia HL60/Adr cells (Gupta et al., 1994) and in the human K562 
leukaemia cell line (Mechetner and Roninson, 1992).
4.4.1 Drug accumulation studies in SKMES-1 and SKMES-1/ADR cells
A major focus of this thesis was to investigate the transport of cytotoxic agents in a number 
of human MDR cell lines. Studies were carried out using the anthracycline adriamycin and 
the vinca alkaloid vincristine, both of which are classified as classical MDR drugs. 
Adriamycin uptake was determined spectrofluorimetrically following direct extraction of the 
drug from the cells, as detailed in section 2.10. Vincristine transport was determined by 
measurement of the cellular level of radiolabeled vincristine (3H-Vincristine). Initial studies 
were carried out on the human lung squamous carcinoma cells line, SKMES-1 and its 
resistant variant, SKMES-1/ADR. The resistant cell line was established by continuous 
exposure of the cells to increasing concentration of adriamycin. It was found to exhibit 
approximately a 45-fold increase in resistance to the selecting agent, relative to the parental 
SKMES-1 cells. Toxicity studies, using a number of anticancer agents, revealed that the 
SKMES-1/ADR cells line was cross resistant to the vinca alkaloid, vincristine (50-fold) and 
the semi-synthetic derivative of podophyllotoxin, VP 16 (3-fold). A low level of cross 
resistance to carboplatin (2-fold) was also noted. In order to determine if the SKMES- 
1/ADR cells exhibited the classical MDR phenotype, Western blot analysis of P- 
glycoprotein expression was performed. The results obtained demonstrated an 
overexpression of P-glycoprotein in the SKMES-1/ADR, while only a very low level of P- 
glycoprotein was detected in the SKMES-1 parental cells.
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To further investigate the role of P-glycoprotein overexpression on the SKMES-1/ADR 
cells, adriamycin accumulation studies were carried out on the parental and resistant cell 
lines. The aim of these studies was to determine if P-glycoprotein expression was 
associated with a reduction in drug accumulation in the SKMES-1/ADR cells. Results 
obtained from basic uptake assays indicated decreased adriamycin accumulation in the 
SKMES-1/ADR cells, relative to the parental cells. An approximate 4-fold decrease in the 
cellular accumulation of the drug was observed in the SKMES-1/ADR cells over a period 
of four hours. To determine whether reduced accumulation resulted from decreased uptake 
or enhanced efflux, the effect of energy inhibition on accumulation was studied. When the 
cells were treated with the metabolic inhibitors, sodium azide and 2-deoxyglucose, in 
glucose free medium a marked increase in cellular accumulation was observed. The level 
of drug accumulation in the SKMES-1/ADR cells after three hours under these conditions 
was comparable to the level observed in the parental cells, thus suggesting inhibition of the 
active efflux mechanism since depletion of ATP levels would ultimately result in inhibition 
of the P-glycoprotein efflux pump. When glycolysis and oxidative phosphorylation was 
restored by addition of glucose a pronounced extrusion of adriamycin was observed in the 
SKMES-1/ADR cells again implicating the involvement of the P-glycoprotein efflux pump.
Adriamycin accumulation was also investigated in the SKMES-1 variants, when the cells 
were at different confluency levels. The purpose of this study was to determine if drug 
accumulation was cell density dependent. Accumulation studies revealed a significant 
decrease in the cellular concentration of drug in confluent SKMES-1 and SKMES-1 /ADR 
cells. Adriamycin accumulation was shown to be greater in cells that were plated at a low 
density. The results correlated with several studies which reported that confluent cancer 
cells in culture were more resistant to anticancer drugs that non confluent cells, even where 
the incubation medium was regularly renewed and if the cells were incubated with drug as 
monolayers, in the presence of controlled pH and atmosphere. Confluency dependent 
resistance has been attributed to either a decrease in drug accumulation or to a reduction 
of cell proliferation (Valeriote et al., 1975; Drewinko et al., 1981; Chambers etal., 1981). 
Confluent cells, grown in monolayers, are tightly attached and are therefore exposed to the 
incubation medium by a smaller surface of plasma membrane than nonconfluent cells. It 
could be suggested that reduced drug accumulation was simply due to geometric parameters, 
however a number of alternative mechanisms have been attributed to reduced drug 
accumulation in confluent cells. Studies have shown that plasma membranes of confluent
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cells appear less permeable to passively diffusing molecules than those of nonconfluent 
cells. This could account for decreased drug uptake in the cells and consequently a 
reduction in the cellular levels of the drug (Pelletier et al., 1990). A significant decrease 
in membrane fluidity has also been reported in confluent cells (Dimanche-Boitrel et al., 
1992). Since membrane fluidity can influence the permeability of the membrane to 
molecules, alterations in fluidity could also result in decreased drug accumulation.
The effect of the calcium channel antagonist, verapamil, on adriamycin accumulation was 
investigated in the parental SKMES-1 and resistant SKMES-1/ADR cells, to determine if 
it could restore drug accumulation in the resistant cells. Early studies by Friche et al. 
(1987) demonstrated an enhancement of daunorubicin accumulation by verapamil in resistant 
cells, to the same level as in the wild-type cells. Tsuruo et al. (1981) also reported an 
enhancement of drug accumulation in P388 resistant cells, to a level comparable to the 
parental cells, following treatment with verapamil. Numerous reports have since described 
the effectiveness of verapamil in restoring cellular levels of anticancer drugs in MDR cell 
lines and thus reversing P-glycoprotein resistance. The exact mechanism by which 
verapamil restores drug accumulation in MDR cells is unknown, although there is 
substantial evidence to suggest that the effect is not directly related to alterations in calcium 
flux or to an effect on calcium channels. Studies by Roberts et al. (1987) demonstrated 
increased drug accumulation in rat glioblastoma cells following treatment with verapamil. 
They reported that verapamil was still active in the absence of calcium and in the presence 
of the calcium channel blockers, EGTA and manganese ions, in the culture medium. The 
results suggested that the action of verapamil on drug resistance was independent of the 
calcium fluxes of the cells and was not due to effects on calcium channels. Studies by 
Naito and Tsuruo (1989) demonstrated that verapamil inhibited vincristine binding to plasma 
membrane preparations from the adriamycin resistant K562/ADM cell line. A substantial 
amount of vincristine binding was still observed following the addition of high concentration 
of calcium or the chelating agent [ethylenebis(oxyethenenitrilo)]tetraacetic acid. These 
findings indicated that calcium ions were not required for vincristine binding and that 
verapamil competitively inhibited the vincristine binding without the involvement of calcium 
ions. In photoaffinity labelling studies, competition of verapamil with a vinblastine 
photoactive analogue for binding to P-glycoprotein has been demonstrated (Safa et 
al., 1986). Further studies using photoactive analogues of verapamil demonstrated that 
verapamil binds directly to the P-glycoprotein molecule, implying that verapamil may
239
directly interact with P-glycoprotein and inhibit drug efflux from the cells (Safa, 1988). 
The mode of inhibition and possible involvement of calcium in the process, however, has 
not yet been established. When the SKMES-1 and SKMES-1/ADR cell lines were treated 
with verapamil, a marked increase in adriamycin accumulation was observed in the resistant 
SKMES-1/ADR cells. The level of cellular accumulation of the drug was comparable to 
the parental cell line, indicating that verapamil was a very effective agent at restoring drug 
accumulation levels in these cells. Since the cells were shown to overexpress P- 
glycoprotein, verapamil may therefore act by competing with the drug for P-glycoprotein 
binding sites and thus inhibit adriamycin efflux. A slight increase in adriamycin 
accumulation was also observed in the SKMES-1 parental cells following treatment with 
verapamil. This result can be explained by the low level of P-glycoprotein expression also 
detected in the parental cells.
The effect of the immunosuppressive agent, cyclosporin A, on adriamycin accumulation was 
also investigated in the SKMES-1 variants. Cyclosporin A has been reported to act as a 
chemosensitizer in many MDR cell lines, by restoration of cellular levels of drug. The 
mechanism of action of cyclosporin is unclear, although as is the case with verapamil it is 
thought to modulate MDR by interacting with drug binding sites of P-glycoprotein. Reports 
have shown that cyclosporin effectively inhibits binding of anticancer drugs to P- 
glycoprotein (Slatter et al., 1986; Twentyman et al., 1987). Photoaffinity labelling studies 
have also demonstrated the binding of a photoactive analogue of cyclosporin to P- 
glycoprotein and shown inhibition of binding by cyclosporin A, cyclosporin H and 
verapamil (Foxwell et al., 1989). These result suggest that the mechanism of action of 
cyclosporin is related to competitive inhibition of P-glycoprotein, although several reports 
have also implicated a role for cyclophilin in the mechanism of action of cyclosporin A. 
Cyclophilins are cytoplasmic proteins of approximately 18 kDa. Amino acid sequence 
analysis has revealed two regions containing consensus sequences for ATP binding (Harding 
et al., 1986). Handschumacher and coworkers (1984) reported that 70-80% of cyclosporin 
A was located in the cytosol of cells as a result of binding to the cyclophilins. Several 
laboratories subsequently demonstrated that the degree of binding of a number of 
cyclosporin analogues to cyclophilin closely paralleled their immunosuppressive activities, 
thus suggesting a central role for cyclophilin in the action of cyclosporins (Quesniaux et al., 
1987). The role of cyclophilin in the chemosenitizing effect of cyclosporin however, 
remains to be clarified. Cyclosporin A proved to be very effective at restoring adriamycin
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accumulation in the SKMES-1/ADR cell line. The cellular level of drug after four hours 
was greater than the level observed in the parental cells. The addition of cyclosporin A also 
caused a slight increase in adriamycin accumulation in the parental cells which was 
consistent with the results obtained with verapamil. The results indicate that cyclosporin 
A was more effective than verapamil at enhancing accumulation in the SKMES-1/ADR 
cells, which could suggest that cyclosporin A caused greater inhibition of the P-glycoprotein 
efflux pump. Alternatively, since cyclosporin A has been shown to affect the physico­
chemical properties of the plasma membrane by binding to phospholipid vesicles (Hayes et 
al., 1985), the additional increase in drug accumulation could be due the direct effect of 
cyclosporin A on the cell membrane. Cyclosporin A has also been reported to depolarize 
cytoplasmic membrane potential. Matyus et al. (1986) demonstrated a decrease in 
membrane potential of murine lymphocytes in the presence of cyclosporin A, as determined 
by flow cytometry and fluorescence spectroscopy. The results indicated that cyclosporin 
A decreased the apparent freedom of motion of membrane lipids, which may have been 
responsible for changes in ion flux. Alterations in ion fluxes may alter membrane 
permeability and thus influence drug uptake, resulting in increase cellular drug 
accumulation.
Vincristine accumulation studies also revealed a reduction in the accumulation of vincristine 
in the SKMES-1/ADR resistant cells, relative to the parental SKMES-1 cell line. 
Approximately a 4-fold decrease in accumulation was observed in the resistant cells over 
a three hour period which was consistent with the results obtained from adriamycin 
accumulation studies. The effect of cyclosporin A on vincristine accumulation was also 
investigated and the results demonstrated that cyclosporin A completely restored 
accumulation in the resistant cells. Cyclosporin A was also shown to be more effective at 
restoring vincristine accumulation than adriamycin accumulation in the SKMES-1 variants. 
The maximum cellular drug level was increased by approximately 11-fold in the SKMES- 
1/ADR cells and approximately 2.6-fold in the parental cells, following treatment with 
cyclosporin A. Since photoaffinity labelling studies have demonstrated vincristine binding 
to P-glycoprotein, the reduction in vincristine accumulation in the SKMES-1/ADR also 
appears to be associated with overexpression of the P-glycoprotein efflux pump. Overall 
the results obtained from studies on the SKMES-1/ADR cells would indicate that the cell 
line is an example of a classical MDR cell line, displaying resistance to a number of the 
MDR associated drugs including adriamycin, vincristine and VP16. P-glycoprotein
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overexpression was associated with a reduction in the cellular accumulation of both 
adriamycin and vincristine in the resistant cells. Restoration of cellular drug levels was 
observed when the cells were treated with metabolic inhibitors, verapamil and cyclosporin 
A which is consistent with classical MDR cell lines.
4.4.2 Adriamycin accumulation studies in the T24 variants
Adriamycin accumulation was also studied in variants of the human bladder carcinoma cell 
line, T24, The parental T24 cells were obtained from the American Type Culture 
Collection and the MDR resistant sublines, T24A and T24V were established by continuous 
exposure to increasing concentrations of adriamycin and VP16 respectively. Toxicity 
studies on the resistant variants revealed that while both variants exhibited resistance to 
adriamycin and VP 16 (the T24V cells were found to be more resistant to adriamycin and 
VP16 than the T24A cells) the cells showed no significant cross resistance or sensitivity to 
cisplatin or 5-fluorouracil. The variants therefore appeared to be cross resistant to the 
classical MDR drugs. To determine if P-glycoprotein was overexpressed in the resistant 
variants, Western blot analysis was carried out on purified membrane fractions of the 
parental and resistant cells. Immunoreactive P-glycoprotein was detected in the T24A and 
T24V cell lines, however only a very low level was detected in the sensitive T24 cells 
(Cleary et al., 1995).
In order to determine if P-glycoprotein overexpression was associated with a reduction in 
the cellular levels of drug, adriamycin accumulation was studied in the three T24 variants. 
The results obtained demonstrated that adriamycin accumulation was significantly reduced 
in both the T24A and T24V cells, when compared with the parental cells. Although the 
T24V cell line exhibited greater resistance to the MDR drugs, the T24A cells were found 
to accumulate the lowest level of drug within the four hour period studied. The effect of 
verapamil and cyclosporin A on the intracellular accumulation of adriamycin was also 
investigated in the T24A and T24V cell lines. A significant increase in drug accumulation 
was observed in the variants following treatment with verapamil and cyclosporin A, 
although both appeared to be more effective at restoring accumulation in the T24A variant. 
The maximum level of accumulation in the resistant cells was greater than the level 
observed in the parental cells, implying that the accumulation deficit in the T24A and T24V
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cells was due to mechanism inhibited by verapamil and cyclosporin A, probably 
overexpression of the P-glycoprotein efflux pump. The results would indicate that, as with 
the SKMES-1/ADR cell, the T24A cell line is an example of a classical MDR cell line, 
although further studies are required to fully characterise the mechanisms of resistance in 
the T24V cell line. P-glycoprotein overexpression appears to play a major role in the 
resistant phenotype, although other mechanisms of resistance may also be involved in the 
T24V cell line to account for the higher level of drug resistance observed in this variant.
4.4.3 Adriamycin accumulation studies in the OAW42 variants
The parental OAW42 cells were obtained from the ECACC (European collection of animal 
cell cultures) and a number of variants were established from a spontaneous MDR resistant 
strain (OAW42-SR) of the parental cell line. Two adriamycin resistant variants, OAW42- 
A1 and OAW4-A, were established by continuous exposure of the OAW42-SR cells to 
drug. An adriamycin sensitive variant, OAW42-S, a clonal subpopulation of the OAW42- 
SR was also included in the study. Toxicity studies, using a number of anticancer agents, 
revealed that the three adriamycin resistant variants also displayed cross resistance to 
vincristine and VP16 but exhibited no significant resistance or sensitivity to cisplatin and 
5-fluorouracil. Increases of approximately 8.3-fold, 14-fold and 29-fold, relative to the 
sensitive OAW42-S cells, were observed in adriamycin resistance in the OAW42-SR, 
OAW42-A1 and OAW42-A cell lines respectively. Western blot analysis was also carried 
out to investigate the role of P-glycoprotein in the resistant phenotype in each of the four 
OAW42 variants. While P-glycoprotein expression was not detected in the OAW42-S cells, 
immunoreactive P-glycoprotein was evident in the three resistant variants. P-glycoprotein 
expression was shown to be related to the level of resistance in the cells. The OAW42-SR 
cells were found to express the lowest level of P-glycoprotein, while the highest level was 
detected in the OAW42-A cells (Moran et al., 1995).
Adriamycin accumulation was also found to be related to the level of resistance in the 
OAW42 variants. A significant reduction in the cellular accumulation of drug was observed 
in the resistant variants, when compared with the sensitive OAW42-S cells. The maximum 
level of adriamycin accumulation was shown to be similar in the OAW42-SR and OAW42- 
A l, while the OAW42-A cells accumulated a lower level of drug. Treatment with
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verapamil and cyclosporin A resulted in a marked increase in adriamycin accumulation in 
the three resistant variants. The cellular accumulation of the drug was enhanced to a level 
greater than that observed in the sensitive OAW42-S cells. These results would indicate 
that the reduction in drug accumulation was predominately P-glycoprotein mediated in the 
OAW42-A1 and OAW42-A variants and that the resistant phenotype of the cells can be 
attributed to P-glycoprotein overexpression. However, other mechanisms must also be 
involved in mediating resistance in the OAW42-SR variant, since the reduction in 
adriamycin accumulation does not appear to be consistent with the level of P-glycoprotein 
detected in the cells. Although drug accumulation was similar for the OAW42-SR and 
OAW42-A1 variants, a lower level of P-glycoprotein was detected in the OAW42-SR cells. 
Immunocytochemical studies have shown that the OAW42-SR cells overexpress the 110 
kDa, LRP protein (Moran et al., 1995). LRP expression has been demonstrated in a number 
of non-P-glycoprotein cell line, all of which were found to be defective in the cellular 
accumulation of drug (Scheper et al., 1993). The authors suggested that the LRP protein 
may be involved in mediating resistance, since reversal of drug resistance in the 
SW1573/2R120 cell line was associated with a decrease in expression of the protein, 
Overexpression of LRP may therefore be associated with the non-P-glycoprotein reduction 
in adriamycin accumulation in the OAW42-SR cell line.
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In addition to a reduction in drug accumulation, many MDR cell lines also exhibit altered 
distribution and compartmentalisation of drug in vesicles, away from the target site. This 
had led to numerous studies investigating the distribution of adriamycin in wild type and 
multidrug resistant cell lines. The majority of studies have involved fluorescent microscopy 
to detect adriamycin localisation since a number of the anthracyclines were found to be 
inherently fluorescent (Egorin et al., 1974) and therefore could be easily visualized under 
UV illumination. Cytofluorescence studies on the cellular localisation of adriamycin in 
MDR cell lines were first described by Chauffert et al. (1984) on adriamycin resistant rat 
colon cancer cells. The studies revealed that initially adriamycin accumulated rapidly in the 
nucleus, however, when the cells were exposed to the drug for longer incubation periods 
adriamycin was localised primarily within the cytoplasmic region. These findings indicated 
that the inherently resistant cells were capable of removing adriamycin from the nucleus and 
distributing it in the cytoplasm, away from its main site of action. Consequently, the cells 
were able to survive and grow in the presence of the drug. Numerous reports have since 
demonstrated altered drug distribution in MDR cell lines and have associated the alteration 
with acquired resistance in the cells. In general, while adriamycin has been shown to be 
primarily associated with the nucleus of sensitive wild type cells, the drug is localised 
primarily within the cytoplasmic region in resistant cell lines (Willingham et al., 1986; 
Hindenburg et al., 1987; Versantvoort et al., 1993; Barrand et al., 1993).
4.5.1 Adriamycin localisation studies in SKMES-1 and SKMES-1/ADR cells
One of the aims of this thesis was to investigate the subcellular distribution of adriamycin 
in a number of MDR cell lines, including the SKMES-1/ADR cell line and the OAW42 
resistant variants, to determine if the acquired resistance observed in the cells was associated 
with altered drug distribution. Fluorescence microscopy studies were initially carried out 
on the sensitive SKMES-1 and its MDR variant, SKMES-1/ADR and the results obtained 
were found to be consistent with results previously reported on adriamycin distribution in 
MDR cells. When the parental cells were viewed following exposure to adriamycin, intense 
fluorescence was clearly visible in the nucleus of the cells indicating the localisation of the 
drug within the nucleus. In contrast, while faint nuclear fluorescence was observed in the
4.5 Adriamycin localisation studies in P-glycoprotein MDR cell lines
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SKMES-1/ADR cells, the majority of adriamycin fluorescence appeared to be localised 
within the cytoplasmic region.
While the exact mechanism by which drug distribution is altered in MDR cell lines remains 
to be clarified, the most likely explanation, however, to account for the altered distribution 
centers on the overexpression of P-glycoprotein. Anthracyclines appears to enter both the 
wild type sensitive and resistant cells passively, in an energy independent process. Studies 
have shown that entry of the anthracycline, daunorubicin into both sensitive and resistant 
cells was unaffected by the metabolic inhibitor, sodium azide (Gervasoni et al., 1991). 
Once the drug has entered the cells, it appears that the sensitive cells continue to accumulate 
drug in their nuclei, while the P-glycoprotein present in the resistant cells actively extrudes 
the drug from the cells. Consequently, a high cytoplasmic concentration of the drug is 
never achieved and thus nuclear accumulation of adriamycin does not occur. Since P- 
glycoprotein has been shown to be overexpressed in the resistant SKMES-1/ADR cells, the 
results suggest that P-glycoprotein was involved in the altered drug distribution pattern in 
the resistant cells.
To further investigate the role of P-glycoprotein in the SKMES-1/ADR cells, the effect of 
a number of known P-glycoprotein inhibitors on adrimaycin distribution was studied, to 
determine if nuclear fluorescence could be restored in the resistant cells. The metabolic 
inhibitors, sodium azide and 2-deoxyglucose, were both found to restore nuclear 
fluorescence in the resistant cells, to a level comparable with the parental SKMES-1 cells. 
The results confirm the involvement of an energy dependent efflux mechanism, probably 
P-glycoprotein, since depletion of ATP levels would result in inhibition of the P- 
glycoprotein efflux pump. These findings are in agreement with a number of reports that 
have demonstrated increased nuclear fluorescence in MDR cell lines, following treatment 
with metabolic inhibitors. In one such study, Chauffert et al. (1984) reported an increase 
in nuclear fluorescence in the inherent adriamycin resistant colon carcinoma cells that were 
exposed to daunorubicin, in the presence of sodium azide. Studies by Gervasoni et al. 
(1991) have also demonstrated complete restoration of nuclear fluorescence following 
treatment with sodium azide in a number of MDR resistant cell lines, including the human 
breast cell line, MCF-7/ADR, the human leukaemia cell line, P388/ADR and the human 
colon cell line, KBV-1. Since previous studies had shown that the resistant cells all 
expressed P-glycoprotein, it was suggested that the increase in nuclear fluorescence in each
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of the cell lines was associated with inhibition of the P-glycoprotein efflux pump. 2- 
deoxyglucose has also been shown to restore nuclear fluorescence in MDR cell lines, 
indicating that this agent is also an effective inhibitor of P-glycoprotein, by depletion of 
cellular ATP levels (Hindenburg et al., 1989).
Reports have suggested that verapamil and cyclosporin A can also restore nuclear 
fluorescence in P-glycoprotein MDR cell lines most likely by binding to P-glycoprotein and 
inhibiting drug efflux. Early studies by Chauffert et al. (1984) demonstrated an increase 
in nuclear fluorescence in resistant rat colon cells, when treated with verapamil. Verapamil 
was also shown to increase nuclear fluorescence in the resistant human colon cell line, KB- 
C4 (Willingham et al., 1986). The authors suggested that verapamil restored nuclear 
fluorescence by inhibiting the binding of daunorubicin to an efflux channel or a binding site 
on the inside of the plasma membrane. This binding site has subsequently been shown to 
be P-glycoprotein thus implicating the role of P-glycoprotein in drug distribution in MDR 
cells. Numerous studies have since demonstrated increased nuclear fluorescence in MDR 
cell lines treated with verapamil (Hindenburg et al., 1987; Schuurhuis et al., 1993; 
Versantvoort et al., 1993; Sebille et al., 1994; Takeda et al., 1994). Verapamil also 
proved to be a very effective agent at restoring nuclear fluorescence in the SKMES-1/ADR 
cells. Treatment with verapamil resulted in an increase in fluorescence to a level 
comparable to the parental SKMES-1 cells. Since studies have shown that verapamil acts 
by binding to P-glycoprotein, these results would suggest that altered drug distribution in 
the SKMES-1/ADR was associated with enhanced efflux of the drug by P-glycoprotein. 
Cyclosporin A was found to be even more effective than verapamil at restoring nuclear 
fluorescence in the SKMES-1/ADR. Following treatment with cyclosporin, the intensity 
of nuclear fluorescence in the resistant cells was greater than the intensity observed in the 
parental cells. Although fewer studies have been carried out using cyclosporin A, these 
results are consistent with a number of reports that have demonstrated an increase in nuclear 
fluorescence in MDR cells when exposed to cyclosporin A (Hindenburg et al., 1987; Sebille 
et al., 1994). These findings suggests that, as is the case for verapamil, restoration of 
nuclear fluorescence is due to inhibition of the P-glycoprotein efflux pump.
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4.5.2 Adriamycin localisation studies in the OAW42 variants
Drug distribution in the OAW42 variants was shown to be inversely related to the level of 
adriamycin resistance in each variant (Moran et al., 1995). Intense nuclear fluorescence 
was observed in the OAW42-S cells, following exposure to the drug. This corresponded 
to the localisation of drug in the nucleus of sensitive cells. Nuclear fluorescence was 
observed in the OAW42-SR and OAW42-A1 cells, although the intensity of fluorescence 
was less than that noted in the sensitive cells. The fluorescence intensity appeared to be 
slightly less in the OAW42-A1 cells, although due to the inherent limitations of the 
fluorescence microscopy technique, differences in nuclear fluorescence were difficult to 
determine. The OAW42-A1 cells have been shown to be slightly more resistant to 
adriamycin than the OAW42-SR cells. It is therefore possible that the differences in 
resistance levels was reflected in the subcellular distribution of the drug. Only faint nuclear 
fluorescence was observed in the OAW42-A cells, which exhibit the highest resistance to 
MDR drugs. Distinct regions of cytoplasmic fluorescence were also visible in the OAW42- 
A1 and OAW42-A cell lines, consistent with the localisation of drug within cytoplasmic 
vesicles in resistant cells (Chauffert et al., 1984; Willingham et al., 1986; Hindenberg et 
al., 1987; Schuurhuis et al., 1991; Coley et al., 1993; Meschini et al., 1994).
The level of nuclear fluorescence was also found to correspond to the level of P- 
glycoprotein expression in each of the variants, suggesting a role for P-glycoprotein in 
altering drug distribution in these cell lines. A low level of P-glycoprotein was detected in 
the spontaneous resistant OAW42-SR cells and also in the low level, adriamycin resistant, 
OAW42-A1 cells. The decrease in nuclear fluorescence could, therefore, be associated with 
overexpression of the P-glycoprotein efflux pump which would result in a decrease in the 
cellular concentration of drug. The OAW42-A cells were shown to express a high level of 
P-glycoprotein which could be responsible for the marked decrease in nuclear fluorescence 
observed in the cells. Treatment with both verapamil and cyclosporin A resulted in an 
increase in nuclear fluorescence in the resistant cell lines. The fluorescence intensity in the 
OAW42-SR, OAW42-A1 and OAW42-A cells was comparable to the level observed in the 
OAW42-S sensitive cells, although again it was difficult to determine which variant 
exhibited the highest level of nuclear fluorescence. Overall, the findings would suggest that 
as in the case of the SKMES-1/ADR cell line altered drug distribution in the OAW42 
variants can be attributed to overexpression of the P-glycoprotein efflux pump.
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4.5.3 Adriamycin localisation studies in the T24 variants
Studies on the subcellular distribution of adriamycin in the human bladder carcinoma T24 
cell line revealed that the drug was localised, predominately in the nucleus of the cells. 
Distinct regions of fluorescence were discernable within the nuclei corresponding to 
adriamycin binding to chromosomal DNA. In contrast, when the adriamycin selected 
variant, T24A, was exposed to the drug for a short time period, the cells showed a mixture 
o f faint nuclear and faint cytoplasmic fluorescence, while longer exposure to the drug 
resulted in a significant increase in the proportion of cells where only cytoplasmic 
fluorescence was observed. Similar observations were noted in the VP16 selected, T24V 
cells when exposed to the drug. Since P-glycoprotein has been shown to be overexpressed 
in both the T24A and T24V cells, these results would suggest that adriamycin was extruded 
from the cells by the P-glycoprotein efflux pump, thus inhibiting the binding of the drug 
to nuclear DNA. Further evidence supporting the involvement o f P-glycoprotein was 
obtained from studies with verapamil and cyclosporin A, since both agents were shown to 
completely restore adriamycin nuclear fluorescence in the T24A and T24V cells (Cleary et 
al., 1995).
4 .5 .4  Confocal laser microscopy
Preliminary studies were also carried out using confocal laser scanning microscopy to 
investigate the subcellular distribution of adriamycin in the SKMES-1 and SKMES-1/ADR 
cell lines. Confocal scanning microscopy is an optical microscopic technique offering 
significant advantages over conventional fluorescence microscopy. In laser scanning 
microscopy the sample is scanned by a diffraction beam of laser light. The light is 
transmitted or reflected, by the in-focus illuminated volume element. Alternatively, the 
fluorescence emission is excited within by the incident light and is focused as in the first 
case onto a photodetector. As the illuminating spot is scanned over the sample, the 
electrical output from the detector is displayed at the appropriate spatial position on a 
monitor, thus building up a two-dimensional image (Shotton, 1989). Several studies have 
recently been published demonstrating the use of this technique in the study of the 
subcellular localisation of anthracyclines in MDR cell lines. Confocal laser microscopy has 
a number of advantages over conventional fluorescence microscopy, principally in terms of
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its greater resolution and elimination of autofluorescence (White et al., 1987). Confocal 
laser microscopy markedly reduces observed fluorescence overlap and scatter, thus enabling 
the precise location of the drug to be determined. This technique also allows the 
quantification of ratios of nuclear fluorescence to cytoplasmic fluorescence (N/C ratio) 
which have been extensively used to evaluate the effect of various agents on drug 
distribution. The N /C ratios cannot be accurately determined by conventional microscopy. 
Confocal scanning laser microscopy, allowing the optical sectioning of the cells, represents 
a suitable tool for the fine intracellular localisation of fluorescent substances and 
consequently the technique has been used to study subcellular anthracycline localisation in 
a number of P-glycoprotein M DR cell lines. These include the Chinese hamster ovary 
CHRC5 cell line (Schuurhuis et al., 1989), the human breast MCF-7 resistant cell lines 
(Schuurhuis et al., 1989; Gervasoni et al., 1991; Meschini et al., 1994), the human 
leukaemia P388/ADR cell line (Gervasoni et al., 1991) and the murine mammary tumour 
cell line, EM T6/AR1.0 (Coley et al., 1993).
Adriamycin distribution in the SKMES-1 and SKMES-1/ADR cells was studied by confocal 
laser microscopy and, although similar results to the fluorescence microscopy studies were 
obtained, the resolution was found to be greatly improved. Nuclear fluorescence was 
observed in the parental SKMES-1 cells following exposure to adriamycin. The drug 
appeared to be located in distinct regions within the nuclei, most likely involving 
chromosomal DNA. Areas within the nucleus were also found to display no fluorescence, 
which was not evident with fluorescence microscopy where significant fluorescence overlap 
was observed in the nuclei of the SKMES-1 cells. No cytoplasmic fluorescence was visible 
in the majority of the SKMES-1 cells viewed, although again this was not evident from 
previous fluorescence microscopy studies due to the fluorescence overlap and out-of-focus 
blur. The resolution of the images obtained for adriamycin distribution was also much 
improved in the SKMES-1/ADR cells. Regions of faint nuclear fluorescence were clearly 
visible when the cells were exposed to adriamycin and viewed by confocal laser 
microscopy. In contrast, these distinct areas of fluorescence were not discernable by 
conventional fluorescence microscopy. The results also demonstrated regions of intense 
cytoplasmic fluorescence in the SKMES-1/ADR cells, which was consistent with the 
localisation of drug in cytoplasmic vesicles. However, observations from the fluorescence 
microscopy studies suggested an overall distribution of the drug within the cytoplasm.
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The addition of verapamil and cyclosporin A was shown to cause a marked increase in 
adriamycin nuclear fluorescence in the SKMES-1/ADR cells. Following treatment with the 
circumvention agents, the intensity of nuclear fluorescence was greater in the SKMES- 
1/ADR cells than in the untreated parental cells. The results clearly demonstrated that the 
fluorescence was greater in the resistant cells, thus indicating a complete restoration of 
nuclear levels of the drug. Although the fluorescence microscopy studies also showed an 
increase in nuclear fluorescence in the SKMES-1/ADR cells, the actual intensity of the 
fluorescence could not be determined. An additional observation from the confocal laser 
microscopy work that was not evident from the conventional fluorescence microscopy 
studies was that no cytoplasmic fluorescence was visible in the majority of the SKMES- 
1/ADR cells following treatment with the circumvention agents. This finding is consistent 
with the redistribution of drug from the cytoplasmic regions to the nucleus. Overall, the 
results clearly show that confocal laser scanning microscopy is a powerful tool for studying 
the subcellular localisation of anticancer agents in MDR cell lines. Although similar 
information can be obtained from conventional fluorescence microscopy, its use in 
determining the precise intracellular location of anticancer drugs in M DR cells is limited.
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4.6 Drug accumulation studies in DLKP and DLKPA10 cells
The accumulation of anticancer drugs was investigated in the human lung squamous 
carcinoma cell line, DLKPA10. This cell line was derived from the adriamycin resistant 
DLKP-A cell line, established by exposure of the parental DLKP cells to increasing 
concentrations of adriamycin (Clynes et al., 1992). The DLKPA10 cell line was established 
by further exposing the DLKP-A cells to increasing concentrations of the drug, to a final 
concentration of 10/ig/ml. The cells readily adapted to growth in the higher drug 
concentrations, which was probably attributable to a more resistant population present in 
the DLKP-A cells, that was subsequently selected out. Toxicity studies revealed that, in 
addition to exhibiting resistance to the selecting agent, the DLKPA10 cells were also cross 
resistant to the MDR drugs, vincristine and VP16 (approximately 3000-fold and 63.3-fold 
respectively) but showed no significant resistance or sensitivity to the anticancer agents, 
cisplatin or 5-fluorouracil. The DLKP-A cells were also shown to exhibit a  similar cross 
resistance profile although the level of resistance observed for vincristine and VP16 was 
substantially lower (approximately 36-fold and 13-fold respectively) than in the DLKPA10 
cell line (Clynes et al., 1992). W estern blot analysis of purified membrane preparations 
illustrated that the DLKPA10 cell line overexpressed the 170 kDa membrane protein, P- 
glycoprotein, usually associated with mediating resistance in classical M DR cell lines 
(Endicott and Ling, 1989; Clynes et al., 1992; Nielsen and Skovsgaard, 1992). A low level 
o f P-glycoprotein was also detected in the parental DLKP cells.
To further investigate the role of P-gly coprotein in mediating resistance in the DLKPA10 
cell line, the accumulation of adriamycin and vincristine was studied in the parental and 
resistant cells. Drug uptake studies illustrated a marked reduction in the cellular 
concentration o f both adriamycin and vincristine in the DLKPA10 resistant cells relative to 
the parental DLKP cell line. A decrease in accumulation of approximately 16-fold was 
observed for both drugs in the DLKPA10 cells. Similar to the results obtained for the 
SKMES-1 variants, drug accumulation in both the parental and resistant cells was found to 
be cell density dependent, with confluent cells accumulating a lower level of the drug than 
non-confluent cells. This confluence dependent resistance was most evident in the 
DLKPA10 cells. The initial results obtained suggested that, similar to the classical MDR 
cell lines, overexpression of the P-glycoprotein pump was associated with the observed 
reduction in drug accumulation, by extruding the drug from the cells thereby reducing the
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cellular concentration of the drug.
The effect o f the circumvention agents, verapamil and cyclosporin A, on drug accumulation 
was also investigated. The purpose of this work was to establish whether these agents could 
reverse the accumulation defect that was observed in the DLKPA10 resistant cells and thus 
verify the role of P-glycoprotein in mediating drug resistance. Verapamil was shown to 
enhance the cellular accumulation of both adriamycin and vincristine in the DLKPA10 cells, 
although the maximum level o f drug accumulated was only approximately 45% and 28% 
of the level observed in the parental DLKP cells for adriamycin and vincristine respectively. 
Cyclosporin A has consistently been shown to be more effective than verapamil at altering 
drug accumulation (Boesch et al., 1991; Sebille et al., 1994). Consequently, drug 
accumulation, following treatment with cyclosporin A, was determined. Although 
cyclosporin A proved to be more effective than verapamil, the maximum level o f drug 
accumulation for adriamycin and vincristine was still only approximately 50% and 31 % of 
the level observed in the DLKP cells. Treatment with higher concentrations of the 
circumvention agents or exposure for longer time periods, did not significantly alter drug 
accumulation, although an increase was observed following pretreatment with cyclosporin 
A. Adriamycin accumulation was restored to approximately 60% of the level observed in 
the parental cells, indicating that cyclosporin A pretreatment was more effective than 
cotreatment at restoring the cellular levels of drug. These results are consistent with other 
reports published demonstrating higher drug retention levels in pretreated cells. Boesch and 
Loor (1994) reported that the cellular concentration of daunomycin was higher in the murine 
resistant M DR, P388 cells, following pretreatment with cyclosporin A than in cells 
cotreated with the circumvention agent. Similar accumulation patterns were also 
demonstrated with verapamil. W hilst the initial results suggested the involvement of P- 
glycoprotein in mediating resistance in the DLKPA10 cells, the results obtained from the 
verapamil and cyclosporin A studies indicate that overexpression of P-glycoprotein can not 
fully explain the accumulation defect in the DLKPA10 cells. Other mechanisms must 
therefore, play a role in mediating resistance to account for the apparent non-P-glycoprotein 
accumulation defect observed in the cell line.
The effect o f a number of metabolic inhibitors on drug accumulation was investigated to 
verify that the reduction in drug accumulation was associated with enhanced active drug 
efflux and to determine if  complete restoration of drug accumulation could be achieved in
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the DLKPA10 cell line. Numerous studies have shown that metabolic inhibitors, including
2-deoxyglucose, sodium azide, dinitrophenol and valinomycin, are effective at reversing the 
drug accumulation defect in classical M DR cells, most likely through inhibition of the P- 
glycoprotein efflux pump (Dano, 1973; Skovsgaard, 1978b; Inaba et al., 1979). Since P- 
glycoprotein is energy dependent, depletion of ATP levels would inhibit the activity of the 
pump and thereby increase the cellular drug concentration. The effect o f the inhibitors, 
sodium azide, 2-deoxyglucose and antimycin A on drug accumulation was investigated in 
the DLKP and resistant DLKPA10 cell lines. Initial studies with sodium azide and 2- 
deoxyglucose revealed that, while both agents increased drug accumulation in the resistant 
cells, the accumulation could not be restored to a level comparable to the parental DLKP 
cells. These finding suggested that a non-ATP-dependent mechanism of drug efflux was 
involved in mediating resistance in the DLKPA10 cell line. However, studies with 
antimycin A disproved this hypothesis, since treatment with antimycin A proved to be very 
effective at restoring the cellular concentration of drug. The maximum level of drug 
accumulated in the DLKPA10 cells was greater than the level observed in the parental cell 
line, thus showing a complete reversal of the accumulation defect in the resistant cells. A 
significant increase was also observed in adriamycin and vincristine accumulation in the 
parental DLKP cells following treatment with antimycin A. Since only a low level o f P- 
glycoprotein was detected in the DLKP cells, the results could indicate that depletion of 
ATP resulted in increased accumulation by mechanisms other than P-glycoprotein. To 
verify that the enhanced drug accumulation in both the sensitive and resistant cells following 
treatment with antimycin A was not a consequence of disruption of membrane permeability 
which would subsequently result in increased drug uptake, cell viability was determined 
using trypan blue. The results obtained showed that the trypan blue was excluded from the 
cells that were treated with antimycin A indicating that the membrane was impermeable to 
the dye. These findings therefore imply that increased drug accumulation in the DLKPA10 
cells was not due to an alteration in membrane permeability.
The results obtained from these studies indicate that, of the three compounds tested, 
antimycin A was the most effective inhibitor of ATP production and thus the most effective 
at inhibiting active drug efflux. These findings could be attributable to the different sites 
of action, since each compound has been shown to act at different stages of ATP 
production. 2-deoxyglucose acts by competing with glucose and thereby inhibiting the 
glycolytic pathway. Consequently, there is a reduction in the amount of pyruvate available
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to enter the citric acid cycle, which leads to a reduction in NADH production (figure 4.6.1). 
This ultimately leads to a reduction in ATP production. Sodium azide and antimycin A 
both act by inhibiting the electron transport chain. The free energy necessary to generate 
ATP is extracted from the oxidation of NADH and FADH2 by the electron transport chain, 
with consequent inhibition of electron transport resulting in inhibition of ATP production. 
The electron transport chain is comprised of a series of four protein complexes through 
which electrons pass from lower to higher standard reduction potential. Electrons are 
carried from  complex I and II to complex III by coenzyme Q (CoQ or ubiquinone) and from 
complex III to complex IV by the membrane protein, cytochrome C (figure 4.6.2). The 
change in standard reduction of an electron pair as it successively traverses complexes I, 
III and IV generates sufficient free energy to power the synthesis of an ATP molecule. 
Antimycin A has been shown to block the transfer of electrons from ubiquinone to 
cytochrome C, while sodium azide blocks the reduction of oxygen catalysed by cytochrome 
oxidase (cytochrome aa3). If antimycin A blocks the action o f ubiquinone the transfer of 
electrons from carriers I and II to carrier III would be inhibited. The carriers before 
ubiquinone, would become reduced, while all the subsequent carriers would become fully 
oxidized. As a result, ATP production would be inhibited from the ubiquinone stage of the 
electron transport chain. Since sodium azide blocks the transport chain at a later stage and 
only the oxidation of cytochrome C by oxygen is affected, therefore only one stage of ATP 
production is inhibited. This would therefore imply that whilst sodium azide does block 
ATP production, it is not as effective as antimycin A. Consequently, this study has found 
that sodium azide may not deplete cellular ATP levels within the limited time period studied 
and thus the P-glycoprotein may have sufficient energy supply to actively pump the drug 
from  the cells. Inhibition of glycolysis may also be ineffective at depleting the cellular 
levels of ATP and may therefore be ineffective at inhibiting P-glycoprotein. Although 
glycolysis may be inhibited, other metabolic pathways including amino acid breakdown, 
lipid metabolism and protein metabolism, would still be functional and could ultimately feed 







































Figure 4.6.1 The sites of electron transfer that form NADH and FADH 2 in glycolysis and the 
citric acid cycles
256










Figure 4.6.2 Stages in cell respiration. Stage i: mobilisation of acetyl-CoA from glucose, fatty 
acids and some amino acids, Stage 2: the citric acid cycle and Stage 3: electron transport and 
oxidative phosphorylation
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The efflux of adriamycin and vincristine from the parental DLKP and the resistant 
DLKPA10 cells was studied, following preloading of the cells in the presence of antimycin 
A, since this agent was found to fully restore drug accumulation in the DLKPA10 cells. 
W hen the cells were reintroduced into glucose containing medium, rapid drug efflux was 
observed in both cell lines, which again suggested the presence of an active efflux 
mechanism. Cyclosporin A was demonstrated to significantly decrease adriamycin and 
vincristine efflux in the DLKPA10 cell line, which was consistent with other published 
reports which suggested that cyclosporin A inhibits drug efflux by binding to the P- 
glycoprotein molecule. M eador et al. (1987) reported a decrease in daunorubicin efflux in 
Ehrlich carcinoma cells and also in hepatoma 129 cells, following treatment with 
cyclosporin A. Studies by Sebille and coworkers (1994) also demonstrated a decrease in 
THP-adriamycin efflux in M DR K562 cells in the presence of cyclosporin A. Verapamil 
has also been reported to inhibit drug efflux in M DR cell lines, although generally it has 
been shown to be less effective than cyclosporin A (Tsuruo et al., 1981; Klohs et al., 1988; 
Boesch et al., 1994; Gruol et al., 1994; Julia et al., 1994). Cyclosporin A did not 
significantly alter adriamycin efflux in the DLKP parental cells indicating a cyclosporin A 
independent efflux mechanism. There was also no significant alteration in vincristine efflux 
in the parental cells following treatment with cyclosporin within the first 60 minutes, 
however a slight increase in efflux was observed after this time.
Another agent which has been shown to increase cellular levels of drug in MDR cell line 
is the carboxylic ionophore, monensin. Studies were carried out to investigate the effect 
of monensin on drug accumulation and efflux in the DLKP and DLKPA10 cell lines. 
Several reports have shown that ionophores increase the cytotoxicity of anticancer agents 
in M DR cells by selectively increasing the cellular accumulation of the drug. The 
ionophores, monensin and nigericin, have been demonstrated to increase daunorubicin 
accumulation in daunorubicin resistant Ehrlich ascites tumour cells (EH R 2/D N R +) in a 
dose dependent manner, while having only a negligible effect on daunorubicin accumulation 
in the wild type cells (Sehested et al., 1988). Studies by Klohs and Steinkampf (1988) 
revealed that increased adriamycin accumulation was observed in the adriamycin resistant 
m urine leukaemia cell line, P388, following treatment with both monensin and nigericin. 
The increase was shown to be associated with inhibition of drug efflux which resulted in 
increased cellular retention of the drug. Increased adriamycin accumulation was also 
observed in the human KB/MDR cells when exposed to monensin. However, monensin did
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not significantly alter cellular levels of the drug in the parental KB cells (Ling et al., 1993). 
The exact mechanism by which monensin and other ionophores increase the cellular 
accumulation of anticancer agents is as yet unknown. However, studies have suggested that 
these agents act by inhibiting the P-glycoprotein mediated efflux of the drug, thus increasing 
the cellular drug levels. A number of laboratories have examined the possible involvement 
of P-glycoprotein in ionophore induced drug accumulation in MDR cell lines. The 
interaction of various ionophore antibiotics with P-glycoprotein has been investigated by 
Naito et al. (1991). The results obtained indicated that a number of ionophores, including 
monensin, nigericin and valinomycin inhibited the binding of radiolabelled vincristine to the 
plasma membrane isolated from resistant K562 cells. The studies also showed that these 
agents reduced the photoaffinity labelling of P-glycoprotein by azidopine, thus suggesting 
competitive binding of the ionophores to the P-glycoprotein binding sites. Further evidence 
supporting the involvement o f P-glycoprotein was obtained from studies by Borrel et al.
(1994), which demonstrated that monensin and nigericin inhibited the P-glycoprotein 
mediated efflux of tetrahydrophranyl-adriamycin (THP-adriamycin) in resistant K562 cells.
In our studies, monensin also proved to be an effective agent at enhancing adriamycin 
accumulation in the resistant DLKPA10 cells, while only having a negligible effect on drug 
accumulation in the parental DLKP cells. A marked increase in the cellular concentration 
of adriamycin was observed in the DLKPA10 cells, although the maximum level was 
significantly less than that observed in the parental cells. Pretreatment with monensin was 
found to result in a greater enhancement of drug accumulation in the resistant cells, 
although complete restoration of drug levels was not observed. An increase in vincristine 
accumulation was also noted in the DLKPA10 cells, following treatment with monensin 
although the results obtained would suggest that it was much less effective at enhancing 
vincristine accumulation than adriamycin accumulation. These findings tend to confirm 
results obtained from monensin toxicity studies. The effect o f monensin on the cytotoxicity 
of a number of anticancer agents was investigated in the DLKPA10 cell line, the results 
showing that, although monensin increased the cytotoxicity o f adriamycin and VP16 it did 
not significantly alter the toxicity profile of vincristine in the cells. The cause of this 
apparent drug specific effect is unknown, although, since both adriamycin and VP16 are 
topoisomerase II inhibitors, the specific effect of monensin may be related to topoisomerase 
inhibition. Alternatively, since vincristine has a higher molecular weight and a more 
complex structure than either adriamycin or VP16, it may be possible that monensin does
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not interact with vincristine. Monensin was also found to decrease drug efflux in the 
DLKPA10 cells, following preloading of the cells. A marked inhibition of adriamycin 
efflux was observed when the cells were exposed to monensin, which was consistent with 
reports published previously. Although treatment with monensin also resulted in a decrease 
in vincristine efflux, its effect was not as great as that observed with adriamycin efflux. 
The results obtained from the monensin studies could suggest that the increase in the 
cellular accumulation of the drug was attributable to the P-glycoprotein efflux pump, since 
inhibition o f the pump would inhibit drug efflux and thus increase cellular levels o f the 
drug. However, monensin may also increase drug accumulation by an alternative 
mechanism since studies have shown that monensin is also effective at altering cellular drug 
accumulation in non-P-glycoprotein M DR cell lines (Marquardt and Center, 1992).
Overall, the results obtained indicated that monensin was more effective than cyclosporin 
A at enhancing drug accumulation and decreasing drug efflux, which suggests that in 
addition to interacting with P-glycoprotein present in the DLKPA10 cells, monensin may 
also act through another mechanism, unaffected by cyclosporin A. The observation that 
monensin had only negligible effect on the parental cells, while cyclosporin A increased 
drug accumulation in these cells, further supports the involvement of a non-P-glycoprotein 
mechanism. Combination treatment with monensin and cyclosporin A proved to be more 
effective at increasing adriamycin accumulation in the DLKPA10 cells than treatment with 
either monensin or cyclosporin A alone. This observation could suggest that these agents 
have different mechanisms of action. It has been proposed that, in addition to the P- 
glycoprotein mediated drug efflux mechanism, an alternative transport system, referred to 
as acidic vesicular trafficking system, may be involved in mediating resistance in MDR cell 
lines. Reports have indicated that the M DR phenotype may in some way be related to an 
increase in plasma membrane traffic which would result in increased drug efflux in resistant 
cells (White and Hines, 1984; Sehested et al., 1988; Ling et al., 1993). Endosomal drug 
trapping, followed by vesicular extrusion to the extracellular medium, has been suggested 
as a possible mechanism for such cellular drug resistance. Studies have shown that 
monensin and other ionophores can disrupt acidic vesicular traffic by increasing the pH 
environment of the membrane lumen (Tarkakoff, 1987; Molleuhauer et al., 1990). It is 
therefore possible that monensin increases drug accumulation in the DLKPA10 cells by a 
combination of P-glycoprotein inhibition and disruption of acidic vesicular traffic.
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The results obtained, thus far, from studies on the DLKPAIO cell line would suggest that, 
although the cells are cross resistant to the classical M DR drugs and overexpress P- 
glycoprotein, other resistance mediating mechanisms must also be involved to account for 
the cyclosporin A/verapamil independent accumulation defect in the cells. Further studies 
were carried out in an attempt to determine these additional mechanism(s). A number of 
drug selected cell lines have been reported to exhibit the MDR phenotype without the 
overexpression of P-glycoprotein and are termed non-P-glycoprotein MDR (McGrath et al., 
1989; Kuiper et al., 1990; Coley et al., 1991). To date, at least two drug resistance 
mechanisms have been detected in non-P-glycoprotein MDR. The first mechanism involves 
an alteration in topoisomerase II activity, while the second mechanism relates to a decreased 
cellular drug concentration at the target due to a decreased accumulation of the drug and/or 
altered distribution of the drug (Center, 1993). In several of the non-P-glycoprotein M DR 
cell lines, drug accumulation was shown to be decreased due to an enhanced drug efflux 
(Slovak et al., 1988; Marquardt et al., 1990; Coley et al., 1991; Versantvoort et al.,
1992). This enhanced efflux was blocked when cellular ATP synthesis was completely 
inhibited by metabolic inhibitors, indicating the presence of active drug transport in non-P- 
glycoprotein M DR cell lines. Since the DLKPAIO was found to possess an active non-P- 
glycoprotein drug efflux mechanism the possible involvement of an alternative transporter 
protein in drug efflux was investigated in the cells.
Studies were carried out to investigate the role of MRP in mediating drug resistance in the 
DLKPAIO cells. The MDR-associated protein (MRP) gene has recently been cloned and 
reports have suggested that the gene is likely to encode a drug transport protein in many 
non-P-glycoprotein cell lines (Cole et al., 1992). Transfection of the MRP gene has been 
shown to confer the M DR phenotype in drug sensitive HeLa cells, without P-glycoprotein 
overexpression (Grant et al., 1994). These MRP transfections were also shown to 
overexpress a 190 kDa membrane protein, which is known to be overexpressed in a number 
of other non-P-glycoprotein M DR cell lines, including the HL60/ADR, GLC4/ADR and 
COR-L23/R cell lines (Barrand et al., 1993; Zaman et al., 1933; Krishnamachary and 
Center, 1994). These cell lines have the common characteristic of decreased drug 
accumulation. Studies have demonstrated that decreased daunorubicin accumulation in cell 
lines overexpressing the 190 kDa protein could be reversed by the isoflavonoid genistein, 
a tyrosine kinase inhibitor (Akiyama et al., 1987). It was also illustrated that genistein did 
not significantly alter drug accumulation in P-glycoprotein MDR cell lines (Versantvoort
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et a l., 1993). Since genistein appears to have a differential effect in non-P-glycoprotein cell 
lines, it has been selected as a probe for non-P-glycoprotein mediated MDR cell lines. 
Versantvoort et al. (1994) studied the effect o f genistein on daunorubicin accumulation in 
the GLC4/ADR M DR cell line. This cell line had been shown to overexpress the MRP 
gene, which was likely to be the gene encoding the drug transporter present in the cells. 
Genistein was found to inhibit the enhanced efflux of daunorubicin in the GLC4/ADR cells, 
suggesting that the agent was a competitive inhibitor of daunorubicin transport possibly by 
interacting with the drug transport protein. Although the exact mechanism of action of 
genistein is unknown, it is unlikely that a tyrosine kinase step is involved (Versantvoort et 
al., 1993). Studies were carried out to investigate the effect of genistein on adriamycin 
accumulation in the DLKP and DLKPA10 cell lines. However, the results did not illustrate 
a significant alteration in drug accumulation in either the parental or resistant cells following 
treatment with genistein. This would suggest that the DLKPA10 cells do not overexpress 
the transporter protein that is present in a number of MRP positive cell lines. Since it is 
generally accepted that the M RP gene encodes the transport protein in these cell lines, the 
results would seem to imply that MRP is not involved in mediating the non-P-glycoprotein 
resistance in the DLKPA10 cells. Further evidence to support the non-involvement of MRP 
was obtained from immunocytochemical analysis and drug distribution studies, which 
showed no overexpression of the protein in the DLKPA10 cell line and no alteration in the 
cellular localisation of adriamycin respectively.
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4.6.1 Drug accumulation studies in the DLKPA clones
A number of clones were isolated from the adriamycin resistant cell line, DLKP-A, and 
were shown to display varying resistance to the drug (M Heenan, PhD thesis). A total of 
nine clones were isolated, four of which were selected for drug accumulation studies to 
establish if any of the clones showed similar accumulation patterns to the DLKPA10 cell 
line. Adriamycin accumulation studies revealed a significant difference in the cellular 
concentration of the drug in each of the clones. The DLKPA 2B cells accumulated the 
highest level o f adriamycin, while the lowest level o f adriamycin accumulation was noted 
in the DLKPA 5F cells. An intermediate level of accumulation was observed in the 
DLKPA 6B and DLKPA 11B cells. The level of drug accumulation was shown to be 
inversely related to the level of resistance in each clone. The DLKPA 5F clone exhibited 
the greatest resistance to adriamycin (approximately 330-fold), followed by the DLKPA 6B 
(approximately 95-fold) and DLKPA 11B cells (approximately 86-fold) and finally the 
DLKPA 2B cells which displayed approximately 37-fold resistance to adriamycin. Since 
the clones were also found to exhibit cross resistance to the MDR drugs, vincristine and 
VP 16 (M Heenan, PhD thesis), the results would therefore suggest that the accumulation 
defect in the clones was associated with overexpression of the P-glycoprotein efflux pump.
In contrast, further studies revealed that the circumvention agents, verapamil and 
cyclosporin A were ineffective at reversing the accumulation defect in two of the clones, 
indicating that the resistance can not be fully explained by P-glycoprotein overexpression. 
Treatment with verapamil resulted in restoration of adriamycin accumulation in the DLKPA 
2B and DLKPA 5F clones to levels comparable to the parental DLKP cells. Similar results 
were obtained following treatment with cyclosporin A, suggesting that the reduction in drug 
accumulation in these clones was associated with P-glycoprotein overexpression. Both 
agents also enhanced adriamycin accumulation in the DLKPA 6B and DLKPA 11B cells, 
although only to a maximum of approximately 70% of the level observed in the parental 
cells. These findings suggested that, while P-glycoprotein appears to play a major role in 
mediating resistance in the DLKPA 6B and DLKPA 11B cells, other mechanisms must also 
be involved to account for the cyclosporin A/verapamil independent accumulation defect 
observed in the cells. The accumulation studies in the DLKPA 6B and DLKPA 1 IB cells 
revealed similar patterns to that observed in the DLKPA 10 cells which could suggest that 
the DLKPA10 cells were selected out from the DLKPA 6B/DLKPA 11B population. 
However, further studies need to be carried out to confirm this.
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4.7 Adriamycin localisation studies in DLKP and DLKPA10 cells
Detailed studies were carried out to investigate the distribution of adriamycin in the resistant 
DLKPA10 cells to determine if, in addition to a reduction in drug accumulation the cells 
also exhibited altered distribution of the drug. Initial fluorescence microscopy studies 
revealed that adriamycin was localised predominantly in the nucleus of the parental DLKP 
cells, following a two hour exposure to the drug. However, the DLKPA10 resistant cells 
displayed an intracellular localisation of the anticancer agent which was notably different 
from the parental cells. W hen the DLKPA10 cells were exposed to the drug for the same 
time period, faint nuclear fluorescence was observed in a small proportion of the cells, with 
the majority of the cells showing only cytoplasmic fluorescence. These results were 
therefore consistent with several reports that had demonstrated altered drug distribution 
patterns in M DR cell lines (Chauffert et al., 1984; Willingham et al., 1986; Hindenburg 
et al., 1987; Gervasoni et al., 1991; Schuurhuis et al., 1991; Coley et al., 1993). Drug 
distribution was also studied in the DLKPA10 cells, following exposure of the cells to a 
higher concentration of the drug. Although a marked increase in cytoplasmic fluorescence 
was observed in the cells, no corresponding increase in nuclear fluorescence was noted. 
Similar results were obtained when the cells were exposed to the drug for longer incubation 
periods, thus eliminating the possibility that nuclear drug exclusion was due to either time 
restraints or concentration effects. Adriamycin fluorescence appeared to be localised in 
distinct regions within the cytoplasm, which were more evident when the cells were exposed 
to high concentrations of the drug. Regions of very intense fluorescence were also visible 
in the perinuclear region following longer drug exposure times.
Confocal laser scanning microscopy studies were also performed to verify the results 
obtained through fluorescence microscopy. Similar to the observations in the SKMES-1 and 
SKMES-1/ADR cell lines, the resolution of the fluorescence images was greatly improved. 
Subsequently the exact localisation of adriamycin could be determined. As expected, 
adriamycin was shown to be localised within distinct regions of the nucleus in the parental 
DLKP cells, confirming the interaction of adriamycin with chromosomal DNA. 
Adriamycin appeared to be exclusively located within the cytoplasm of the DLKPA10 
resistant cells. Distinct regions of adriamycin fluorescence were clearly visible within the 
cytoplasm, particularly in regions close to the nucleus. In addition, intense adriamycin 
fluorescence was visible at the nuclear envelope.
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Studies were also carried out to determine if nuclear drug exclusion observed in the 
DLKPA10 cells, was a consequence of reduced cellular drug concentration in these cells. 
Quantitative drug accumulation studies revealed that the cellular concentration of adriamycin 
in the DLKPA10 cells, after four hour exposure to the drug was equivalent to the 
concentration of drug in the parental DLKP cells after exposure for just five minutes. 
Subsequently, adriamycin distribution was studied in the DLKP and DLKPA10 cells, 
following incubation periods of five minutes and four hours respectively. The results 
however, illustrated that despite equivalent intracellular concentrations, different distribution 
patterns were observed in the cell lines. Faint nuclear fluorescence was detected in the 
parental DLKP cells, while intense cytoplasmic fluorescence was clearly visible in the 
resistant cells. These findings suggest that the reduced intracellular levels of the drug were 
not principally responsible for the decrease in nuclear fluorescence and that alternative 
mechanisms are involved in nuclear drug exclusion in the DLKPA10 cells.
In order to determine if the altered drug distribution pattern in the DLKPA10 cells was 
associated with P-glycoprotein overexpression, the effect of a number of P-glycoprotein 
inhibitors on the subcellular localisation of adriamycin was investigated. Verapamil and 
cyclosporin A were both shown to enhance nuclear fluorescence in the resistant cells, 
although the intensity o f nuclear fluorescence was less than that observed in the parental 
DLKP cells. Both agents were also found to increase nuclear fluorescence in the parental 
cells. Results obtained from confocal laser microscopy studies demonstrated that, although 
cyclosporin A increased nuclear fluorescence in the DLKPA10 cells, distinct regions of 
fluorescence were still clearly visible in the cytoplasm, indicating partial restoration of 
nuclear fluorescence in the resistant cells. These findings suggested that, while P- 
glycoprotein was probably associated with altered drug distribution in the DLKPA10 cells, 
other non-P-glycoprotein mechanisms must also play a role, to fully explain the decrease 
in adriamycin nuclear fluorescence. A number of studies have shown that verapamil and 
cyclosporin A do not significantly alter drug distribution in non-P-glycoprotein M DR cell 
lines. In a study by Barrand et al. (1993) daunorubicin was shown to be confined to 
cytoplasmic perinuclear regions in the non-P-glycoprotein resistant human lung cell line, 
COR-L23/R. The addition of cyclosporin A resulted in only a slight increase in 
cytoplasmic fluorescence but had no effect on nuclear fluorescence while treatment with 
verapamil resulted in a slight increase in both cytoplasmic and nuclear fluorescence. 
Verapamil was also shown to more effectively modulate adriamycin nuclear fluorescence
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in P-glycoprotein positive resistant variants o f the human non-small cell lung cancer cell 
line, SW1573, than in non-P-glycoprotein resistant variants (Schuurhuis et al., 1991).
The effect of the calmodulin inhibitor, trifluoroperazine, on the subcellular distribution of 
adriamycin was also investigated in the DLKPA10 cells, since studies have shown that 
calmodulin inhibitors can increase anthracycline retention in MDR cells. Calmodulin is a 
Ca2+ binding protein that participates in numerous Ca2+ regulatory processes. It has four 
high affinity Ca2+ binding sites, two on each of its globular domains. The binding of Ca2+ 
to any of these four binding sites triggers a large conformational change in that domain, 
which is thought to expose a nonpolar surface. The hydrophobic interactions of 
calmodulin's target proteins with one or both of these nonpolar surfaces is believed to 
mediate calmodulin's Ca2+dependent regulatory processes. Several reports have 
demonstrated modulation of the cytotoxicity of anthracyclines and vinca alkaloids by 
calmodulin inhibitors. Reduction in cytotoxicity was shown to be associated with enhanced 
drug accumulation and cellular retention levels (Tsuruo et al., 1982; Ganapathi and 
Grabowski, 1983; Ganapathi and Grabowski, 1988). The exact mechanism by which 
calmodulin inhibitors act is unknown, although it has been suggested that enhanced drug 
accumulation may be due to the membrane perturbing effect of these calcium modifiers. 
Ca2+-calmodulin activates the Ca2+-ATPase of the plasma membrane, which regulates the 
cellular concentration of Ca2+. Inhibition of the Ca2+-ATPase would subsequently lead to 
alterations in the cellular levels of calcium, which may also play a role in modulating drug 
resistance. Our studies, however, showed no significant alteration in the subcellular 
distribution or retention of adriamycin in the DLKPA10 cells, thus implying that Ca2+ 
calmodulin complexes do not play a major role in drug distribution in this resistant cell line.
Adriamycin distribution was also investigated in the DLKP and DLKPA10 cells, following 
treatment with the metabolic inhibitors, sodium azide, 2-deoxyglucose and antimycin A, to 
determine if inhibition of ATP production could restore nuclear adriamycin levels in the 
DLKPA10 cells. Initial findings revealed that both sodium azide and 2-deoxyglucose had 
a toxic effect on the parental cells causing cell lysis in a large percentage of the cells. 
However, neither compound appeared to be toxic to the resistant cells within the time 
period studied. These results suggested that the DLKP cells were more susceptible than the 
DLKPA10 cells to metabolic inhibition. It could be possible that greater levels o f ATP are
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produced in the resistant cells, associated with the presence of the energy dependent P- 
glycoprotein pump. Since cellular ATP levels would therefore be lower in the sensitive 
cells, depletion of ATP levels would occur more rapidly in these cells, resulting in cell 
lysis. It has been reported that human breast cancer cells (MCF-7) with acquired resistance 
to adriamycin exhibit an enhanced glycolysis rate (approximately 3-fold) when compared 
to their parental cells, confirming the occurrence of some modification in their energy 
metabolism, following the onset of the resistant phenotype (Cohen and Lyon, 1987). More 
recent studies have also demonstrated alterations in glucose metabolism in drug resistant 
LoVo cells. A significant increase in the oxidative pathway of glucose metabolism as well 
as in acetyl-CoA production was observed in adriamycin resistant LoVo cells. The number 
of glucose carbon atoms metabolised in the resistant cells, through the pentose phosphate 
pathway, was also significantly higher than in adriamycin sensitive cells (Fanciulli et al.,
1993). These findings could therefore suggest a modified glucose metabolism in the 
DLKPA10 cells, however each resistant cell line might develop its own metabolic alterations 
so further studies need to be carried out to determine if increased metabolism is a 
characteristic of the DLKPA10 cell line.
Fluorescence microscopy studies demonstrated intense adriamycin nuclear fluorescence in 
viable DLKP cells, following exposure to each of the three inhibitors. W hile the 
fluorescence intensity appeared similar in sodium azide and 2-deoxyglucose treated cells and 
was comparable to levels observed in cells exposed only to the drug, nuclear fluorescence 
in antimycin A treated cells was greater than in cells treated with the drug alone. These 
findings were consistent with the results obtained from the quantitative adriamycin 
accumulation studies, where antimycin A was shown to significantly increase adriamycin 
accumulation in the DLKP parental cells. W hen the DLKPA10 cells were exposed to 
adriamycin in the presence of sodium azide and 2-deoxy-glucose, an increase in cytoplasmic 
fluorescence was observed, although no corresponding increase in nuclear fluorescence was 
noted. Adriamycin appeared to be localised in distinct areas within the cytoplasm, in 
particular in the perinuclear region of the cells. These results were unexpected, since 
several studies had reported that treatment with these agents resulted in redistribution of 
drug, from the cytoplasmic regions to the nucleus, in a number of M DR cell lines 
(Chauffert et al., 1984; W illingham et al., 1986; Maymon et al., 1994). Pretreatment of 
the DLKPA10 cells with the inhibitors did, however, result in an enhancement of 
adriamycin nuclear fluorescence. Although a marked increase in nuclear fluorescence was
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observed, the intensity was less than that noted in the parental cells. A decrease in 
cytoplasmic fluorescence was also observed, probably due to the redistribution of the drug 
to the nucleus. W hile it would appear from these observations that pretreatment with the 
inhibitor is necessary to alter the subcellular distribution of adriamycin in the resistant cells, 
further work showed that cotreatment with antimycin A effectively restored nuclear levels 
of adriamycin in the DLKPA10 cells. Intense nuclear fluorescence was clearly visible in 
all cells viewed and the fluorescence intensity appeared to be greater than that observed in 
the parental DLKP cells. These findings confirm results obtained from quantitative studies, 
where it was found that antimycin A was more effective than either sodium azide of 2- 
deoxyglucose at increasing adriamycin concentrations in the DLKPA10 cells. Antimycin 
A completely reversed the accumulation defect, while sodium azide and 2-deoxyglucose 
only partially restored drug accumulation in the resistant cells. These results therefore 
reiterate that treatment with sodium azide and 2-deoxyglucose does not completely deplete 
ATP stores in the DLKPA10 cells and that consequently there may be sufficient ATP 
available to drive the P-glycoprotein efflux pump. In contrast, antimycin A appears to 
effectively deplete ATP levels thus inhibiting P-glycoprotein mediated drug efflux.
Additional studies were carried out to investigate the effect of antimycin A on adriamycin 
pretreated DLKPA10 cells. Following preloading, distinct regions of intense cytoplasmic 
fluorescence were clearly visible in the cells, particularly in areas close to the nucleus. 
W hen the cells were treated with antimycin A, a marked increase in nuclear fluorescence 
was observed in the majority of cells viewed. A significant decrease in cytoplasmic 
fluorescence was also noted following exposure to antimycin A, demonstrating the 
redistribution of drug from the cytoplasmic vesicles to the nucleus. These findings suggest 
that antimycin A can in some way disrupt the cytoplasmic vesicles and thus prevent the 
localisation of drug within the cytoplasm. Since depletion of ATP levels would also inhibit 
P-glycoprotein mediated drug efflux, adriamycin would be redistributed to the nucleus. The 
mechanism by which antimycin A can apparently disrupt cytoplasmic vesicles is unclear, 
although it is possible that it could be due to pH alterations within the cells, since it was 
noted that the addition o f antimycin A caused an increase in the pH of the culture medium. 
Studies have shown that shifts in intracellular pH leads to alterations in drug accumulation 
and distribution in M DR cells (Simon et al., 1994), although further work needs to be 
carried out to determine if antimycin A induced drug redistribution is due to pH alterations 
in the DLKPA10 cells.
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A number of reports have also demonstrated that ionophores, including monensin and 
nigericin can reduce the cytotoxicity of anthracyclines in MDR cell lines by increasing the 
cellular accumulation and altering the subcellular distribution of the drug. Ionophores are 
a heterogenous group of antibiotics capable of altering the membrane permeability of small 
inorganic ions. There are two basic types of ionophores; channel forming and carrier 
ionophores (Figure 4.7.1). Channel forming ionophores {e.g. gramicidin) form trans 
membrane channels or pores through which their selected ions can diffuse. Carrier 
ionophores can in turn be divided into two groups: those such as valinomycin and nonactin 
which transport cations as lipid-soluble charged complexes and those such as nigericin and 
monensin (figure 4.7.2), which contain a charged carboxyl group and transport cations as 
lipid-soluble, electrically neutral complexes. In our studies both monensin and nigericin 
were shown to enhance nuclear fluorescence in the DLKPA10 cells. Similar to observations 
with cyclosporin A and verapamil treatment, the intensity was not as great as that observed 
in the parental DLKP cells, although monensin did appear to be more effective at increasing 
nuclear accumulation of the drug. Regions of cytoplasmic fluorescence were also visible, 
although the intensity and quantity of the vesicles detected appeared less than that noted 
when the cells were exposed only to adrimaycin.
Considerable confusion exists regarding the exact mechanism(s) by which ionophores bring 
about their effect in resistant cells. A number of studies have shown that ionophores act 
by inhibiting the P-glycoprotein mediated efflux of anthracyclines and thereby increasing 
cellular levels of the drug. Naito et al. (1991) reported that a number of ionophores, 
including monensin and nigericin, inhibited the binding of vincristine to the plasma 
membrane of resistant K562 cells. They also showed that photoaffinity labelling of P- 
glycoprotein by azidopine was markedly reduced in the presence of the ionophores. In 
studies by Borrel et al. (1994) THP-adriamycin accumulation was found to be enhanced in 
resistant cells, following treatment with monensin. This effect was caused by inhibition of 
the P-glycoprotein mediated efflux of THP-adriamycin. Inhibition of P-glycoprotein by 
monensin could also contribute to the increase in nuclear fluorescence in the resistant 
DLKPA10 cells. However, since monensin proved to be more effective than cyclosporin 
A at enhancing nuclear adriamycin accumulation, it would appear that monensin also exerts 
its effect in the DLKPA10 cells by a non-P-glycoprotein mechanism. It has also been 
proposed that ionophores can alter drug distribution in MDR cells by disrupting intracellular 
vesicular traffic. The involvement of an acidic vesicular traffic transport system in MDR
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cell lines was described independently by Sehested et al. (1987a) and Beck et al. (1987), 
who suggested that the lysosomal system in M DR cells was involved in drug efflux and that 
drugs such as adriamycin and vinblastine, which are weak bases, could become trapped in 
these acidic compartments by protonation. According to this proposal, these lysosomal 
vesicles then migrate to the plasma membrane where they fuse and extrude their contents 
to the outside. Evidence supporting the involvement o f acidic vesicular traffic has been 
obtained from a number of studies, which have shown that agents which are known to 
interact with acidic compartments could potentiate the cytotoxicity of anticancer agents 
and/or inhibit anthracyclines efflux (Klohs and Steinkampt, 1988; Sehested et al., 1988; 
M arquardt and Center, 1992). Reports have also demonstrated an increase in plasma 
membrane traffic (endo/exocytosis) in MDR cell lines which could be attributed to the 
acidic vesicular traffic transport system in the cells. Sehested et al. (1987a) reported a 
significant increase in plasma membrane traffic in four Ehrlich ascites tumour cell lines 
resistant to daunorubicin, adriamycin, vincristine and vinblastine respectively. Further 
studies also demonstrated an increase in plasma membrane traffic in daunorubicin resistant 
P388 leukaemia cells (Sehested et al., 1987b).
The mechanism by which ionophores disrupt intracellular vesicular traffic is unclear, 
although it is generally believed that these agents act by abolishing the Na+K + gradient, 
which would lead to an increase in the pH environment in the membrane lumen and 
subsequent disruption of the acidic vesicles. The majority of studies to date have used 
either monensin or nigericin to investigate the effect of ionophores on acidic vesicles. It 
has been proposed that these agents insert into membranes and facilitate the exchange of 
N a+ or K + ions for protons. (Monensin has been shown to have a greater affinity for N a+ 
while nigericin has a greater affinity for K +). The loss of protons would subsequently 
result in an increase in the intracellular pH environment, disruption of the acidic 
compartments and a decrease in drug efflux. The subcellular adriamycin distribution pattern 
observed in the DLKPA10 cells could also implicate the involvement of an acidic vesicular 
traffic transport system in the resistant cells. Confocal laser microscopy studies clearly 
demonstrated the presence of fluorescent vesicles within the cytoplasm which is consistent 
with the localisation of drug within cytoplasmic acidic vesicles. Since both monensin and 
nigericin enhanced adriamycin nuclear fluorescence and decreased the quantity of 
cytoplasmic vesicles in the DLKPA10 cells, it is possible that these agents disrupted acidic 
vesicular traffic and thus inhibited drug efflux.
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It has been suggested that the cytotoxic actions of drugs, such as monensin and nigericin 
may be due to a decrease in cellular ATP levels (Rotin et a l., 1987; Mariani et al., 1989). 
Reduced cellular ATP levels could ultimately affect the subcellular localisation of 
anthracyclines in a number of ways. Depletion of ATP levels would result in inhibition of 
the P-glycoprotein efflux pump, thus increasing the cellular concentration of the drug. 
Alternatively, studies have shown that vacuolar ATPases are involved in driving the uptake 
of drug into constituted organelles. Moriyama et al. (1993) demonstrated the uptake of 
radiolabelled daunorubicin in acidic vesicles, that were reconstituted with purified F-type 
H +-ATPase, upon addition o f ATP. Further studies showed that the accumulation of both 
adriamycin and daunorubicin in acidic organelles of cultured BNL C L.2 cells was decreased 
by inhibiting vacuolar ATPase, thus indicating energy dependent uptake. If this system was 
representative of the uptake of anticancer agents in M DR cells, depletion of ATP levels 
would subsequently inhibit the uptake of drug into cytoplasmic vesicles. These findings 
suggest that depletion o f ATP levels by monensin may increase nuclear fluorescence in a 
number of ways. However, it is unlikely that monensin alters the subcellular localisation 
o f adriamycin in the DLKPA10 by inhibition of vacuolar ATPases. Treatment of these cells 
with the vacuolar ATPase inhibitor, bafilomycin A l, did not significantly alter adriamycin 
distribution in these cells. Although a number of studies have demonstrated altered 
intracellular distribution of anthracyclines following treatment with bafilomycin A l 
(Marquardt and Center, 1991; Rhodes et al., 1994), it did not appear to significantly affect 
the localisation of adriamycin within cytoplasmic vesicles in the DLKPA10 cells.
It seems clear from these findings that monensin may alter the subcellular distribution of 
adriamycin in the DLKPA10 cells by a number of mechanisms. It is possible that it acts 
by P-glycoprotein inhibition, although other non-P-glycoprotein mechanisms must also be 
involved to account for the observation that monensin was more effective than the P- 
glycoprotein inhibitor, cyclosporin A, at enhancing nuclear fluorescence. The results 
obtained from the microscopy studies confirm the findings from the quantitative 
accumulation studies, where it was found that pretreatment with monensin almost restored 
adriamycin accumulation in the DLKPA10 cells to the level observed in the parental cells. 
These results would therefore suggest that, in addition to P-glycoprotein inhibition, 
monensin acts by disrupting acidic vesicular traffic within the cells. However, further 
studies need to be carried out to identify the mechanisms by which monensin and nigericin 
can increase drug accumulation in the DLKPA10 cell line.
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(a) Carrier ionophore (b) Channel-forming ionophore
Figure 4.7.1 The ion transport modes of ionophores: (a) carrier ionophores transport ions by 
diffusing through the lipid bilayer, (b) Channel-forming ionophores span the membrane with a 
channel through which ions can diffuse
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Figure 4.7.2 Structure of the ionophore monensin
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The detection of the cytoplasmic vesicles in the DLKPA10 cells prompted a number of 
studies to determine if adriamycin was actually localised within cellular organelles (e.g. 
lysosomes or Golgi apparatus). A number of intracellular sites have been postulated for 
adriamycin localisation in M DR cell lines. Since reports had shown that lysosomal 
inhibitors could cause redistribution o f anthracyclines in MDR cells, the role o f lysosomes 
in mediating resistance in the DLKPA10 cells was investigated. Lysosomes are membrane- 
encapsulated organelles that contain approximately fifty hydrolytic enzymes, including a 
variety of proteases known as cathepsins. The function of lysosomes is to digest materials 
ingested by endocytosis and to recycle cellular components. The lysosome maintains an 
internal pH of approximately 5 and the enzymes have acidic pH optima. Lysosomes recycle 
intracellular constituents by fusing with membrane enclosed regions of cytoplasm, known 
as autophagic vacuoles, subsequently breaking down their content. They similarly degrade 
substances taken up by the cells through endocytosis. Since the lysosomes are acidic 
organelles, it is possible that weak bases such as adriamycin and the vinca alkaloids could 
become localised within these compartments.
To determine if adriamycin was localised within lysosomes in the DLKPA10 cells, the 
effect o f lysosotropic inhibitors, chloroquine and methylamine, on the subcellular 
distribution of the drug was investigated. These agents, both of which are weak bases, 
freely penetrate the lysosomes in uncharged form. However, they accumulate in a charged 
form, thereby increasing the intralysosomal pH and inhibiting lysosomal function. 
Lysosotropic agents strongly prefer to stay in aqueous phases, thus phospholipid membranes 
become a barrier to any incoming substances (Ohkuma and Poole, 1978; Poole and 
Ohkuma, 1981). Early studies showed that lysosotropic agents, including chloroquine and 
methylamine, along with other agents known to interact with lysosomes, could reverse drug 
resistance to the anthracyclines and vinca alkaloids in MDR cells (Shiraishi et al., 1986a; 
Zam ora and Beck, 1986). These studies also demonstrated an increase in drug 
accumulation together with a reduction in drug efflux in the resistant cells following 
treatment with these agents. Klohs and Steinkampf (1988) also reported increased drug 
accumulation in P388R cells, following treatment with a number of agents known to interact 
with lysosomes. Recent studies by Dubowchik et al. (1994) showed that a number of 
lipophilic nitrogenous bases exhibited potent reversal of adriamycin resistance in the 
HCT116-VM 46 cell line. These agents were also shown to neutralise the activity of 
lysosomes. In our studies, chloroquine and methylamine did not appear to significantly
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the subcellular localisation of adriamycin in the DLKPA10 cells. If  these vesicles were 
being actively transported to the extracellular environment in order to facilitate decreased 
intracellular drug levels, then inhibition of the vesicular traffic by brefeldin A could lead 
to increased intracellular drug levels and subsequent enhancement of cytotoxicity. Brefeldin 
A is a fungal metabolite which has been shown to inhibit the transport o f membrane and 
secretory proteins from the endoplasmic reticulum to the Golgi apparatus in various cell 
types. In addition, brefeldin A has also been found to disrupt the Golgi apparatus by 
disassembly of the cisternal stacks (Fujiwara et al., 1988; Ulmer and Palade, 1989; 
M arquardt and Center, 1992). The mode of action of brefeldin A is unknown, although it 
is thought to affect Golgi specific coat proteins that may be involved in maintaining the 
structural integrity of the organelle and in regulating membrane transport in the secretory 
pathway (Serafmi et al., 1991). Treatment with brefeldin A has been demonstrated to alter 
the subcellular distribution of anthracyclines in the large cell lung carcinoma COR-L23/R 
cell line. Rhodes et al. (1993) reported a redistribution of the drug from the cytoplasm to 
the nucleus following exposure to brefeldin A. The redistribution was accompanied by a 
decrease in perinuclear fluorescence, which suggested that the drug was localised within the 
Golgi apparatus. Quantitative studies showed an increase in the cellular concentration of 
daunorubicin in COR-L23/R cells treated with brefeldin A, indicating a decrease in drug 
efflux. It has been proposed that brefeldin A inhibited the Golgi apparatus membrane 
trafficking system and subsequent drug efflux, resulting in increased accumulation of the 
drug.
Brefeldin A  did not appear to significantly alter the subcellular distribution of adriamycin 
in the DLKPA10 cells within the time period studied. Adriamycin fluorescence was still 
clearly visible within the perinuclear region, although, due to the inherent limitation of the 
microscope any alterations in fluorescence intensity was difficult to determine. Quantitative 
studies revealed that brefeldin A was also ineffective at altering drug accumulation in the 
resistant cells. No significant increase in the cellular concentration of drug was observed 
in the cells when exposed to brefeldin A. Adriamycin accumulation and distribution was 
also studied in the DLKPA10 cells, following pretreatment with brefeldin A. However, the 
results showed that pretreatment did not appear to be any more effective than cotreatment 
at altering drug accumulation and localisation in the resistant cells. The observation that 
brefeldin A  does not appear to effect drug distribution in the DLKPA10 cells suggests that 
the Golgi apparatus membrane trafficking system does not play a major role in drug efflux
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in these cells. It may, however, be possible that the concentration of brefeldin A  was not 
sufficient to actually disrupt the Golgi apparatus. Due to the toxicity of brefeldin A  on the 
DLKPA10 cells, the concentration used in these studies was less than that used in  previous 
reports, although studies have shown that brefeldin A was also ineffective at altering 
daunorubicin distribution in resistant HL60/ADR cells (Marquardt and Center, 1992).
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4.7.1 Adriamycin localisation studies in DLKPA clones
Preliminary studies were also carried out to investigate the subcellular distribution of 
adriamycin in the DLKPA clones. The results obtained clearly indicated different 
adriamycin fluorescence patterns in each of the four clones studied. The level o f nuclear 
fluorescence was found to be inversely related to the resistance levels in the cells. One 
unexpected observation from these studies, however, was that all the clones displayed 
heterogenous fluorescence staining. Nuclear fluorescence was clearly visible in the DLKPA 
2B cells, although the intensity of staining varied within the cell population. While 
approximately 65 % of the cell population displayed intense fluorescence, the remaining cells 
had only faint nuclear fluorescence. A mixed fluorescence pattern was also observed in 
both the DLKPA 6B and DLKPA 11B clones, with approximately 50% and 35% of the 
cells respectively displaying quite intense nuclear fluorescence. Cytoplasmic fluorescence 
was observed in the remaining cells and appeared to be localised in distinct regions. The 
majority of the DLKPA 5F cells displayed only faint nuclear fluorescence but intense 
fluorescence was noted within the cytoplasm, particularly in the perinuclear region. 
Adriamycin localisation in the DLKPA 5F cells was, therefore, similar to observations in 
the DLKPA 10 cells. The addition of verapamil or cyclosporin A was shown to completely 
restore nuclear adriamycin accumulation in the DLKPA 2B and DLKPA 5F clones. Intense 
nuclear fluorescence was observed in both cell variants. While treatment with these agents 
was also found to enhance nuclear levels of the drug in the DLKPA 6B and the DLKPA 
11B, the intensity o f fluorescence was significantly less than that observed in the other two 
clones.
These findings are consistent with the results obtained from quantitative studies, where it 
was shown that both verapamil and cyclosporin A could not restore cellular levels of 
adriamycin in the DLKPA 6B and DLKPA 11B clones. Overall, results obtained from 
adriamycin transport studies on the DLKPA clones suggest that decreased drug 
accumulation and altered intracellular distribution in the DLKPA 2B and DLKPA 5F is due 
to overexpression of P-glycoprotein. In contrast, while P-glycoprotein appears to play a 
m ajor role in mediating resistance in the DLKPA 6B and DLKPA11B clones, further work 
is required to determine alternative mechanism(s) involved in the verapamil/cyclosporin A 
independent accumulation defect observed in these clones.
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4.8 Correlation between drug accumulation and growth inhibition
Although studies have shown a strong correlation between drug accumulation and resistance 
in some M DR cell lines (Pereira and Garnier-Suillerot, 1994), a number of reports have 
also illustrated a discrepancy between the amount of drug accumulated at steady state by 
drug sensitive and highly resistant cells and their degree of resistance to anticancer agents 
(Beck, 1984; Hu and Chen, 1994). These observations could suggest that, either factors 
other than drug accumulation may be involved or that they reflect a discrepancy between 
the short term measurements of drug accumulation and the long term growth inhibition. 
Studies were carried out to establish if drug accumulation correlated with the level of 
adriamycin resistance in the SKMES-1/ADR and DLKPA10 cells. The results obtained 
from studies on the SKMES-1/ADR cells suggested that decreased drug accumulation in this 
cell line was due to P-glycoprotein expression, while results from studies on the DLKPA10 
cells suggested that in addition to overexpression of P-glycoprotein, other mechanisms were 
also involved in reduced drug accumulation. Consequently, if drug accumulation was not 
consistent with the level o f resistance in the SKMES-1/ADR cells, it would reflect a 
discrepancy between short term accumulation studies and long term toxicity studies.
The effect o f verapamil and cyclosporin A on the toxicity of adriamycin was, therefore, 
investigated in the SKMES-1/ADR cells, under similar conditions to those employed in the 
adriamycin accumulation studies. While adriamycin accumulation was measured over a 
period of four hours, growth inhibition was determined after five days. The results 
obtained from these studies were difficult to interpret, since treatment with adriamycin or 
the circumvention agent alone had a toxic effect on the cells. However, a decrease in cell 
viability o f approximately 40% was observed in the SKMES-1/ADR cells following 
exposure with verapamil or cyclosporin A for four hours. Since the accumulation defect 
in these cells was shown to be completely reversed by both verapamil and cyclosporin A, 
lower cell viability was expected. These findings illustrate a discrepancy between short term 
accumulation and long term toxicity in the SKMES-1/ADR cells. Also, another 
inconsistency that was noticed in these studies was that, although cyclosporin A was found 
to be more effective than verapamil at enhancing drug accumulation this was not reflected 
in the toxicity studies, where both agents were found to exert similar toxicity. The results 
obtained from studies on the DLKPA10 cell line illustrated a correlation between drug 
accumulation and drug resistance following treatment with both verapamil and cyclosporin 
A. Both agents were found to partially restore adriamycin accumulation in the resistant
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cells to a level o f approximately 50-60% of that observed in the parental cells. W hen the 
effect o f verapamil and cyclosporin A on adriamycin toxicity was studied under conditions 
similar to the accumulation studies, a decrease in cell viability of approximately 37% and 
47% , respectively was observed. These results are therefore consistent with partial 
restoration of adriamycin accumulation in the DLKPA10 cells. Cyclosporin A proved to 
be more effective than verapamil at inhibiting cell growth, which again was consistent with 
the results obtained from drug accumulation studies. The effect of monensin on adriamycin 
toxicity was also investigated. However, monensin proved to be extremely toxic to the 
DLKPA10 cells in long term growth inhibition assays. Subsequently, it was not possible 
to determine if a correlation existed between drug accumulation and resistance in the 
DLKPA10 cells.
4 .9  Alterations in membrane fluidity in M DR cells
The results obtained from drug transport studies in the DLKPA10 cells suggest that the drug 
accumulation defect in this cell line is predominantly caused by a combination of P- 
glycoprotein overexpression and the existence of an acidic vesicular traffic system. 
However, these mechanisms do not fully account for the accumulation defect observed, 
since the apparent inhibition of both mechanism does not appear to fully restore drug 
accumulation to a level comparable to the parental cells. Consequently, further studies were 
carried out in an attempt to identify an alternative mechanism responsible for decreased 
drug accumulation in the DLKPA10 cells. Several reports have shown that, in addition 
to alteration in membrane proteins, MDR cell lines can also exhibit several other changes 
in membrane properties (Alon et al., 1991). A number of studies have demonstrated that 
lipid structural order is often increased in MDR cells. Ramu et al. (1984) demonstrated 
alterations in the relative amounts of phospholipids in anthracycline resistant variants of the 
murine leukaemia cell line, P388. W hile increased amounts of sphingomyelin and 
triglyceride were detected in the resistant cells, a decrease in phosphatidylcholine levels was 
observed, relative to the sensitive parental cells. Alterations in the level o f phospholipids 
was also reported in the vinblastine resistant human leukaemia CEM cell line. An increase 
in the levels of sphinogomyelin and cardiolipin and a decrease in the levels of 
phosphatidylethanolamine and phosphatidylserine was observed in the cells (W right et al., 
1985). M ontaudon et al. (1986) showed that MDR C6 cells had increased membrane
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fluidity, which could be accounted for by an increase in the content o f unsaturated fatty 
acids. They also demonstrated that culturing resistant cells in polyunsaturated fatty acids 
resulted in a 2-fold increase in adriamycin sensitivity, with only relatively m inor changes 
in fatty acid composition. These results suggested that drug resistance was very sensitive 
to changes in membrane lipid composition and/or physical properties. In 1977, Ling et al. 
postulated that a decrease in membrane fluidity might be responsible for the diminished 
influx of drugs, such as colchicine, in MDR cells. Since alterations in membrane lipid 
structure has been shown to alter membrane fluidity, altering the lipid composition and/or 
physical properties of the membrane may enhance drug uptake in MDR cell lines. A 
number o f studies have illustrated an increase in net drug uptake in MDR cells by altering 
the lipid composition of the growth media. Zjilstra et al. (1987) demonstrated that 
incorporation of docosahexaenoic acid into resistant cells caused an increase in the 
accumulation of adriamycin and a reversal of cell resistance. Callaghan et al. (1993) also 
reported a significant increase in uptake of vincristine and rhodamine dyes in CHRC5 cells 
by the addition of membrane rigidifying agents, including the saturated fatty acids, stearic 
acid and the cholesterol derivative, cholestryl hemisuccinate.
The relationship between membrane physical properties and MDR was investigated in the 
DLKPA10 cells. In these studies, adriamycin accumulation was determined in the cells 
following treatment with the amphiphiles, stearic acid and cholestryl hemisuccinate. Both 
agents spontaneously partition into membranes and may subsequently affect membrane 
fluidity. The results obtained showed that the addition of stearic acid did not significantly 
alter the cellular accumulation of adriamycin in either the DLKP or DLKPA10 cells. 
However, treatment with cholesterol hemisuccinate resulted in a slight enhancement of drug 
accumulation in both cell lines, which may indicate that this agent was incorporated into the 
membrane of the DLKPA10 cells and altered fluidity, leading to an increase in drug uptake. 
This result was unexpected, since toxicity studies had shown that stearic acid was more 
effective than cholestryl hemisuccinate at decreasing adriamycin resistance in the DLKPA10 
cells. The findings would suggest that while stearic acid reduces adriamycin toxicity in the 
resistant cells, its effect does not appear to be associated with increased drug accumulation. 
In contrast, cholestryl hemisuccinate appears to slightly alter adriamycin accumulation in 
the cells, without having any effect on adriamycin toxicity. It is clear from these results 
that further studies are required to determine the effect of alterations in membrane 
properties on modulating resistance in the DLKPA10 cells.
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4.10 Antibodies in the study of MDR in DLKPA10 cells
Given that an alternative mechanism(s) may be involved in mediating decreased drug 
accumulation in the DLKPA10 cells, additional studies were carried out in an attempt to 
identify a novel antigen, which could contribute to the resistant phenotype in these cells. 
Antibodies were, therefore, raised against the DLKPA10 cell line and preliminary 
characterisation studies were carried out to establish if an MDR related antigen was either 
overexpressed or down regulated in the cells, relative to the sensitive DLKP cells. A 
number of monoclonal antibodies, which have proved to be useful tools in the study of 
MDR, have been generated, including antibodies to P-glycoprotein, topoisomerase I and II, 
LRP, M RP, glutathione-S-transferase and metallothionein. Several investigators have 
generated antibodies from mice immunized with whole cell extracts. Lathan et al. (1985) 
produced monoclonal antibodies against the P-glycoprotein of drug resistant Chinese hamster 
ovary CHO cells by immunization with viable CHOC5 cells. Two monoclonal antibodies, 
MRK16 and MRK17, which also recognise the 170 - 180 kDa P-glycoprotein, were 
produced by immunization with cellular extracts of the adriamycin resistant human 
myelogenous leukaemia cell line, K562/ADM (Hamada and Tsuruo, 1986). M irski and 
Cole (1989) produced a panel o f antibodies following immunization with cellular extracts 
o f the non-P-glycoprotein cell line H69/AR.
A number of immunization procedures have also involved the use of cell membrane extracts 
to produce antibodies against membrane associated antigens. A number of monoclonal 
antibodies were generated by immunization with purified plasma membranes, isolated from 
the colchicine resistant Chinese hamster ovary CHRB30 cell line and the vincristine resistant 
human leukaemia CEM /VBL300 cell line. This panel of antibodies, which included the 
commercially available C219 monoclonal antibody, were all specific for P-glycoprotein 
(Kartner et al., 1985). M ore recently, Hipfner et al. (1994) produced monoclonal 
antibodies from mice immunized with membrane enriched fractions from the M DR H69/AR 
cells, which express high levels of the 190 kDa protein, to obtain a probe for 
immunodetection of MRP. In our studies, an immunization programme was carried out 
using whole cell extracts of the resistant DLKPA10 cell line, in an attempt to raise 
antibodies that were not necessarily associated with the plasma membrane. A total o f three 
fusions were performed, which involved the fusion of normal antibody producing B cells, 
obtained from mice immunized with the DLKPA10 cells, with SP2 myeloma cells. Positive
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hybridomas were obtained from two of the fusions. However, when the clones were 
screened against both the parental DLKP and the DLKPA10 cells by ELISA, only a small 
number were found to display selective immunoreactivity. The majority of these clones 
showed stronger immunoreactivity against the DLKP than the DLKPA10 cells. These 
results were unexpected, since the DLKPA10 cells overexpress a high level o f P- 
glycoprotein. It was anticipated that a number o f antibodies to P-glycoprotein would be 
generated. Although a number of clones displayed immunoreactivity against the DLKP 
cells, only one hybridoma (D8-8) was selected for further characterisation. The selected 
hybridoma was grown up as ascitic fluid in Balb/c mice and a suitable working dilution 
(1:100) was determined by ELISA.
4.10.1 C haracterisation  of the  D8-8 antibody
Results obtained from the screening procedure suggested that the D8-8 antibody was 
generated against an antigen that was either overexpressed in the parental cells or 
downregulated in the resistant DLKPA10 cells. Consequently, preliminary studies were 
carried out in an attempt to characterise the D8-8 antibody and to ascertain the role o f the 
antigen in the M DR phenotype observed in the DLKPA10 cells. The supernatants from the 
D8-8 hybridoma were initially screened against a number of rat monoclonal antibodies to 
determine the class and subclass of the antibodies produced. These isotyping studies 
revealed that the antibody was of the IgG class with subclass 1. W estern blot analysis was 
performed on purified membrane extracts from the immunogen, DLKPA10, and the 
parental DLKP cells. The proteins were subjected to denaturing polyacrylamide gel 
electrophoresis, transferred to nitrocellulose blots and then probed with the D 8-8 antibody 
to determine the molecular weight and levels of expression of the antigen, bound by the 
antibody. The results illustrated that the D8-8 antibody preferentially reacted with an 
antigen of approximately 180 kDa in the DLKP cells under the experimental conditions 
employed. The results obtained by W estern blot analysis were, therefore, consistent with 
the initial ELISA results, demonstrating strong immunoreactivity of the D8-8 antibody 
against the DLKP cells. Immunocytochemical studies were also performed with the D8-8 
antibody on acetone fixed, cytospin preparations of the DLKP and DLKPA10 cells. While 
positive immunoreactivity was observed in the majority of the DLKP cells viewed, only 
faint staining was noted in the DLKPA10 cells. Cytoplasmic staining was visible in the 
DLKP cells, although cell surface staining was also noted in a large proportion of the cells.
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This was particularly evident in areas of contact with neighbouring cells, where intense 
staining was observed, perhaps implying that the antigen may be involved in cell adhesion 
or intracellular communication. Since the immunocytochemical studies revealed 
heterogenous staining of the antibody within the DLKP cell population, additional studies 
were carried out in three independent clones isolated from the parental cell line (S McBride, 
PhD thesis). The aim of this work was to establish the extent of preferential binding of the 
antibody with a particular cell type within the cell population. Positive immunoreactivity 
was observed with all three clones, although with varying degrees of staining intensity. 
W hile two of the clones (DLKP-I and DLKP-SQ) showed similar staining patterns, with 
positive staining in the majority of cells, only faint staining was observed in the DLKP-M 
clone. These studies indicate selective binding of the antibody to different cell types within 
the parental population. Immunocytochemical studies were also preformed on the OAW42 
and SKMES-1 variants to investigate if similar staining patterns were observed in these 
cells. The D8-8 antibody displayed stronger immunoreactivity against the OAW42-S cells, 
although some staining was also observed in the OAW42-A resistant variant. Studies on 
the SKMES-1 variants demonstrated positive immunoreactivity in both the SKMES-1 and 
SKM ES-1/ADR cells, although the staining intensity appeared to be slightly greater in the 
parental SKMES-1 cells. The results would, therefore, suggest that the D8-8 antibody 
preferentially binds to sites on the sensitive cell lines, an effect which is most clearly seen 
in the DLKP cells.
Immunofluorescence was carried out on live cells to detect the presence of cell surface 
antigens. The immunoreactivity of the D8-8 antibody against the DLKP, OAW42-S and 
SKMES-1, together with their respective resistant variants was investigated. The results 
obtained illustrated that, while cell surface fluorescence was visible in the DLKP cells, the 
intensity of surface fluorescence was substantially greater in the resistant DLKPA10 variant. 
Intense fluorescence was also visible on the surface of the OAW42-S, OAW42-A, SKMES- 
1 and SKMES-1/ADR cells. However, no significant differences were disguisable in the 
intensity o f fluorescence between the sensitive and related resistant variants in either the 
OAW42 or SKMES-1 variants. These findings, therefore, indicate that the D8-8 antibody 
appears to bind strongly to a particular antigen on the surface of each of the cell lines 
studied, although with the exception of the DLKP parental cells where the intensity was 
greatly reduced. These results, however, were not consistent with those obtained through 
the immunocytochemical studies, where a higher level o f staining with the antibody was 
observed in the parental DLKP cells.
283
Overall, the results would suggest that, while the D8-8 antibody preferentially binds to a 
cell surface antigen in the DLKPA10 resistant cells, it preferentially binds to an internal 
antigen in the parental cells. This could imply differential cellular localisation of the 
antigen in the sensitive and resistant cells. It is also possible, that if  the antigen was 
localised on the cell surface of the DLKPA10 cells it could be destroyed during fixation. 
Consequently, the antigen would not be detected by immunocytochemical studies having 
been destroyed during the fixation step of the procedure. In addition, destruction of cell 
surface antigens may also occur during denaturation. Therefore, the cell surface antigen 
previously recognised by the D 8-8 antibody in the DLKPA10 may subsequently be 
destroyed during polyacrylamide gel electrophoresis, possibly explaining why the binding 
of the antibody was not detected by W estern blot analysis. The results obtained from 
studies on the OAW42 and SKMES-1 variants would suggest that the antibody recognizes 
an antigen that has both intracellular and cell surface localisation in the cells. Although 
there appears to be no significant difference in cell surface localisation of the antigen 
between the sensitive and resistant variants, the resistant variants appear to express higher 
intercellular levels of the antigen. It is clear from these findings that further work is 
required to determine the role, if  any, of this antigen in the M DR cell lines. Since the 
antigen appears to be externalised to an equal extent in the OAW42 and SKMES-1 sensitive 
and resistant variants, it mat not be implicated directly with resistance in these cells. It is 
possible that the antigen may play a role in cell-cell communication or cell-cell adhesion, 
although this remains to be clarified.
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4.11 Conclusions and future work
The establishment and characterisation of novel platinum resistant variants of the human 
lung carcinoma cell line, DLKP, represents the objective of the early work reported in this 
thesis. In this regard, three carboplatin resistant variants were established, exhibiting 
resistance to the selecting agent of approximately 4-, 8- and 16-fold. These variants were 
also found to be cross resistant to cisplatin. Cross resistance to the classical MDR drugs, 
including adriamycin and vincristine, however, was not displayed. Characterisation studies 
revealed that the mechanism of resistance in these cells does not appear to be either P- 
glycoprotein or topoisomerase II mediated. Through further studies, it was also 
demonstrated that these resistant variants did not exhibit any significant alterations in the 
activity of the GST enzymes, although this had been implicated in numerous platinum 
resistant cell lines. M etallothionein expression was, however, found to be increased with 
the level of expression correlating broadly with the degree of platinum resistance in the 
respective variants. Two methods of study were applied in determining the extent of 
metallothionein expression in the platinum resistant DLKP variants. Given that 
metallothionein expression has been associated with increased resistance to heavy metals, 
including cadmium, lead and zinc, the cadmium chloride toxicity profile was determined. 
All three variants were found to exhibit cross resistance to cadmium chloride, exhibiting 
2.7-, 9- and 10-fold levels respectively. In addition immunocytochemical studies were 
carried out to investigate metallothionein expression. Again, positive correlation between 
platinum  resistance and metallothionein expression was detected in all three variants. 
Although the parental cells were found to exhibit positive immunoreactivity, the ex te n t, as 
indicated by the intensity of staining, was significantly less than in the established resistant 
variants. These results therefore, indicate overexpression of metallothionein in the resistant 
variants and that this overexpression may contribute to the resistant phenotype in the cells. 
Further work involving W estern blot analysis for protein detection could confirm the results 
obtained from the immunocytochemical studies.
Although metallothionein expression appears to have a role in mediating the resistant 
phenotype, alternative mechanisms must also be involved, since differences in the level of 
metallothionein expression, particularly in the DLKPC 25 variant, does not reflect the 
different levels of platinum resistance in the DLKPC variants. Consequently, additional 
studies were carried out to establish if resistance in the DLKPC cells resulted from 
decreased intracellular platinum accumulation. Platinum uptake could not be measured
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directly, as a flameless atomic absorption spectrometer was not available for use. However, 
indirect studies were carried out to determine if  alteration of membrane permeability, with 
subsequent increased platinum uptake would result in increased cytotoxicity in the 
established DLKPC variants. The results obtained, however, suggested that this was not 
the case, since the addition of amphotericin B, which has been shown to increase membrane 
permeability in cisplatin resistant cells, did not significantly alter the toxicity profile of 
carboplatin in any of the variants. N a+K +-ATPases have also been shown, through a 
number of studies, to be central to platinum accumulation in some resistant cells. 
Accordingly, the toxicity profile of ouabain, a N a+K +-ATPase inhibitor, in the DLKPC 
resistant variants was determined. The results obtained demonstrated that the variants 
exhibited slight cross resistance to ouabain, although ouabain did not significantly alter the 
cytotoxicity of carboplatin in the cells. These results suggest that alterations in Na+K +- 
ATPases may be involved in mediating resistance in the DLKPC variants, although further 
work involving direct methods o f studying platinum accumulation is required before the 
contribution of N a+K +-ATPases to the resistant phenotype of the DLKPC variants can be 
clarified.
The cellular accumulation and subcellular distribution of anticancer drugs in a number of 
human M DR cell lines represents another focus of this work. The results obtained 
demonstrated a reduction in drug accumulation in each of the M DR lines studied, relative 
to their respective parental cells. The addition of verapamil and cyclosporin A, agents 
known to interact with P-glycoprotein, resulted in complete restoration of cellular drug 
levels in the M DR cell lines, SKMES-1/ADR, T24A, T24V and the OAW42 resistant 
clones. These findings, therefore, suggested that the accumulation defect observed in each 
of these cell lines was P-glycoprotein mediated and additionally that these cell lines 
exhibited characteristics consistent with the classical M DR phenotype. These results 
differed, however, from the results obtained for the DLKPA10 cell line. Although 
cyclosporin A and verapamil enhanced drug accumulation in these cells, the maximum level 
o f drug accumulated was substantially less than that observed in the parental cells. These 
results could suggest the presence of a mutated form of P-glycoprotein no longer sensitive 
to verapamil or cyclosporin A treatment, since studies have reported that these agents 
competitively interact with a common binding site of P-glycoprotein (Foxwell et al., 1989; 
Tamai and Safa, 1990). Alternatively, the results could suggest that in addition to P- 
glycoprotein overexpression an alternative mechanism exists causing a decrease in drug
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accumulation in the resistant DLKPAIO cells. Consequently, further studies were carried 
out to identify this non verapamil/cyclosporin A-sensitive accumulation defect in the cells. 
M etabolic inhibition studies revealed that sodium azide and 2-deoxy-glucose were effective 
at partially restoring drug accumulation. Complete restoration, however, of cellular drug 
levels was observed following treatment with antimycin A, indicating an energy dependent 
non-P-glycoprotein accumulation defect in the resistant DLKPAIO cells. Although 
numerous studies had reported increased drug accumulation in MDR cell lines when treated 
with the metabolic inhibitors, sodium azide or 2-deoxy-glucose, literature searches revealed 
no information on the use of antimycin A in the study of MDR. These findings suggest that 
antimycin A is substantially more effective than the well documented metabolic inhibitors, 
sodium azide and 2-deoxy-glucose, in reversing the drug accumulation defect in the resistant 
cells. This could be explained by the different sites of action attributable to each of these 
metabolic inhibitors, as they each act at different stages of ATP production. While sodium 
azide and antimycin A both act by inhibition of the electron transport chain, sodium azide 
inhibits ATP production at a later stage of the chain and consequently appears less effective 
at depleting ATP levels in the DLKPAIO cells.
Adriamycin subcellular distribution was studied, with the results demonstrating different 
localisation of the drug in sensitive and resistant cells. While adriamycin was localised in 
the nuclei of sensitive cells, the drug distribution appeared to be concentrated predominantly 
in vesicles within the cytoplasm of resistant cells. While verapamil and cyclosporin A were 
shown to completely restore adriamycin nuclear fluorescence in the P-glycoprotein cells 
lines, SKMES-1/ADR, T24A, T24V, OAW42-A1 and OAW42-A, these agents could only 
partially restore nuclear fluorescence in the DLKPAIO cells. These results were consistent 
with results obtained from the quantitative studies. Nuclear fluorescence was restored, 
however, following treatment with antimycin A, thus indicating an energy dependent altered 
drug distribution pattern in these cells. Pretreatment with the metabolic inhibitors, sodium 
azide or 2-deoxy-glucose, could only partially restore nuclear levels of the drug in the 
DLKPAIO cells, further illustrating the effectiveness of antimycin A in depleting cellular 
levels o f ATP. Initially it was thought that nuclear drug exclusion resulted from reduced 
cellular levels of the drug. However, when the subcellular distribution of adriamycin was 
studied in the DLKP and DLKPAIO cells at equivalent intracellular concentrations, nuclear 
exclusion of the drug was still observed in the resistant cells. These results indicate that 
the altered drug distribution pattern could result from factors other than bulk influx/efflux 
rates although, given the limitations of the study and the substantially different exposure
287
times further studies would be required to establish this conclusively.
The observation of intense fluorescence staining in the cytoplasmic regions of resistant cells 
prompted a number of further studies. These studies were aimed at determining if 
adriamycin was localised within cellular organelles, including lysosomes and the Golgi 
apparatus. A number of studies have suggested that an alternative membrane trafficking 
system, involving either the Golgi apparatus or the lysosomal system, could exist in MDR 
cells. These could operate to remove drug from the cells. However, the results obtained 
in our studies suggested that adriamycin was not associated with either the Golgi apparatus 
or the lysosomes in the DLKPA10 cells, since treatment with the Golgi disrupting agent, 
brefeldin A or the lysosomotropic agents, chloroquine and methylamine, did not 
significantly alter the subcellular distribution of the drug. Further studies suggested that 
adriamycin is localised in acidic vesicles and that an alternative acidic vesicular traffic 
transport system may play a role in drug exclusion in resistant cells. Depletion of cellular 
ATP levels, by antimycin A treatment, resulted in disruption of these acidic vesicles, 
indicating that an active mechanism is required to sustain the drug in the vesicles. 
M onensin, an agent known to disrupt acidic vesicular traffic, was found to increase the 
cellular concentration of adriamycin and to redistribute the drug into the nucleus in the 
DKLKPA10 cells. The mechanism by which monensin acts is unclear, although it is 
generally believed that it acts by abolishing the Na+H + gradient, resulting in an increase 
in the pH environment and subsequent disruption of the acidic vesicles. However, when 
the cells were preloaded with adriamycin, it was found, unexpectedly, that although 
antimycin A caused subcellular drug redistribution, treatment with monensin did not appear 
to disrupt the cytoplasmic vesicles within time period studied. Accordingly, further work 
is required to establish the exact mechanism by which monensin acts, although it would 
appear from the results obtained that it act by inhibiting the sequestration of drug into the 
vesicles rather than disruption of the vesicles.
The results would, therefore, suggest that in, addition to P-glycoprotein mediated drug 
efflux an alternative acidic vesicular transport system exists in the DLKPA10 cells. 
Although vincristine accumulation in the DLKPA10 cells was also increased following 
treatment with monensin, the extent, unexpectedly, was found to be substantially lower than 
with adriamycin. Further studies also revealed that while treatment with monensin resulted 
in a decrease in the cytotoxicity of adriamycin and VP16, no alteration in vincristine 
toxicity in the DLKPA10 cells was noted. The cause of this apparent drug specific effect
288
of monensin is unclear, although since both adriamycin and VP 16 are topoisomerase II 
inhibitors, the divergent effect of monensin may be related to topoisomerase inhibition. 
Substantial further work on VP16 accumulation in the DLKPA10 cells is required to 
determine the effect of monensin on VP16 accumulation. Specifically, it may be possible 
that adriamycin (and possibly VP 16) are localised in acidic vesicles within the cytoplasm 
and that disruption of these vesicles by monensin treatment results in an increase in the 
cellular concentration of the drug. In contrast, since vincristine has a higher molecular 
weight and a more complex structure, localisation of the drug may not occur within the 
vesicles. Subsequently, the increase in the cellular concentration of vincristine following 
treatment with monensin may in fact be mediated by alternative mechanisms, including 
inhibition of P-glycoprotein or metabolic inhibition.
The results obtained from drug transport studies suggest that the drug accumulation defect 
in the DLKPA10 cell line is predominantly related to combination of P-glycoprotein 
overexpression and the existence of an acidic vesicular transport mechanism. However, 
since the apparent inhibition of both mechanisms does not appear to completely restore drug 
accumulation, other mechanisms may also be involved. Consequently additional, 
preliminary, studies were carried out to identify an alternative mechanism responsible for 
decreased drug accumulation in these cells. In particular results obtained from studies 
carried out to determine the effect of amphiphiles on adriamycin accumulation in the 
resistant cells, suggested that membrane fluidity may be decreased in the resistant cells since 
treatment with cholestryl hemisuccinate slightly increased drug accumulation in the cells. 
Cholesteryl hemisuccinate and other amphiphiles partition into membranes subsequently 
affecting membrane fluidity, possibly resulting in increased drug accumulation. Given that 
membrane fluidity may be decreased in the DLKPA10 cells, detailed studies of the effect 
o f various membrane altering agents on drug accumulation and distribution in the resistant 
cells is needed to clarify the involvement of alterations in membrane fluidity in decreased 
drug accumulation in the DLKPA10 resistant cells.
To establish if an antigen associated with decreased drug accumulation was overexpressed 
in the DLKPA10 cells, antibodies were raised against the resistant cells. It was found that 
the antibody displaying the highest level o f immunoreactivity preferentially bound to the 
parental cells. This would suggest that expression of the recognised antigen is 
downregulated in the DLKPA10 cells. However, its role, if any, in mediating resistance 
in the DLKPA10 cells is unknown. Although, it remains to be clarified, the preliminary
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MAB Monoclonal antibody
MDR Multidrug resistance











NCTCC National Cell & Tissue Culture Centre
NEAA Non essential amino acids
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate buffered saline
PEG Polyethylene glycol
P-gP P-glycoprotein
PMSF Phenylmethyl sulfonyl fluoride
psi Pounds per square inch
RNA Ribonucleic acid
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Appendix 6.2 Sample calculation of ICg, value
Carboplatin Concentration (pg/ml)
Sample calculation
IC50 of carboplatin from above graph =  8.5/ng/ml 
Molecular weight of carboplatin =  375
Calculation =  8.5 x 106
375
=  22666.7 nM 
ICJ0 value =  22.67 M
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Appendix 6.3 Sample calculation of subcellular adriamycin concentration
80 -  








0 200 400 600 800 lOQO 1200
Adriamycin concentration (nM)
A standard curve was prepared from the fluorescence of known adriamycin concentrations 
over a range of 0 - 1000 nM. The cellular concentration of adriamycin in each sample was 
quantitated from the linear standard curve.
Sample calculation
Fluorescence value obtained =  28
Adriamycin concentration from above graph =  400nM
400 nmoles/1 — 0.4 nmoles/ml
Drug extracted in total of 4mls
Total no of cells
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=  1.6 nmoles/sample 
=  1600 pmoles/sample
=  8 x 10s per well
=  2000 pmoles per 106 cells
=  2 nmole per 10s cells
Appendix 6.4 Molecular Weights of agents used in these studies
Adriamycin 580
Vincristine 824.9





Antimycin A  548.6
Monensin 670.9
N igericin 725
Brefeldin A  280.4
Genistein 270.2
Chloroquine 319.9
Methylamine 31.1
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